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P2 plasma membrane preparation, pellet from medium
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PAGE polyacrylamide gel electrophoresis
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PEI polyethyleneimine
PI phosphotidylinositol
PKC protein kinase C
PVP polyvinylpyrolidone
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s.c. subcutaneous
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S 1 supernatant fraction from low speed centrifugation
The pathology of Alzheimer's disease highlights the importance o f hippocampal and 
cortical presynaptic cholinergic receptors The presynaptic hippocampal nAChRs represent 
one possible avenue for development o f rational cholinergic drug therapy. The fact that the 
administration o f nicotine apparently enhanced attention in Alzheimer patients (Sahakian et 
al., 1989), demonstrates the value o f targeting the nicotinic receptors, but unfortunately the 
side effects of nicotine are legion, precluding any major therapeutic role for the drug. The 
propensity of the nAChRs to desensitise upon exposure to agonist also means that potential 
drugs would have a limited concentration 'window1 in which to facilitate the release of 
ACh Clearly, a more complete pharmacological understanding of these presynaptic 
nAChRs would assist the rational design of drugs to combat Alzheimer's disease and other 
dementing diseases.
A reproducible superfusion protocol was established for the Brandell SP-06 
apparatus, initially based upon the work o f Thorne (1990). Using this apparatus, 
superfusion of [ ’HJcholine-loaded cortical, then hippocampal synaptosomes, was 
characterised with respect to the optimal synaptosomal loading concentration, response to 
a general depolarising agent (KC1), and Ca2 -dependence.
Dose-dependent agonist-evoked ['HJACh release from hippocampal synaptosomes 
was demonstrated in response to a nicotine challenge. Both agonist- and KCl-evoked 
release was shown to be Ca2+-dependent. Nicotine- but not KCl-evoked release, was shown 
to be mediated via presynaptic nAChRs using the nicotinic antagonist DHPE. In addition to 
nicotine, a variety of agonists was shown to mediate dose-dependent [JH]ACh release, 
enabling the estimation o f EC50 values for the following agonists: nicotine, cytisine, (+)- 
anatoxin-a, iso-arecolone and ABT-418. A characteristic pattern o f nAChR desensitisation 
at higher agonist concentration, was seen for each agonist Repetitive agonist stimulation 
revealed profound nAChR desensitisation, even at agonist concentrations producing sub- 
maximal transmitter release. The peptide, substance P (SP) did not affect the apparent 
affinity or binding density o f [3H]nicotine. Similarly, nicotine does not alter the binding 
characteristics o f [3H]SP. Agonist-induced nAChR desensitisation was affected by SP in a 
complex manner, consistent with the possible interaction of hippocampal tachykinin 
receptors.
In a comparison o f control rats, and MSA and nbM lesioned rats (using excitotoxic 
amino acids), small decreases in ChAT activity were found with no corresponding decrease 
in [3H]nicotine binding density. Preliminary studies using the technique of in vivo 
microdialysis, confirmed that systemic injection o f  nicotine was able to evoke ACh release 
in the hippocampus o f freely moving rats.
I'm  grateful to so many people who, in one way or another, helped me during my time in 
Bath First and foremost, to my friend and supervisor Sue W onnacott. for always knowing the right 
thing to say, for guiding and encouraging me unstintinglv But also for being interested in films, the 
Arts and French - 'people skills' in spades. Thank you.
Thanks to my industrial supervisor Dr Pete Hutson at M erck Sharp & Dohme, for his 
enthusiasm  and support, and to M SD as a whole, together with the SERC for financial support. 
Thanks also to Drs. Bruce Livett, Peter Rowell, Sharon Grady, Mike M arks and A1 Collins for 
taking an interest in my project, taking the time to talk to me, and for providing ideas for 
experiments. I 'm  especially grateful to Al, for inviting me to his lab ’ in Boulder.
Thanks to my parents, Sheila and George, who have always supported me in whatever I've 
wanted to do., however far out o f  their ken. It may be a standing joke that they believe I can walk on 
water, but with so much faith behind you it's  hard to fail and I love them dearly.
Everyone in the Biochemistry Dept, in Bath, past and present, and to the various members 
o f  labs' 2.12 and 3.20: M ark, Phil, Liz, Alison, Sanjiv, Georgina. Paul, Helen, and Su. Everyone in 
the Animal House; especially Lesley, Ewan (Babe Ruth with a rounders bat) and Peter (firem an's 
lift!) who never failed to brighten my mornings.
Thanks to the following; Iggv, Chris, Jim, Andy, Sarah. Liz, Jam m y & Anne, Jamie & 
Lisa, Becky. Jo, Anna, Ruth, Dawn & Jim. A long list o f  people who constitute my closest friends. 
T heir emotional generosity humbles me, and w ithout them I'm  not sure w hat I would have done 
sometimes. Special mention to Jamie, my evil twin (despite not being that evil, and having hair too 




N ICOTINIC A U TO RECEPTO RS IN TH E RAT HIPPOCAM PUS REGULATE 
A CETY LCH O LIN E RELEASE I
N ICOTINIC A UTO RECEPTO RS IN TH E RAT HIPPOCAM PUS REGULATE 
A CETY LCH O LIN E RELEASE. 2
ABBREVIATIONS 3
SUM M ARY 5




PUBLICATIONS RESULTING FROM  W O R K  IN THIS THESIS 17
COM M UNICATIONS 17
PUBLICATIONS 17
CH APTER 1. INTRODUCTION 19
1.1. ALZH EIM ER'S D ISEASE 19
1.1.1. ALZHEIMER PATHOLOGY 20
1.1.1.1. Amyloid peptide and Alzheimer's disease 21
1.1.1.2. Tau protein and Alzheimer’s disease 23
1.1.13. ApoE and Alzheimer's disease 23
1.1.2. CHOLINERGIC RECEPTOR CHANGES 24
1.2. THE H IPPO CAM PUS 25
1.2.1. CHOLINERGIC INNERVATION 25
1.2.2. CHOLINERGIC RECEPTORS IN THE HIPPOCAMPUS 26
/ .  3. A CETYLCHOLINE RECEPTORS 26
1.3.1. MUSCARINIC RECEPTORS 27
1.31.1. Mechanism Of Action Of m AChRs 28
91.3.1.2. Localisation of mAChRs 29
1.3.1.3. niAChR Subtypes 30
1.3.2. NICOTINIC RECEPTORS 31
1.3.2.1. Molecular Biology of nAChRs 33
1.3.2.2. Functional Expression of 11ACI1R genes 37
1.3.2.3. Functional Diversity Among Helcrologously Expressed nAChRs 39
1.3.2.4. Presynaptic nAChRs In Brain 42
1.3.2.5. Desensitisation of nAChRs 43
1.4. THE CHOLINERGIC HYPOTHESIS 46
1.4.1. MODELING ALZHEIMER PATHOLOGY 46
1.41.1. Effects O f Cholinergic Drugs 46
! .4.1.2. Lesions O f Cholinergic Pathways 48
1.4.1.3. Comparison O f Lesions And Pharmacological Intervention With Respect To The Effects 
O f Cholinergic Drugs 49
1.5. TECHNIQUES USED FOR STUDYING TRANSMITTER RELEASE AND ITS MODUL4 TION 50
1.5.1. IN  VITRO METHODS: SYNAPTOSOMES AND SUPERFUSION 50
1.5.1.1. Synaptosomes 50
1.5.1.2. Superfusion 51
1.5.2. IN  VIVO METHODS: MICRODIALYSIS 52
1.6. SUBSTANCE P AND ALZHEIMER'S D ISE4SE 53
1.6.1. SUBSTANCE P AND nAChRs 54
1.6.1.1. Effects On Transmitter Release 54
1.6.2.2. Effects On Nicotinic Agonist Binding To nAChRs 55
1.7. SUM M 4RY TO CHAPTER I 56
1.8. AIM S OF THE PROJECT 56





2.1. THE SUPERFUSION SYSTEM  60
2.1.1. PERCOLL DISCONTINUOUS DENSITY GRADIENTS. 60
2.1.2. BRAIN TISSUES 60
2.1.3. SYNAPTOSOME PREPARATION 60
2.1.4. PROTEIN DETERMINATION 61
2.1.5. CHOLINE UPTAKE 61
2.1.6. THE SUPERFUSION PROTOCOL 62
2.1.6.1. Agonist-Evoked Release 62
2.1.6.2. Antagonists 63
10
2. RADIOLIGAND BINDING . ISS. I YS 63
2.2.1. Th INICOTINE BINDING 63
2.2.11. General Binding 63
2.3.1.2. Competition Binding 64
2.2.3. | ’H |SP BINDING 64
2.3.3.1. General Binding 64
2.3.3.2. Competition Binding 65
2.3. CHOLINEACETYLTRANSFERASE 65
2.4. AIICRODIA L YSIS 65
2.4.1. SURGERY 65
2.4.2. MICRODIALYSIS ASSAY 66
2.4.3. HPLC 66
CHAPTER 3. CHARACTERISATION OF A SUPERFUSION SYSTEM  TO STUDY 
ACETYLCHOLINE RELEASE 67
3. I . INTRODUCTION 67
3.2. METHODS 69
3.2.1. SYNAPTOSOME PREPARATION 69
3.2.2. CHOLINE UPTAKE 69
3.2.3. SUPERFUSION 70
3.2.4. EXPRESSION OF RELEASE DATA 70
3.3. RESULTS AN D  DISCUSSION 72
.3.3.1. CHOLINE UPTAKE 72
3.3.2. RESPONSES TO VARYING CONCENTRATIONS OF POTASSIUM 74
3.3.3. VARIATION IN PROTEIN CONCENTRATION 75
3.3.4. TYPICAL SUPERFUSION PARAMETERS FOR HIPPOCAMPAL SYNAPTOSOMES 79
3.3.5. THE CALCIUM-DEPENDENCE OF [3H]ACh RELEASE 80
3.4. SUMMARY OF CHAPTER 3 82
CHAPTER 4. AGONIST-EVOKED ACETYLCHOLINE RELEASE 84
4 .1 INTROD UCTION 84
4.2. METHODS 85
4.3. RESULTS 86
4.3.1. CALCIUM DEPENDENCE 86
4.3.2. NICOTINE-EVOKED ACh RELEASE 86
4.3 .2 .1. Nicotine Concentration 86
4.3.2.2. Nicotinic Nature O f The Response 90
4.3.3. FURTHER ANTAGONIST STUDIES 92
4.3.4. FURTHER AGONIST-EVOKED RELEASE 93
4 .3 .4 .1. Cytisine 93
4.3.4.2. (+)-Anatoxin-A 95
4.3.4.3. Iso-arccolonc 97
4.3 4.4. ABT-418 99
4.3.4.5. Acetylcholine 101
4.4. DISCUSSION 106
4.4.1. CALCIUM DEPENDENCE OF AGONIST-EVOKED | ’H|ACh RELEASE 106
4.4.2. AGONIST-EVOKED | 3H |ACh RELEASE 106
4.4.3. ANTAGONIST STUDIES 108
4 .4 .1. POSSIBLE nAChR SUBTYPES IN THE RAT HIPPOCAMPUS 109
4.4.2. AGONIST-EVOKED DESENSITISATION 112
CHAPTER 5 DESENSITISATION STUDIES 114
5 .1. INTRODUCTION 114
5.1.1. REPETITIVE AGONIST STIMULATION 114
5.1.2. SUBSTANCE P 115
5.1.2.1 SP and [3H]nicotinc Binding Sites 115
5.1.2.2. Nicotine and [3H]SP Binding Sites 116
5.2. METHODS 116
5.2.1. REPETITIVE AGONIST STIMULATION 116
5.2.2. SP 117
5.3. RESULTS 117
REPETITIVE STIMULA TION 117
5.3.1. REPETITIVE NICOTINE STIMULATION 117
5.3.2. REPETITIVE CYTISINE STIMULATION 120
SP STUDIES 121
5.3.3. SP AND NICOTINE-EVOKED [3H]ACh RELEASE. 121
5.3.4. SP AND THE NICOTINE-EVOKED S2/S1 RATIO 122
5.3.5. [3H]NICOTINE BINDING AND SP 123
5.3.5.1. Competition Binding 123
5.3.5.2. Saturation Binding 124
5.3.6. [3H]SP BINDING AND NICOTINE 125
5.3.6.1. Saturation binding 125
5.3.6.2. Competition Binding 127
5.4. DISCUSSION 127
5.4.1. REPETITIVE AGONIST STIMULATION 127
5.4.2. POOL DEPLETION 128
5.4.3. EFFECTS OF SP ON NICOTINE-EVOKED [3HlACh RELEASE 130
5.4.4. RADIOLIGAND BINDING, NICOTINE AND SP 131
5.4.4.1. [3H]Nicotine Binding 131
5 4.4.2. [ ISP Binding 
CHAPTER 6 M ICRODIALYSIS 134
6.1 INTRODUCTION I.U
6.1.1 IN 171 O METHODS FOR STUDYING NEUROTRANSMrTTER RELEASE 13 4
6.!. 1.1. Cup Perfusion Technique 134
6.11.2.  Push-Pull Perfusion Technique 134
6.1.13.  In Vivo Microdialvsis 135
6.1.2. MICRODIALYSIS AND ACh RELEASE 142
6.1.2.1. Hippocampal ACh Release in Response to Nicotinic Drags 143
6.2. METHODS 144
6.3. RESULTS 144
6 .3 .1. EFFECTS OF SYSTEMIC ADMINISTRATION OF NICOTINE 144
6.3.2. EFFECTS OF SYSTEMIC ADMINISTRATION OF MECAMYLAMINE 145
6.4. DISCUSSION 147
6.4.1. NICOTINE ADMINISTRATION 147
6.4.2. MECAMYLAMINE ADMINISTRATION 148
CHAPTER 7. CONCLUSIONS 151
7.1. nAChRs AND AD 151
7.2. AGONIST THERAPY 152
7.3. HIPPOCAMPAL nAChR AUTORECEPTOR SUBTYPE 154
7.4. nAChRs AND SP 155
7.5. MICRODIALYSIS 156
7.6. EXCITOTOXIC LESIONS 157
APPENDIX: LESION STUDIES 158
INTRODUCTION 158
STUDY 1: INSTITUTE OF PSYCHIATRY 158
STUDY 2: MERCK SHARP & DOHME 160
APPENDIX: CHEM ICAL STRUCTURES 164
tiJ
FIGURE 1.1. THE MUSCARINIC RECEPTOR ARRANGEM ENT IN
THE LIPID BILAYER. 29
FIGURE 1.2. A SCHEM ATIC REPRESENTATION OF THE 
ARRANGEM ENT OF A SECOND MESSENGER RECEPTOR  
MECHANISM  IN A MEMBRANE. 30
FIGURE 1.3. SCHEMATIC MODEL OF THE TOPOLOGY OF AN 
IDEALISED NACHR. 34
FIGURE 1.4. SCHEMATIC DIAGRAM OF THE MODIFIED CYCLICAL 
M ODEL TO EXPLAIN DESENSITISATION. 46
FIGURE 3.1 A. SCHEMATIC REPRESENTATION OF THE BRANDELL 
SP-06 APPARATUS 69
FIGURE 3.1B. DETAILED VIEW OF BRANDELL SUPERFUSION  
CHAM BER 69
FIGURE 3.2. S2 KCL-EVOKED RELEASE OF [3H]ACH. 76
FIGURE 3.3. THE EFFECTS OF VARYING PROTEIN  
CONCENTRATION IN THE SUPERFUSION CHAM BER. 78
FIGURE 3.4. TYPICAL SUPERFUSION PROFILE. 81
FIGURE 4.1. NICOTINE-EVOKED RELEASE OF [3H]ACH. 88
FIGURE 4.2A. NICOTINE DOSE RESPONSE CURVE FOR A 
REPRESENTATIVE EXPERIMENT. 88
FIGURE 4.2B. NICOTINE DOSE RESPONSE CURVE TRANSFORMED  
TO PERCENT SPECIFIC RELEASE. 88
FIGURE 4.3. NICOTINE DOSE-RESPONSE CURVE. 90
FIGURE 4.4. CURVE FIT TO THE HILL EQUATION FOR  
NICOTINE. 90
FIGURE 4.5. THE EFFECT OF 1 ^M DH(3E ON 10 [iM NICOTINE- 
EVOKED [3H]ACH RELEASE. 92
FIGURE 4.6. CYTISINE DOSE-RESPONSE CURVE. 96
FIGURE 4.7. CURVE FIT TO THE HILL EQUATION FOR  
CYTISINE. 96
FIGURE 4.8. (+)ANATOXIN-A DOSE-RESPONSE CURVE. 98
FIGURE 4.9. ISO-ARECOLONE DOSE-RESPONSE CURVE. 99
14
FIGURE 4.10. CURVE FIT TO THE HILL EQUATION FOR ISO- 
ARECOLONE. 100
FIGURE 4.11. ABT-418 DOSE-RESPONSE CURVE. 101
FIGURE 4.12. CURVE FIT TO THE HILL EQUATION FOR 
ABT-418. 102
FIGURE 4.13. ACETYLCHOLINE DOSE-RESPONSE CURVE. 103
FIGURE 4.14. ACETYLCHOLINE DOSE-RESPONSE CURVE. 106
FIGURE 4.15. DHPE BLOCKS BOTH PEAKS OF THE ACH DOSE 
RESPONSE CURVE. 107
FIGURE 5.1. HISTOGRAM SHOW ING THE EFFECTS OF 
REPETITIVE NICOTINE STIMULATION. 121
FIGURE 5.2. A REPRESENTATIVE ISOTHERM SATURATION  
BINDING OF [3H]NICOTINE TO HIPPOCAMPAL SI 
M EM BRANES. 126
FIGURE 5.3. SATURATION ISOTHERM FOR THE BINDING OF [3H]
SP TO HIPPOCAMPAL SI M EM BRANES. 127
FIGURE 6.1. RAT SKULL AND DIFFERENT TYPES OF DIALYSIS 
PROBE. 138
FIGURE 6.2. DIFFUSION IN A TISSUE IS IMPEDED BY CELL  
M EM BRANES. 141
FIGURE 6.3. NICOTINE-EVOKED, IN  VIVO RELEASE OF 
HIPPOCAM PAL ACETYLCHOLINE. 146
FIGURE 6.4. M ECAM YLAM INE-EVOKED, IN  VIVO RELEASE OF 
HIPPOCAM PAL ACETYLCHOLINE. 147
TA BLE 1.1 MUSCARINIC RECEPTOR NOMENCLATURE 31
TA BLE 1.2 PROPERTIES OF CLONED AND SEQUENCED 
NEURONAL nAChR GENES 35
TABLE 1.3: RELATIVE ABUNDANCE AND DISTRIBUTION OF 
NEURONAL nAChR SUBUNITS IN THE MAMMALIAN CNS. 37
TABLE 3.1 VARIATION IN [3H]ACh RELEASE FROM CORTICAL 
SYNAPTOSOMES, WITH RESPECT TO DIFFERENT PROTEIN 
CONCENTRATIONS. 76
TABLE 3.2 VARIATION IN [3H]ACh RELEASE FROM HIPPOCAMPAL 
SYNAPTOSOMES, WITH RESPECT TO DIFFERENT PROTEIN 
CONCENTRATIONS 77
TABLE 3.3: THE Ca2+-DEPENDENCE OF KC1-EVOKED [3H]ACh 
RELEASE. 80
TABLE 3.4: THE EFFECT OF 5 jiM EDTA ON EVOKED [3H]ACh 
RELEASE. 82
TA BLE 4.1 THE CONCENTRATION-DEPENDENCE OF NICOTINE- 
EVOKED [3H]ACh RELEASE. 88
TABLE 4.2: ANTAGONISM OF NICOTINE-EVOKED [3H]ACh 
RELEASE BY DH(3E. 90
TABLE 4.3: THE EFFECT OF 1 jiM AND 10 |aM MLA ON THE ABILITY
OF 1 \xM NICOTINE TO EVOKE TRANSMITTER RELEASE 92
TABLE 4.4: THE CONCENTRATION-DEPENDENCE OF CYTISINE- 
EVOKED [3H]ACh RELEASE. 94
TABLE 4.5: THE CONCENTRATION-DEPENDENCE OF ANTX- 
EVOKED [3H]ACh RELEASE. 96
TABLE 4.6: THE CONCENTRATION-DEPENDENCE OF ISO- 
ARECOLONE-EVOKED [3H]ACh RELEASE 98
TABLE 4.7: THE CONCENTRATION-DEPENDENCE OF ABT-418- 
EVOKED [3H]ACh RELEASE 100
TABLE 4.8: ACETYLCHOLINE-EVOKED [3H]ACh RELEASE IN THE 
ABSENCE OF ATR OR PHY. 102
TABLE 4.9: ACh-EVOKED [3H]ACh RELEASE IN THE PRESENCE OF 
BOTH ATR AND PHY. 104
TABLE 4.10: COMPARISON OF MAXIMAL EVOKED [3H]ACh 
RELEASE AND AGONIST CONCENTRATION REQUIRED TO 
PRODUCE MAXIMAL RELEASE. 109
TABLE 4.11: COMPARISON OF ECJ0 VALUES FOR (-)-NICOTINE,
ANTX, AND CYTISINE IN DIFFERENT NEURONAL nAChR 
PREPARATIONS. 110
TABLE 5.1: RELEASE OF [3H]ACh EVOKED BY SUCCESSIVE 
STIMULATIONS WITH NICOTINE. 119
TABLE 5.2: RELEASE OF [3H]ACh EVOKED BY SUCCESSIVE 
STIMULATIONS WITH CYTISINE. 122
TABLE 5.3: EFFECT OF SP PRETREATM ENT ON NICOTINE-EVOKED 
[3H]ACh RELEASE. 123
TABLE 5.4: EFFECT OF SP ON THE AGONIST-EVOKED S2/S1 
RATIO. 124
TABLE 5.5: EFFECT OF SP ON THE EQUILIBRIUM BINDING OF 20 
nM [3H]NICOTINE. 124
TABLE 5.6: EFFECT OF SP ON SATURATION BINDING OF 
[3H]NICOTINE TO HIPPOCAMPAL SI MEMBRANES. 125
TABLE 5.7: COMPETITION BINDING OF [3H]SP AGAINST 
NICOTINE. 128
TABLE 7.1: POTENTIAL THERAPEUTIC DRUGS BASED ON 
NICOTINE AGONISTS. 155
TABLE A .l: [3H]NICOTINE BINDING IN THREE BRAIN REGIONS 
FOLLOW ING EXCITOTOXIC LESIONS. 160
TABLE A.2: ChAT ACTIVITY IN CORTEX AND HIPPOCAMPUS 
FOLLOW ING EXCITOTOXIC LESIONS. 160
TABLE A.3: EFFECT OF QUISQUALATE LESIONING OF THE MSA 
ON HIPPOCAMPAL CHOLINERGIC PARAMETERS. 162
C O  M M  U N I C  A T I  O N  S
Wilkie, G I ., Hutson, P H , Stephens, M.W., Whiting, P., & Wonnacott, S., (1993). 
H ippocam pal nicotinic autoreceptors m odulate acetylcholine release.
Biochem. Soc. Trans., 21: 429-431.
Wilkie, G.I., Hutson, P H., Stephens, M W , Whiting, P., & Wonnacott, S., (1993). 
H ippocam pal nicotinic autoreceptors m odulate acetylcholine release.
Society for Neuroscience Abstract, 19: 123.1
Sullivan, J.P , Anderson, D.J , Donnelly-Roberts, D , Wilkie, G , Wonnacott, S., 
Garvey, D.S., Williams, M„ & Arneric, S P , (1994).
ABT-418: In vitro properties of a novel cholinergic channel activato r (ChCA) for the 
potential trea tm en t of Alzheimer's disease.
International Symposium On Nicotine: The Effects O f Nicotine On Biological Systems II. 
Abstact, P25.
P U B L I C A T I O N S
Thomas, P., Stephens, M., Wilkie, G , Amar, M., Lunt, G.G., Whiting, P., 
Gallagher, T., Pereira, E., Alkondon, M., Albuquerque, E.X., & Wonnacott, S., (1993). 
(+)-Anatoxin-a is a potent agonist at neuronal nicotinic acetylcholine receptors.
J. Neurochem., 60: 2308-2311.
Wonnacott, S., Wilkie, G., Soliakov, L., & Whiteaker, P., (1994).
Presynaptic nicotinic autoreceptors and heteroreceptors in the CNS.
In: The Effects o f Nicotine on Biological Systems (Eds. Clarke, P.B .S ., Quik, M., Thurau, 
K., Adlokofer, F.X.). Birkhauser Verlag. Basel-Boston-Berlin
18
QUAND v o u s  serez bien vieille, au soir a la chandelle, Assise aupres du feu, devidant et filant,
Direz chantant mes vers, en vous esmerveillant: 
Ronsard me celebroit du temps que j ’estois belle.
Lors vous n’aurez servante oyant telle nouvelle, 
Desja sous le labeur a demy sommeillant,
Qui au bruit de mon nom ne s’aille resveillant, 
Benissant vostre nom de louange immortelle.
Je seray sous la terre, et, fantosme sans os,
Par les ombres myrteux je prendray mon repos:
Vous serez au fouyer une vieille accroupie,
Regrettant mon amour et vostre fier desdain.
Vivez, si m’en croyez, n’attendez a demain: 
Cueillez des aujourd’huy les roses de la vie.
P. De Ronsard
F o r  C h r i s t i n a .
w -
,N you are old and grey and full of sleep, 
And nodding by the fire, take down this book, 
And slowly read, and dream of the soft look 
Your eyes had once, and of their shadows deep:
How many loved your moments of glad grace, 
And loved your beauty with love false or true, 
But one man loved the pilgrim soul in you, 
And loved the sorrows of your changing face:
And bending down beside the glowing bars, 
Murmur, a little sadly, how Love fled 
And paced upon the mountains overhead 
And hid his face amid a crowd of stars. 
W.B. Yeats
a w r r a  i. i m o M c n o i M
1 .1. A L Z H E I M E R ' S  D I S E A S E
One o f the most feared and devastating aspects of ageing is the deterioration of 
memory and other mental processes that occurs with increasing frequency in advancing 
years. About 5% or more of the population above the age o f 65 years suffers from 
dementia, a severe impairment in cognitive functions; an additional 10% of individuals 
exhibit mild-to-moderate abnormalities in their cognitive abilities (Blessed, 1980). The most 
common cause o f this dementia is Alzheimer's disease (AD-here used to refer to both the 
senile and presenile Alzheimer's disease). Its characteristic feature o f a relentlessly 
progressive decline in intellectual abilities in the absence of marked changes in alertness or 
sensory or motor abilities (Cummings & Benson, 1983), the lack of an effective treatment, 
and its unknown aetiology (Henderson, 1986) have combined to make AD a major health 
problem. Mental infirmity is the major reason for the confinement o f elderly individuals in 
nursing homes; and, in the USA for example, the cost of nursing home care alone for 
patients whose chief symptom is dementia was estimated to exceed $6 billion per year by 
1980 (Coyle et a/., 1983). Today, it is estimated that the cost to American society for 
diagnosing and managing Alzheimer’s disease, primarily for custodial care, is in the region 
of $80 billion annually (Selkoe, 1991).
Generally the onset of senile dementia is heralded by impairments in recent memory. 
Affected individuals may be able to recall in considerable detail life events from the distant 
past, but they cannot remember what occulted just minutes earlier. Inevitably, higher 
cognitive functions deteriorate and the patients lose the ability to read, write, calculate, or 
use language appropriately. The loss o f cognitive abilities may be accompanied by 
psychiatric symptoms such as irritability, emotional lability, paranoid delusions, and 
hallucinations. Affected individuals remain alert until the terminal stages; and the dementia 
occurs commonly in the absence of focal neurological deficits such as paralysis or sensory 
loss, which frequently accompany cerebrovascular disease.
Presenile dementia of the Alzheimer’s type is a rare disorder in which the 
individuals, typically in their fifties, develop a progressive deterioration of cognitive 
functions indistinguishable from senile dementia. The demonstration that the pathological 
alterations in the brains of more than half o f elderly demented individuals are similar to
those found in the brains o f patients suffering from the presenile form o f AD (reviewed in 
Coyle et al., 1983) suggests that these are related disease processes.
1.1.1. ALZHEIMER PATHOLOGY
Alzheimer's disease was first described by Alois Alzheimer in 1907 (Alzheimer, 
1907). At post-mortem, he wrote: “Scattered through the entire cortex, especially in the 
upper layers, one found miliary foci that were caused by the deposition o f a peculiar 
substance in the cerebrai cortex.” Evidence has emerged in the past decade that this 
peculiar substance is a protein fragment - the |3-amyloid peptide (discussed below, section
1.1.1.1.). In 1911 Simchowicz (Simchowicz, 1911) drew attention to the common finding 
of granovascular degeneration, that is, intracellular vacuoles, in hippocampal pyramidal 
neurons, and more recently cerebrovascular amyloidosis and the presence o f Hirano bodies 
have been recognised as common pathological findings (Glenner, 1983).
As alluded to previously, the pathology is complex and consists o f granovascular 
degeneration and the presence o f senile plaques and neurofibrillary tangles (NFTs). Silver 
staining techniques have shown the senile plaques to be 20-200 nm in diameter 
(Marchbanks, 1982) which consist o f abnormal axon terminals (derived from cholinergic, 
adrenergic and somatitinergic neurones; Perry & Perry, (1985) and dendritic processes, 
often intermingled with astrocytes and microglial cells, associated with a core o f 
extracellular amyloid (Perry et al., 1978; Marchbanks, 1982; Coyle et al., 1983). The 
amyloid peptide subunit (A4 or p protein) encoded on chromosome 21, is an insoluble, 
highly aggregating, small polypeptide o f 4.5 kilodaltons (kDa; Kang et al., 1987) which has 
a high co-localisation with aluminosilicates (Candy et al., 1986). This has lead to the 
hypothesis that aluminium may be an initiating factor in the disease. However it may be the 
amyloid peptide that traps the aluminium and so elevated aluminium is probably secondary 
in the progression o f  the disease (McGeer, 1984).
The NFTs, particularly in the perikaryon o f pyramidal cells, are composed o f 
bundles o f tightly packed paired helical filaments (PHFs; 10-12 nm in diameter; 
Marchbanks, 1982; Coyle et al., 1983), consisting largely o f the microtubule-associated 
protein, tau (section 1.1.1.2.) in an abnormal state o f  phosphorylation (Mandelkow & 
Mandelkow, 1993). There have been opposing reports on whether the correlation between 
the severity o f dementia (and the reduction in ChAT) is better mapped to the number o f 
senile plaques (Perry et a l, 1978; Sitaram, 1984) or NFTs (Wilcock & Esiri, 1982;
Wilcock et al., 1982). However there is a high density of both these pathological features 
in the brain o f patients with Alzheimer's disease.
1.1.1.1. Amyloid peptide and Alzheimer's disease
Senile plaques are extracellular deposits o f a heterogeneous substance called 
'amyloid’. They also contain dystrophic neurites (neural cell processes) and glial cells. 
Although plaques are particularly abundant in the cerebral cortical parenchyma o f AD 
victims, other extracellular amyloid deposits occur in the walls o f cerebral and meningeal 
blood vessels.
Glenner & Wong (1984) isolated and partially sequenced the major protein 
constituent o f cerebrovascular amyloid deposits, a 4 kDa peptide. Subsequently, Masters et 
al., (1985) showed that this 39-43 amino acid molecule called the (3-amyloid peptide or 
peptide, was also the principle constituent o f  senile plaques. Other proteins, including 
ubiquitin, apolipoprotein E (apoE; discussed in section 1.1.1.3.), interleukin-1, lysosomal 
hydrolases and oci-antichymotrypsin, are also found in plaques.
When the first full-length cDNA encoding the (3-amyloid peptide was cloned and 
sequenced (Kang et al. , 1987) it was found to encode a protein that is much larger than the 
4 kDa (3-peptide. Hence, the (3-peptide is derived by proteolysis from this larger protein, 
called the amyloid precursor protein (APP). APP is a large, multidomain protein containing 
a single membrane-spanning region, with the amino terminus extending into the 
extracellular environment, and a short region at the carboxyl terminus projecting into the 
cytoplasm. Approximately two thirds o f the (3-amyloid peptide portion o f APP is 
extracellular, whereas the remaining third is integrated into the membrane.
Expression o f  APP is complex. The primary RNA transcript o f  APP undergoes 
differential splicing to  generate mRNAs coding for at least five forms o f  APP. APP is also 
post-translationally modified: the molecule undergoes 0 -  and N-glycosylation,
phosphorylation, and sulphation on tyrosine residues (Ashall & Goate, 1994). APP is also 
regulated compartmentally within the cell: surface APP can be secreted or internalised into 
the endosomal-lysosomal system, to add to this complexity, APP is also processed by 
multiple proteolytic pathways.
What has emerged from investigations o f the rare, familial forms o f AD is that 
mutations that lead to AD can occur in different genes in different families, and that 
different mutations can occur at the same genetic locus in different families. The gene 
encoding APP was mapped to chromosome 21 (St. George-Hyslop et al., 1987), and this 
suggested that the AD-like pathology seen in Down’s syndrome was due to overexpression 
o f the APP gene. This idea was further supported by the discovery that some familial forms 
o f AD were linked to chromosome 21.
Levy et a l, (1990) showed that patients with Dutch-type amyloidosis (HCHWA-D) 
have a point mutation within the P-peptide sequence o f APP at amino acid position 22, 
causing a glutamate residue to be substituted for a glutamine residue (Levy, et al., 1990) 
patients with HCHWA-D do not develop AD, but they do have diffuse P-amyloid deposits 
within the cerebral cortex, and cerebrovascular P-amyloid deposits, these patients are prone 
to brain haemorrhage. This discovery was the first to show that a specific defect in the APP 
gene can cause P-amyloid to be deposit.
Persuasive evidence that APP can have a primary role in AD came from the 
discovery by Goate et al., (1991) that a point mutation in the APP gene (position 717, near 
the carboxy-terminal amino acid o f the P-peptide) co-segregated with the disease in at least 
one early-onset AD family. Subsequently, APP mutations at the same and other codons 
within the APP gene were found in other AD families. None o f these mutations occurs 
within the p-amyloid peptide o f the APP molecule, but they do occur very close to the ends 
o f the P-peptide sequence.
Point mutations in the APP gene are not always the cause o f  familial AD. Recent 
research has shown that a mutation in a gene on chromosome 14 can also cause familial 
AD (Ashall & Goate, 1994). Chromosome 14 mutation(s) accounts for the majority o f 
cases o f early-onset AD. The identity o f the genes (or genes) involved is not yet clear, and 
whether or not it encodes a product that is directly involved in APP metabolism has yet to 
be determined. A gene on chromosome 19 also appears to be linked to some forms o f late- 
onset AD. This may be the apoE gene (section 1.1.1.3.).
The conclusion that familial AD is genetically heterogenous and can apparently be 
caused by many different genetic defects on different chromosomes should perhaps come as 
no surprise. AD is very common, occurs in many ethnic groups and is similar in pathology 
to the normal process o f brain ageing. It is reasonable that the syndrome that is known as
AD could arise in somewhat different forms from many distinct genetic alterations. All 
these alterations, however, appear to act through a critical common mechanism involving 
the increased deposition of P-amyloid peptide.
1.1.1.2. Tau protein and A lzheim er’s disease
As outlined above, NFTs and their constituents, the PFLFs, consist largely of the 
microtubule-associated protein tau in an abnormal state o f phosphorylation. Normal tau 
protein is abundant in axons, where it stabilises microtubules. It consists o f several isoforrns 
generated by alternative splicing o f a single gene. The carboxy-terminal half contains three 
or four imperfect repeats which contribute to microtubule binding and are homologous to 
other microtubule-associated proteins (MAPs). Abnormal tau is more extensively 
phosphorylated than normal tau, aggregates irreversibly into PHFs and is highly resistant to 
proteases. It can be differentiated from its normal counterpart by SDS gel electrophoresis, 
where the abnormal protein runs at 60-68 kDa, compared with 47-67 kDa for the normal 
protein.
Phosphorylation o f normal tau generally occurs at Ser-Pro (SP) or Thr-Pro (TP) 
motifs (tau has seven SP and ten TP motifs), suggesting that the kinase responsible belongs 
to the class o f proline-directed kinases such as the 42 kDa MAP kinases. The different 
Alzheimer-like characteristics o f pathological tau might depend on different causes 
affecting different sites, and with different consequences. For example many authors have 
reported that phosphorylation o f tau or other MAPs affects microtubule assembly 
(Mandelkow & Mandelkow, 1993), illustrating that such properties as microtubule binding, 
assembly, and dynamic instability might be differently affected by tau phosphorylation.
1.1.1.3. ApoE and Alzheimer's disease
ApoE is associated with NFTs and P-amyloid peptide in senile plaques. It also 
appears to play a part in the redistribution o f  lipids that follows deafferentation and 
neurodegeneration in the brain. The gene for apoE is on chromosome 19, within the 
genomic region previously associated with late-onset familial AD (Poirier et al.t 1993).
ApoE is a polymorphic protein associated with plasma lipoproteins. It interacts with 
the ‘remnant receptor’ (apoE receptor) and the low-density-lipoprotein (LDL) receptor 
(apoE/B receptor) o f  the liver and other organs to modulate the catabolism o f triglyceride
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rich lipoprotein particles. ApoE is unique among apolipoproteins in that it has a special 
relevance to nervous tissue: it is involved in the mobilisation and redistribution of 
cholesterol in repair, growth, and maintenance o f myelin and neuronal membranes during 
development or after injury (Poirier et al., 1993).
The importance o f apoE is underscored in AD by its presence within the plaques 
and dystrophic neurites that characterise AD (Namba, et al., 1991), by the fact that apoE 
mRNA is reduced in the hippocampus in AD (Poirier, et a l, 1991) and by the ability o f 
apoE to bind tightly to the soluble and insoluble forms of (3-amyloid (Namba et a l, 1991).
ApoE is encoded by a gene on the long arm o f chromosome 19, within a region 
previously associated with familial late-onset AD (Poirier et al., 1993). Common apoE 
polymorphisms are determined by alleles designated s4, e3, and s2 (Mahley, 1988), and the 
finding that the apoE allele e4, confers a high probability that an individual will develop 
late-onset AD, was reported recently (Saunders et a l, 1993). A quarter o f the population 
o f the world carries this allele, and 2-3% o f people are homozygotes. Penetrance o f AD in 
homozygotes is believed to exceed 90% and heterozygotes are at substantially increased 
risk.
The co-localisation o f apoE with the major neuropathological features o f AD 
suggests some relationship to the cause o f AD. One possibility is that the age-related 
decline in cell number and lipid content that happens normally in the human brain is 
exacerbated by the presence o f certain apoE alleles in susceptible individuals. Furthermore 
if apoE disrupts lipase activity (Yamada & Murase, 1980) in the brain and alters the 
transport o f cholesterol and phospholipids in brain areas vulnerable to ageing, a direct 
consequence would be aberrant and/or defective reinnervation and poor synaptic plasticity.
1.1.2. CHOLINERGIC RECEPTOR CHANGES
Since neurotransmitter-specific neuronal systems have been shown to have a role in 
the pathophysiology o f disorder like Parkinson’s disease and Huntington’s disease, 
investigators have begun to focus on the role o f neurotransmitters in the symptoms of 
disorders o f cognition and memory.
AD is characterised by an extensive degeneration o f  the cholinergic system in the 
human nucleus basalis o f Meynert, (nBM) neocortex and hippocampus (Hardy et a l, 1985;
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Candy et al., 1986; Quirion et al., 1986; Plotkin et al., 1986; Araujo et al., 1988), mainly 
based upon measures o f choline acetyltransferase activity (ChAT). The reduction in 
neuronal input is due to atrophy in the cholinergic nuclei: the nBM has a severe reduction 
in ChAT o f up to 75% (Whitehouse et al., 1981, 1982; Sitaram, 1984); the medial septal 
nucleus and the nucleus o f the diagonal band have shown 55% and 65% reductions in 
ChAT activity, respectively (Henke & Lang, 1983). The validity o f  using ChAT as a 
marker for Alzheimer's disease was shown by Perry et al., (1978) who quantitatively 
correlated the reduction in cortical and hippocampal ChAT with both the numbers of 
neuritic plaques and the severity o f dementia as measured by cognitive and behavioural 
rating scales.
The bulk o f the neurochemical work on Alzheimer's disease has concentrated on 
measuring transmitter or metabolite levels and/or enzyme activities for synthesis or 
metabolism. Using radiolabelled transmitters, agonists or antagonists, changes in receptor 
densities could also be determined (Davies & Verth, 1978). The decrease in ChAT activity 
in post-mortem AD brains also correlated with a decrease in cortical and hippocampal 
nicotinic receptor density, and muscarinic M2-subtype receptor density (Perry et al., 1986; 
Lapchak et al., 1989). Changes in the density o f M l-subtype muscarinic receptors, as 
defined by high affinity [3H]pirenzipine binding, do not correlate with changes in ChAT 
activity however (Lapchak et al., 1989). The existence o f presynaptic nAChRs was 
established in a number o f  studies (W onnacott et al., 1989; Wonnacott, 1990; Lapchak et 
al, 1989; Boksa, 1987; Rowell et a l, 1984), and are thought to function as positive 
feedback autoreceptors. The fact that decreases in the M2 mAChR population mirror the 
changes in nAChR density, strengthen the argument that M2 mAChR are also 
presynaptically distributed with the nAChR at least in the cortical and hippocampal regions 
studied, functioning as negative feedback autoreceptors. The degeneration o f cholinergic 
axons in Alzheimer's disease would spare the majority o f postsynaptically located M l 
mAChR, hence no significant changes in receptor density are observed.
_7.2. THE H I P P O C A M P U S
1.2.1. CHOLINERGIC INNERVATION
Although ACh was the first substance to be established as a transmitter, both in the 
PNS where it was retrospectively identified as the chemical substance responsible for the 
reported vagal inhibition o f the heart, and the CNS (motor axon collateral excitation of
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Renshaw cells), the effects o f synaptically released ACh in mammalian brain have been 
difficult to demonstrate. Numerous biochemical and histochemical studies over the years 
have described the widespread distribution o f ACh and its metabolic enzymes AChE and 
ChAT in the brain, and iontophoretic studies have delineated the distribution of 
cholinoceptive cells. Whilst the cholinergic innervation o f most brain structures is diffuse 
and in most cases relatively sparse compared to other inputs (Nicoll et al., 1985), one 
exception to this general rule is the septo-hippocampal pathway originating primarily from 
neurons in the medial septal nucleus and from neurons in the diagonal band. The pioneer 
studies o f  Lewis and Shute (1967), established that this pathway is particularly rich in 
AChE and the loss o f both AChE and ChAT in the hippocampus following lesions to this 
pathway led these authors to conclude that the septo-hippocampal pathway is the major 
source for the cholinergic input to the hippocampus. More recent immunohistochemical 
studies on the distribution o f ChAT by Houser et al., (1983) and Cuello & Sofroniew, 
(1984) are in complete accord with the earlier conclusion, although non-cholinergic 
afferents have clearly been identified in this pathway (Wainer et al., 1985).
1.2.2. CHOLINERGIC RECEPTORS IN THE HIPPOCAMPUS
Both nicotinic and muscarinic AChRs coexist in the hippocampus. Although 
muscarinic antagonist binding studies originally indicated a uniform population of 
muscarinic receptors, but by 1980, it was realised that the mAChR-mediated actions o f 
ACh could not be accounted for by a single receptor subtype. In particular, radioligand- 
binding studies revealed tissue -specific differences in the affinity o f  the antiulcer drug 
pirenzepine, suggesting the presence o f at least two receptor subtypes (Hammer et a l, 
1980). A high-affinity antagonist site, M l, prevalent in the hippocampus, is well 
characterised and apparently unaltered in Alzheimer's disease (Birdsall et al., 1984), 
although antagonist sites o f medium and low affinities - grouped as M2 - have been 
reported to be reduced (Caulfield et al., 1982). One possible explanation for this differential 
reduction in M2 mAChR compared to M l receptors is a difference in localisation. M l 
receptors are thought to be postsynaptic, whereas M2 receptors may be colocalised with 
presynaptic nicotinic receptors (Perry et a l, 1989; section 1.1.2.),
A  C E T Y L  C H O L IN E  _REC_EP T O R S
In 1914, Sir Henry Dale provided the basis for the classical definition o f muscarinic 
and nicotinic acetylcholine receptors: muscarinic receptors are selectively activated by
muscarine and blocked by atropine; nicotinic receptors are activated by nicotine and 
blocked by curare. This definition lasted over 60 years, despite isolated reports that the 
picture might not be so simple. It is now known, as a result o f molecular biological studies, 
that there are multiple variants o f both muscarinic and nicotinic receptors. These receptors 
are members o f two quite distinct gene superfamilies and only share the property o f being 
activated by the same ligand, acetylcholine.
The nAChR and mAChR have opposing effects on ACh release from presynaptic 
nerve terminals. Nicotine and nicotinic agonists have an excitatory effect on basal ACh 
release, an effect which is antagonised by nicotinic antagonists (Briggs & Cooper, 1982; 
Moss & Wonnacott, 1985; Rowell & Winkler, 1984; Wessler et al., 1986; W onnacott et 
a l, 1989; Nordberg et al., 1989; Thomas et al., 1993; Wilkie et al., 1993). In contrast, 
muscarine and its agonists have an inhibitory effect on evoked ACh release which can be 
blocked by muscarinic antagonists (LeFresne et al., 1978; Marchi et al., 1981; 1983; 
Briggs & Cooper, 1982; Baux et al., 1987). Briggs & Cooper (1982) hypothesised that the 
nAChR acts as an accelerator o f  ACh release, at low ACh concentrations, while the 
mAChR acts as a brake on release, at high ACh concentrations, thereby achieving fine 
regulation o f ACh release. The two types o f cholinergic receptor differ both in structure 
and mechanism o f action.
1.3.1. MUSCARINIC RECEPTORS
By sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) the 
mAChR comprises a single polypeptide o f 70-80 kDa (Birdsall et a l, 1979; Peralta et al., 
1987). Sequence analysis, electron diffraction and limited proteolysis studies have shown 
the receptor to have a short extracellular glycosylated N-terminal region which is thought 
to be associated with the binding site (Hall, 1987), see figure 1.1. There are seven 
hydrophobic regions o f  20-25 amino acids which span the membrane (Birdsall & Hulme, 
1987; Hall, 1987; Peralta et a l, 1987). Intracellularly there is a long cytoplasmic loop 
between transmembrane regions 5 and 6 that is thought to be the site o f interaction with G- 
proteins (see below). The cytoplasmic hydrophilic C-terminal sequence contains serine and 
threonine residues that can be phosphorylated by protein kinases. This phosphorylation may 
play an important role in desensitisation and internalisation o f the receptor (Birdsall & 
Hulme, 1987; Hall, 1987). The model (figure 1.1) leaves little o f the N-terminal structure 
for selective and stereospecific ligand binding so the binding site may lie in the pocket 
formed by the transmembrane domains (Kerlavage et a l, 1987).
1.3.1.1. M echanism  O f Action O f m AChRs
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The muscarinic response o f the mAChR is slow (latency 100 ms and duration 300- 
500 ms duration; Sokolovsky & Bartfai, 1981) due to its integrated response via three 
proteins, see figure 1.2. The binding o f ACh initiates the binding o f a guanine nucleotide 
regulatory protein (G protein) to the mAChR, which acts as a transducer to an appropriate 
effector system (Bourne, 1986; Hall, 1987). G proteins are a family o f heterotrimeric 
proteins: a common (3/y complex (Gp.y; 35 kDa and 10  kDa, respectively) that is thought to 
anchor the protein to the cytoplasmic face o f the membrane and an a  chain (Ga; 41-45 
kDa) that binds GTP and determines the specificity o f the G protein for receptor and 
effector (Gilman, 1984; Bourne, 1986). More recent evidence has also suggested that 
mAChRs may act via the Gp^ subunits themselves, as well as via Ga subunits (reviewed by 
Caulfield, 1993). thus it appears that activation o f phospholipase C (PLC), adenylyl cyclase 
(AC), as well as the cardiac Kf channels may be produced by Gp.y subunits, but the 
physiological role o f this route, as well as its importance relative to the Ga route, has yet to 
be established.
Coupling to a receptor causes the G protein to release GDP and bind GTP. The 
activated G protein can regulate the function o f an effector, hydrolysis o f bound GTP to 
GDP terminates the regulatory effects o f  the G protein (Bourne, 1986). The Mi, M3 and 
M5 receptors activate PLC via a pertussis toxin-insensitive G protein, these subunits are 
thought to mediate primarily excitatory synaptic transmission. M 2 and M 4 receptors inhibit 
AC activity via a pertussis toxin-sensitve G protein and mediate primarily inhibitory 
synaptic transmission (McKinney & Coyle, 1991; Wei et al., 1994)
Coupling o f G proteins to these enzymes (probably via the third intracellular loop 
between TM -V and TM-VI, see figure 1.3B.) results in the generation o f second 
messengers (reviewed by Caulfield, 1993), either cyclic adenosine monophosphate or 
inositol triphosphate and diacylglycerol, respectively, which in turn may alter the activity o f 
protein kinases. Phosphorylation by protein kinases causes receptor desensitisation and 
alters the open or closed state o f a number o f ion channels. G proteins are able to bind 
directly to K+ channels without the intervention of any second messenger. In central 
neurons, activation o f mAChR increases the K f membrane conductance resulting in 
hyperpolarisation and so inhibiting ACh release from presynaptic cells due to reduced 
action. Alternatively mAChR activation may lead to cell depolarisation due to inhibition o f 





FIGURE 1.1. The muscarinic receptor arrangement in the lipid bilayer showing seven 




FIGURE 1.2. A schematic representation of the arrangement of a second messenger receptor 
mechanism in a membrane. R: receptor; G: G protein; E: effector.
1.3.1.2. Localisation of mAChRs
In the CNS the presynaptic localisation o f the mAChR has been well documented 
based on release studies. Muscarinic agonists (oxotremorine, carbachol) reduced 
electrically- or high K - evoked release o f ACh from synaptosomes (Nordstrom & Bartfai, 
1980; Marchi et al., 1981; Raiteri et al., 1984; Vickroy & Cadman, 1989) and slices (Szerb 
& Somogyi, 1973; Hadhazy & Szerb, 1977; Weiler, 1989; Marchi & Raiteri, 1989) 
whereas the muscarinic antagonist, atropine restored or enhanced ACh release. Thus there 
is a documented, presynaptic inhibitory effect on ACh release.
However binding studies with the muscarinic antagonist [3H]QNB suggested that 
there were only postsynaptic mAChR, as there was no reduction in binding after lesion in 
the medial septal nucleus (Yamamura & Snyder, 1974). In 1982, Bowen & Marek showed 
that the classic muscarinic antagonists (QNB, atropine and scopolamine) had a 10 fold 
lower affinity for the presynaptic mAChR than for the postsynaptic receptors. This suggests 
that the low concentration o f QNB (1 nM) used by Yamamura & Snyder may have been 
too low to detect a presynaptic mAChR effect. Using [3H]dexetimide, a muscarinic
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antagonist, Consolo et al (1984) reported a 20 % reduction in receptor binding alter septal 
lesioning supporting the view o f a presynaptic mAChR.
1.3 .1.3. m A C hR  Subtypes
The classical approach to receptor classification has been the discovery and 
characterisation o f selective antagonists and agonists. In the case o f the muscarinic 
receptors, this has also provided the evidence for the existence o f subtypes, but their 
relatively low selectivity, allied to the large number o f subtypes, has led to some confusion 
as regards the definition o f the receptor subtypes.
Historically, the first cardioselective muscarinic antagonist to be discovered was 
gallamine (which is also a nicotinic antagonist). More recently other cardioselective 
antagonists that lack nicotinic actions: AF-DX 116, himbacine, and methoctramine, have 
been described. All these antagonists are more potent on cardiac receptor than the 
receptors on smooth muscle that mediate contraction. The reverse selectivity is shown by 
4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) and hexahydrosiladifenidol. 
A different selectivity is shown by pirenzepine, the drug which in the late 1970s and early 
1980s, had a major role in the appreciation o f the existence o f  mAChR subtypes. 
Pirenzepine binds and acts selectively on a muscarinic subpopulation found in neural tissue 
while it has a lower affinity for the receptors found in heart and smooth muscle (Hammer et 
al, 1980). Because o f  the lack o f highly selective muscarinic drugs, the results o f binding, 
pharmacological and molecular studies must be combined to arrive at a robust definition of 
mAChR subtypes. The appeal o f such an approach adopted by Hulme et al., in their 1990 
review, is that it may be possible to define a  muscarinic receptor subtype in terms o f its 
amino acid sequence, pharmacological profile (in binding and functional studies), and its 
ability to activate selectively one effector mechanism. Table 1.1. summarises the different 
mAChR subtypes.
Pharmacological characterisation
Subtype M, m 2 m 3 - -
Other names M ia, A M2a, cardiac M2, M2p, B m 2
used M2, C glandular M2
previously
Selective Pirenzepine AF-DX 116, p-Fluorohexahydro- - -
antagonists Telcnzepine himbacine. siladifenidol.
mcthoctraminc Hexahydro-
gallamine siladifenidoi
M, > M3 M2 > Mj > M3 ^ Mj > M2
^ M 2 m 3
Molecular characterisation
Sequences m l m2 m3 m4 m5
Other names mAChRI, mAChRII mAChRIII mAChR IV
used M l M2 M4 M3
previously
Numbers of 460 466 589/590 478/479 53 1/532
amino acids
G protein IP3 AC IP3 AC IP3
coupling via:
TABLE 1.1: MUSCARINIC RECEPTOR NOMENCLATURE (as recommended by the 4th Symposium on 
Subtypes of Muscarinic Receptors and the British Pharmacological Society Nomenclature Subcommittee. 
1989). IP3: triphosphoinositide; AC: adenylyl cyclase.
1.3.2. NICOTINIC RECEPTORS
The superfamily o f ligand-gated ion channels (LGIC) which mediate rapid 
excitatory and inhibitory synaptic transmission in the nervous system includes the muscle 
nAChR, the neuronal nAChR , the y-amino butyric acid (GABAa) receptor, the glycine 
receptor, and the 5HT3 receptor,. Binding o f agonist to these receptors induces the rapid 
opening o f their ion channels, which are selectively permeable to either cations or anions, 
thereby altering the membrane potential o f the cell.
The best characterised nAChR is that obtained from the electric organs of Torpedo 
spp. and Electrophorus electricus. The receptor has been extensively characterised, serving 
as a model for the study o f the structure, function and modulation o f LGICs (Changeux, 
1990). The nAChR is a 250-kDa pentameric complex o f four types o f subunits in a
stoichiometry of a 2Py5. Each subunit is an integral membrane protein, and the five subunits 
have been proposed to be arranged around a central pore (figure 1.3A). The receptor has 
two ACh binding sites, one on each a  subunit, which when occupied by ligand triggers the 
opening o f the channel, allowing permeation by cations (Changeux, 1990). The structure 
and functional characteristics o f the nAChR have been further elucidated by molecular 
cloning and sequencing. The subunits are highly homologous proteins, each consisting o f a 
large extracellular NH2-terminal region and four transmembrane domains (M1-M4) as 
shown in figure 1.3B. The ACh binding site is located on the extracellular NH2-terminal 
domain o f the a  subunit whereas the channel pore is believed to be formed by the a-helices 
o f the M2 membrane-spanning region of the five subunits (see figure 1.3C.; Changeux,
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FIGURE 1.3. Schematic model of the topology of an idealised nAChR. A) pentameric subunit 
structure viewed through the plane of the membrane. B) Membrane topology, viewed through the plane of 
the membrane of an individual subunit containing transmembrane domains M1-M4. C) Schematic model 
representing the arrangement of the transmembrane a-helices within each subunit around the central ion 
channel.
I.3.2.I. Molecular Biology of nAChRs
Biochemical studies demonstrate that the nAChR from rat and chick brain are 300- 
kDa complexes, initially thought to be composed exclusively of two types o f subunits, a  
and p (Lindstrom et a l,  1987; Halvorsen & Berg, 1990), inevitably, the situation has 
turned out to be more complex with the discovery of a3p 4 a5  nAChRs in chick ciliary 
ganglia (Conroy et al., 1992; Vernallis et al., 1993) and homo-oligomeric a  7 nAChRs 
(Couturier et al., 1990; Seguela, et al., 1993). Recombinant DNA technology has resulted 
in the identification of ten genes in rat and chicken neural tissue that are homologous to 
muscle nAChR genes (table 1.2. adapted from Sargent, 1993). These genes encode 
polypeptides with four hydrophobic, putative transmembrane domain in the approximate 
relative positions o f their muscle counterparts (Figure 1.3.). The overall amino acid 
homology between the products of these genes from the same species is 40-55% (table
1.2.) This homology approaches 100% in the putative transmembrane regions (especially 
M l-M3) and in selected stretches of the N-terminal extracellular domain, whereas the 
amino-acid sequence in the putative cytoplasmic segment between M3 and M4 is divergent. 
All genes code for a protein with two cysteines separated by 13 residues that align with 
cysteines 128 and 142 of the Torpedo a  subunit. The deduced gene products fall into two 
classes, based on whether they have adjacent cysteine residues at positions 192 and 193 
(Torpedo a  numbering) that are found in all a  subunits from muscle and electric organ and 
that are affinity alkylated by the agonist bromoacetylcholine (BAC) and by the antagonist
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4-(N-maleido)benzyltrimethlammonium (MBTA). Seven o f the genes code for polypeptides 
which have adjacent cysteines, and these are assigned to the a  class; three do not (non-a or 
p). The muscle a  gene is designated a l ,  and the seven neuronal a  subunits are designated 
a 2 - a 8 , more or less in order o f discovery. The a  subunits themselves fall into two classes, 
based on subunit homology: a l  and a 8 , which encode a-Bgt-binding components, have 
substantial amino acid homology with one another, but less homology with other a  
subunits than they have with each other (table 1 .2 .).
The neuronal non-a subunits are named n a l-n a 3  (n a  for non-a) in chicken and P2 - 
P4 in rat. For clarity and ease o f comparison the terms P2, P3, and p4 will be employed 
here for both species. Rat and chicken genes o f  the same name are highly homologous 
(>70% amino acid identity). The p designation does not mean that these gene products 
most closely resemble muscle P genes (see table 1 .2 .), because they do not. At least in rat, 
however, the P2 and p4 gene products can substitute for the muscle P 1, but not for the a l ,  
y, or 5 gene products, in generating functional, muscle-like nAChRs in Xenopus oocytes 
following injection o f mRNAs (Deneris et al., 1988). Based on sequence information alone, 
there is no reason to classify the three p subunits into a single group, since they are as 
different from each other as they are from the a  subunit. Based on heterologous expression 
studies, however, at least P2  and P4 .belong together because either can encode for a 
functional nAChR when coexpressed with a2 , a3 , or a 4  (see section I.3.2.2.),
S ub u n it P r o b e M a t u r e  
p e p t id e  M„
#  AMINO 
ACIDS
C o nsensus
N -l in k e d
GLYCOSY LATI 
ON SITES A
C y s t e in e s ' H o m o l o g y  (s u b u m t /% )
R at® chicken a 2 55,500 29, 79, 185 133, 147, a  1/48
a 2 484 197. 198
a 3 m ouse a  I 54,800 24, 141 128, 142. a  1/52, a2/58
474 192, 193
a 4 - l  c rat a3 . 67,100 24, 141 128. 142, a  1/53, a2/68. a.3/59
mouse a  1 600 192, 193
cx5 rat p3 48,800 112, 140, 180 127, 141, u l-a4 /44-55
424 191. 192
a 6 PCR 53,300 24, 141 66, 128, 142, a l ,  a2 , a4 , a5/41, 49, 49.
463 200, 201 45; a3/59; p2-p4/43-47
a 7 PCR (based 54,200 24, 68, 111 116, 128, a2 -a5 . p2-p4/31-37
on chicken 480 142, 200, 201
a7 , a8 )
P2 rat a3 54,300 26, 141 128, 142 p 1/45; a l-a5 /44 -50
475
(33 rat a3 50,200 26, 141 128, 142 p i, |32/40, 44; a  1/45; a2 -
434 a4/50-56; a5/68
(34 rat P2 53,300 15, 72, 117, 132, 146 p 1/43; p2/64; p3/44;
475 145 a  1/43; a2-a5/46-52
n o n -a2  D universal 56,100 41, 98, 143, 6, 26, 101 alternatively spliced p4?
oligo 499 171 158, 172
C hicken  E chicken a l , 58,100 31, 81 135, 149, a l/5 0
a 2 Y 505 199, 200 rat a l U l
a 3 chicken a2 54,800 24, 141 128, 142, a l/5 3 ; a2/65
474 192, 193 rat a3/83
a 4 chicken a2 68,400 29, 79 133,147, 197, a  1/51, a2/80 a3/66
599 198 rat a4/73
a 5 linkage to 49,000 26, 140, 180 127, 141, a  1/45; a-a4/50-55
a3  F 425 191, 192 rat a5/84
a 6 chicken P4 54,100 23, 140 127, 141, P4/48
463 191. 192 rat a6/80
a7 chicken a3 54,600 24, 68, 111 116, 128, a l - a 6 ,  |32-p4/35-42
480 142, 190, 191 rat a7/87
. a 8 chicken a l 55,200 24, 111 116, 128, a i m
481 142, 190, 191
P2 chicken y 54,000 26, 143 130, 144 al-a4 /44 -55
473 *. rat P2/85
P3 chicken a5 50,100 28, 143 130, 144 a5/67
435 rat P3/82
P4 linkage to 53,500 26, 115, 143 130, 144 p2/70; a l-a5 /44 -52
a3 467 rat P4/74
TABLE 1.2: PROPERTIES OF CLONED AND SEQUENCED NEURONAL nAChR GENES
A Consensus n-linked glycosylation sites and cysteines are given only for the n-terminal 
extracellular domain (amino acids 1~200).
B The sequence for the rat a6 gene has not yet been published. A rat a8  gene has not yet been 
identified.
c Two cDNAs were isolated for the oc4 gene that were virtually identical over the region of overlap 
and are likely to arise from alternative splicing.
D The rat non-a-2 gene differs from the P4 gene in having a 69 base insertion, as well as two 
smaller insertions, a deletion and an inversion.
E The sequences for the chicken a6 and (33 genes have not yet been published.
F The chicken a5 and (34 genes were identified by virtue of their linkage to ot3: some recombinant 
a3 phage contained more restriction fragments recognised by a3 probes than could be accounted for by the 
presence of a3 alone, the a3, a5, and (34 genes are also linked in the rat and human genome.
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aBgt-BIN D IN G  nAChRs
In vertebrate brain, nicotinic receptors that recognise a -B g t with high affinity (a - 
Bgt-AChRs) are distinct from those that do not. For example, a-Bgt-A ChRs do not display 
high affinity binding for [3H]-(-)-nicotine ([3H]nicotine) (W onnacott, 1986) unlike, for 
example, the a 4 p 2  subtype. Schoepfer et a l, (1990) demonstrated that the majority of a -  
Bgt-AChRs in chicken brain contain a 7  and/or a 8  subunits, because mAbs to a l  and a 8 
fusion proteins immunoprecipitate a large fraction o f the high affinity 125I-a-B g t binding 
sites (an a7-specific mAb alone immunoprecipitates >90% of a-Bgt-A ChRs). These 
studies demonstrate that the a l  and a 8  gene products represent the principal agonist 
binding subunits of a-Bgt-AChRs. Immunoadsorption of a-Bgt-A ChRs with a mAb to a l  
does not precipitate detectable amounts o f  material recognisable with mAbs to a 4  or P2 ; 
conversely mAb 270 (p 2 ) immunoadsorption does not precipitate detectable a l -  or a 8 -like 
immunoreactivity (Schoepfer et a l, 1990). This suggests that a l  and a 8  subunits do not 
commonly associate with a 4  or P2 subunits to form nAChRs in chicken brain. McLane et 
al., (1990) showed that peptides unique to  aS  bind a-B gt (as do those from a l ,  a l ,  and 
a 8 ), whereas peptides from the corresponding regions of a 2 -a 4  do not. However, whether 
a5-specific antibodies can immunoprecipitate 125I-a-B gt binding sites from brain extracts, 
remains to be determined.
RADIOLIGAND BINDING AND IN  SITU  STUDIES
Radioligand binding and in situ hybridisation have been used to visualise nAChRs 
labelled with high affinity by [3H ]nicotine and bungarotoxin-sensitive nAChRs and 
corresponding receptor mRNA in rat brain (reviewed in Williams et a l,  1994). Those 
nAChR sites labelled with high-affinity by [3H]nicotine are abundant in selective areas o f 
the cerebral cortex (predominantly layers III and IV), thalamus, interpeduncular nucleus 
and the superior colliculus, but show a low-to-m oderate distribution in hippocampus, and 
hypothalamus (Clarke et a l, 1985). nAChRs labelled by [125I]-a-B gt, are enriched in the 
hippocampus, hypothalamus and layers I and IV o f  the cerebral cortex (Clarke et a l, 1985; 
Clarke, 1992). The distribution o f nAChR subunit mRNAs in rat correlates reasonably well 




ct4, P2, P4 High Widespread
a3 Medium Limited: Brain stem motor nuclei, locus 
coeruleus, thalamus, autonomic ganglia, 
medial habenula
a7 , a6 , p3 Low Restricted: Hippocampus, thalamus, 
autonomic ganglia
a5 , a2 Very low Focal: Hippocampus, cortex
TABLE 1.3: RELATIVE ABUNDANCE AND DISTRIBUTION OF NEURONAL nAChR SUBUNITS IN 
THE MAMMALIAN CNS. Adapted from Williams et al., 1994.
The distribution of the a4(32 subunit combination coincides with the distribution of 
high-affinity nicotine binding sites in rat brain, supporting the immunoprecipitation 
experiments o f Whiting & Lindstrom (1987), who determined that a4  and (32 subunits 
associated principally but not exclusively with one another.
In summary, molecular and biochemical approaches have identified a family of 
nAChR subunits that fall into two classes (ACh binding or a  subunits, and P subunits), 
based on the presence o f adjacent cysteines and on reactivity with ACh affinity alkylating 
agents. Immunoprecipitation studies suggest that many neuronal nAChRs are composed of 
both a  and P subunits (e.g. a4p2), other nAChRs might contain two or more kinds of a  
subunits (Conroy et al. 1992), possibly in addition to p subunits.
1.3.2.2. Functional Expression of nA C hR  genes
One of the aims of this study was to attempt to identify the nAChR subunits making 
up the presynaptic hippocampal nAChRs. The functional expression o f nAChR genes is of 
interest if the studies aid in the identification o f possible subunits which may combine to 
form functional receptors. Boulter et al., (1987), Wada et al., (1988), and Deneris et al., 
(1989) found that Xenopus oocytes expressed functional nAChRs after injection o f mRNAs 
from the rat a2 , a3 , or a4  genes in combination with either the P2 or P4 gene products.
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Injection o f any one mRNA species alone did not lead to the appearance o f  functional 
responses, except a 4 , which produced small depolarisations in response to high 
concentrations o f ACh in about one third o f  the trials. The same six combinations o f 
chicken genes are functional when expressed following injections o f cDNAs into the oocyte 
nucleus, with transcription under the control o f a heat shock or SV40 prom oter(Ballivet et 
a l, 1988; Couturier et al., 1990). These results demonstrate that functional nAChRs can be 
synthesised from specific combinations of a  and p subunits and complement the 
biochemical findings, which suggest that native nAChRs consist of a /p  heteromers.
It was thought until very recently that the a l  gene was exceptional in its ability to 
encode a functional homo-oligomeric nicotinic channel (Couturier et al., 1990): the authors 
found that voltage-clamped oocytes previously injected with a l  cDNA respond to nicotinic 
ligands by producing inward currents. These channels are unusual in the sense that P 
subunit expression is apparently not needed; barring the existence o f  endogenous p 
subunits in the oocyte, these nAChRs must consist of a l  homo-oligomers. Currents from 
a l  nAChRs are blocked by low concentrations of a -B g t (IC50 = 0.7 nM) and less potently 
by nBgt (Couturier et al., 1990). Coinjection of P2, p3 or P4 cDNA, along with a l  cDNA, 
did not result in functional responses with properties any different from those expressed in 
oocytes injected with a l  cDNA alone. Thus, in oocytes at least, a l  subunits apparently 
cannot coassemble with known neuronal P subunits to form hetero-oligomers that have 
functional properties different from those of a l  homo-oligomers. Recently, functional a 8 
homomers expressed in oocytes have been reported (Anand et a l, 1994; Gotti et a l,  1994; 
Gerzanich et a l, 1994). Immunohistochemical studies (reviewed in Gerzanich et a l, 1994) 
suggest that these receptors have a prominent role in the chick retina.
The rat p3 gene does not form functional nAChRs when coinjected as mRNA with 
a 2 , a3  or a 4  genes (Deneris et a l, 1989). The rat a5  and a 6  genes likewise do not 
participate in the formation o f functional nicotinic channels in oocytes when injected in 
combination with several other a  and p genes as mRNAs (Boulter et a l,  1990). These 
subunits may form functional nAChRs when coexpressed with undiscovered (or untested) 
subunits (Conroy et a l,  1992), or they may be members o f another family o f  ligand-gated 
channels. Another important possibility is that these gene products require post- 
translational modifications not made by the oocyte in order to function.
Expression o f  nAChRs is not restricted to oocytes: Whiting et a l,  (1991) stably 
expressed nAChRs in mouse fibroblasts by transfecting them with chicken a 4  and P2
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cDNAs. The fibroblasts acquire functional responses that are pharmacologically similar to 
those in chicken brain, where both a 4  and P2 are widely expressed (Morris et al., 1990). 
The responses o f  the M10 cells stably transfected with chicken a 4 p 2  nAChRs is discussed 
further in chapter 4.
I.3.2.3. Functional Diversity Among Heterologously Expressed nAChRs
AGONIST POTENCY
Neuronal nAChRs are distinct from muscle nAChRs in agonist potency. For 
example, suberyldicholine is generally more effective than ACh on muscle nAChRs, 
whereas ACh is generally more effective than suberyldicholine on neuronal nAChRs 
(Lukas, 1989). Neuronal nAChRs themselves are quite distinct with regard to agonist 
potency. Mulle et al., (1991) found that the order o f potency for neurons from the rat 
interpeduncular nucleus was cytisine > ACh > nicotine; for nAChRs on neurons from the 
medial habenula, it was nicotine > cytisine > ACh. These differences could possibly reflect 
differences in nAChR subunit composition (Luetje & Patrick, 1991). In 1991, Luetje & 
Patrick measured the rank order potency for the agonists cytisine, nicotine, ACh and 1,1- 
dimethyl-4-phenylpiperazinium on nAChRs expressed in oocytes from rat P2  or p4 
subunits in combination with a2 , a3 , or a 4  subunits. Each pair-wise injection yielded 
nAChRs with a unique rank order potency. One o f the most surprising findings was that the 
p subunit which had traditionally been assigned a structural role i.e. providing a structural 
framework for the a  subunits, influenced agonist efficacy as much as the nature o f the a  
subunit. Strikingly, the authors reported that sensitivity to one agonist, cytisine, was almost 
completely determined by the P subunit: nAChRs containing the p4 subunit were more 
sensitive to cytisine than to any other agonist tested, whereas nAChRs containing the P2  
subunit were quite insensitive to cytisine.
Other studies have, however, produced conflicting results. In the rat 
interpeduncular nucleus (IPN) at least six nAChR genes are expressed: a2 , a3 , a4 , a5 , P2 
and P4. The channel conductance o f IPN neurons measured by Mulle et a l, (1991) 35 pS, 
is very close to that o f the largest class o f  heterologously expressed a 2 p 2  nAChRs (34 pS: 
Papke et a l, 1989); therefore, the a 2 p2  combination may be the principal class o f nAChRs 
on IPN neuronal cell bodies. Mulle et a l,  (1991) found that cytisine was as effective as 
ACh in eliciting responses from the IPN neurons, which according to the oocyte studies o f 
Luetje & Patrick would seem to rule out a major role for p2-containing nAChRs.
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Similar attempts to match native nAChRs with heterologously expressed nAChRs 
o f defined composition fail in the medial habenula and in rat PC 12 cells. In the medial 
habenula, for example, nAChR channel conductance (26 pS) is closest to the larger 
conductance class o f  heterologously expressed a 3 p 4  channels (22 pS), but the agonist rank 
order potency for habenular nAChRs resembles neither a3 p 4  nAChRs nor any other class 
o f heterologously expressed nAChRs raises an important question. Do oocytes faithfully 
translate mRNAs and modify and assemble their translation products? Results from 
experiments o f muscle nAChRs suggest that oocytes can translate and assemble subunits 
for muscle nAChRs accurately (reviewed in Lingle et a l, 1992). If  the oocytes are not at 
fault, then the failure to match native and expressed nAChRs may mean that additional 
nAChR genes are yet to be identified or that native nAChRs consist o f subunit 
combinations that have not yet been tested in oocytes. In particular, native nAChRs may 
consist o f more than one a  and/or P type, for example the ot3P2a5 receptors reported in 
chick ciliary ganglia (Vemallis et a l, 1993). At least two approaches can be envisioned that 
could reveal the presence o f hetero-a and hetero-p-containing nAChRs. One approach is to 
inject multiple a  and/or P subunit mRNAs into oocytes and search for channels that have 
properties not seen when only one a  and one P are injected. Another approach is to 
perform sequential immunoprecipitations with subunit-specific antibodies (Conroy et a l, 
1992).
ANTAGONIST POTENCY
Antagonists have also been useful in distinguishing muscle nAChRs from their 
neuronal counterparts and in distinguishing among different neuronal nAChRs. Paton & 
Zaimis (1949) demonstrated that decamethonium (CIO) was more effective than 
hexamethonium (C 6 ) in blocking muscle nAChRs, whereas C6  was more effective in 
autonomic ganglia. This led to the terms “CIO receptor” (muscle) and “C6  receptor” 
(neuronal). Currently, several antagonists distinguish between neuronal and muscle 
nAChRs (Lukas, 1990).
Snake toxins haven proven useful for differentiating between neuronal nAChRs 
(reviewed in Chappinelli, 1991; Loring & Zigmond, 1988). The sensitivity o f 
heterologously expressed nAChRs to nBgt is dependent upon the nature o f  the subunit 
content (Luetje et a l,  1990). Incubation o f  oocytes with 100 nM nBgt for 30 minutes 
completely blocks ACh-induced currents elicited following washing out o f  the toxin in
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oocytes previously injected with rat a3  and p2 mRNAs; under the same conditions, nBgt is 
completely ineffective at blocking function of a2P2  nAChRs (the sensitivity of a4p2  
nAChRs is intermediate between a 2 p 2  and a3P2  nAChRs). Site-directed mutagenesis 
studies have shown that the amino acid at position 198 o f the a  subunit (glutamine in a3 , 
proline in a 2 )  is critically important in determining the difference in nBgt sensitivity 
between a3P 2  and a2P2 nAChRs (Sargent, 1993). All three classes of P2-containing 
nAChRs were blocked by neosurugatoxin, which seems to be highly effective on all 
neuronal nAChRs so far tested (Luetje et a l, 1990). It is an oversimplification to state that 
nBgt is an efficacious antagonist at all a3  containing nAChRs, again the p subunit 
influences the pharmacology; ACh-induced currents elicited from a3P 2  nAChRs are 
blocked by pre-incubation with lOOnM nBgt, but those elicited from a 3 p 4  nAChRs are less 
sensitive (Duvoisin et a l, 1989).
For all their evident usefulness, it is becoming apparent that heterologous nAChR 
expression studies must be treated as one paradigm, rather than the sole and definitive 
answer, for the advancement o f our understanding o f the plethora o f  potential nAChR 
subtypes. It is too early to say whether the observed pharmacological differences between 
the expressed nAChRs can be used as diagnostic tools for identifying native nAChRs, at 
least until a population o f native .channels is identified as arising from a specific 
combination o f subunits in order to compare their properties with those o f  heterologously 
expressed channels.
STOICHIOM ETRY
Neuronal nAChRs may have an a :P  stoichiometry o f 2:3, because their activation is 
typically characterised by Hill coefficients o f  about 1.5 and because their size (-300  kDa) is 
consistent with a pentameric structure. Anand et al., (1991) used 35S-methionine to 
metabolically label nAChRs expressed following injection o f chicken a 4  and p2 mRNAs 
into Xenopus oocytes. They found 1.46 times more 35S in p subunits than in a  subunits 
after correction was made for their methionine content. This ratio is very close to the 
expected value o f  1.5 for a stoichiometry of a 2p3, which suggests that expressed a4P2 
nAChRs are pentamers that contain two a  and three P subunits. Comparable results were 
reported by Whiting et a l, (1991) for a 4 p 2  nAChRs stably expressed in mouse fibroblasts. 
Cooper e ta l ,  (1991) concluded that a 4 p 2  nAChRs have two a  and three P subunits based 
on the number o f channel conductance populations observed when oocytes express a
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mixture of a4 , 02, and an a 4  or 02 whose putative M2 transmembrane domain has been 
altered by site-directed mutagenesis. A stoichiometry of ct203  for native nAChRs would 
seem likely based on these findings and by analogy with muscle nAChRs, which are 
pentamers containing two a  subunits.
I.3.2.4. Presynaptic nAChRs In Brain
nAChRs in autonomic ganglia are responsible for mediating fast excitation, and it is 
generally assumed that the same holds true for central nAChRs. Nicotinic responses have 
been elicited from neuronal cell bodies in several areas o f brain, including for example, 
retina, spinal cord, hippocampus, cerebral cortex and septal nucleus in rats, and the retina 
and lateral spiriform nucleus in chickens (reviewed in Clarke, 1990; Sargent, 1993). 
However, definitive evidence that central synaptic transmission is mediated by nAChRs 
only exists at the motor neuron-Renshaw cell synapse in the spinal cord (reviewed in Nicoll 
et a l, 1990). The presence o f functional nAChRs on many neuronal cell bodies suggests 
that nAChRs mediate postsynaptic nicotinic responses widely in the nervous system; 
though attempts to document this function have been largely unsuccessful (Brown et al., 
1983), awaiting further characterisation o f central synaptic pathways.
Although nicotinic responses can be elicited from many different areas o f  the brain, 
they are not as prominent as might be expected based on mapping studies. This discrepancy 
may be explained if many o f the nAChRs are located on nerve terminals, from which 
recordings cannot be directly made. In the rat IPN, Brown et a l, (1984) and Mulle et a l, 
(1991) characterised one such set o f nAChRs found on the terminals o f neurons that arise 
from the medial habenula. Another approach to  the characterisation o f  the nAChRs is the 
use o f synaptosomes, ensuring that the receptors under study are presynaptic in origin. The 
best characterised presynaptic action o f nicotine concerns the enhancement o f dopamine 
release in the striatum (reviewed by Chesselet, 1984; Rapier, 1988, 1990). Nicotine and its 
agonists are also able to stimulate the release o f  both [3H]ACh and [3H]GABA from 
hippocampal synaptosomes (W onnacott et a l, 1989) and it is thought that these nicotinic 
autoreceptors on cholinergic terminals may subserve a physiological role in the feedback 
regulation o f ACh release. Hexamethonium-sensitive nicotine- and DM PP-evoked release 
o f ACh from cortical synaptosomes has been reported (Rowell & Winkler, 1984), and a 
similar phenomenon has been demonstrated in synaptosomes o f the myenteric plexus 
(Briggs & Cooper, 1982). The presence o f  nicotinic receptors corresponding to 
[3H]nicotine binding sites on cholinergic terminals in cortical and limbic regions helps to
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explain the deficits in these ligand binding sites in the brains o f Alzheimer patients (section 
1. 1.2.2.).
I.3.2.5. Desensitisation o f nAChRs
It is well known that high agonist concentrations can cause a desensitisation of 
nAChRs: functional studies nearly thirty years ago demonstrated desensitisation of 
ganglionic nAChRs, and the same phenomenon was demonstrated at the beginning o f the 
1980’s in skeletal muscle (reviewed by Ochoa, 1989). More recent studies have reported 
data which is compatible with the desensitisation o f nAChR mediating the release o f a 
variety o f transmitters in CNS tissue at much lower agonist concentrations (Rapier et al., 
1988; Rowell and Hillebrand, 1992; Grady et al., 1994).
So, in addition to stimulating nAChR channel opening, ACh is able to inactivate 
channel function by three different mechanisms. Over increasing ACh concentration ranges, 
these inactivation processes are termed slow desensitisation (seconds to  minute time scale), 
fast desensitisation (milliseconds to seconds), and self inhibition (reviewed in Changeux et 
al., 1984). Slow and fast desensitisation are thought to be triggered by agonist binding to 
receptor sites (see below), whereas self inhibition is thought to occur by either a channel 
blocking mechanism (Sine & Steinbach, 1984) or an allosteric site mechanism (Pasquale et 
al, 1983).
There is evidence that several processes subsequent to nicotinic receptor activation,
such as voltage operated Na+ and Ca?+ channel opening, can also undergo desensitisation 
(Marley, 1988). In addition, there is evidence that nicotine-induced desensitisation may 
have several components, depending on whether receptor activation and release occurs 
(Boksa and Livett, 1984).
The acute desensitisation produced by nicotine and other agonists is accounted for 
by the tw o-state receptor model originally proposed by Katz and Thesleff (1957; see also 
Ochoa et al., 1989). This model is presented below, where R represents the ground state 
receptor, R’ is the desensitised form, and N represents nicotine:
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N  +  R ' R 'N
K 3
This model predicts two routes leading to nicotinic receptor desensitisation: (a) R 
+N RN o  R*N and (b) R  <=> R ' +N <=> R !N. The first route would involve the RN 
complex and would result in a functional response, whereas the second route does not. The 
observation that functional responses, such as nicotine-evoked transmitter release from 
synaptosomes (Grady et a l, 1992; 1994; Rowell & Hillebrand., 1994) require low 
micromolar concentrations o f nicotine is consistent with this two-route model where R  +N 
<=> RN has an E C 5 0  o f  approximately lpM . The second route R  o  R ’ +N <=> R ’N has 
been reported to have an EC 5 0  value in the lower nanomolar range, stabilising the
desensitised conformation o f  the receptor without eliciting a response (Bowman et a l, 
1990; Franke et a l, 1992; Wessler et a l, 1992; Grady et a l, 1994; Rowell, 1994). This 
process has been termed ‘inactivation’ rather than desensitisation (Rowell & Hillebrand, 
1994) but this is an unnecessary distinction.
Both fast and slow inactivation are believed to involve conformational changes in 
the receptor (reviewed Ochoa, 1989). Slow desensitisation is known to proceed at ACh 
concentrations where negligible channel opening occurs and the Hill coefficient for slow 
rates is 1.0 (Neubig et a l, 1982). Consequently, it has been suggested that slow 
desensitisation occurs from a singly-liganded nAChR state (i.e. only one activating site 
bound to agonist). Consistent with this scheme, an irreversibly bound agonist analogue, 
bromoacetylcholine, also blocks agonist binding to desensitised receptors (Damle & Karlin, 
1978).
Previous quenched-flow results in both Electrophorus (Aoshima et a l,  1981) and 
Torpedo vesicles (Hess et a l, 1982; Huganir et a l, 1.986) are consistent with a model 
where fast desensitisation occurs from a doubly liganded ‘pre-open’ nAChR state in rapid 
equilibrium with the open channel state.
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The Katz and Thesleff model o f  receptor desensitisation was modified by Changeux 
et al., (1984) to  take account o f the kinetics o f desensitisation. In this model four states of 
the receptor are proposed:
R  and A = resting and active states, respectively
I and D = represent rapidly and slowly desensitised states o f  the receptor
States D and A represent ion channel configurations with the highest and lowest 
ligand affinity, favoured in the presence and absence o f ligand respectively. This model 
differs primarily from the cyclic model proposed in that a rapidly desensitising intermediate 
state between R  and D is suggested, this state has been substantiated by binding studies 
using fluorescent agonists (Changeux, 1981), binding studies with the non-competitive 
channel blocker prehydrohistrionicotoxin (Alberquerque et al., 1974, Dolly et al., 1977), 
and single channel recordings from embryonic muscle which suggest multiple conductance 
states (Hamil & Sakmann, 1981).
FIGURE 1.4. Schematic diagram of the modified cyclical model to explain 
desensitisation (Changeux e t al., 1984). In this model intermediate states are accounted for, based upon 
kinetic data. R  and A = resting and active receptor states respectively, A has the lowest ligand affinity and 
is favoured in the absence of ligand. I and D = rapidly and slowly desensitised states of the receptor, D has 
the highest affinity for the ligand and is favoured in its presence.
The fast component (I) acts to increase the rate o f ion flux whilst the slow 
component (D) acts to reduce ion flux to  undetectable levels (W alker et al., 1982). Patch 
clamp studies show that nAChR can spontaneously open to the active state (A), even in the 
absence o f agonist. This is presumed to be a thermodynamic effect (Jackson, 1984) and is a 
process accelerated by the presence o f agonist (Jackson, 1986).
In quenched flow experiments with Torpedo and Electrophorus vesicles using high 
agonist concentrations (50 and 100 mM ACh), Forman & Miller (1988) revealed an 
nAChR inactivation process occurring before fast desensitisation, which they termed rapid
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inactivation. A process which they postulated to be almost certainly the same as the self 
inhibition by agonists observed in integrated flux experiments (Forman et a l,  1987). 
Forman & Miller (1988) showed that self inhibition/rapid inactivation may occur only after 
channel activation, suggesting a mechanism in which agonists bind selectively to open 
channels. This proposed mechanism is consistent with published data that the self-inhibitory 
potencies o f agonists are voltage dependent (Sine & Steinbach, 1984)
TH E C H O U N E R G J C  H Y P O T H E S I S
The changes in cholinergic function and transmitter abnormalities detailed in section 
1. 1.2., taken together with evidence for the role o f the cerebral cholinergic systems in 
behaviour taken from other lines o f enquiry, have led to the development o f the cholinergic 
hypothesis o f dementia in AD (Perry, 1986; Smith & Swash, 1978): the hypothesis which, 
at the time was called the “single greatest impetus to research into Alzheimer's disease” 
(Collerton, 1986).
Although there are numerous alternative versions, in its commonest form the 
cholinergic hypothesis consigns the classical pathological signs o f AD to a subsidiary role 
and states that the loss o f cholinergic functions causes or contributes to some o f the 
intellectual impairments particularly the memory deficits o f AD (Bartus et al., 1982; Coyle 
etal., 1983; Perry, 1986;Rossor, 1981).
1.4.1. MODELING ALZHEIMER PATHOLOGY
1.4.1.1. Effects O f Cholinergic Drugs
One strategy used in clinical neuropsychopharmacology is to administer drugs that 
selectively alter central neurotransmission and then determine whether these manipulations 
produce symptoms similar to those seen in the disorder. Many studies, for example, have 
demonstrated that antimuscarinic agents such as atropine and scopolamine can disrupt both 
the acquisition and performance o f a variety o f  learned behaviours, (Hagan et a l , 1988; 
Aigner & Mishkin, 1986). In contrast, compounds such as physostigmine (PHY) that 
enhance central cholinergic tone by inhibiting the catabolic enzyme acetylcholinesterase 
(AChE) can, under certain circumstances, enhance performance in learning and memory 
tasks, (Aigner & Mishkin, 1986). In addition, at appropriate doses a variety o f muscarinic 
receptor agonists can enhance the performance o f animals on tests o f  learning and memory
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(Hagan et a l,  1988). This body o f research has provided strong evidence that unspecified 
cholinergic systems in the brain play important roles in forms o f  learning and memory.
In much o f the resultant literature it has become commonplace to discuss the 
general similarities that exist between the learning and memory impairments seen in AD and 
those produced in young human subjects by antimuscarinic drugs such as scopolamine, 
(Bartus et al., 1982). However more recent analyses have raised substantial questions 
about the adequacy o f the scopolamine syndrome as a model for the mnemonic deficits 
occurring in AD. For example, there is evidence that the specific deficits produced by 
scopolamine in humans differ substantially from those seen in AD, (Beatty et al., 1986; 
1988). In fact, Beatty et al., (1986) concluded that the dissimilarities outweigh the 
similarities. These results are compatible with other data showing that in young normal 
subjects the pattern o f changes in regional cerebral blood flow produced by scopolamine 
differs from that seen in subjects with AD, (Honer et al., 1988). To some extent these 
observations are not surprising because, while muscarinic antagonists produce an acute, 
short-lasting blockade o f cholinergic receptors that are primarily postsynaptic, AD is a 
chronic, slowly progressing, irreversible disorder that involves, in addition to the 
documented changes in presynaptic function, substantial pathology o f many other 
neurotransmitter systems, (Gottfries, 1990). Even if cholinergic degeneration was the sole 
pathological feature o f AD, because both muscarinic and nicotinic transmission would be 
impaired, muscarinic antagonists might not be expected to model the cognitive deficits in 
this disease. In any event, the behavioural differences that exist between the scopolamine 
syndrome and AD indicate that if there are specific cognitive impairments due to 
cholinergic dysfunction in AD, their identity remains unknown. To complicate matters 
further, Kish et al., (1989) reported that although ChAT activity in the neocortex of 
patients with dominantly inherited olivopontocerebellar atrophy (OCPA) is reduced to as 
great an extent as it is in AD, OCPA patients do not show the disabling dementia that is so 
characteristic o f Alzheimer's disease. Importantly though, Kish et a l, (1989) noted that in 
contrast to AD, hippocampal ChAT activity is not reduced in OCPA, raising the possibility 
that some aspects o f cognitive impairment in AD are associated with dysfunction o f  the 
septo-hippocampal projection. Equally important, these findings question whether impaired 
cholinergic function in the cortex contributes to cognitive decline in Alzheimer's disease.
1.4.1.2. Lesions O f Cholinergic Pathways
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Studies o f  the behavioural effects o f  lesions o f cholinergic cells are important 
because the chronic depression o f  cholinergic function produced by destruction of 
cholinergic cells may more closely resemble the cholinergic lesion in AD, secondly because 
they are a means o f examining the role o f  specific cholinergic pathways in behaviour, and 
thirdly because they allow cholinergic functions to be examined without the complicating 
side-effects o f  drugs. However, such experiments are not without their own difficulties 
since there is no specific neurotoxin for cholinergic neurons. The early promise o f toxins 
such as AF64A (Walsh et a l, 1984) has yet to be fulfilled (Jarrard et al., 1984). Thus, at 
present, lesions o f  cholinergic pathways cause variable amounts o f collateral damage. It is 
not yet clear how much o f the behavioural deficits which follow lesions o f areas containing 
cholinergic cells are caused by this.
The many cholinergic cells in the mammalian brain may be classified as either 
intrinsic, local circuit neurons such as those found in the striatum and neocortex, or 
extrinsic neurons which provide projection pathways innervating distant areas o f brain 
(section 1.2.1.), O f these latter group o f  neurons, two have so far attracted major interest 
for their role in behaviour. These are: (i) the cholinergic cells o f the nBM which provide a 
specific topographical innervation o f the neocortex and the amygdala, and (ii) the cells of 
the medial septal area which, together with the cells o f the vertical nucleus o f the diagonal 
band o f Broca, provide the cholinergic innervation o f the hippocampus (figure 1.1.).
In AD, both these projection pathways appear to be affected to  varying degrees 
(section 1 .1 . 1 ), Combined lesions o f these pathways may therefore provide a useful animal 
model o f AD (Overstreet & Russell, 1984). Combined lesions o f  the medial septal 
area/nBM lesions disrupt performance in the radial arm maze (Knowlton et a l, 1985) 
though the significance o f this is not clear since both media septal and nBM lesions alone 
cause poor performance in the same task (Hepler et a l, 1985; Olton et a l,  1984).
Lesions O f The Nucleus Basalis O f M eynert
Electrolytic or neurotoxic lesions o f  the nBM in the rat bring about the 
degeneration o f  the cholinergic neurons constituting approximately 90% o f its neuronal 
population (W oolf et a l, 1986), which projects to the cortex. Their destruction is followed 
by a large decrease in cortical cholinergic parameters such as ChAT activity, and high
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affinity choline uptake (HACU). However, the cells o f the nBM in the rodent do not form a 
discrete nucleus as they do in primates but instead are spread throughout the ventral 
pallidum. Thus, if sufficient cells are destroyed to have a substantial effect on central 
cholinergic function, large areas o f  the ventral pallidum are also damaged. The behavioural 
effects seen after lesions o f the nBM may therefore reflect collateral pallidal damage 
(Flicker et a l, 1983; Wishaw et a l, 1985) or, depending upon the lesioning technique, 
disruption o f  fibres o f passage. Fine et a l, (1985) have reported that although lesions o f the 
nBM cause both acquisition and retention deficits in passive avoidance learning, only the 
retention deficits are reversed by grafting cholinergic cells onto the neocortex. Thus it is 
possible that the acquisition deficit may be due to non-cholinergic or pallidal factors
Lesions O f The Medial Septal Area
Fimbria transection is the standard technique used to disrupt cholinergic innervation 
to the hippocampus. Lesions result in marked reductions o f several presynaptic cholinergic 
parameters. For example, Araujo et al., (1993) reported reductions in the following areas: 
ChAT activity (50%), [3H]ACh synthesis (59%), and basal and veratridine (1 |iM )-evoked 
[3H]ACh release (by 44 and 57%, respectively). It is worth bearing in mind that a similar 
problem to that seen with nBM lesions occurs with attempts to remove the cholinergic 
innervation o f the hippocampus. If  all cholinergic afferents are interrupted by lesioning the 
fimbria-fornix, other hippocampal fibres are also destroyed. Conversely, if smaller medial 
septal lesions are made, only part o f the cholinergic innervation is disrupted. Although the 
effects o f  these various lesions are well characterised, the specific role o f  the cholinergic 
innervation o f the hippocampus remains controversial (Gray, 1982), although it is clearly 
necessary for performance upon complex tasks (Dunnett et a l, 1982; Gage et a l, 1984).
I.4 .I.3 . Comparison O f Lesions And Pharmacological Intervention With 
Respect To The Effects O f Cholinergic Drugs
There have been few direct comparisons o f  the effects o f  cholinergic drugs and 
lesions o f cholinergic cells. Atropine and nBM lesions have similar effects upon 
performance in the Morris water maze (Wishaw et a l, 1985), while medial septal and nBM 
lesions have effects upon delayed matching to  position which, when combined are similar to 
the effects o f scopolamine (Dunnett, 1985).
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In summary, the investigation o f  the behavioural effects o f  lesions o f cholinergic 
cells is still in its infancy. While lesions o f cholinergic nuclei produce performance deficits 
on behavioural tasks, it is not obvious how these deficits relate to the deficits caused by 
anticholinergic drugs, or how they relate to the symptoms o f Alzheimer's disease.
The Effects O f Cholinergic Dysfunction In Normal Subjects, Compared W ith The 
Symptoms O f Alzheimer’s Disease
Attempts to draw parallels between the behavioural signs o f AD and the effects of 
manipulating cholinergic function have to surmount several obstacles. These fall into three 
groups; the difficulties already described in defining the effects o f depressing cholinergic 
function in normals, the problems o f defining the symptoms o f AD, and the problems of 
comparing the two.
It is not easy to accurately define the symptoms o f  AD. Clinically, the disease tends 
to be diagnosed by exclusion. There is no definite diagnostic pre-mortem test other than 
cerebral biopsy. Thus any randomly selected group o f AD patient is liable to be extremely 
heterogeneous and any homogeneous group is liable to be unrepresentative o f the general 
run o f patients.
Since there is no agreement upon how the effects o f  anticholinergic drugs or lesions 
o f cholinergic cells should be interpreted, comparisons with AD patients on the basis of 
concepts such as ‘memory’ or ‘attention’ are not currently possible at anything other than 
the most superficial level. The more limited comparison o f  whether depressing cholinergic 
function causes performance deficits similar t6  AD is all that can presently be achieved.
1.5._ T E C H N I Q U E S m U S E D  m F O R  . S T U D Y I N G  _ T R A N S M I T T E R  
R E L E A S E  A N D J T S  M O D U L A T I O N
1.5.1. I N  VITRO  METHODS: SYNAPTOSOMES AND
SUPERFUSION
1.5.1.1. Synaptosomes
Synaptosomes are isolated nerve terminals prepared by controlled homogenisation 
o f brain (McMahon & Nicholls, 1991). The axon is torn off the terminal, which reseals and
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remains bioenergetically competent for several hours, showing high respiratory control 
(Kauppinen & Nicholls, 1986), maintaining a plasma membrane potential o f -60 to -80 mV 
in low K" medium (Scott & Nicholls, 1980) and a cytoplasmic free Ca2f concentration o f 
0.1-0.2 pM  (Ashley, 1986; Tibbs et al., 1989; McMahon & Nicholls, 1991a) and releasing 
neurotransmitter by mechanisms which respond to the same inhibitors and modulators as 
more complex preparations.
Synaptosomes are capable o f  releasing neurotransmitter in a Ca2*-dependent 
manner when depolarised with high K+ concentrations (Briggs & Cooper, 1982; Rapier et 
al., 1989) or electrically (DeBelleroche & Bradford, 1973) and contain all the machinery 
for transducing a depolarising stimulus into an influx o f Ca2+, inducing synaptic vesicle 
exocytosis (M cM ahon & Nicholls, 1991b). De novo transmitter synthesis (Birch & Fillenz, 
1985), and the ability to accumulate exogenous transmitter (Bogdanski et al., 1968), are 
also functions conserved within these structures. The synaptosome can, thus, be used to 
study the integration o f metabolism, mitochondrial and plasma membrane ion circuits and 
the machinery for the uptake, storage and exocytosis o f neurotransmitters.
Although brain slices, like synaptosomes are also capable o f  respiration for several 
hours after preparation, their use in studies on presynaptic function is complicated by their 
histological integrity. Drug diffusion through slices can be a problem, and any presynaptic 
effect may be indirect, mediated via interconnections with other neuronal or non-neuronal 
elements. Synaptosomes permit direct access o f drug, and though devoid o f  axons and cell 
bodies which may normally influence neuronal activity, they provide a simple system for 
examining nerve terminal function in a precisely controlled manner, an advantage they hold 
over in vivo techniques.
I.5 .I.2 . Superfusion
Over the last four decades, a variety o f techniques has been employed to study 
neurotransmitter release within the CNS, including superfusion o f  synaptosomes. A number 
o f apparatuses for superfusion o f synaptosomes have been reported in the literature that 
display various capabilities and limitations (Raiteri et a l, 1974; M ulder et al., 1975; 
Redbum et al., 1975; Collard et al., 1981; Klaff et al., 1982; Drapeau & Blaustein, 1983; 
Minnema & Michaelson, 1985; Pearce et al., 1991). The continuous superfusion of 
synaptosomes allows for direct examination o f  neurotransmitter release from nerve endings 
and varicosities and has a number o f  advantages over static incubation systems. This
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approach can obviate problems associated with accumulation o f neuroactive species and 
provide superior temporal resolution o f transmitter release. Preparations derived from brain 
tissue, such as synaptosomes are replete with neuroactive species, many o f  which 
accumulate in the incubation medium, particularly under depolarising conditions. 
Accumulation o f endogenous neuroactive species in incubations with brain synaptosomes is 
sufficient to alter transmitter release and presynaptic receptor function (Nordstrom & 
Bartfai, 1980; Pearce et al., 1986; Pedata et al., 1986). The facilitatory effect on 
transmitter release produced by addition o f receptor antagonists to static incubations o f 
brain synaptosomes also provides evidence o f  the significant concentrations o f endogenous 
receptor agonists achieved in these incubations (Nordstrom & Bartfai, 1980). In an 
analogous manner, accumulation in the ‘biophase’ about nerve terminals in intact tissue 
preparations, such as brain slices, has been used to demonstrate autoreceptor by numerous 
laboratories (Suzuki et al., 1988, Weiler, 1989). Clearly, accumulation o f endogenous 
neuroactive species can represent a significant confounding problem to investigators who 
wish to study the actions and underlying mechanisms o f  experimental manipulations and 
agents that modulate neurotransmitter release.
The principle o f superfusion is that synaptosomes, brain slices or minces, often 
preloaded with radiolabelled transmitter or precursor, are continuously superfused with a 
balanced salt solution, containing glucose to maintain metabolic activity. The effect o f 
drugs introduced into the system, can be monitored by the release o f labelled transmitter. 
The justification o f using slices or synaptosomes is that in both systems the extracellular 
environment o f the tissue can be altered, an ability which is hampered in in vivo studies o f 
the brain, where the blood-brain barrier severely limits the ability to  alter ion and metabolite 
concentrations surrounding brain cells, and makes quantifying any changes very difficult. 
Superfusion o f synaptosomes, while being less representative o f the in vivo situation in the 
CNS than slices, allows the study o f presynaptic effects without the complicating range of 
postsynaptic influences present in slices. Although superfusion systems originally were 
employed to obviate the confounding effects o f transmitter reuptake, the importance o f  this 
approach to  minimising the effects o f endogenous species by prompt removal o f the 
superfiisate has been recognised (Raiteri, etal., 1974).
1.5.2. IN  VIVO METHODS: MICRODIALYSIS
The very qualities o f synaptosomal superfusion that make the technique useful for 
studying neuronal receptors in terms o f being a relatively simple system, divorce it from the
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in vivo situation and it is often pertinent to make a comparison between the two. There is 
an increasing need for more accurate and detailed information concerning the complex 
biochemical reactions in the normal and abnormal brain. The ideal method must provide 
instantaneous and reliable concentration measurements o f a wide variety o f interstitial 
substances in discrete brain areas. Furthermore, normal tissue structure and metabolism 
should be left unchanged following a particular experimental procedure. None of the 
available techniques fulfils these requirements. Chapter 6  details the various in vivo 
methods for studying transmitter release and its modulation, with a particular emphasis on 
in vivo microdialysis.
1 .6 . _ S U B S T A N C E _ P  A N D A L Z H E J M E R ' S  D I S E A S E
Although the most consistent peptidergic abnormality which has been described in 
Alzheimer's disease is a loss o f somatostatin in the cerebral cortex o f  Alzheimer patients, 
reductions in a number o f other common neuropeptides have also been reported (Beal & 
Mazurek, 1987). Reductions o f substance P (SP) in AD brain have been reported at 20- 
30%, in areas such as the hippocampus, cortex, and temporal lobe and indeed SP has been 
directly localised to approximately 5% o f  the neuritic plaques themselves (Armstrong & 
Terry, 1985).
The primary structure o f the eleven amino acid peptide, SP was determined 1971 
(Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2), and this knowledge facilitated 
studies on its putative role as a neurotransmitter or neuromodulator (Nicoll et a l, 1980). 
Within the CNS, SP has been localised in various nerve fibres (Hokfelt et a l, 1980) and in 
cellular organelles from nerve endings (Schenker et a l, 1976). SP is released from nerve 
tissue within the CNS by depolarising stimuli (Schenker et a l, 1976) and can alter the 
activity o f  certain neurons when applied in their vicinity (reviewed in Nicoll et a l, 1980).
SP belongs to a family o f structurally related peptides, the tachykinins. The peptides 
in this family exhibit biological activities similar to those o f SP and share a common 
COOH-terminal sequence, Phe-X-Gly-Leu-M et-NH2, the COOH terminal residue o f  which 
is amidated, The NH 2-terminal sequence is unique for each peptide and accounts for its 
specific action.
One o f  the hallmarks o f Alzheimer pathology is the deposition of P-amyloid peptide 
in the neuritic plaques. Exposure o f  primary hippocampal neurons to p-amyloid causes
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neuronal degeneration, giving rise to the hypothesis that P-amyloid may cause neuronal 
degeneration when it accumulates abnormally in AD (Kowall et a l, 1991). The biological 
effects of p-amyloid are mediated by an internal peptide sequence (amino acids 25 to 35) 
that is homologous to the tachykinin family (Yankner et al., 1990), and SP was found to 
inhibit the effects of P-amyloid on cultured hippocampal neurons in a dose dependent 
manner, when coinjected intracerebrally, and also administered systemically (IP injection), 
(Kowall et al., 1991). These observations may form a basis for neuropeptide therapy in 
Alzheimer's disease, with the ongoing development o f non-peptide tachykinin ligands 
(McLean et al., 1993).
1.6.1. SUBSTANCE P AND nAChRs
In addition to its direct participation in Alzheimer's disease, SP is o f interest in this 
study since it has been shown to colocalise with ACh in the neocortex (Vincent et al., 
1983), modulate nAChR-mediated transmitter release, bind to the nAChR directly, and 
facilitate nAChR desensitisation, (see below).
1.6.1.1. Effects On Transmitter Release
Both inhibitory and facilitatory actions of SP on nicotinic responses have been 
reported (Livett & Zhou, 1991). First, inhibitory actions: Belcher & Ryall (1977), and 
Krnjevic and Lekic (1977), showed that in cat spinal cord that electrophoretically 
administered SP inhibits the ACh-evoked nicotinic activation o f  Renshaw cells, but has no 
effect on the excitation caused by either muscarinic agonists or excitatory amino acids. At 
the frog neuromuscular junction, Steinacker-,(1977) showed that SP (ICTM o^M ) exhibits 
an initial phase o f  synaptic inhibition and then a later phase (60-180 min) o f  synaptic 
facilitation. At the M authner fiber-giant fibre synapse in the hatchetfish, SP shows 
predominantly presynaptic and postsynaptic inhibitory action (Steinacker et al., 1976) and, 
in the rat and chick sympathetic ganglia, SP inhibits the nicotinic depolarisation of 
ganglionic neurons (Akasu et al., 1983) In isolated bovine adrenal chromaffin cells, SP 
inhibits the ACh- and nicotine-evoked release o f catecholamines, but not that evoked by 
K+, veratridine or muscarinic agonists (Livett et al., 1979; Role et a l, 1981; Higgins & 
Berg, 1988).
In addition, SP enhances ACh-induced desensitisation and reduces the number o f 
bursts evoked by ACh (Clapham & Neher, 1984). In PC 12 cells, SP inhibits the increase in
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nicotinic agonist-induced 23Na* influx and enhances the desensitisation o f  this nicotinic 
response (Simasko et a l, 1986; 1987).
Facilitatory actions o f SP on the nicotinic response: in addition to the 
aforementioned inhibitory actions, SP shows facilitatory actions in a number o f neural and 
endocrine systems. In isolated bovine chromaffin cells, SP (10*5 M), present together with 
high concentrations o f ACh or nicotine, completely protects against nicotinic 
desensitisation (Livett & Boksa, 1984; Boksa & Livett, 1984). SP also protects against 
desensitisation o f  45Ca2+ uptake into these cells (Boksa, 1985). The ability o f SP (10 ' 6 M) 
to exhibit inhibitory or facilitatory effects on catecholamine secretion depends on the 
concentration o f nicotinic agonist used (Khalil et a l, 1988).
1.6.2.2. Effects On N icotinic A gonist B inding To nA C hR s
Min & Weiland (1993), studied the effects o f SP on the binding o f  agonists to the 
nAChR o f torpedo electroplaque. They reported that the peptide had no effect on 125I-a- 
Bgt and did not bind to the high affinity local anaesthetic site, but increased the apparent 
affinity o f the cholinergic agonists carbamylcholine and acetylcholine at equilibrium. The 
effect o f SP on the equilibrium binding o f  [3H] ACh was examined directly, and the peptide 
appeared to increase the affinity o f the binding o f  the second molecule o f  agonist, with no 
effect on the binding o f the first molecule o f ACh. This result indicates that SP can affect 
the co-operative interactions between agonist binding sites. In the same study, SP (Min & 
Weiland, 1993) also appeared to increase the rate o f carbamylcholine-induced 
desensitisation. In a parallel study, Min et a l, (1994) examined the binding o f  tritiated SP 
to nAChR-enriched Torpedo electroplaque membranes. The authors found that SP 
interacted directly with two populations o f  binding sites on the nAChR. The lower affinity 
sites (Kd = 25 pM ) would appear to reflect interactions either with the receptor, perhaps at 
the protein-lipid interface, as proposed for the low affinity sites o f  local-anaesthetic-type 
blockers (Heidmann et a l, 1983), or with components o f the membrane. The high affinity 
component o f binding (Kd = 0.55 pM), which is seen only in the presence o f  agonist and o f 
which there is only one site for each receptor, is likely to represents the functionally 
relevant interaction with the receptor. The binding affinity o f the agonist-induced high 
affinity binding site was significantly different from the SP binding to G  protein-coupled 
receptors (Min et a l, 1994). Interestingly, SP specifically labelled the y and 6  subunits, 
which, although consistent with a binding site within the ion channel as proposed by Min et
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nr/., (1993) means that the relevance o f this SP binding site to neuronal nAChRs which lack 
the y or 6  subunits is questionable.
In summary, there is a large body o f evidence suggesting that SP is colocalised with 
ACh, is involved in the pathology o f  Alzheimer's disease, and is able to modulate nAChR- 
mediated transmitter release. The possible role o f substance P in the modulation o f ACh 
release by presynaptic hippocampal nAChRs merits examination.
1. 7._ S U M M A R Y  TO C H A P T E R . 1
The characteristic pathology o f Alzheimer's disease emphasises the importance o f 
the hippocampal cholinergic system in higher cognitive function. Anatomically, this system 
is slowly being understood and the various sub-cortical brain regions which innervate both 
the hippocampus and the neocortex are increasingly well documented. On a 
pharmacological level however, the role o f the hippocampal muscarinic and nicotinic 
acetylcholine receptors, is far from clear and complicated by the still burgeoning 
heterogeneity o f these receptor subtypes. Both nAChRs and mAChRs exist presynaptically, 
and have been shown to modulate hippocampal ACh release both in vitro and in vivo. The 
presynaptic nAChRs which facilitate ACh release, represent an opportunity for therapy o f 
early stage dementia, while the cholinergic anatomy is sufficiently intact to respond to 
modulation.
The identity o f the presynaptic nAChR subtype(s) is unknown, and the paucity o f 
subtype-specific nicotinic ligands precludes any direct identification o f  the subtype(s) 
present in the rat hippocampus, but a more complete pharmacological profile is essential 
before any rational cholinergic drug therapy can be contemplated. An in vitro 
pharmacological profile o f  the nAChRs should address issues such as agonist and 
antagonist specificity, propensity o f the receptor to desensitise, and modulation o f  this 
desensitisation phenomenon by substance P. In vivo, the effect o f nicotine on ACh release 
in the rat hippocampus is poorly understood, and a microdialysis study addressing this 
problem would complement the in vitro studies.
1.8.mA I M S  OF THE P R O J E C T
The importance o f cortical and hippocampal presynaptic nAChRs as therapeutic 
targets in dementing diseases has been outlined. In the past few years, the advances in
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recombinant DNA technology have led to the identification o f an increasing number of 
nAChR subunits which in turn provides for a multitude o f potential combinations, 
suggesting that many functional subtypes o f  neuronal nAChR are possible (section
1.3.2.1.) Though information derived from heterologous expression systems combined 
with in situ hybridisation studies has provided in vitro model systems in which the 
pharmacology o f  compounds acting at putative subtypes o f  neuronal nAChRs can be 
evaluated using electrophysiological and biochemical techniques (section I.3.2.3.), at the 
present time the subtype identity o f native nAChRs is largely unknown. M uch in the way of 
basic research is needed before the development o f a program o f rational drug design can 
be contemplated. As such, the main aim o f this project was to probe the pharmacology of 
the presynaptic hippocampal nAChRs: it was hoped that building up a pharmacological 
profile with a number o f the available nicotinic agonists and antagonists, would yield some 
clues as to the physiological/pharmacological roles o f these nAChRs.
On a practical level, the goals o f  the present work were:
(a) To build upon the superfusion work o f  Thorne (1990), and establish a superfusion 
protocol using the automated Brandell SP-06 and SP-12 machines, suitable for the study of 
[3H]ACh release from hippocampal synaptosomes.
(b) To build a pharmacologically profile o f  the presynaptic nAChR in the rat hippocampus 
using a variety o f  nicotinic ligands.
(c) To study the effects o f repetitive agonist stimulation, and exposure to  substance P, on 
nAChR desensitisation/inactivation.
(d) To investigate the in vitro binding o f  [3H]nicotine and [3H] substance P to rat 
hippocampal membranes.
(e) To analyse the binding o f [3H]nicotine and ChAT activity o f  rat hippocampal 
preparations from normal and cholinergically lesioned rats.
(f) To assess the ability o f nicotine to evoke ACh release in the hippocampus o f freely 
moving rats using the technique of in vivo microdialysis.
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C H A P T E R  2 .  H A T E R I A L S  M b  H E T H O b S
M A T E R I A L S
CHEM ICALS
[Methyl-'H]choline chloride ([3H]Ch; 80 Ci/mmole; 1 mCi/ml in 95% ethanol) and 
[Methyl -3H]acetyl Coenzvme A ([3H]AcCoA; 3 Ci/mmole) were obtained from Amersham 
International (Amersham, Bucks., UK). The [3H]choline was stored at -20°C. The 
[3H]AcCoA was diluted with Triton X-100 buffer to give a final concentration of 2 mM 
(specific activity 10 pCi/pmole) and stored at -20°C in 100 pi aliquots.
(-)N-methyl-[3H]nicotine (85.1 Ci/mmole; 1 mCi/ml), and [3H][Sar9, 
M et(02) 1 ^ substance P ([3H]SP; 32.5 Ci/mmole; 1 mCi/ml) were obtained from NEN. 
[3H]nicotine was stored at -20°C in a 10-fold concentration o f mercaptoethanoic acid to 
minimise the oxidative degradation of nicotine. [3H]SP was stored at -20°C.
(-)Nicotine hydrogen (+)tartrate was purchased from BDH chemicals (Poole, 
Dorset, UK). Physostigmine was obtained from Sigma Chemical Company Ltd. (Poole, 
Dorset, UK). DH(3E was a gift from Merck, Sharp & Dohme Research Laboratories 
(Harlow, Essex, UK). ABT-418 was a gift from Abbott Laboratories, (Abbott Park, 
Illinois, USA). MLA was a gift from Prof. M. Benn, Dept. O f Chemistry, University of 
Calgary, (Canada). (+)Anatoxin-a was donated by Dr. E X. Albuquerque, Department of 
Pharmacology and Experimental Therapeutics, University of Maryland (Baltimore, USA).
Percoll was obtained from Pharmacia (Milton Keynes, UK).
Optiphase 'Safe' scintillant was used for determination o f radioactivity in a Packard 
1600 TR liquid scintillation counter, giving a counting efficiency o f 50-55%.
All other reagents were obtained from Sigma Chemical Company Ltd (Poole, 
Dorset, UK), Aldrich (Gillingham, Dorset, UK), or BDH (Poole, Dorset, UK) and were of 
an analytical (AR) grade.
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BUFFERS
ARTIFICIAL CEREBROSPINAL FLUID (aCSF)
Composition in mM: 125 NaCl; 2.5 KC1; 1.18 MgCl2; 1.26 CaCl2. Containing 
neostigmine (2 |.iM, Sigma), and stored at 4°C.
KREB’S BICARBONATE
Kreb's bicarbonate buffer used throughout the experimental procedures was freshly 
prepared and had a final composition (mM): 118 NaCl, 2.35 KCI, 1.2 M gS0 4 .7 H20 , 1 .2  
KH2P 0 4, 25 NaHC0 3 , 2.4 CaCl2 .2H20  and 1 0  D-glucose, equilibrated to pH 7.4 using 
95% 0 2/5% C 0 2 for 2  hours at room temperature.
LOWRY SOLUTIONS
2 % (w/v) N a2C 0 3 in NaOH.
1% (w/v) CUSO4.
Folin’s reagent diluted 1:1 with DDW
PBS
K2H P 0 4 8  mM; KH2P 0 4 2  mM; NaCl 7.5 mM. Fresh solution made up before each 
assay in double distilled water (DDW), from stocks stored at 4°C, pH 7.5 with NaOH.
TRIS
Tris 50 mM. Stored in the dark at 4°C and pH to 7.4 with dilute HC1 before use. 
TRIS-Mg2+
Tris 50 mM; MgCl2 2 mM. Stored in the dark at 4°C and pH to 7.4 with dilute HC1 
before use.
TRITON X-100
50 mM phosphate (K2HP0 4 ; Na2H P0 4 ), NaCl 200 mM; ED TA  1 mM; 0.5% Triton 
X -1 0 0 . Stored in the dark at 4°C.
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M E T H O D S
2 . 1 .. THE  S U P E R F U S I O N  SYSTEM
2.1.1. PERCOLL DISCONTINUOUS DENSITY GRADIENTS.
Percoll filtered through a Millipore AP-15 pre-filter to remove aggregates, was 
used to form solutions o f  23% (v/v), 15%, 10% and 3% Percoll in 0.32 M sucrose. After 
adjustment o f the pH to 7.4 with dilute NaOH/HCl, four step gradients were formed by the 
sequential layering o f 2 ml o f  each Percoll solution into Sorvall 15 ml polycarbonate tubes. 
A peristaltic pump with a fine bore needle (25G), set to a slow running speed o f 1 ml/min in 
order to minimise disturbance at the density interfaces, was used for layering. The gradients
were stored overnight at 4°C before use, (Thorne et a l, 1991).
2.1.2. BRAIN TISSUES
Tissues were derived from adult male Sprague-Dawley rats (250-350 g, Bath 
University Animal House breeding colony). The rats were killed by cervical dislocation, 
decapitated, the brains removed rapidly and placed ventral surface down on sucrose-soaked 
filter paper over ice. The brain stem and cerebellum were removed leaving the forebrain. 
An incision was made along the length o f the longitudinal fissure, separating the cerebral 
hemispheres, but leaving the diencephalon intact. The neocortex (hippocampus still 
attached) was peeled back from the diencephalon, and the latter was removed en masse. 
Typical tissue weights were: 90-100 mg / hippocampus.
2.1.3. SYNAPTOSOME PREPARATION
The subcellular fractionation o f hippocampal SI supernatant on discontinuous 
Percoll gradients was a described by Dunkley et al. (1987; 1988).
Excised tissue was homogenised (10% w/v in 0.32 M  sucrose, pH 7.4) in a pre­
cooled glass-Teflon homogeniser o f 0.31 mm clearance, by 2 x 6  strokes at 200 rpm. The 
supernatant (S I) formed from a 1 0  min 1 0 0 0  g spin, was diluted with sucrose and 2  ml 
aliquots were layered onto the gradients using a large bore needle (19G) This and all
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subsequent centrifugation steps were carried out in the Sorvall RC 5B Superspeed 
centrifuge (SM  24 rotor). One gradient was used per hippocampus.
After layering, the Percoll gradients were centrifuged for exactly 5 min (excluding 
acceleration and deceleration times) at 32,000 g. The synaptosome fraction - F4 - at the 
interface o f the 23% and 15% Percoll/sucrose layers was removed with a Pasteur pipette 
and washed in tw o resuspension/centrifugation steps prior to the final resuspension. In each 
step the F4 fractions from 2 gradients were pooled, resuspended in 10 ml o f  buffer and 
centrifuged for 15 min at 15,000 g. The buffer used throughout was K reb’s bicarbonate. 
After the final wash the pellet was gently resuspended in buffer to a protein concentration 
o f approximately 1 mg/ml (for hippocampi from 4 rats, this was approximately 2100 pi).
All centrifugation steps were carried out at 4°C and tissue preparations were held 
on ice until use, to  preserve synaptosomal viability.
2.1.4. PROTEIN DETERMINATION
Protein concentrations were determined using the method o f  Lowry et a l., (1951). 
Standard curves were constructed using a frozen stock o f 1 mg/ml bovine serum albumin 
(BSA) over the concentration range 0-350 pg/ml.
Duplicate samples (0.2 ml) o f BSA standards or F4 synaptosomes, diluted 1 in 5, 1 
in 1 0  with distilled water were incubated with 1 ml alkaline cupric tartrate (freshly prepared 
by mixing 1 volume 1% (w/v) CuS0 4 .5 H20 , 1 volume 2% (w/v) sodium tartrate and 1 0 0  
volumes 2 % (w/v) Na2CC>3 in 0 .1M NaOH), at room temperature for 1 0  min. After 
incubation, Folin-Ciocalteau’s reagent (0 .1  ml; diluted 1:1 with distilled water) was added 
to each sample and the colour allowed to develop at room temperature for 40 min. 
Absorbance was read at 690 nm in a Titertek Multiscan Spectrophotometer, using distilled 
water as a blank.
2.1.5. CHOLINE UPTAKE
The F4 synaptosome preparation (1900 pi) was incubated at 37°C for 10 min 
before the addition o f [3H]Ch (lOOpl: 16 pM, 0.5 mCi/ml: prepared by 1:1 dilution o f stock 
[3H]Ch with 20 pM  choline chloride; final assay concentration 0.8 pM). After 30 min at
37°C the mixture was centrifuged in a bench microfuge (1  min, 3000 g). The supernatant
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was discarded, removing excess [3H]Ch that had not been taken up by the synaptosomes. 
The pellet was gently resuspended in K reb’s buffer to 2 ml; triplicate samples (10 pi) were 
filtered on Whatmann GFC filters pre-moistened with Kreb’s buffer in a Millipore manifold 
filtration unit to determine [3H]Ch uptake. Radioactivity was measured in 3 ml o f 
scintillant.
Samples ( 1 2  x 150 pi) o f the [3H]Ch-loaded F4 fraction were taken for superfusion.
2.1.6. THE SUPERFUSION PROTOCOL
2.1.6.1. A gonist-Evoked Release
The effects o f nicotinic agonists on ACh release were studied using the Brandell 
SF-06 superfusion system.
The [3H]Ch-loaded synaptosomes (150 pi) were loaded into each o f the perfusion 
chambers. In each case the synaptosome sample was placed on a Whatmann GFF filter, 
pre-moistened with Kreb’s buffer, in the superfusion chamber. Another Whatmann GFF 
filter was positioned on top o f  the synaptosomes before connecting the apparatus. Kreb’s 
buffer (maintained at 37°C in a water bath) was pumped through the chamber at a flow rate 
o f  250 pl/min. The superfiisate (3 min fractions, 750 pi) was collected into minivials and 3 
ml o f scintillant added to each before the radioactivity was measured.
After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse 
o f  agonist (made up in Kreb’s buffer); tw a  such stimulations were routinely given before a 
third stimulation with 2 0  mM KC1 (KC1 isotonically replacing NaCl) was administered. The 
agonist pulse was separated from the bulk flow o f the Kreb’s buffer by 10 s air bubble 
(Rapier et a l  1988). The responses to successive stimulations were designated SI, S2 and 
S3 and evoked release was quantified by summing the radioactivity in fractions contributing 
to  a peak o f  release, after subtraction o f  the baseline (see 3.5. DATA ANALYSIS). This 
was converted to pmol [3H]ACh released per mg protein, by reference to the specific 
activity o f  the [3H]Ch used to load the synaptosomes and the amount o f  tissue loaded into 




The effect o f antagonists was examined by introducing the drug into the perfusion 
buffer three fractions before the agonist pulse and maintaining it throughout the remainder 
o f the experiment. All subsequent agonist or KC1 pulses were delivered in Kreb's buffer 
containing the antagonist.
2.2.  R A D J O L I G A N D  B IN D IN G  A S S A Y S
In all binding assays, the SI fraction (see section 2.1.3.) was used as the source of 
rat brain membranes. This was either prepared on the day o f the assay, or stored frozen as 
aliquots at -20°C, at a protein concentration o f 1 mg/ml.
2.2.1. [3H]NICOTINE BINDING
2.2.1.1. General Binding
The equilibrium binding procedure was based on the rapid filtration assay of 
Romano & Goldstein (1980). Assays were conducted in triplicate in conical bottomed 
polystyrene tubes to facilitate the small incubation volume o f 270 pi. For routine binding, 
the reaction mixture consisted o f 250 pi membrane suspension and lOpl [3H](-)-nicotine 
(final concentration 20 nM). Non-specific binding was defined by incorporation o f 10 pi o f 
a solution o f  (-)-nicotine bitartrate (final concentration 1 0  pM). Specific binding was 
calculated as total binding minus non-specific binding. The reaction was initiated by adding 
the suspension o f  membranes with vortex mixing and each sample was incubated at room 
temperature for 30 minutes, then at 4°C for 1 hour. The reaction was terminated by adding 
4 ml o f ice-cold buffer and quickly filtering at 4°C under vacuum through Whatmann GF/C 
glass microfibre filters, followed by 2 x 4 ml washes o f buffer. In order to retard the non­
specific binding o f  nicotine, the filters were preincubated for at least 1 hour in 0.3% (w/v) 
polyethylenimine at 4°C. After filtration, the filters were placed in scintillation vials 
containing 5 ml Packard Optiphase Safe scintillation fluid, allowed to come to room 
temperature and then counted in a Packard 1600 liquid scintillation counter. Specific 
binding was calculated as the difference between total and non-specific binding.
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2.3.I.2. Competition Binding
For competition binding assays was used at a final assay concentration o f 10 nM. 
Total incubation volume was 270 pi: 5 pi o f [3H](-)-nicotine was added to 5 pi o f
competing compound (10"10-10"3M) and the reaction initiated by the addition o f 250 pi o f 
membrane suspension. For each competing compound, 3-6 experiments were performed on 
different membrane preparations. For competition assays involving substance P, a cocktail 
o f protease inhibitors (40 pg/ml bacitracin, 2 pg/ml chymostatin and 4 pg/ml leupeptin) 
were included in the assay buffer to prevent proteolysis o f the peptide.
2.2.3. [3H]SP BINDING
2.3.3.I. General Binding
The protocol for neurokinin receptor binding assays was based on the procedure o f 
Quirion & Dam (1993). Briefly the protocol is as follows: 200pl o f  the hippocampal SI 
homogenate was incubated for 90 min at 25°C in 400 pi o f a buffer containing 50 mM Tris- 
HC1 (pH 7.4 at 4°C), 3 mM MnCh, 0.02% BSA to minimise losses o f ligand to 
nonreceptor surfaces, 40 pg/ml bacitracin (Sigma, St. Louis, M O), 2 pg/ml chymostatin 
(Sigma) and 4 pg/ml leupeptin (Sigma) to ensure the stability o f  the radiolabelled ligand 
during the incubation period, and various concentrations o f [3H ][Sar9,M et(0 2 ) n ]substance 
P ([3H]SP) for saturation (0.01 to 50 nM). Nonspecific binding was determined in the 
presence o f 5 pM  unlabelled SP. Under such assay conditions, the radiolabelled probe has 
been reported to be highly stable during incubation (Quirion & Dam, 1993).
Incubations were terminated by rapid filtration through Whatmann GF/C filters 
presoaked in 0.1 % polyethylenimine (PEI) for at least 3 hours prior to filtration. The use 
o f PEI-treated GF/C filters minimises binding o f ligand to filters. Filters were washed 3 
times with 3-4 ml o f cold 50 mM Tris-HCl buffer (pH 7.4). After filtration, the filters were 
placed in scintillation vials containing 5 ml Packard Optiphase Safe scintillation fluid, 
allowed to  come to room temperature and then counted in a Packard 1600 liquid 
scintillation counter. According to Quirion & Dam, (1993), under such assay conditions, 
[3H]SP apparently binds to a single class o f high affinity (Kd 1.4 ± 0.5 nM), low capacity 
(Bmax 160 ± 3.0 fmol/mg protein) sites in rat brain homogenates. The same authors report 
that at concentrations approximating Kd values, specific binding reached rapid equilibrium 
(< 30 min) at 25°C and represented between 70 and 75% o f  total binding. The ligand,
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[3H]SP, specifically and selectively labels the N K -l/SP  receptor subtype since only NK -1  
competitors such as substance P and unlabelled [Sar9,M et(0 2 ) n ]SP behave as potent 
competitors (Kj in low nanomolar range) in this assay whereas selective NK-2 
([NleIO]NKA4_io) and NK-3 (senktide) analogues are virtually inactive (Dam et al., 1990).
2.3.3.2. C om petition  B inding
Competition assays were essentially as described in section 2 .3 .2 .1 ., with the 
radioligand[3H]SP used at a final assay concentration o f  2  nM, and incubated with nicotine 
concentrations o f  0.1 nm -1 pM.
2 . 3._ C H O L I N E  A C E T Y L T R A N S F E R A S E
The protocol used to determine ChAT activity was based on the liquid cation- 
exchange method described by Fonnum (1975). The washed SI fractions were resuspended 
in Triton X-100 buffer to give a protein concentration o f 1 mg/ml. Samples (10 pi) were 
incubated for 1 0  min at 37°C with 2 0  pi o f assay buffer in the presence and absence of 
formic acid. The assay buffer, freshly prepared, comprised 12.5 mM choline chloride, 0.1 
mM neostigmine bromide, 0.2 mM [3H]acetyl-coenzyme A (specific activity 10 
mCi/mmol), and 5 mg o f bovine serum albumin/ml in phosphate buffer. After 10 min, the 
reaction was stopped by adding 20 pi o f formic acid. [3H]ACh was extracted in 0.3 ml of 
heptan-2-one containing tetraphenylboron (15 mg/ml). A sample (150 pi) o f the upper, 
organic phase was counted for radioactivity in 5 ml o f Optiphase-Safe (LKB) in a Packard 
scintillation counter. The nonspecific acetyltransferase activity was determined in the 
presence o f bromoacetylcholine (0.1 mM),*a ChAT inhibitor.
2.4._ M J C R O D I A L Y S I S
2.4.1. SURGERY
All animal surgery was carried out by Dr Pete Hutson or staff at the animal surgery 
unit at M erck Sharp & Dohme Research Laboratories, Harlow, Essex. Animals were 
maintained in a vivarium on a 12 h light/12 h dark cycle (lights on at 0700) and were 
provided with free access to food and water. Following surgery, animals were transferred 
to post-operative care for 2 hours and closely observed. Following recovery, animals were
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transferred to clear perspex microdialysis chambers which were sufficiently large to allow 
the rats to move around freely.
Male Sprague-Dawley rats (250-300 g) were anaesthetised with pentobarbitone (60 
mg/kg, i.p., Sagatal, RMB) and implanted with a dialysis probe in the hippocampus (A -4.8 
mm from bregma; L 4.8 mm; V 8.0 mm below dura) coordinates according to Paxinos and 
Watson. The probe was essentially as described by Hutson et al., (1985) except that a 
single piece o f quartz tubing (VS 150/40, SGE) was used instead o f  two glass capillaries 
and a membrane length o f 5 mm was used.
2.4.2. MICRODIALYSIS ASSAY
Nicotine solutions were prepared by dissolving the tartrate salt in saline (pH always 
above 5.0), which was administered as subcutaneous injection in the flank; mecamylamine 
solutions were prepared from the hydrochloride and delivered intraperitoneally (i.p.). 
Microdialysis was performed in conscious, freely moving animals over a period o f 6 h. 
Approximately 18 h following recovery from surgery the probe was perfused with aCSF at 
a rate o f 2  pl/min. Two hours after the start o f the experiment, (establishment o f the 
baseline) drug samples were administered and microdialysate samples were collected at 2 0  
min intervals and frozen at -70°C until required for analysis o f  acetylcholine by HPLC with 
a post-column enzyme reactor and electrochemical detection essentially as described by 
Damsma et al., (1988).
2.4.3. HPLC
The system used was a Chromspher 5 |iM  C l 8  reverse phase column ( 1 0 0  x 3 mm) 
as a pre-column to saturate the mobile phase with silica, a Chromspher guard column (10 x 
2.1 mm) and a Chromspher 5 |^M C l 8  reverse phase analytical column (100 x 3 mm) pre- 
loaded with lauryl sulphate (5 mg/ml in mobile phase). The enzyme reactor (10 x 2.1 mm) 
was loaded with 500fil mobile phase containing 80 units acetylcholine esterase (EC 3.1.1.7 
type VI-5 from electric eel, Sigma) and 40 units choline oxidase (EC 1.1.3.17 from 
Alcaligenes, Sigma). The mobile phase consisted o f  0.2M KH2P 0 4 and 0.3 mM EDTA (pH 
8.0 with 5M KOH). This was filtered (0.45(im) and degassed with helium before use at as 
flow rate o f 0 . 6  ml/min without recycling. A BAS LC $B electrochemical detector 
(platinum electrode set at +0.5 V) was used to detect the evolved hydrogen peroxide.
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c h a p t e r  3 . c i i i i r a c t c r i s a t i o n  o r  a  s m p c r p m s i o n  s y s t e m  t o  
S T M b T  A C E T Y L C H O L I N E  R E L E A S E
?: 1-. INTRODUCTION
Thorne (1990) had adapted the earlier work of Rapier et al., (1988), and optimised 
a home-made superfiision system to study nicotine-evoked [3H]ACh release from 
hippocampal synaptosomes. However, the responses to nicotine, though quantifiable, were 
relatively low, and it was hoped that the use o f an automated apparatus would eliminate 
much of the variability between superfusion chambers and maximise the sensitivity of the 
procedure. A Branded Superfusion SP-06 apparatus was adopted for this purpose.
As shown in figure 3.1 A. the SP-06 is a relatively simple design. An electrical 
heating block maintains a water bath at 37°C. In the water bath are located the reservoir 
buffer containing oxygenated Kreb’s buffer and also any agonist/KCl solutions. A perfusion 
pump ensures an constant flow of buffer between the reservoir and the tissue block (shown 
in detail in figure 3 .IB.). The superfiision buffer is driven upwards through the tissue 
chamber and the superfusate collected by the fraction collector below. Pulses of drug 
solution are given by moving the aspirator block from the reservoir buffer into the drug 
solutions.
In order to characterise superfusion achieved using the Branded Superfusion SP-06 
apparatus, initial studies utilised cortical rather than hippocampal synaptosomes. The cortex 
was chosen since it is a brain region with good cholinergic innervation (from the nBM, 
figure 1. 1.) and a comparatively large amount o f tissue is obtained from each rat, so 
consequently fewer rats were sacrificed during the characterisation process.
Many factors needed to be characterised before the Branded SP-06 could be used 
routinely to assay responses of the presynaptic nAChR to agonists. In order to achieve 
maximum sensitivity of the automated apparatus, one o f the primary aims o f moving up 
from the home-made rig of Rapier et al., (1988; 1990) or Thorne et a l, (1990; 1991), it 
was necessary to re-examine Thorne’s standard superfusion protocol in terms of: amount 
of protein loaded per chamber, the flow rate o f Kreb’s buffer, the calcium dependence of 
the responses to agonist and potassium, and the concentration o f potassium used as a 
standard in each superfusion experiment. Each o f these parameters was examined initially
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FIGURE 3.1 A. SCHEMATIC REPRESENTATION OF THE BRAN DELL SP-06 APPARATUS
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FIGURE 3 .IB. DETAILED VIEW OF BRANDELL SUPERFUSION CHAMBER
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with cortical and then with hippocampal synaptosomes. The standard superfusion protocol 




Cortical synaptosomes were isolated on Percoll gradients essentially as described by 
Dunkley et a l, (1988). Excised tissue was homogenised (10% w/v in 0.32 M  sucrose, pH 
7.4) in a pre-cooled glass-Teflon homogeniser o f  0.31 mm clearance, by 2 x 6  strokes at 
2 0 0  rpm. The supernatant (S i)  formed from a 10 min 1000 g spin, was diluted with 0.32 M  
sucrose and 2  ml aliquots were layered onto the gradients using a large bore needle (19 G) 
This and all subsequent centrifugation steps were carried out in the Sorvall RC 5B 
Superspeed centrifuge (SM  24 rotor). Four gradients were used per cortex.
After layering, the Percoll gradients were centrifuged for exactly 5 min (excluding 
acceleration and deceleration times) at 32,000 g. The synaptosome fraction F4, at the 
interface o f the 23% and 15% Percoll/sucrose layers was removed with a Pasteur pipette 
and washed in two resuspension/centrifugation steps prior to  the final resuspension. In each 
step the F4 fractions from 2 gradients were pooled, resuspended in 10 ml o f buffer and 
centrifuged for 15 min at 15,000 g. The buffer used throughout was oxygenated Kreb’s 
bicarbonate. After the final wash the pellet was gently resuspended in buffer with a Pasteur 
pipette, to a protein concentration o f  approximately 1 mg/ml. All centrifugation steps were
carried out at 4°C and tissue preparations were held on ice until use, to preserve 
synaptosomal viability.
3.2.2. CHOLINE UPTAKE
The F4 synaptosome preparation (950 pi) was pre-incubated at 37°C for 1 0  min 
before the addition o f  [3H]choline (100 pi: 16 pM, 0.5 mCi/ml: prepared by 1:1 dilution o f 
stock [3H]Ch with 20 pM  choline chloride; final assay concentration 0.8 pM). After 30 min
at 37°C the mixture was centrifuged in a bench microfuge (1 min, 3000 g). The supernatant 
was discarded, removing excess [3H]Ch that had not been taken up by the synaptosomes. 
The pellet was gently resuspended in K reb’s buffer to 1 ml; triplicate samples (10 pi) were 
filtered on Whatmann GFC filters pre-moistened with Kreb’s buffer in a Millipore manifold
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filtration unit under gentle suction and immediately washed with 5 ml Kreb’s buffer to 
determine [3H]Ch uptake. Radioactivity was measured in 3 ml o f  scintillant.
3.2.3. SUPERFUSION
The superfusion parameters: flow rate; mg protein per chamber, size o f agonist 
pulse and size o f air bubble, were initially derived from M oss & W onnacott (1985), as 
modified by Rapier et al. (1988), and Thom e (1990).
Routinely, all six superfusion chambers o f the SP-06 apparatus were used. In each 
case, the synaptosome sample was placed on a Whatmann GFF filter disc, pre-moistened 
with K reb’s buffer, in the superfusion chamber (see figure 3.1B.), Another pre-moistened 
Whatmann GFF filter disc was positioned above the synaptosomes before the lower and 
upper plugs were gently positioned in the superfusion chamber.
Briefly, 150 pi o f the Percoll F4 fraction (approximately 200 pg protein) were 
loaded per chamber and superfused with Kreb's buffer (oxygenated for 2  hours before the 
start o f the superfiision and adjusted to  pH 7.4 with NaOH if necessary) at a flow rate o f 
250 pl/min. The superfiision chamber was positioned over the fraction collector which was 
set to collect superfiisate fractions at three minute (750 pi) intervals, directly into minivials. 
To each fraction 3 ml o f scintillant was added before the radioactivity was measured.
After a 45 min washout period, the synaptosomes w ere stimulated at 30 min 
intervals with a 20 s (83 pi) pulse o f  agonist (made up in K reb’s buffer) separated from the 
bulk flow o f buffer by 1 0  s air bubbles to ’prevent diffusion o f  the agonist along the length 
o f the superfiision tubing, ensuring that the drug reached the chamber as a discrete pulse. 
One or two such stimulations were routinely administered before a final stimulation with 2 0  
mM KCl was given.
3.2.4. EXPRESSION OF RELEASE DATA
The responses to successive stimulations were designated S I, S2  and S3 and 
evoked release was expressed in three different ways:
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i) Fmol [3H]ACh Released/mg Protein.
In all experiments, the stimulus-evoked release o f  [3H]ACh was determined as the 
amount o f radioactivity above baseline for three fractions after the stimulus . The baseline 
due to basal release, was determined by first-order extrapolation o f  the amount of 
radioactivity released during the three fractions immediately prior to the stimulus (Rowell 
et al., 1987). Radioactivity was converted to femtomoles o f ACh by reference to the 
specific radioactivity o f  [3H]Ch used to load the synaptosomes. This method o f  expressing 
the data is the most widely used in this thesis, and was adopted because it provides an 
comparison o f evoked release in absolute terms, after Rapier et al., (1988). The only 
drawback o f this method is that the stimulus-evoked release was proportional to the uptake 
o f the labelled transmitter. Quite simply, if the uptake o f  transmitter was relatively low then 
the resultant baseline release was also relatively low and stimulus-evoked [3H]ACh release 
was found to be proportionally lowered. This becomes a problem if the results o f two 
experiments with quite different [3H]Ch uptake values are compared. This problem was 
countered by introducing a correction factor into the calculation o f the evoked [3H]ACh 
release, such that all values expressed were corrected for a [3H]Ch uptake value o f 80 
pmol/mg hippocampal protein, or 40 pmol/mg cortical protein, see section 3.3.3.
ii) Percentage Increase Over Baseline.
As above, the rate o f  baseline release during the three fractions immediately prior to 
the stimulus was calculated by a first-order elimination equation (Rowell & Hillebrand, 
1994), the resulting correlation coefficients being greater than 0.95 in all experiments. 
Baseline release was then extrapolated under the stimulus-induced peaks, and the increase 
in [3H]ACh release was determined as the area under the curve expressed as the percentage 
o f baseline, following the methods o f Rowell & Winkler (1984) as modified by Rowell & 
W onnacott (1990). The major merit o f  this method is that no correction factors need to be 
introduced into the calculation since evoked release is being expressed as a proportion o f 
the baseline, so inherent variations o f  this baseline are integral to the calculation.
iii) % Radioactivity Remaining.
Again, the stimulus-evoked release was calculated by extrapolating the baseline 
under the peaks and the increase in [3H]ACh release was determined as the area under the 
curve expressed as the percentage o f the radioactivity present in the tissue at the time o f the
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stimulation (by summing all subsequent fractions including the radioactivity remaining on 
the Whatmann GFF filters at the end o f  the superfusion experiment). This method o f 
expressing release data has been particularly used for short superfusion experiments such as 
the ten minute 86Rb+ flux assays o f  Marks et al., (1993), and Grady et al., (1992), but is 
less useful for a one or two hour superfusion study because the calculation o f radioactivity 
remaining becomes laborious. In this method no correction factors need to be introduced 
since the variability in [3H]Ch uptake is reflected in the amount o f  radioactivity remaining 
on the filters at the end o f the experiment. This method is dependent on a homogenous 
synaptosome preparation since any experimental variation in distribution o f the [3H]Ch- 
loaded synaptosomes into the chambers will be emphasised by differences in the 
radioactivity remaining on the filters: though not widely quoted in this thesis, this method 
of expressing the superfusion release data is included for completeness and to emphasise 
the reproducibility o f the superfiision protocol.
3 .3 . _ R E _ S U L T S A N D  D I S C U S S I O N
3.3.1. CHOLINE UPTAKE
A prerequisite for a sensitive superfiision system is a means o f  radiolabelling the 
neurotransmitter for its identification. Here synaptosomes were loaded with [3H]Ch which 
is rapidly converted to [3H]ACh (W onnacott & Marchbanks, 1976), based on previously 
established conditions (Thome, 1990) see section 3.2.2.
Cortical synaptosomes typically, accumulated 45.7 ±  5.0 pmol/mg protein/30 min 
(mean ± SEM; n= 8 ), compared with 99.8 ± 8.3 pmol/mg protein/30 min (mean ± SEM; 
77=24), for hippocampal synaptosomes. The lower uptake o f the cortical synaptosomes is 
likely to reflect the lower proportion o f  cholinergic terminals in this tissue. In a study 
involving the measurement o f [3H]Ch uptake into human cortical and hippocampal 
synaptosomes, Rylett et al., (1983) reported that sucrose-gradient isolated hippocampal 
synaptosomes accumulated 0.505 pmol Ch/LDH unit/min compared to  a figure of 0.232 
pmol Ch/LDH unit/min for cortical synaptosomes. The authors chose to  express the uptake 
in these units because for the more crude synaptosome fraction obtained from sucrose 
gradients, a useful measure o f synaptosomal integrity is the level o f  occluded LDH activity. 
While it is not possible to directly compare these figures with those obtained in this study, it 
is clear that the cortical synaptosomes accumulate approximately half as much [3H]Ch as 
the hippocampal synaptosomes, a similar proportion to that reported here. Other studies
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have reported a range o f uptake values for cortical and hippocampal synaptosomes: Raiteri 
et al., (1984) using Ficoll-sucrose-isolated cortical synaptosomes and a rather different 
incubation method to determine uptake, reported 80.5 ± 17.2 pmol/mg protein. Thome et 
al., (1988) using essentially the procedure described in section 3.2.2., reported an uptake o f 
145 pmol/mg for Percoll-isolated hippocampal synaptosomes, compared with 2 2  pmol/mg 
protein for sucrose-isolated synaptosomes from the same brain region; an uptake range o f 
100-150 pmol/mg protein, over a period o f several months for Percoll-isolated 
hippocampal synaptosomes has been reported by the same author (Thorne, 1990); and in 
1991 Thorne et a l, published an uptake value o f 160 pmol/mg protein for the same 
preparation o f  hippocampal synaptosomes.
In common with the literature discussed above, the uptake o f [3H]Ch showed some 
variability between experiments in the present study (the range for hippocampal 
synaptosomes was 40-120 pmol/mg protein/30 min). Factors contributing to this variability 
probably include fluctuations in incubation temperature as well as the age o f  the [3H]Ch 
and cold choline stocks but ultimately the major variable was the quality o f the 
synaptosome preparation. The uptake o f [3H]Ch was routinely used as a diagnostic tool to 
determine the viability o f the synaptosome preparation. Consequently, uptake was taken 
into consideration in analysing the subsequent release data, as the release o f radiolabel was 
proportional to uptake.
To directly compare stimulus-evoked release data, expressed as fmol/mg protein, 
the data were normalised to an uptake o f 80 pmol/mg protein/30 min. The figure represents 
the mean for [3H]Ch uptake into hippocampal synaptosomes after the first few months o f 
the project. As the protocol became more familiar, the uptake value increased but it is 
important to note that the value that the uptake is corrected to is not important per se, 
rather it is important that the correction is made.
For example, 1 pM  nicotine was often used as a control in experiments 
investigating the phenomenon o f nicotinic agonist-evoked release: an examination o f the 
[3H]ACh release evoked by 1 pM  nicotine in uncorrected fmol/mg protein, compared with 
the [3H]Ch uptake value for each respective experiment, is instructive:
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Experiment 1 897 62.5 1148
Experiment 2 1137 84.8 1205
Experiment 3 1646 105 1254
Examination o f the uncorrected data is not encouraging since it would appear that 
the. variation in response to the 1 pM  nicotine stimulus was very great. However when the 
[3H]Ch uptake values for the individual experiments were taken into consideration and the 
release data corrected for an uptake o f  80 pmol/mg protein/30 min, the responses to 
nicotine were very similar, suggesting that the correction is useful.
In summary, the uptake values described in this chapter for both hippocampal and 
cortical synaptosomes are typical for the literature, and it is interesting to note that in the 
work o f  Thorne etal., (1988; 1990; 1991) there was a significant variation in uptake over a 
period o f time, just as in the present study. Having established that the Percoll procedure 
produced viable synaptosomes (tested by uptake o f [3H]Ch), it was important to verify that 
the synaptosomes would respond to a general depolarising agent, such as KC1.
3.3.2. RESPONSES TO VARYING CONCENTRATIONS OF 
POTASSIUM
Pilot studies were carried out with cortical synaptosomes to  determine if the 
potassium was efficacious as a depolarising agent and if so, how the transmitter release 
varied with KC1 concentration.
For the purposes o f clarity, concentrations o f KC1 are expressed in millimolar, 
above that concentration normally found in Kreb’s buffer (2.8 mM), thus K reb’s buffer is 
defined as 0 mM KC1. A 20 mM KC1 pulse was used in each chamber as the first stimulus, 
SI, in order to  standardise the response o f  the synaptosomes. For S2 the KC1 concentration 
was varied between 0 mM (Kreb’s buffer) and 50 mM. A pulse o f  K reb’s buffer was used 
as S3 in all six chambers. The SI response was 198 ± 23 fmol [3H]ACh released/mg protein 
(mean + SEM). The standard error indicating the fairly low variability between chambers in 
the Brandell SP-06 apparatus. The responses to the S2 stimulus are represented in figure
3.2.
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FIGURE 3.2. S2 KCI-EVOKED RELEASE OF [JH]ACh. Synaptosomes were loaded with 
[3H]Ch and superfused. After a 45 min washout period, all chambers were stimulated with a 20 s pulse of 
20 mM KC1, SI, in Kreb's bicarbonate buffer: This was followed 30 min later by a second 20 s pulse of KC1 
(S2; 0-50 niM) shown above.
The S3 buffer pulse as well as the 0 mM (buffer) S2 stimulus, attempted to quantify 
the 'air bubble effect' reported by Thorne (1990), who reported that the air bubble 
separating test drug from buffer, itself caused an apparent release o f fH ]A Ch of up to 30% 
of maximal agonist-evoked release, emphasising how sensitive the synaptosomes are to 
mechano- as well as chemical stimulation. The 'air bubble effect' amounted to 10.4 ± 5.1 
fmol [3H]ACh released/mg protein (mean ± SEM), representing 6% o f the standard (20 
mM) KCl-evoked release, and <1% of maximal nicotinic agonist-evoked release (see 
chapter 4).
Expressed graphically, the release o f [3H]ACh increases in direct proportion to 
increased KC1 concentration, over the concentration range tested. A variety o f KC1 
concentrations are found in the superfusion literature regarding KCl-evoked [3H]ACh or 
[3H]dopamine release: Rapier et a l, (1988; 16 mM and 28 mM), Thome (1990; 20 mM), 
Grady et a l,  (1992; 20 mM), and Rowell & Hillebrand (1994; 15 mM). Since the evoked 
release was apparently linear, at least up to a concentration o f 50 mM KC1, in order to 
facilitate comparison with the previous studies by Thorne (1990), 20 mM KC1 was adopted 
as the standard concentration and used henceforth.
3.3.3. VARIATION IN PROTEIN CONCENTRATION
The ideal situation for studying transmitter release from synaptosomes would be the 
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released transmitter was removed from the vicinity o f the synaptosomal receptors, ensuring 
that any problems o f transmitter re-uptake, or positive or negative feedback on the 
presynaptic receptors, would be minimised. Similarly, a monolayer is ideal because if 
synaptosomes are packed tightly on top o f  one another, transmitter release may be masked 
as synaptosomes take up radiolabelled choline (derived from the hydrolysis o f released 
[3H]ACh ) from neighbouring synaptosomes before the superfusate has left the superfusion 
chamber.
The design o f  the superfusion chamber in the Brandell apparatus (see figure 3.1.), 
particularly the fact that the Kreb's buffer is forced to flow from the bottom  to the top o f 
the chamber, ensures that whatever the synaptosomal concentration, the synaptosomes are 
not crowded onto the lower GFC filter.
In order to optimise the response o f  [3H] ACh, responses to agonist were examined 
with varying protein concentrations loaded into the superfusion chamber. Using 10 pM 
nicotine as the agonist challenge for the SI and S2 pulses, with 2 0  mM KC1 as the S3 
pulse, the protein concentration was varied between approximately 100 pg and 250 pg per 
chamber. The results are summarised in table 3.1. below:
PR O TEIN  C O N C E N T R A T IO N  (m g/cham ber) 94.8 ± 2.6 158 ±  4.4 237 ± 6.4
[3H ]A C h R E L E A SE  (fmol/mg p ro tein ):
S I: 10 pM  N IC O T IN E 169 ± 0 .9 123 ± 13 181 ± 3 .7
S2: 10 pM  N IC O T IN E 137 ± 33 109 ± 3 6 127 ± 2 6
S3: 20 m M  KC1 131 ± 25 105 ± 13 118 ± 2 .5
TABLE 3.1: VARIATION IN [3H]ACh RELEASE FROM CORTICAL SYNAPTOSOMES, WITH 
RESPECT TO DIFFERENT PROTEIN CONCENTRATIONS. Values are fmol ACh released/mg protein 
(mean ± SEM), corrected for a [3H]Ch uptake of 40 pmol/mg protein/30 min. (n=3).
The experiment was repeated with hippocampal synaptosomes, varying the protein 
concentration between approximately 80 pg and 200 pg., with 10 pM  nicotine again being 
used for the SI and S2 pulses, and 20 mM KC1 used for S3. The results are shown in table
3.2. below:
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PROTEIN CONCENTRATION (mg/chamber) 197 ± 3 .5 132 ± 2.5 84.6 ± 7 .4
[3HlACh RELEASE (fmol/mg protein):
SI: 10 pM NICOTINE 149 ± 4 4 210 ± 76 734 ± 91 *
S2: 10 pM NICOTINE 109 ± 14 112 ± 30 432 ±88*
S3: 20 mM KC1 283 ± 11 241 ± 5 .7 274 ±35
TA B LE 3.2: VARIATION IN [^HJAQi RELEASE FROM HIPPOCAMPAL SYNAPTOSOMES, WITH RESPECT TO 
DIFFERENT PROTEIN CONCENTRATIONS. Values are fmol ACh released/mg protein (mean ± SEM),
corrected for a [3H]Ch uptake of 80 pmol/mg protein/30 min. (n=3). Significantly different from other 
protein concentrations, *p<0.05.
Varying the concentration o f cortical synaptosomes loaded into the superfusion 
chamber seemed to have little effect upon the sensitivity to either nicotine or potassium, 
with none o f the protein concentrations tested producing significantly different responses 
when compared to either o f the other protein concentrations.1
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FIGURE 3.3. THE EFFECTS OF VARYING PROTEIN CONCENTRATION IN THE 
SUPERFUSION CHAMBER [3H]ACh release was examined by stimulating three different 
concentrations of synaptosomes, in duplicate chambers, for hippocampal (HP) and cortex (CX) 
preparations. The SI stimulation with 10 pM nicotine is shown. Symbols represent the mean ± SEM of 
three independent determinations for each tissue. The release reported for the lowest concentration of HP 
synaptosomes is significantly different (*) from both other concentrations at the p<0.05 level.
1 (p<0.05, using the standard test (Parker’s adaptation of Student’s t-test) for the differences between the 
means of 2 small samples, population variances not assumed to be equal)
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In contrast, the lowest concentration o f hippocampal synaptosomes yielded 
significantly higher 1 responses to 1 0  pM  nicotine in both the SI and S2 stimulations. The 
data for S 1 stimulation o f hippocampal and cortical synaptosomes is summarised in figure
3.3. above. However, KCl-evoked release was consistent at all three protein concentrations 
examined in both brain regions.
The rise in evoked release is not directly proportional to the fall in protein 
concentration, so clearly there is no simple explanation for these results. If  the difference in 
responsivity with the hippocampal synaptosomes were simply a result o f  crowding/re­
uptake o f transmitter, similar differences in response to S3 ( 2 0  mM KC1) would be 
expected. The absence o f such increases suggests that while re-uptake may complicate the 
observed transmitter release at higher protein concentrations, it is not the only factor 
involved. The magnitude o f release for the two higher protein concentrations o f 
synaptosomes mirror that obtained by Thorne (1990), using similar loading conditions. 
High concentrations o f hippocampal synaptosomes in the superfusion chamber, 
nevertheless caused a significant drop in transmitter release which is undesirable: the 
increased response to nicotine at the lowest protein concentration represents a step forward 
in the development o f a more sensitive superfusion assay, and as such this concentration o f 
protein (between 80 and 1 0 0  pg/chamber) was adopted as the standard protocol for future 
hippocampal superfusion studies.
For both cortical and hippocampal nicotine-evoked [3H]ACh release, the SI agonist 
challenge provokes more transmitter release than the S2 challenge. For the cortical 
synaptosomes the S2/S1 ratio for 1 p M  nicotine-evoked release varied between 0.89 and 
0.70, depending on the concentration o f  protein in the superfusion chamber. In comparison, 
the S2/S1 ratio for hippocampal synaptosomes varied between 0.73 and 0.53, i.e. at the 
higher protein concentrations, the S2 response was approximately half the magnitude o f the 
SI response. The reasons for this attenuation o f agonist-evoked response upon repetitive 
agonist stimulation include pool depletion and nAChR desensitisation, and are discussed in 
section 5.3.1.
Hippocampal synaptosomes release more [3H]ACh in response to both nicotine and 
KC1 than cortical synaptosomes. One reason for the apparent difference is that the number 
o f cholinergic terminals in the cortex as a proportion o f the total number o f  nerve terminals, 
may be smaller than in the hippocampus. I f  a smaller proportion o f  the F4 cortical 
synaptosomes are cholinergic, the average [3H]Ch uptake values will be lower than in the
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hippocampus, which is exactly what was recorded (cortex: 45.7 pmol/mg protein/30 min; 
hippocampus: 99.8 pmol/mg protein/30 min). This is important since released [3H]ACh was 
corrected for [3H]Ch uptake. Taking such differences in [3H]Ch uptake into account, the 
KCl-evoked release in both tissues was very similar, as were the responses to nicotine at 
the two highest hippocampal protein loading concentrations. At the lowest hippocampal 
protein concentration, the responses to 1 0  |iM  nicotine were still significantly higher than 
the corresponding cortical responses, even taking into account the differences in [3H]Ch 
uptake.
3.3.4. TYPICAL SUPERFUSION PARAMETERS FOR 
HIPPOCAMPAL SYNAPTOSOMES
Having established the loading conditions for the chamber and the typical uptake of 
the hippocampal synaptosomes (section 3.3.1.), it was necessary to quantify the 
superfusion profile. The baseline in a typical superfusion profile varies in direct proportion 
to the [3H]Ch uptake, high uptake generally produces a higher baseline and vice versa. 
Nevertheless it was possible to quantify this baseline by examining the basal release of 
transmitter at selected points during the experiment. Fractions 13, 23 and 33 represent 
points just prior to the S I, S2 and S3 stimulations, respectively. M ean released 
radioactivity values (cpm), for the hippocampal superfusions were (m ean  ±  SEM ; n=25);
F r a c t io n  13 : 9 2 7 1  ±  8 3 2
F r a c t io n  2 3 :  8 2 0 8  ±  7 0 4
F r a c t io n  3 3 :  7 1 4 9  ±  5 6 1
Radioactivity released was assumed to be [3H]ACh, since previous studies (Rowell 
& Winkler, 1984; Thom e 1990) have shown that in excess o f  90% o f the radioactivity was 
[3H]ACh. The shallow slope o f  the baseline (see figure 3.4. for a typical example), 
demonstrates that the synaptosomes release transmitter slowly and steadily. It is worth 
stressing the important features o f this profile, including: the stability o f  the baseline, 
making the extrapolation under the peaks straightforward; (see section 3.2.4.) and the 
relative height o f  the peaks demonstrating assay sensitivity. A sharp baseline slope is 
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FIGURE 3.4. TYPICAL SUPERFUSION PROFILE. Synaptosomes were loaded with 
[3H]choline and supervised. After a 45 min washout period, the synaptosomes were stimulated with a 20 s 
pulse of 5 pM nicotine in Kreb's bicarbonate buffer: SI. This was followed 30 min later by a second 20 s 
pulse of 5 pM nicotine: S2. Thirty minutes later, a 20 s pulse of 20 mM KC1 was administered: S3. Values 
arc the mean ± SEM from one experiment, n = 6. T Indicates pulse arriving at the synaptosomes.
Generally, the evoked release for all agonists studied, and potassium, followed a 
similar pattern. The peaks were generally sharp with the majority o f the evoked [3H]ACh 
contained in one, or more rarely two fractions.
3.3.5. THE CALCIUM -DEPENDENCE OF |3H]ACh RELEASE
To investigate whether the superfusion system was monitoring a physiological
response, various experiments were carried out using Kreb's buffer lacking Ca^+ (buffer
osmotically corrected with Na+). Table 3.3. shows the calcium dependence o f a number of 
superfusion parameters, for a series o f experiments using 20 mM KC1 as the stimulus.
K R E B S
+ C a 2+
K R EB 'S 
-C a  2+
Ca 2+ 
DEPENDENCE
% fmol/mg 100 ± 16 57.7 ± 8.6 42.3% *
% BASELINE 125 ± 18 55.2 ± 6 .2 55.6% *
%  RADIOACTIVITY 
REM A ININ G
3 . 4 4  ± 0 .77 1.73 ± 0 .22 49.7% *
TABLE 3.3: THE Ca2+-DEPENDENCE OF KC1-EVOKED [3HlACh RELEASE Values are % fmol 
[3H]ACh released/mg protein, corrected for a [3H]Ch uptake of 80 pmol/mg protein/30 min (assuming
100%, release in presence of Ca2+), total peak area as a percentage of the baseline, and peak area as a 
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Whether the evoked release was calculated in terms o f fmol [3H]ACh released/mg 
protein, or as a percentage increase over the baseline, or as a percentage o f the 
radioactivity remaining on the filters at the end o f  the superfusion experiment, the results in 
the absence o f Ca2+ are significantly lower than in normal Kreb’s buffer, yielding a calcium 
dependency o f approximately 50%.
Another interesting effect o f superfusing in the absence o f calcium is revealed by an 
examination o f the baseline release. If  the release at fraction 23, immediately prior to the S2 
pulse is examined for example, it is clear that the basal release differed significantly
(p<0.05) between normal and Ca^+-free Kreb's, (mean ± SEM; n= 5):
Kreb's Fraction 23: 12574 ± 9 5 0 c p m  
- Ca2+ Fraction 23: 16032 ± 966 cpm
The higher baseline and steeper slope o f  this baseline in the absence o f  calcium 
indicated that the synaptosomes were less metabolically stable, releasing the transmitter at a 
higher basal rate than those synaptosomes superfused with standard Kreb's buffer. The 
baseline in the presence o f calcium was higher than that reported in section 3.3.3. but this is 
a non-significant difference and is due to experimental variation and the small number 
(n=5). Rowell & Winkler (1984) observed that nicotine-evoked release o f ACh from mouse 
cerebral cortical synaptosomes was 58% calcium dependent. The authors postulated that
the non-calcium dependent release could be a result o f  mobilisation o f internal Ca^+ stores 
which contribute to the release process (Crosland et a l,  1983).
To investigate the possibility that mobilisation o f  internal Ca2+ artificially lowered 
the calcium dependence, the experiments were repeated in the presence o f 5 pM  EDTA. 
An advantage o f using a chelating agent such as EDTA was that not only would any 
internal Ca2+ be chelated, but also any contaminating Ca2+ in the distilled w ater used to 
prepare the superfusion buffers, such external Ca2+ contamination might also be a factor in 
the relatively low calcium dependence The pH o f the Kreb's buffer containing EDTA was 
carefully maintained at pH 7.4, and the results are outlined in table 3.4.
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K R E B 'S K R E B ’S 
+ EDTA
C a2+
D EPEN D EN CE
%  F M O L /M G 100 ± 5 .0 18.8 ± 3.9 81.2% *
%  BA SELIN E 132 ± 12 13.7 ± 2 .3 89.6% *
%  R A D IO A C TIV ITY  
R E M A IN IN G
3.22 ± 0 .1 4 1.00 ± 0.14 68.9% *
TABLE 3.4: THE EFFECT OF 5 jxM EDTA ON EVOKED [3HlACh RELEASE Values are fmol [3H]ACh 
rcleased/mg protein, corrected for a [3H]Ch uptake of 80 pmol/mg protein/30 min., total peak area as a 
percentage of the baseline, and peak area as a percentage of the radioactivity remaining, (mean ± SEM; 
>7=6). = p<0.05.
In the presence o f EDTA, the calcium dependence o f  the KCl-evoked release 
averaged 79.9%, a figure which compares favourably with the reports o f  Rowell & Winkler 
(1984), Thom e et al., (1991), and Rapier et a l, (1988), the latter reporting that KCl- 
evoked [3H]dopamine release from striatal synaptosomes was 63.9% dependent on 
exogenous calcium. The superfusion baseline in the presence o f  ED TA  was significantly 
higher (p<0.05), with a steeper slope than the baseline with normal K reb’s buffer and a 
comparison o f  the basal release at fraction 23, immediately prior to the S2 pulse illustrates 
this point, (mean ± SEM; n= 5):
Kreb's Fraction 23: 8 8 8 6  ± 775 cpm
± 5 pM  EDTA Fraction 23: 13292 ±1081 cpm
3.4-. SUMMARY OF CHAPTER^
The aim o f  this chapter was to establish a working protocol for the measurement of 
[3H]ACh release from hippocampal synaptosomes using the Brandell SP-06 superfusion 
apparatus. A large amount o f work had already been carried out by Thom e (1990), as far 
as establishing the optimal conditions for isolating hippocampal synaptosomes using Percoll 
gradients, and loading these synaptosomes with [3H]Ch. This expertise was adopted, but a 
new protocol was needed to maximise sensitivity using the automated apparatus. This 
protocol needed to cover such factors as: the amount o f protein loaded per superfusion 
chamber; the response o f the synaptosomes to a general depolarising agent such as KC1; 
and the calcium-dependence o f evoked [3H]ACh release. Taking T hom e’s protocol as a 
starting point, modifications were made if  increases in sensitivity could be demonstrated.
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As a result o f the results presented in this chapter, the following superfusion 
protocol was adopted. Routinely, Percoll-enriched synaptosomes were prepared from the 
hippocampi o f  two rats. These synaptosomes were loaded with [3H]Ch (0.8 pM; 30 min), 
and approximately 100 fig loaded into each superfusion chamber. The synaptosomes were 
superfiised at 37°C with 250 jal o f Kreb’s buffer/min, and 3 min fractions collected in 
minivials. Scintillant (3 ml) was added to the superfiisate, the mixture mixed and counted 
in a Packard 1600 scintillation counter. A routine superfusion experiment consisted o f a 
washout period (45 min) to remove excess [3H]Ch and achieve a stable baseline, followed 
by stimulations (agonist or KC1) at 30 min intervals. It was found that the single biggest 
variable in the protocol was the synaptosomal uptake o f [3H]Ch, which in turn determined 
the extent o f  basal and evoked [3H] ACh release. Evoked release could be expressed in a 
number o f ways: as an absolute number o f femtomoles o f [3H]ACh released/mg o f protein 
loaded into the superfusion chamber, necessitating correcting for the variable uptake o f 
[3H]Ch; as a percentage increase over the baseline; and as a percentage o f the radioactivity 
remaining on the filters at the end o f the superfusion system.
To put the results reported in this chapter, into context with the superfusion 
literature is quite difficult, not only is the measurement o f  [3H]ACh release fairly rare, 
especially compared with [3H]dopamine release, but the differences in superfusion 
apparatus design, and protocol in different laboratories, make direct comparison between 
studies difficult. To take an example, Grady et a l, (1992; 1994) used an open superfusion 
system at room temperature, with no dead volume, a pulse size o f 200-300 pi and fractions 
collected at 30 s, or minute intervals to characterise nAChR-evoked [3H]dopamine release 
from mouse striatum. The present study used a closed superfusion system maintained at 
37°C, with a pulse size o f 83 pi in a total chamber volume o f 2 0 0  pi, collected fractions o f 
750 pi at 3 min intervals with the ultimate aim o f characterising nAChR-evoked release 
from rat hippocampus. Nevertheless, if differences between the differing superfusion 
systems are taken into account there is be no reason why comparisons should not be 
instructive.
Having defined a protocol for the sensitive measurement o f [3H]ACh release from 
hippocampal synaptosomes, and determined that the synaptosomes were not only 
responsive to challenges o f KC1, but that such evoked release was calcium-dependent, the 
next chapter moves on to deal with agonist-evoked release.
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C H A P T E R  4, d Q O N t t T ' E V O K C b  A Q E T T L C I 1 0 L M E  R C L C 4 5 C
4.1 INTRODUCTION
The objective of this part of the study was to use the Brandell SP-06 apparatus to 
examine nicotinic agonist-evoked [3H]ACh release from superfused, F4 synaptosomes 
produced by the Percoll method (chapter 2).
A variety o f aspects of the agonist-evoked transmitter release were examined in 
turn. Firstly, the calcium dependence and nicotinic nature of the nicotine-evoked release 
were verified. Then, satisfied that the evoked release was both calcium dependent and 
mediated via nAChR, the next stage in the pharmacological characterisation process was to 
examine the concentration dependence o f agonist-evoked release. This was accomplished 
by testing the efficacy of nicotine, then several other nicotinic agonists, to evoke release of 
[3H]ACh over a range o f concentrations, which varied according to the agonist being 
studied. By comparing the results obtained with the different agonists, an agonist profile of 
the hippocampal nAChR was built up, which allowed the delineation o f several common 
features o f nicotinic agonist-evoked release. Furthermore the EC50 values obtained for 
agonist-evoked release were compared to agonist pharmacological profiles for the same 
agonists in two different experimental paradigms for defined nAChR subtypes: mouse M10 
fibroblast cells and Xenopus oocytes stably expressing chick a4 p 2  nAChR. This 
pharmacological comparison enables one to speculate on the subtype or subtypes of 
nAChR expressed presynaptically in the rat hippocampus, and is especially useful in light of 
the paucity o f subtype-specific ligands that could be used to more directly elucidate the 
identity of the hippocampal autoreceptor under study.
In addition to the agonist-evoked release studies, this chapter also reports the 
results o f studies with the a l  subtype-selective nicotinic antagonist methyllycaconitine 
(MLA) and its effects on nicotine-evoked, as well as basal [3H]ACh release. Also included 
are studies with the acetylcholine esterase (AChE) inhibitor physostigmine (PFIY), which 
has been reported to produce transient improvements in memory related tasks (Davis et al., 
1978; Christie et al., 1981). The exact mode o f drug action is unclear however since PHY 
has been reported to interact directly with the nAChR (Pereira et al., 1993) via a novel 
agonist binding site. The effects o f PFIY on basal and nicotine-evoked release were thus
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examined to ascertain whether the AChE inhibitor was having a direct effect on the 
hippocampal nicotinic autoreceptors.
4 . 2._ M E T H O D S
Synaptosome Preparation
Hippocampal synaptosomes were prepared and isolated on four step discontinuous 
Percoll gradients, as described in chapter 2. The F4 fraction was washed twice with Kreb's 
buffer ( 1 0  ml; 15 min at 15,000 g) to remove the Percoll. The pellet was resuspended in 
Kreb's buffer, preincubated at 37° for 10 min and then loaded with [3H]Ch (0.8 pM; 30 min 
at 37°C). Excess [3H]Ch was removed by washing with Kreb's buffer (1 ml) followed by 
centrifugation (1 min at 3,000 g) before resuspension in Kreb's buffer (1 ml) and samples 
(150 pi) placed in superfusion chambers (see section 2 . 1 .6 .),
Superfusion
The synaptosomes were superfused with Kreb's buffer for an initial 45 min washout 
period. The effect o f nicotinic agonist concentration on [3H]ACh release was studied by 
varying the agonist concentration in the initial stimulus - SI. The nicotinic nature o f  the 
response was studied by introducing buffer, containing the nicotinic antagonist DH13E (1 
pM) 15 min after the S 1 pulse. The subsequent S2 (agonist) and S3 (KC1) pulses were with 
drugs made up in the DH13E buffer, see section 2.2.2, Other antagonists were studied in the 
same way.
The effect o f PHY on basal release was studied by superfiising one half o f  the 
chambers with standard Kreb's buffer and comparing the release o f [3H]ACh with that 
obtained by superfusing with Kreb's buffer containing PHY (1 pM ) Effects on nicotine- 
evoked [3H]ACh release were studied by introducing the drug 15 min after the SI 
(nicotine) pulse in the standard antagonist protocol. PHY was also used in the standard 
agonist protocol to ascertain whether the drug could directly provoke [3H]ACh release via 
the nAChRs.
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4.3._ R E S U L T S
4.3.1. CALCIUM DEPENDENCE
To assess the calcium dependence o f the nicotinic agonist-evoked [3H]ACh release 
from hippocampal synaptosomes, a concentration o f 5 mM EDTA was used to chelate the 
Ca2' ions in the Kreb’s buffer. In three independent experiments the ability o f 1 pM
nicotine to evoke release o f [3H]ACh in the presence o f 5 mM EDTA, was compared to the
control response in the presence o f Ca2+:
S 1 (1 pM  nicotine) + Ca2+: 521 fmol/mg protein.
SI (1 pM  nicotine) - Ca2+: 65 fmol/mg protein. (w=3)
This calcium dependency o f 87.5% compares well to the dependency o f the KCl- 
evoked transmitter release in section 3.3.4.,
4.3.2. NICOTINE-EVOKED ACh RELEASE
4.3 .2 .1 . N icotine C oncen tration
The effect o f nicotine concentration on [3H]ACh release was studied by varying the 
agonist concentration in the SI pulse between 100 nM and 50 pM. Figure 4.1. shows a 
representative superfusion profile obtained in the course o f determining the dose- 
dependency o f  nicotine-evoked release. For representation purposes, the baselines for the 
individual chambers have been averaged with the agonist-evoked release superimposed 
upon this averaged baseline. However, it can be seen from the small standard error bars o f 
the baseline that the variance between chambers was small.
Figure 4.2A. shows the dose response curve for the representative experiment 
shown in figure 4.1. For each dose response experiment, the data were converted to 
percent specific release (figure 4.2B.), taking the [3H]ACh release evoked by 10 pM  
nicotine as 100%. By converting each individual experiment to percent specific release and 
then averaging the results, it was possible to estimate an EC 50 value for nicotine-evoked 
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FIGURE 4.1. NICOTINE-EVOKED RELEASE OF [3H]ACh. Synaptosomes were loaded with 
[3H]Ch and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse 
of nicotine (SI: 0.5-50 pM) in Kreb's bicarbonate buffer, 30 min later all chambers were stimulated with a 
20 s pulse of KC1 (S2: 20 mM). Basal release was averaged in the six chambers and evoked release plotted 
above this common baseline. Basal values are mean ± SEM, n = 6 . Each peak represents the data from one 
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FIGURE 4.2A. NICOTINE DOSE RESPONSE CURVE FOR A REPRESENTATIVE 
EXPERIMENT. Synaptosomes were loaded with [3H]Ch and superfused. After a 45 min washout period, 
the synaptosomes were stimulated with a 20 s pulse of nicotine in Kreb's bicarbonate buffer. Basal release 
was subtracted to give evoked release which was converted to fmol [3H]ACh and plotted against nicotine 
concentration. Values are from one experiment. The points have been fitted to the non-linear Pliska 
equation (Pliska, 1994).
FIGURE 4.2B. NICOTINE DOSE RESPONSE CURVE TRANSFORMED TO PERCENT 
SPECIFIC RELEASE. The data from figure 4.2A. were converted to percent specific release, taking that 
release recorded at 10 pM nicotine to be 100%.
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Nicotine stimulated a concentration-dependent increase in [3H]ACh release up to 10 
pM, after which there was a sharp attenuation in evoked [3H]ACh release. The dose- 
response curve (figure 4.2A.) was clearly bell-shaped. The dose-response experiments were 




fmol A C h R ELEA SED / 
mg PR O T E IN
n
0 .1 122 ± 5 3
0.5 381 ± 6 2 6
1 .0 865 ±221 6
5.0 9 0 4 ± 159 6
1 0 . 0 1335 ± 9 2 6
50.0 689 ± 190 3
TABLE 4.1: THE CONCENTRATION-DEPENDENCE OF NICOTINE-EVOKED [3H]ACh RELEASE. 
Values are fmol [3H]ACh released/mg protein (mean ± SEM), and were corrected for a [3H]Ch uptake of 80 
pmol/mg protein/30 min.
The maximum response to nicotinic stimulation was consistently between four and 
five-fold higher than the response elicited by a subsequent stimulation with 20 mM KC1: 
Maximum response to nicotine (10 pM):
1335 ± 92 fmol/mg protein 
Response to 20 mM KC1:
251 ± 5 9  fmol/mg protein (w=6 )
This contrasts sharply with the nicotinic stimulation o f  [3H]dopamine release from 
striatal synaptosomes, which is typically about one quarter o f that seen with 20 mM KC1 
(Rapier et a l,  1988).
If  a dose-response curve for the averaged nicotine-evoked release data is plotted, 
(figure 4.3.) the resultant graph is not clearly 'bell-shaped' rather, there a broad ‘shoulder’ 
at the nicotine concentrations o f 1 pM  and 5 pM  followed by a further dose-dependent 
increase in [3H]ACh release. At the highest concentration o f 50 pM  nicotine there was a 
sharp attenuation o f  ACh release.
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FIGURE 4.3. NICOTINE DOSE-RESPONSE CURVE. Synaptosomes were loaded with f3H]Ch 
and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse of 
nicotine in Kreb's bicarbonate buffer. Basal release was subtracted to give evoked release which was 
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FIGURE 4.4. CURVE FIT TO THE HILL EQUATION FOR NICOTINE. The data from 
individual nicotine-evoked dose response curves were converted to percent specific release, taking that 
release recorded at 10 fiM nicotine to be 100%, the data averaged, and then fitted to the non-linear Hill 
equation to enable an estimate of the concentration at which 50% maximal response was observed.
If the release data are fitted to the Hill equation and plotted (figure 4.4.), it is 
possible to calculate an EC 5 0  value for the nicotine-evoked [3H]ACh release from
hippocampal synaptosomes. This value is 0.99 ± 0.23 pM for n=3-6.
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4.3.2.2. Nicotinic Nature O f The Response
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There exist two possible mechanisms by which nicotine could conceivably evoke 
[3H]ACh release from the loaded synaptosomes. As a lipophilic molecule it is feasible that 
the nicotine moiety permeates the synaptosomal membrane directly, and interacts with 
[3H]ACh-containing vesicles in the active zone o f  the synaptosome, causing transmitter 
release. The other possibility is that the nicotine mediates the [3H]ACh release via a 
presynaptic nAChR.
These two mechanisms can be differentiated by the use o f a nicotinic antagonist 
such as DHI3E the principal alkaloid fraction o f seeds from Eryihrina spp. DHBE is one of 
only a handful o f  antagonists that potently inhibit the binding o f nicotine to membranes 
from brain, and is equipotent as a neuromuscular and ganglionic blocker (Wonnacott, 
1987), suggesting that its potency as an antagonist is not subtype-specific.
Using the standard antagonist protocol (section 2.I.6.2.) o f adding DHBE 15 min 
before the S2 agonist stimulus and perfusing in the presence o f  the antagonist for the 
remainder o f the experiment (including the S3 KC1 pulse), the ability o f  1 pM  DHflE to 
inhibit that release evoked by 10 pM  nicotine was tested.
The results are shown in table 4.2. below:
CHAM BERS 1-3 CHAM BERS 4-6
SI lO p M N IC . 10 pM  NIC.
FM O L/M G 1269 ± 201 1010 ± 2 5 1
% ABOVE BASELINE 76.0 ± 8.0% 75.1 ± 2 9 .5%
S2 10 pM  NIC. 10 pM  NIC. + 1 pM  DHBE
FM O L/M G 456 ± 63 .3 127 ± 66 .3*
% ABOVE BASELINE 27.8 ± 2 .6% 9.1 ± 4 .8 *
S3: 2 0  mM KC1 20 mM KC1 + 1 pM  DHBE
FM O L/M G 203 ± 17.0 214 ± 3 7 .0
% ABOVE BASELINE 12.6 ± 1.3% 15.0 ± 4 .3 %
TABLE 4.2: ANTAGONISM OF NICOTINE-EVOKED [3H]ACh RELEASE BY DHpE. Fmol/mg values 
are corrected for a [3H]Ch uptake of 80 pmol/mg protein/30 min. Section 2.I.6.2. details the administration 
of the antagonist. Percent above baseline values are calculated by expressing the peak of release over the
baseline. = significantly different from control at the p<0.05 level of significance. (n=7)
These data are represented graphically in figure 4.5.
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FIGURE 4.5. THE EFFECT OF 1 pM DH(3E ON 10 pM NICOTINE-EVOKED l3H]ACh 
RELEASE. Data were obtained from table 4.2. Control release defined in the absence of DHpE for S2 and 
S3. * = significantly different from control at the p<0.05 level of significance.
The release of [3H]ACh evoked by 10 pM nicotine was inhibited by 1 pM DHBE. 
Importantly, the various methods o f expressing the data yield the same result. In terms of 
fmol transmitter released/mg protein, the percent inhibition of the S2 pulse was: 72.1%. 
This compares with the data expressed as percent increase over the baseline release of 
transmitter, in which the inhibition o f the S2 response was: 67.3%. In both cases there was 
no inhibition o f the potassium-stimulated, S3 response. The preservation o f the KC1 
response is vital to demonstrate that the antagonist is acting specifically at the nAChR and 
not causing a general depression o f transmitter release, indeed by comparing the basal 
release at fraction 30, 26 minutes after the introduction of the antagonist into the perfusion 
buffer, it is possible to examine whether basal release of transmitter is significantly altered 
in the presence o f 1 pM DHBE.
Release at F30:
Control: 1243 ± 8 7  fmol/mg
+ 1 pM DHBE: 1232 ± 69 fmol/mg (n= l)
Plainly, the basal release o f transmitter was unaffected by the antagonist. Also 
evident from the data is the fact that the superfusion system was very reproducible, since 
the standard error was very small and the difference between the baselines in the control 
and the antagonist conditions was negligible.
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In summary, 1 pM DHBE effects a large antagonism o f the nicotine-evoked
2+
[ H]ACh release from hippocampal synaptosomes (approximately 90% o f the Ca - 
dependent release is antagonised). Thus, it is clear that nicotine is evoking release o f 
tritiated transmitter via presynaptic nAChR.
4.3.3. FURTHER ANTAGONIST STUDIES
Having established that nicotine evoked the release o f [3H]ACh via a nAChR- 
dependent mechanism, the use o f further, subtype-specific, nicotinic antagonists could shed 
light on the contribution o f possible nAChR subtypes present on the presynaptic membrane, 
to the total nicotine-evoked transmitter release.
Using the same antagonist protocol o f adding the antagonist to the perfusion buffer 
after the SI stimulus and continuously perfusing in the presence o f antagonist to the 
remainder o f  the experiment, the effects o f both 1 pM  and 10 pM  ML A, on 1 pM  nicotine- 
evoked release, were tested.
CH A M B ER S C H A M BER S C H A M B ER S
1 - 2 3-4 5-6
S I 1 pM  NIC. 1 pM  NIC. 1 pM  NIC.
F M O L /M G 873 ± 100 1073 +223 1137 + 234
%  A BOV E B A SELIN E 169 ±26.0% 182 + 40.0% 170+36.0%
S2 1 pM  NIC. 1 pM  NIC. 1 pM  NIC.
+1 pM M L A + 10 pM  MLA
F M O L /M G 335 + 8 8 286 + 19.5 181 ± 42*
% A BOV E B A SELIN E 66.9 ± 19.0% 52.4 + 4.7% 27.5 ±7.2% *
S3 20 mM KC1 20 mM KC1 20 mM KC1
+1 pM M L A + 10 pM  MLA
F M O L /M G 251 + 59 .0 206 + 23.3 202 + 51.7
%  A BOV E B A SELIN E 48.2 ± 12.8% 37.7 + 4.4% 29.9 ± 7.6%
TABLE 4.3: THE EFFECT OF 1 pM AND 10 pM MLA ON THE ABILITY OF 1 pM NICOTINE TO 
EVOKE TRANSMITTER RELEASE. Fmol/mg values are corrected for a [3H]Ch uptake of 80 pmol/mg 
protein/30 min. Percent above baseline values are calculated by expressing the peak of release over the
j|{
baseline at fraction 20 (midpoint of the experiment). = significantly different from control at the p<0.05 
level of significance. (n=4)
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Both 1 |iM  MLA and 10 >.iM MLA were able to inhibit the release o f transmitter 
evoked by I jiM  nicotine, but to markedly different extents. I f  the inhibition o f the S2 
stimulus is summarised:
Percent inhibition o f S2 response: 1 jiM MLA 10 fiM MLA
Fmol/mg protein 14.6% 46.0%  *
% above baseline 21.7% 58.9% *
If the effect on the KCl-evoked [3H]ACh response is examined, it is clear that the 
MLA was able to inhibit non-nAChR-evoked transmitter release to a small extent.
Percent inhibition o f S3:
20 mM KC1 response: 1 |iM  MLA 10 pM  M LA
Fmol/mg 17.9% 19.5%
This inhibition, reported previously by Drasdo et a l, (1992) was neither statistically 
significant nor dose dependent.
The possibility that MLA was simply inhibiting basal release o f  transmitter could be 
examined by comparing the magnitude o f  release at fraction 30, an arbitrary point during 
the superfusion profile that may be used as a marker o f basal release:
Control , + 1 fiM M LA + 10 ^iMMLA
Fmol/mg at F30: 555 ± 4 4  658 ± 41  679 ± 4 9
(/?): 4 7 7
There was no significant inhibition o f basal release with either concentration of 
MLA, suggesting that the alkaloid is inhibiting evoked transmitter release, albeit both 
nAChR-mediated and to a small extent KCl-evoked release, rather than having more 
general effects on the overall release profile.
4.3.4. FURTHER AGONIST-EVOKED RELEASE
4.3.4.I. Cytisine
Cytisine is an alkaloid found in the seed of Laburnum anagyroides, and was 
originally characterised as an nicotinic agonist at autonomic ganglia. In binding studies 
cytisine binds to nAChR with higher affinity than nicotine, low non-specific binding and a 
slow rate o f  dissociation from the receptor (Pabreza et al., 1990), making it a useful and 
widely used tool to study neuronal nicotinic receptors.
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The drug was used in the present study over a concentration range identical to that 
used in the nicotine study, i.e. 100 nM to 50 jiM (section 4.3.2.1.), to study whether the 
drug could evoke [3H]ACh release from the hippocampal synaptosomes, and if so, how the 
release profile compared to that obtained with nicotine. The results are shown in table 4.4.
[CYTISINE] p.lM fmol ACh RELEASED 
/nig PROTEIN
0 .1 160 ± 6 0
0.5 3 9 4 ± 124
1 .0 770 ± 130
5.0 1181 ±71
1 0 .0 1456 ±215
50.0 624 ± 98
TABLE 4.4: THE CONCENTRATION-DEPENDENCE OF CYTISINE-EVOKED [3H]ACh RELEASE. 
Values are expressed as fmol ACh released/mg protein (mean ± SEM), and were corrected for a [3H]Ch 
uptake of 80 pmol/mg protein/30 min. (A/=3).
Expressed graphically (figure 4.6.) this data yields a dose response curve similar to 
that obtained with nicotine. From 100 nM to 10 jiM, cytisine evokes [3H]ACh release in a 
concentration-dependent manner. There follows a sharp attenuation in the evoked release 
at the highest cytisine concentration, again suggesting nAChR desensitisation.
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FIGURE 4.6. CYTISINE DOSE-RESPONSE CURVE. Synaptosomes were loaded with (3H]Ch 
and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse of 
cytisine in Kreb's bicarbonate buffer. Basal release was subtracted to give evoked release which was 
converted to fmol [3H]ACh and plotted against cytisine concentration. Values are the mean ± SEM, n = 3. 
The points have been fitted to the non-linear Pliska equation (Pliska, 1994).
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The release data were fitted to the Hill equation enabling an ECJ0 value for cytisine-evoked 
release to be calculated (figure 4.7.), This value o f 1.06 pM was not significantly different 
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FIGURE 4.7. CURVE FIT TO TH E H ILL EQUATION FO R CYTISINE. The data from 
table 4.4. were converted to percent specific release, taking that release recorded at 10 pM cytisine to be 
100%, and then fitted to the non-linear Hill equation to enable an estimate of the concentration at which 
50% maximal response was observed.
4.3.4.2. (+)-Anatoxin-A
(+)-Anatoxin-a (ANTX) is a potent nicotinic agonist isolated from blue green algae 
(Anabaena flos-aquae) that can cause deaths o f cattle and wildfowl (Carmichael et al,
1975). ANTX is a potent competitor o f [3H]nicotine and [l25I]-a-B gt binding to brain 
membranes (MacAllan et al., 1988; Wonnacott et al, 1991), but such binding assays 
provide little indication o f functional efficacy. ANTX has been used as an effective nicotinic 
agonist in preparations of cultured neurons (Aracava et al., 1987; Alkondon & 
Albuquerque, 1990), and has been used to probe central nAChR in both in vitro assays 
(Swanson et al., 1986; 1991; Wonnacott et al., 1991; Thomas et al., 1993) and in various 
behavioural paradigms (Stolerman et al., 1992).
In keeping with its greater potency in binding studies, ANTX was tested over a 
different range o f concentrations than cytisine and nicotine: from 10 nM to 10 pM. The 
results are summarised in table 4.5. represented graphically in figure 4.8.
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[ANTXJ OiM) fmol ACh RELEASED 
/mg PROTEIN
0.01 14± 12
0 .1 63 ± 15
0.5 1225± 177
1.0 8 0 1 ± 118
10.0 179 ± 77
TABLE 4.5 THE CONCENTRATION-DEPENDENCE OF ANTX-EVOKED [3H]ACh RELEASE. 
Values are expressed as fmol ACh released/mg protein (mean ± SEM), and were corrected for a [3H]Ch 
uptake of 80 pmol/mg protein/30 min. (n=3).
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FIGURE 4.8. (+)ANATOXIN-a DOSE-RESPONSE CURVE. Synaptosomes were loaded with 
[3HlCh and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse 
of ANTX in Kreb's bicarbonate buffer. Basal release was subtracted to give evoked release which was 
converted to fmol [3HlACh and plotted against ANTX concentration. Values are mean ± SEM, n = 3.
This dose response curve shows the potency of ANTX in the hippocampal 
synaptosome preparation. The exceptionally steep shape of the graph precludes fitting the 
data to the Hill equation to estimate the EC5o, since to successfully fit the equation without 
a large inherent error, there must be at least 3 points between 10% and 90% specific 
release. Since this is not possible with ANTX, a crude EC$0 was calculated by constructing
a linear regression between the concentrations 100 nM and 500 nM (maximal release). The 
value corresponding to 50% maximal release was calculated and used as the estimate for
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the EC50. These individual values were then averaged to give an estimate o f the EC50 o f 
0.14 ± 0.04 fiM («=3).
4.3.4.3. Iso-arecolone
Iso-arecolone was introduced into neuropharmacological research following the 
discovery o f  its high potency as a nicotinic agonist in peripheral pharmacological 
preparations (Haglid 1967), and has since been used in a variety of in vivo behavioural 
paradigms, in addition to in vitro binding studies (Reavill et a l, 1987; Reavill et a l., 1990), 
which have suggested that as a com petitor at the high affinity [3H]nicotine binding site, the 
agonist is between 1 0  and 50 times less potent than nicotine or cytisine. As such, to 
ascertain whether iso-arecolone was effective at evoking [3H]ACh release from the 
hippocampal synaptosome preparation, a range o f between 10 fiM and 500 jiM was used in 
the superfusion assay. The data are summarised in table 4.6. and represented graphically in 
figure 4.9.
[ISO -A RECO LO N E]
(liM)
fmol ACh R ELEA SED  
/m g PR O T E IN
1 0 113 ± 36
25 5 3 6 ± 106
50 763 ± 109
75 1546 ± 371
1 0 0 1260 ± 3 3 0
500 265 ± 5 1
TABLE 4.6: THE CONCENTRATION-DEPENDENCE OF ISO-ARECOLONE-EVOKED [3H]ACh 
RELEASE. Values are expressed as fmol ACh released/mg protein (mean ± SEM), and were corrected for 
a [3H]Ch uptake of 80 pmol/mg protein/30 min. (N=  3).
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FIGURE 4.9. ISO-ARECOLONE DOSE-RESPONSE CURVE. Synaptosomes were loaded 
with [3H]Ch and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s 
pulse of iso-arecolone in Kreb's bicarbonate buffer. Basal release was subtracted to give evoked release 
which was converted to fmol [3H]ACh and plotted against iso-arecolone concentration. Values are mean ± 
SEM, n = 3.
In common with the data for A N TX , the dose response curve for iso-arecolone 
showed a sharp increase in evoked release up to a distinct peak, at 75 \iM  iso-arecolone, 
followed by an equally sharp attenuation o f evoked release. Fitting the data to the Hill 
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FIGURE 4.10. CURVE FIT TO THE HILL EQUATION FOR ISO-ARECOLONE. The data 
from table 4.6. were converted to percent specific release, in each experiment 75 pM iso-arecolone evoked 
maximal [3H]ACh release, which was taken to be 100%, and then fitted to the non-linear Hill equation to 
enable an estimate of the concentration at which 50% maximal response was observed.
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4.3.4.4. ABT-418
ABT-418 (3-methyl-5-(l-methyl-2-pyrrolidinyl)isoxazole, a novel analogue o f (-)- 
nicotine in which the pyridine ring was replaced with an isoxazole bioisostere (see appendix 
for structure), is a potent agonist at the a 4 f 2  subtype o f neuronal nAChR (Arneric et a l, 
1994), and became available towards the end o f the present study as a gift from Abbott 
Laboratories (Abbott Park, Illinois, USA). The ability o f  ABT-418 to evoke [3H]ACh from 
the hippocampal synaptosome preparation was tested over the range 0.1 to 100 pM, i.e. 
over a wider range than nicotine or cytisine to allow for any possible reduction in potency. 
The data obtained, are summarised in table 4.7. In common with the other agonist dose- 
response experiments, in each ABT-418 assay, nicotine-evoked [3H]ACh release was used 
as an internal standard. For each o f the other agonists tested, the nicotine standard (either 1 
pM  or 5 pM ), evoked a release o f  [3H]ACh which was not significantly different from the 
release obtained in the course o f determining the nicotine dose-response curve (section
4.3.2.1.). I f  the nicotine-evoked release did differ by more than one standard deviation the 
whole experiment was disregarded. However it became apparent during the course of 
determining the ABT-418 dose-response curve that the 5 pM  nicotine standard evoked 
consistently low [3H]ACh release (see table 4.7.). Standard 5 pM  nicotine-evoked [3H]ACh 
release was taken as 904 fmol/mg protein (table 4.1.), compared to  511 fmol/mg protein 
obtained in the present series o f experiments. It was decided to normalise the ABT-418 
release data to enable comparisons with the other agonist dose-response curves. The 
legitimacy o f  such an adjustment is discussed in section 4.4.2.
[ABT-418] (pM ) fmol A Ch R ELEA SED  
/m g PR O T E IN
0 .1 170 ± 31 .5
1 .0 309 ± 4 4 .7
5.0 553 ± 87 .8
1 0 760 ± 28.0
1 0 0 389 ± 9 7
5 pM  N icotine 511 ± 78
TABLE 4.7: THE CONCENTRATION-DEPENDENCE OF ABT-418-EVOKED [3H]ACh RELEASE. 
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FIGURE 4.11. ABT-418 DOSE-RESPONSE CURVE. Synaptosomes were loaded with [3HJCh 
and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s pulse of 
ABT-418 in Kreb's bicarbonate buffer. Basal release was subtracted to give evoked release which was 
converted to fmol [3H]ACh and plotted against ABT-418 concentration. Values are mean ± SEM, n = 3-4.
The adjusted data were plotted as figure 4.11. which shows that ABT-418 in 
common with the other agonists tested, caused a dose-dependent increase in [3H]ACh 
release up to the concentration o f 10 pM, above which there was a marked attenuation of 
evoked transmitter release, consistent with ABT-418-induced nAChR desensitisation..
The release data were fitted to the non-linear Hill equation, and the EC50 value for 
ABT-418-evoked transmitter release was calculated as 2.60 ± 0.12 pM
100 -I EC50 = 2.60 pM  (± 0.12)
90 n = 0.51 (± 0.39)
PJ H  T& 80 -
2j 70 -
a  60 -
S  50 -Pu
u  4 0  -
Oh 30 -
GO
S  2 0  - 
10 - 
0  -
- 8  -7 - 6  -5 -4
LOG ABT-418 CONCENTRATION (M)
FIGURE 4.12. CURVE FIT TO TH E H ILL EQUATION FOR ABT-418. The data from table 
4.7. were converted to percent specific release, taking that release recorded at 10 pM ABT-418 to be 100%, 
and then fitted to the non-linear Hill equation to enable an estimate of the concentration at which 50% 
maximal response was observed.
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The calculated EC50 value for ABT-418-evoked [3H]ACh release was 2.60 ± 0.12 
approximately tw o fold less potent than either nicotine- or cytisine at evoking [3H]ACh 
release. Using the paradigm o f nAChR-mediated 86Rb+ efflux from mouse thalamic 
synaptosomes, M arks et a l, (1994) have reported an EC50 value o f  6  jaM for ABT-418- 
evoked efflux, which compares well to the value calculated in the present study.
4.3.4.5. Acetylcholine
. An agonist profile o f the presynaptic hippocampal nAChR would not be complete 
without an examination o f the responses to acetylcholine (ACh) - the endogenous ligand 
for the both nAChRs and mAChRs.
The inhibitory role o f mAChR autoreceptors on superfused synaptosomes has been 
characterised: in a series o f  elegant experiments, Marchi et a l,  (1981) showed that the 
presence o f  exogenous ACh in the superfusion medium produced dose-dependent inhibition 
o f the depolarisation-evoked [3H]ACh release. The EC 50 o f this response was 10 pM  ACh. 
Importantly it was shown that the inhibitory activity o f extracellular ACh was inhibited by 
0.1 pM  atropine (ATR), which itself had no significant effect on the KCl-evoked release o f 
ACh. Thus, to investigate the role o f  the nAChR in isolation, it is possible to exclude any 
possible role o f  mAChR by the addition o f  ATR. Since the mAChR are inhibitory, one 
would not expect to observe a change in basal release on application o f  exogenous ACh via 
the mAChR. The work o f Marchi et a l, demonstrated inhibition only o f  KCl-evoked 
depolarisation o f  the synaptosomes.
Therefore, ACh was applied as an agonist in the standard superfusion protocol 
whereby the loaded synaptosomes were stimulated by various concentrations o f ACh forty- 
five minutes after the start o f the superfusion. The concentration o f  ACh was varied over 
the range 1 to  500pM , with the results summarised in table 4.8. and represented graphically 
in figure 4.13.
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fmol [3H]ACh released/mg protein
[ACh] (pM ) 1.0 10 50 100 500
SI 88.5 552 835 1357 1615
SEM 46.0 139 311 572 262
n 3 4 3 4 3
TABLE 4.8: ACETYLCHOLINE-EVOKED [3HJACh RELEASE IN THE ABSENCE OF ATR OR PHY. 
Values are fmol ACh released/mg protein (mean ± SEM), corrected for a [3H]Ch uptake of 80 pmol/mg 
protein/30 min. (w=3-4).
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FIGURE 4.13. ACETYLCHOLINE DOSE-RESPONSE CURVE. Synaptosomes were loaded 
with [3H]Ch and superfused. After a 45 min washout period, the synaptosomes were stimulated with a 20 s 
pulse of ACh in Kreb's bicarbonate buffer. Basal release was subtracted from agonist-induced peaks to give 
evoked release which was converted to fmol [3H]ACh at each ACh concentration. Values are mean ± SEM, 
with n = 3-4.
The resultant dose response curve bears little resemblance to those curves obtained 
for the other agonists in this study. Maximal [3H]ACh release was evoked at ACh 
concentrations o f between 100 and 500 jiM with no obvious desensitisation at higher 
agonist concentrations and the relatively wide window of activation - the synaptosomes 
respond to the agonist over almost three orders o f magnitude - were clearly unusual.
Despite the stringent washing procedures involved in the isolation o f the 
synaptosomes by the Percoll method, membrane-bound cholinesterases remain in the 
preparation: cholinesterases which would be sufficient to hydrolyse an unknown proportion 
of the exogenous ACh pulse. As a result the concentration o f ACh actually reaching the 
nAChRs was likely to be significantly lower than that concentration applied. Hence future 
perfusions involving ACh as an agonist were carried out in the presence o f 0.5 pM ATR
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and 1.0 pM  PHY. Before further experiments utilising ACh could be determined, it was 
useful to examine the effects o f PHY and ATR on basal release.
Basal release expressed in fmol/mg, was compared at fraction 30 in a large number 
o f experiments in the presence and absence o f  PHY and ATR. The results are summarised 
below:
F30 (fmol/mg) mean ± SEM 
Routine Superfusion buffer: 381 ± 17 («=18)
Buffer + 1 pM  PHY + 0.5 pM  ATR 389 ± 19 («=35)
Clearly, neither the muscarinic antagonist nor the cholinesterase inhibitor 
significantly altered the basal release o f  [3H] ACh, which agrees with the finding o f Marchi 
et al., (1981). However the possibility remains that either atropine o f  PHY could alter 
agonist-evoked release o f  [3H]ACh. To address this possibility, control SI response to 1 
pM  nicotine was examined in the presence and absence o f ATR and PH Y :
S 1 (fmol/mg) mean ± SEM
1 pM  nicotine 865 ± 221  (n=$)
1 pM  nicotine 848 ± 1 1 4  (n=7)
+ 1 pM  PHY + 0.5 pM  ATR
Again, neither PHY nor ATR significantly alter the agonist-evoked release o f 
[3H]ACh. Confident that the superfusion conditions themselves would not complicate 
interpretation, the ACh-evoked release experiments were repeated. Anticipating that the 
PHY would shift the dose response curve, the ACh was tested over the range o f 0.5 pM  - 
50 pM  in common with nicotine and cytisine. The initial range o f concentrations used was 
0.5 pM, 1 pM , 5 pM, 10 pM, and 50 pM, but this was subsequently expanded to include 
three intermediate concentrations o f  2.5 pM , 7.5 pM  and 12.5 pM. The results are 
summarised in table 4.9.
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[3H]ACh release (fmol/mg protein)
[ACh] (pM ) 0.5 1.0 2.5 5.0 7.5 10 12.5 50
SI 207 1126 1245 423 0 1210 958 804
SEM 47 190 337 61 0 311 151 296
n 4 9 3 8 3 5 3 4
TABLE 4.9: ACh-EVOKED [3H]ACh RELEASE IN THE PRESENCE OF BOTH ATR AND PHY 
Values are fmol ACh released/mg protein (mean ± SEM), corrected for a [3H]Ch uptake of 80 pmol/mg 
protein/30 min..
Judging by the greatly enhanced potency of ACh in the presence of the 
cholinesterase inhibitor, PHY effectively blocked the action o f the endogenous AChE, with 
the result that full agonist responses (operationally defined as being above 1200 fmol/mg, in 
common with all the other agonists studied) were observed in the concentration range of 1 
pM-50 pM
When these results are plotted, it becomes obvious that the dose response curve 
does not follow the pattern seen for the other agonists. Rather than an a single inverted 'U' 
shape indicative o f desensitisation at higher agonist concentrations, the dose response curve 
for ACh-evoked release shows two distinct peaks o f release: at 2.5 pM  and at 10 pM with 
a clear and reproducible drop in efficacy at both 5 pM and 7.5 pM.
^  1800 - OD
j j  1600 -
g 1400 - 
w 1200 -oo
2 j iooo - 
uj 800 -
js 600 - 
V
<  400 - 
£  200 - 
0 -
-7 - 6  -5 -4 -3
LOG ACh CONCENTRATION (M)
FIGURE 4.14. ACETYLCHOLINE DOSE-RESPONSE CURVE. Synaptosomes were loaded 
with [3H]Ch and superfused in the presence of 1 pM PHY and 0.5 pM ATR. After a 45 min washout 
period, the synaptosomes were stimulated with a 20 s pulse of ACh in Kreb's bicarbonate buffer. Basal 
release was subtracted from agonist-induced peaks to give evoked release which was converted to fmol 
[3HJACh at each ACh concentration. Values are mean ± SEM, n = 3-9.
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Although such a complex curve precluded the possibility o f curve fitting the data to 
the Hill equation and estimating the EC5 0 , it was possible to estimate very crude values in 
an analogous manner to that employed for the ANTX dose-response curve. Half-maximal
release of [3H]ACh was evoked by ACh concentrations of approximately 0.5-1.0 pM, and 
7.5-10 pM.
To ensure that both peaks o f release were mediated via nAChR, the nicotinic 
antagonist DH(3E was added to the perfusion buffer at a concentration o f 1 pM. As 
previously described (section 4.3.2.2.), DH(3E has a broad nicotinic specificity and could be 
expected to block the responses mediated via all nAChR present in the synaptosomal 
membrane, irrespective of subtype.
Two concentrations o f ACh were tested, 1 pM and 10 pM representing both peaks 
of release. As a internal control, 1 pM nicotine was also tested in each experiment. The 
results o f 3 independent experiments are shown in figure 4.15.
STIMULATION
FIGURE 4.15. DHpE BLOCKS BOTH PEAKS OF THE ACh DOSE RESPONSE CURVE.
Synaptosomes were loaded with [3HfCh and superfused. After a 45 min washout period, the synaptosomes 
were stimulated with a 20 s pulse of 1 pM nicotine, 1 pM ACh or 10 pM ACh in Kreb's bicarbonate buffer 
in the presence and absence of 1 pM DHpE. Values are mean ± SEM, n = 3. Evoked release for each drug 
concentration in the absence of DHpE was taken as the 100% control response.
The results indicate that DHPE antagonised the [3H]ACh release evoked by both 
test concentrations of ACh in addition to the nicotine control. Thus it would appear that 
the release o f [3H]ACh over the concentration entire range o f the double-peaked dose 
response curve was mediated via nAChRs.
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4 A . D I S C U S S I O N
4.4.1. CALCIUM DEPENDENCE OF AGONIST-EVOKED 
[3H]ACh RELEASE
Neuronal nAChR have a substantial permeability to Ca2\  and currents through 
these neuronal nAChR, (but not muscle nAChR), are modulated by external Ca2+. In 
contrast to the muscle receptor where external Ca2+ decreases the current carried by 
monovalent cations, in neuronal nAChR ACh-induced currents increase as the extracellular 
Ca2r concentration increases (Vernino et a l, 1992). Application o f nicotinic agonists such 
as nicotine and ACh to CNS neurons (medial habenular neurons) have been shown to cause 
an increase in intracellular Ca2+ concentration ([Ca2+]j) up to the micromolar range. An 
increase that was reversibly abolished when Ca2* was removed from the perfusion medium 
(Mulle et a l, 1992). This modulation by external Ca2+ is observed even when whole-cell 
patch-clamped medial hebenula neurons were internally dialysed with simple electrolyte 
solutions containing 10 mM EGTA or BAPTA which strongly chelate Ca2+ (Mulle et a l,
1992), therefore external not internal Ca2+ accounts for the modulation o f  the nicotinic 
agonist-induced response.
In section 4.3.1. calcium dependence o f  nicotine-evoked [3H]ACh release was 
determined as 87.5%. Similar figures for calcium dependency are reported in the literature: 
Rowell & Winkler (1984) reported that nicotine stimulated [3H]ACh release from mouse 
cerebral cortical synaptosomes was 58% calcium dependent, a rather low figure perhaps 
resulting from the use o f only 100 pM  EDTA to chelate calcium in the superfusion buffer; 
Rapier et a l, (1988) reported a 60% calcium dependency o f nicotine-evoked dopamine 
release from striatal synaptosomes, without the use o f chelating agents in the superfusion 
buffer.
4.4.2. AGONIST-EVOKED [3H]ACh RELEASE
The shape o f  the agonist dose-response curves was consistent with marked 
desensitisation o f nAChRs at higher agonist concentrations (Marley, 1988) and contrasts 
with the dose-response curves obtained for example, when studying the ability o f nicotine 
to evoke [3H]dopamine release from striatal synaptosomes (Rapier et a l,  1988: Grady et 
a l, 1992). This may reflect differences between nicotinic auto- and hetero-receptors. A 
bell-shaped dose response curve has been reported by Araujo et a l, (1988) who studied
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endogenous ACh release from hippocampal and cortical slices in response to nicotine, and 
found maximal release in the 1 pM  to 1 0  (aM range.
The EC 50 values for nicotine and cytisine compare favourably to values reported in
the literature for other presynaptic nicotinic nAChR. For example, for release o f 
[3H]dopamine from rat striatal synaptosomes, Rapier et al. (1988) reported an EC 50 value
of 3.8 pM  for nicotine-evoked release; whilst in 1992, Grady et al. reported EC 50 values
for nicotine- and cytisine-evoked [3H]dopamine from mouse striatal synaptosomes o f 0.48 
pM  and 0.483 jaM respectively.
ANTX was approximately seven times more potent than nicotine or cytisine when 
comparing the EC 50 values, and twenty times more potent when comparing the
concentrations that elicited peak responses. This discrepancy reflects the particularly steep 
dose-response curve for ANTX compared to the other two agonists. As an agonist at the 
presynaptic nAChR, ANTX is approximately an order o f magnitude more potent than 
nicotine and cytisine, which is consistent with the literature (Thomas et al., 1993).
Iso-arecolone was approximately forty times less potent than nicotine or cytisine 
when comparing EC 50 values and approximately eight times less potent, when comparing
the dose required to give a maximal response: a discrepancy again caused by the relative 
steepness o f  the dose response curve for iso-arecolone.
Scaling up the ABT-418-evoked [3H]ACh release data according to the magnitude 
o f the internal nicotine standard has a precedent in the literature. Using 86Rb+ flux from 
mouse striatal synaptosomes as an experimental paradigm, Grady et a l, (1992; 1994) 
reported that agonist- and KCl-evoked efflux can vary 300% over many months, 
necessitating using an internal standard in each experiment, and adjusting the data 
according to this internal standard if  data collected over a considerable time period are to 
be compared.. The variation in agonist-evoked release was not a problem for most agonists 
since responses to  the internal nicotine standard varied very little. A  possible explanation is 
that the bulk o f the agonist dose-response curves (excluding ABT-418) were determined in 
one six month period, whereas the experiments utilising ABT-418 w ere carried out over a 
year later.
The calculated EC50 value for ABT-418-evoked [3H]ACh release was 2.60 ± 0 .1 2 , 
approximately two fold less potent than either nicotine or cytisine at evoking [3H]ACh
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release. Using the paradigm o f nAChR-mediated 86Rb* efflux from mouse thalamic 
synaptosomes, M arks et al., (1994) have reported an EC 50 value o f 6 pM  for ABT-418- 
evoked efflux, which compares well to the value calculated in the present study. M arks et 
a l, (1994) also reported ABT-418-induced desensitisation o f the thalamic nAChRs at 
doses comparable with nicotine-induced nAChR desensitisation in the same preparation, 
again in agreement with this study. Inverted-’U ’ shaped dose response curves have also 
been reported in behavioural studies involving ABT-418-induced retention o f inhibitory 
avoidance training in mice (Decker et al., 1994), suggesting that the relevance o f agonist 
dose-dependency extends beyond in vitro biochemical/pharmacological studies.
In summary, one o f  the obvious things to note about the agonist dose response 
curves (figures 4.3., 4.6., 4.8., 4.10., and 4.11.) is that all the agonists evoked an 
approximately equal maximum release o f [3H]ACh, in fact none o f the maximal responses 
were statistically different from one another (p>0.05; paired ‘t ’-test). So while the 
potencies o f the agonists varied considerably from extremely potent (ANTX) to  less potent 
than nicotine (iso-arecolone), the agonists were equally efficacious, table 4.10. presents a 
summary.
Nicotine Cytisine ANTX Iso-arec ABT-418 ACh *
Maximal [3HJACh 1335 ' 1456 1225 1546 1345 1245 ±337;
release (fmol/mg) ±92 ±215 ± 177 ±371 ±50 1210 ±311
[Agonist] producing 10 pM 10 pM 500 nM 100 pM 10 pM 2.5 pM;
maximal release 10 pM
TABLE 4.10: COMPARISON OF MAXIMAL EVOKED [3H]ACh RELEASE AND AGONIST 
CONCENTRATION REQUIRED TO PRODUCE MAXIMAL RELEASE. Data obtained from tables 4.1., 
4.4., 4.5., 4.6., and 4.9., and figure 4.11. * ACh-evoked release in the presence of ATR and PHY, data 
from both peaks of [3H]ACh release are quoted.
4.4.3. ANTAGONIST STUDIES
Methyllycaconitine (MLA), the toxic alkaloid from the seeds of Delphinium spp. is
125
three orders o f magnitude more potent in competition binding assays at the [ I]a-
125 • 3bungarotoxin ([ I]a-B gt) binding site than at the [ H]nicotine binding site: the reported
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for inhibition o f  [ I]a-B gt to rat brain P2 is o f  the order o f 1 nM (W ard et a l, 1990), 
whilst the Kj for inhibition o f  [3H]nicotine in the same preparation is 3.7 pM  (MacAllan et
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a l, 1988). Thus I pM  MLA would be expected to block all a7-m ediated release without 
significantly affecting any o f the other nAChR subtypes present. 10 |iM  M LA on the other 
hand would be expected to significantly inhibit all the nAChR present in the presynaptic 
membrane.
The inhibition o f 10 (nM nicotine-evoked [3H]ACh release by the lower 
concentration o f  MLA (1 pM) did not reach statistical significance in common with the 
studies o f Drasdo e ta l ,  (1992), who reported a non-significant, 16% inhibition o f nicotine- 
evoked [3H]dopamine release from rat striatal synaptosomes. In contrast, 10 |aM MLA did 
significantly inhibit 10 jiM nicotine-evoked [3H]ACh release, also in agreement with 
Drasdo et a l, (1992).
The inhibition o f the KCl-evoked release was largely independent o f MLA 
concentration and it is possible that the M LA was perhaps able to non-selectively channel 
block at micromolar concentrations, thus preventing either nicotine or KC1 from evoking 
100% o f the release observed in the control chambers. I f  approximately 2 0 % o f the 
inhibition observed was independent o f  the nAChR as indicated by the inhibition o f the 
KCl-evoked release, then it is clear that 1 pM  MLA had little inhibitory effect on the 
nAChR-mediated transmitter release, thus ruling out any major role for the a 7  receptor 
subtype.
4.4.1. POSSIBLE nAChR SUBTYPES IN THE RAT 
HIPPOCAMPUS
COMPARISON W ITH OTHER STUDIES
The subunit composition o f  the nAChR mediating feedback modulation o f ACh 
release in the hippocampus is unknown, but one candidate is the a 4 p 2  subtype. This
defined nAChR, stably expressed in mouse M10 cells (Whiting et a l,  1991) was examined
86 + .
using a Rb influx assay (Stephens, 1994; Thomas et a l, 1993). The results are similar 
with the data presented in this chapter.
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ECW b iM )
nA C hR
PR EPA R A T IO N
(-)-NICOTINE CYTISINE (+)-ANTX
PR ESY N A PTIC 0.99 ± 0.23 1.06 ± 0 .15 0.14 ± 0 .0 4
nA C hR s (4) (3) (3)
ct4P2 * 2.7 ± 0 .7 3.7 ±1 .1 0.048 ± 0 .018
nA C hR (5) (3) (4)
TABLE 4.11: COMPARISON OF EC50 VALUES FOR (-)-NICOTINE, ANTX, AND CYTISINE IN
DIFFERENT NEURONAL nAChR PREPARATIONS. Data are mean ± SEM (no. of preparations). * Data 
from Stephens (1994).
The rank order o f potency in both preparations is the same: ANTX > nicotine = 
cytisine. That the agonist cytisine is as potent as nicotine in the presynaptic hippocampal 
synaptosome preparation would appear, on first analysis to rule out a role for any p2 - 
containing nAChR subtypes: Luetje & Patrick (1991), found cytisine to be largely devoid 
o f  agonist potency at p2-containing nAChR expressed in Xenopus oocytes. However, the 
mouse M10 cells stably express a defined nAChR subtype containing the p2 subunit, and in 
this preparation the results clearly indicated that cytisine was a full and potent agonist. 
Cytisine was also examined on a4P2  chick nAChRs using the oocyte expression system by 
Bertrand (personal communication) and found to  be a full agonist with an E C 5 0  value of
1.8pM, comparable to that derived for cytisine in both the hippocampal synaptosome and 
cell expression system. Very recent data suggest that the antagonist DHPE may not have 
the pan-subunit specificity that was previously envisaged (section 4.3.2,2.). Luetje et a l, 
(1993) report that in oocytes expressing combinations of a3 , P2 and P4 subunits, nAChRs 
comprising p2 subunits are 50 fold more sensitive to block by DHPE than nAChRs 
comprising p4 subunits. Indeed, in the reported study, 3 pM  D HpE did not produce a 
statistically significant block in a3 p 4  subunits. This is interesting because in the present 
study ACh-evoked release was blocked by 1 pM  DHpE, suggesting that the p2 receptor is 
involved, which is compatible with the in situ hybridisation studies outlined below. A note 
o f caution should be added however, because it was the oocyte studies with P2- and P4- 
containing nAChRs o f Luetje & Patrick., (1991), that initially reported a lack o f  cytisine 
potency at p2-containing nAChRs.
I l l
Compared to nicotine, ABT-418 has reduced potency to interact with the subunit 
forms o f  nAChR found in sympathetic ganglia, and it does not compete for a-B g t sites in 
brain or at the neuromuscular junction. ABT-418 was reported to be equipotent with 
nicotine at evoking 86Rb+ efflux from mouse thalamic synaptosomes (Arneric et al., 1994; 
Marks et al., 1994), thought to result from the activation o f  the putative a4 p 2  nAChRs 
(Marks et al., 1993), but 10-fold less potent than nicotine at evoking [3H]dopamine release 
from rat striatal slices, a preparation that has been suggested to involve a3  subunit 
activation. The observed pharmacology o f  ABT-418 is also compatible with the presence 
of a4J32 receptors, in terms o f equipotency in evoking [3H]ACh release, compatible with 
the studies o f  Arneric et al., (1994).
It is reasonable to assume that the presynaptic nAChR in the hippocampus could 
contain a 02 subunit, indeed from the rank order o f agonist potency, and the comparison of 
EC50 values in the three preparations, the a4 p 2  subtype would appear to be a good 
candidate for the presynaptic hippocampal nAChRs.
ACh-EVOKED [3H]ACh DOSE RESPONSE CURVE
A particularly puzzling aspect o f  the agonist dose response curves, was the shape o f 
the curve evoked by the endogenous agonist ACh. The evidence for two distinct peaks of 
release is contrary to the studies with the other agonists. One possible explanation is that 
ACh was activating more than one subpopulation o f nAChRs, each with a distinct 
pharmacology and presumably different affinities for ACh. The major problem with this 
explanation is that if subpopulations exist, which is perfectly feasible, then why was the 
differential agonist sensitivity not revealed with any o f the other agonists? The answer 
could lie in the range o f agonist concentrations chosen to probe the hippocampal nAChRs. 
An examination o f  figures 4.3. and 4.6. shows that the dose response curves for nicotine 
and cytisine are sufficiently broad that they could result from overlapping distinct curves, 
masking the existence o f more than one nAChR subunit combination.
IN  SITU  EVIDENCE
With respect to the hippocampus, information from in situ hybridisation studies can 
suggest which subunits may be present to contribute to functional nAChR, although these 
studies are more difficult to  interpret in the case o f presynaptic receptors. The cholinergic
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innervation o f  the rat hippocampus arises from cell bodies in the medial septum and 
diagonal band o f  Broca (Fibiger & Vincent, 1987) (see figure 1.1.) According to the 
extensive study o f  Wada etal. (1989), these regions express a4> P 2 = a2 » o c3 . Notably, no 
specific hybridisation o f the p4 subunit has been seen in the septum (Dineley-Miller & 
Patrick, 1992). This would appear to discount the possibility o f  nAChR containing P4, to 
explain the observed cytisine efficacy. Perhaps more complex subunit combinations (see 
section 1.3.2.1.) including a2 , may occur. The a5  subunit has been shown to be associated 
with a 4  and a 2  in brain (Conroy et al., 1992) but a5  is not expressed in the septum, as 
judged by in situ hybridisation (W ada et al., 1989).
a l  nAChRs
Although there are few quantitative data available for other subunit combinations, 
we can confidently discount the a l  subtype: the latter shows much lower sensitivity to 
agonists (Bertrand et a l, 1992; Amar et al., 1993) and the presynaptic autoreceptor is 
insensitive to a -B g t (W onnacott et al., 1989).
SUMMARY
In summary, from the available pharmacological and in situ hybridisation data, the 
candidates for the presynaptic hippocampal nAChR are various combinations of a4 , a 2  and 
to a lesser extent a3 , in combination with the P2 subunit. The evidence presented in this 
chapter suggests a strong role for the a4 p 2  subunit; there are no ligands available to dissect 
out any contribution by the a l  subunit, though any contribution by a3  could be selectively 
blocked by neuronal bungarotoxin (nBgt) which is a potent antagonist of a3-containing 
nAChR whilst only weakly antagonising either a4 p 2  or a2 p 2  receptor subtypes (Luetje et 
al., 1990). Unfortunately, nBgt has not been available to carry out the necessary 
experiments to delineate any role of a3-containing nAChR subtypes.
4.4.2. AGONIST-EVOKED DESENSITISATION
In a global sense, desensitisation (also known as tachyphylaxis, tolerance, 
refractoriness, subsensitivity or down-regulation; see Ochoa et al., 1989) refers to the loss 
o f cell or tissue response after an appropriate stimulus is applied repeatedly or for a 
prolonged period o f time. It is well documented the desensitisation o f  the nAChR can be
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triggered by prolonged or repeated exposure to agonists and results in inactivation o f the 
nAChR ion channel (section 1.3.2.4.),
From the results reported in this chapter, it would appear that each agonist studied 
is able to induce desensitisation o f the nAChRs at sufficiently high concentration, within the 
duration o f the agonist pulse (20 s), yielding inverted-’U’ shaped dose-response curves. 
This would at first seem to be a particularly rapid phenomenon, however Rowell & 
Hillebrand (1994) reported that nicotine-evoked [3H]dopamine release was subject to 
desensitisation even at nanomolar concentrations o f agonist, and was found to be a first- 
order process with a half-time o f approximately 40 s. Marks et a l, (1994) reported ABT- 
418-induced desensitisation o f [3H]dopamine release from striatal synaptosomes, at both 
non-stimulating (nanomolar) and stimulating (micromolar) concentrations, with a similar 
rate o f onset that increased with increasing agonist concentration. Hence it is conceivable 
that the lower doses o f agonists used in the present study were also able to evoke nAChR 
desensitisation, but this phenomenon was not apparent because o f  the relatively short 
agonist exposure time.
The phenomenon o f desensitisation is studied in more detail in the next chapter.
CHAPTER 5 bCSEIMSITaS^TiOIM 5 1 ^ bflES
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5 . 1._ I N T R O D U C T I O N
5.1.1. REPETITIVE AGONIST STIMULATION
Using the experimental paradigm o f [3H]ACh release from synaptosomes to study 
the hippocampal nAChRs (chapter 4), it was found that for each o f the agonists studied, 
agonist-evoked transmitter release yielded bell-shaped dose-response curves suggestive o f 
nAChR desensitisation at higher agonist concentrations. The extent o f  this desensitisation 
at the various agonist concentrations can be studied by stimulating the synaptosomes twice 
in succession at each agonist concentration, giving the second agonist stimulus (S2), 30 
min after the first (SI). In this way, nAChR desensitisation induced by submaximal 
concentrations o f  agonist may be studied. In chapter 4 desensitisation was only apparent at 
the highest doses o f agonist and it was thought that this could be a reflection on the 
methodology since several groups (e.g. Rowell & Hillebrand, 1994) have reported that 
nanomolar concentrations o f nicotine are able to induce nAChR desensitisation, albeit at a 
slower rate than at micromolar concentrations.
This procedure o f repetitive stimulation is a common pharmacological tool used to 
study desensitisation. For example, Rapier et al., (1988; 1990) used the technique to study 
nicotine-evoked [3H]dopamine release from rat striatal synaptosomes The study reported 
that there was decreased responsiveness with repeated exposure to nicotine, suggesting 
nAChR desensitisation. Also using [3H]dopamine release as the experimental paradigm, 
Grady et a l, (1994), and Rowell & Hillebrand, (1992; 1994), approached the problem 
slightly differently. By continuously superfusing synaptosomes in the presence o f a wide 
range o f  nicotine concentrations, including nanomolar nicotine concentrations that do not 
themselves elicit transmitter release, both groups showed that nicotine pretreatment 
attenuates the subsequent ability o f a discrete pulse o f nicotine to evoke [3H]dopamine 
release.
In this chapter the effects o f  repetitive agonist stimulation on the release o f 
[3H]ACh from the rat hippocampal synaptosomes will be examined, by delaying the second 
stimulation for 30 min, the nAChRs are allowed to recover and the [3H]ACh evoked by the 
S2 pulse is an index revealing the extent to which this recovery is complete.
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5.1.2. SUBSTANCE P
As outlined in section 1.7., a number o f  studies have shown that SP is able to 
modulate the nAChR-mediated release o f neurotransmitters in CNS and PNS tissue 
preparations, and specifically to influence the rate and extent o f nAChR desensitisation. In 
chapter 4 it was established that at high concentrations, a 20 s pulse o f  nicotine (S I) is 
sufficient to produce rapid nAChR desensitisation. There is also the possibility that much 
lower concentrations are also able to significantly induce desensitisation, which will be 
investigated in this chapter, at the same time the effects o f SP pretreatment on this 
desensitisation phenomenon will be investigated.
Grady et al., (1992; 1994), and Rowell & Hillebrand, (1992; 1994) used an 
experimental design in which striatal synaptosomes were superfused with non-activating 
concentrations o f  nicotine to induce desensitisation, then stimulated with an activating 
nicotine concentration. The resultant transmitter release was then compared to that 
obtained with no nicotine pretreatment. The present study utilised an analogous 
experimental design, [3H]Ch-loaded hippocampal synaptosomes were superfused in the 
presence and absence o f SP and then challenged with an activating (micromolar) 
concentration o f  nicotine (SI). The ability o f  nicotine to evoke release subsequent to 
pretreatment with a range o f SP concentrations should yield information about the ability of 
SP to induce nAChR desensitisation in its own right.
In addition to any possible effects on SI nicotine-evoked [3H]ACh release, the 
ability o f SP to modulate agonist-induced nAChR desensitisation was studied by repeating 
the repetitive agonist stimulation experiments in the presence o f SP. In this way, any 
changes in the recovery o f the nAChR from SI-induced desensitisation would be reflected 
by changes in the S2/S1 ratio.
5.I.2.1 SP and [3H]nicotine Binding Sites
Further to  the superfusion studies mentioned above, the interaction o f SP with the 
hippocampal nAChRs was investigated by conducting [3H]nicotine binding assays. By 
directly competing SP (10‘9 - 10'5 M) with 20 nM [3H]nicotine, it is possible to assess 
whether the peptide is acting as a competitive inhibitor at the hippocampal nAChRs. 
Saturation binding o f [3H]nicotine in the presence and absence o f SP (10*5 M), provides
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information as to whether SP affects the K<j or Bmax o f the [3H]nicotine binding in the 
hippocampus.
5.I.2.2. Nicotine and [3H]SP Binding Sites
An estimation o f the density o f  rat hippocampal SP binding sites was not possible 
due to the prohibitive cost o f tritiated SP ligands - it was not economically viable to carry 
out more than a pilot saturation study using hippocampal SI membranes (section 2.1.3.), 
Saturation binding with [3H][Sar9,M et(02)1 ^ substance P ([3H]SP), a ligand specific for the 
NK1/SP receptor (see section 2.3.3.), was estimated in a saturation binding assay with a 
limited range o f [3H]SP concentrations. Reports o f SP binding in mammalian brain are 
scarce, and usually limited to competition binding studies, presumably because the 
radioligands are so expensive. However functional studies using unlabelled SP have 
established that NK1 receptors are present in limbic and midbrain dopaminergic areas 
(Mantyh et a l, 1989) where they mediate SP-induced increases in dopamine turnover 
(Cador et a l, 1989). In the locus coeruleus, SP has an excitatory action that is mediated 
through activation o f NK1 receptors (McLean et a l, 1991). See also section 1.6. for 
further evidence o f SP receptors in the CNS.
SP has been reported (Min & Weiland,1993) to interact with two populations o f 
binding sites on the nAChR, a low affinity and a high affinity site (section 1.6.2.2.), The 
high-affinity binding site is dependent on the presence o f nicotinic agonist (Min et a l,
1993), therefore the saturation binding o f [3H]SP in the presence and absence o f nicotine, 
was examined, to test whether the equilibrium binding o f the tritiated ligand would differ 
significantly in the presence and absence o f nicotine.
5 .2._ METHODJS
5.2.1. REPETITIVE AGONIST STIMULATION
The standard protocol for agonist-evoked release (section 2.2.6.1.) was adapted as 
follows: after a 45 min washout period the synaptosomes were stimulated with a test pulse 
o f agonist (nicotine or cytisine; SI); following a 30 min recovery period the synaptosomes 
were stimulated again with an identical pulse o f  agonist (S2). The results are expressed in 
terms o f  the S2/S1 ratio, corrected in each case for an uptake o f  [3H]Ch o f  80 pmol/mg 
protein/30 min. In each experiment, a standard pulse o f 1 pM  nicotine was included as both
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SI and S2, to serve as a control. I f  the SI control response differed from the mean 1 pM 
nicotine response (865 ± 221 fmol/mg protein; section 4.3.2.1.) by more than one standard 
deviation, the experiment was disregarded. To control for the effects o f  [3H]ACh pool 
depletion, causing an apparent attenuation in responsiveness in the S2 pulse, 20 mM KC1 
was also used as SI and S2 test pulses. Since KCl-evoked [3H]ACh release is not mediated 
by the nAChRs (section 4.3.2.2.), the extent to which pool depletion causes any apparent 
decrease in the S2 /S1 ratio can be assessed.
5.2.2. SP
Synaptosomes were superfused according to the standard agonist-evoked release 
protocol (section 2 .2.6.I.), which was adapted as follows: Kreb’s buffer included leupeptin 
(4 pg/ml), chymostatin (2 pg/ml), bacitracin (40 |ig/ml), and BSA (200pg/ml). These 
protease inhibitors and BSA, served to protect SP from proteolytic degradation by endo- 
and exo-peptidases present in the synaptosomal preparation, and were added after the 
gassing stage to  prevent excessive frothing o f the Kreb’s buffer. SP was dissolved in the 
Kreb’s buffer. The pH o f the buffer was always maintained at 7.4.
To study the effects o f SP on the agonist S2/S1 ratio, all chambers were initially 
superfused with K reb’s buffer containing the protease inhibitors and BSA, in the absence of 
SP and challenged with a 20 s pulse o f  lp M  nicotine (SI). The synaptosomes were allowed 
the usual 30 min recovery period before the S2 pulse, but for the last 6 min, the reservoir 
buffer was changed and the synaptosomes were superfused in the presence o f  SP (10'6 - 10‘ 
9 M). This is an adaptation o f the protocol used by Khalil et a l, (1988), to  probe the effect 
o f SP on nicotine induced desensitisation m cultured bovine adrenal chromaffin cells.
The protocols for radioligand binding are detailed in section 2.3.
5.3._ R E S mU L T S  
R E P E T IT I V E  S T IM U L A T IO N
5.3.1. REPETITIVE NICOTINE STIMULATION
The effect o f  repeated stimulation with (-)-nicotine was studied over the 
concentration range 10*7 - 5xlO'5 M  and the results are shown in table 5.1. At a
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concentration o f 100 nM nicotine, the second agonist stimulus (S2) was equal to 100% of 
the SI pulse. As the concentration o f  nicotine increased, the S2 stimulus declined as a 
percentage o f  the SI response: the S2/S1 ratio declined to approximately 0.25. At every 
nicotine concentration over 100 nM, the S2 release was significantly smaller (p<0.01) than 
the SI release. At the highest nicotine concentrations o f 10 |iM  and 50 pM, a subsequent 
nicotine pulse (S2) was able to evoke only approximately 25% o f  that release seen with 
drug-naive synaptosomes (S I).
[Nicotine] SI S2 S3 S2/S1
[iM 20 m M  KC1
[3H ]A C h RELEA SE (fmol/mg)
0.1 122 ± 5 122 ±21 247 ± 22 1.0
0.5 400 ± 71 247 ± 63 200 ± 48 0.62
1.0 820 ± 97 289 ± 34 241 ± 2 7 0.35
5.0 904 ± 159 288 ±81 308 ± 41 0.32
10.0 1335 ± 9 2 277 ± 49 234 ± 22 0.21
50.0 688 ±191 183 ± 5 6 272 ± 18 0.27
TABLE 5.1: RELEASE OF [3H]ACh EVOKED BY SUCCESSIVE STIMULATIONS WITH NICOTINE. 
Values are mean ± SEM, n=3-4
At 50 pM  nicotine, the SI release in absolute terms (688 ± 1 9 1  fmol/mg protein), 
was intermediate between that release observed in response to 0.5 pM  nicotine (400 ± 7 1  
fmol/mg protein) and 1.0 pM  nicotine (820 ± 97 fmol/mg protein). I f  pool depletion was 
completely responsible for the decrease in S2/S1 ratio with increasing agonist 
concentration, then the S2/S1 ratio for 50 pM  nicotine (0.27) should also be intermediate 
between the S2/S1 ratio for 0.5 pM  nicotine (0.62), and that ratio for repetitive stimulation 
by 1.0 pM  nicotine (0.35). This is clearly not the case, and although pool depletion cannot 
be ruled out as a contributing factor in the decreased S2/S1 ratio, especially at maximal 
[3H]ACh release (the ratio at 10 pM  nicotine: 0.21, exceeds that at 50 jiM: 0.27), it would 
seem likely that agonist-induced receptor desensitisation is a major cause o f  the attenuation 
o f transmitter release upon repetitive agonist stimulation.
Supporting evidence comes from experiments using 20 mM KC1 as the SI and S2 
stimuli. The S2/S1 ratio for 20 mM KCl-evoked release is 1.09 (data from nine
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independent assays), arguing against pool depletion playing a major role in the observed 
attenuation o f  agonist-evoked release.
At each concentration o f nicotine, the synaptosomes were challenged for a third 
time (S3) with 20 mM KC1. An examination o f the results o f  the S3 stimulus is 
enlightening. The mean KCl-evoked release was 253 ± 16 fmol/mg protein. Table 5.1. 
breaks down the S3 stimulus results according to the concentration o f nicotine used in the 
SI and S2 challenges; however none o f the individual S3 values were statistically different 
(p>0.05) from the calculated mean, providing perhaps the most convincing evidence pool 
depletion alone is not sufficient to account for the decrease observed in the S2/S1 ratio, 
assuming that agonists and KC1 evoke [3H]ACh release from the same intra-synaptosomal 
pool. Rowell & Hillebrand (1994) reported that agonist-induced desensitisation recover 
relatively slowly compared to the onset, and that the recovery from a 20 min exposure to 
30 nM nicotine was 85% after 40 min. It is therefore entirely reasonable that using the 
much shorter exposure time o f 20 s, the recovery from 100 nM nicotine-induced 
desensitisation was complete in the present study. It also seems feasible that recoveries o f 
less than 30% were noted after 30 min using the much higher nicotine concentrations in the 
range 10 to 50 pM. The release data are represented in figure 5.1.
The histogram (figure 5.1.) summarises the effects o f repetitive agonist stimulation. 
The SI response at increasing nicotine concentrations has been described previously 
(section 4.3.2.1.). The S2 responses were also broadly bell-shaped, which is to be 
expected: as the concentration o f  S2 nicotine increases, the amount o f  evoked [3H]ACh 
release also increased correspondingly, but at nicotine concentrations exceeding 1 pM, the 
effects o f SI-induced nAChR desensitisation were sufficient to cause attenuation o f the 
subsequent S2-evoked response. In addition at the highest nicotine concentrations, the S2 
challenge itself was probably able to induce nAChR desensitisation within the 20 s time 
scale o f  the pulse. The KCl-evoked [3H]ACh release remained relatively consistent and did 
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FIGURE 5.1. HISTOGRAM SHOWING THE EFFECTS OF REPETITIVE NICOTINE 
STIMULATION. Data were taken from table 5.1.
5.3.2. REPETITIVE CYTISINE STIMULATION
To control for the possibility that the nAChR desensitisation induced by 
repetitive stimulation, was a phenomenon peculiar to the agonist nicotine, the repetitive 
agonist stimulation experiments were repeated using cytisine (10'7- 10‘5 M). The results are 
summarised in table 5.2. and mirror the trends observed using nicotine. The S2/S1 ratios 
generally decrease with increasing agonist concentration, the only anomaly being the 
particularly low value of 0.21, recorded for a cytisine concentration o f 1.0 M, though 
since the data are from only three independent sets o f experiments, this low ratio could be 
simply experimental variation with three low S2 values at this concentration leading to a 
falsely low ratio, a possibility that could be examined if further experiments were carried 
out.
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[Cytisine] SI S2 S3 S2/S1
HM 20 mM KC1
[3H]ACh RELEASE (fmol/mg)
0.1 160 ± 6 0 187 ± 2 0 183 ± 45 1.17
0.5 394 ± 124 309 ± 63 181 ± 3 8 0.78
1.0 775 ± 127 166 ± 3 7 239 ± 93 0.21
5.0 993 ± 160 279 ± 70 197 ± 3 0 0.28
10.0 1456 ± 215 242 ± 58 335 ± 51 0.17
TABLE 5.2: RELEASE OF [3H]ACh EVOKED BY SUCCESSIVE STIMULATIONS WITH CYTISINE. 
Values are mean ± SEM, n=3.
The mean KCl-evoked S3 release o f [3H]ACh was: 237 ± 2 7  fmol/mg protein. This 
is not significantly different (p>0.05) from the S3 release in the repetitive nicotine 
stimulation experiments (253 ± 16 fmol/mg protein and none o f the individual S3 mean 
values shown in table 5.2. are significantly different (p>0.05) from this overall mean value. 
The individual values do not show any trends: it would seem that the release o f  [3H]ACh 
evoked by KC1 was independent and unaffected by the concentration o f the previous 
nicotine stimuli.
S P  S T U D I E S
5.3.3. SP AND NICOTINE-EVOKED [3H]ACh RELEASE.
To study the effects o f SP on SI release, the synaptosomes were superfused with 
SP (10'6 - 10‘9 M ) dissolved in the Kreb’s*buffer throughout the duration o f  the experiment. 
Nicotine (1 pM ) was used as the SI test pulse in each case. One chamber was always 
superfused using Kreb’s buffer containing the protease inhibitors but no SP, to  control for 
any effects that the protease inhibitors themselves might have on basal and agonist-evoked 
[3H]ACh release. The results for control SI (1 pM  nicotine), release o f  [3H]ACh, versus 
SP-pretreatment are summarised in table 5.3. At no concentration does SP pretreatment 
significantly change the nAChR-mediated release o f [3H]ACh from hippocampal 
synaptosomes compared to the control release in the absence o f  SP.
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CONDITION 1 pM  NICOTINE-EVOKED  
ACh RELEASE (fmol/mg)
(n)
Control 654 ± 25 3
1 0 9 M SP 576 ±81 2
1 0 8 M  SP 741 ± 7 6 2
1 0 7 M  SP 647 ± 52 2
10 6 M  SP 665 ± 43 2
TABLE 5.3: EFFECT OF SP PRETREATMENT ON NICOTINE-EVOKED [3H]ACh RELEASE. Values 
are Ihe mean ± SEM, or mean ± range, where n - 2 .
In section 5.3.1. the release evoked by 1 pM  nicotine was 820 ± 97 fmol/mg, this is 
significantly larger (p<0.05) than the control [3H]ACh release in table 5.3. o f 654 ± 24.9 
fmol/mg. The difference between the two protocols was the presence o f  the protease 
inhibitors leupeptin, bacitracin, and chymostatin as well as BSA, in the SP experiments.
A possible interpretation is that although SP has no appreciable effect at any 
concentration on the S l-evoked release, the protease inhibitors and/or the BSA, inhibit 
nicotine-evoked [3H]ACh release by approximately 20%. The effects o f the protease 
inhibitors on the basal release profile was examined. In a single experiment, six chambers 
were superfused in the presence, and six chambers in the absence o f  the protease inhibitors 
and BSA. At fraction 13, immediately prior to the SI challenge, the basal release was: 
K reb’s buffer: 9947 ± 147 cpm
K reb’s + Inhibs./BSA: 9817 ± 121 cpm
Clearly there is no difference between the basal [3H]ACh in either condition. 
Furthermore, in section 3.3.3. the typical basal release at fraction 13 was calculated to be 
9271 ± 832 cpm (n=25), and so the release in the presence o f the inhibitors was completely 
typical.
5.3.4. SP AND THE NICOTINE-EVOKED S2/S1 RATIO
All chambers were challenged with an S 1 pulse o f 1 pM  nicotine. The mean evoked 
[3H]ACh release was 629 ± 25 fmol/mg. The S2 challenge (1 pM  nicotine) gave a mean S2 
response o f  255 ± 16 fmol/mg (n=4) and this was taken to be 100%. A reduction o f 
approximately 20% in the SI value with only a small, non-significant, reduction in S2 
means that the S2/S1 ratio was 0.41, with the apparent increase reflecting the reduced SI 
response. The S2 responses following SP pretreatment (10*9 - 10"6 M; 6 min prior to S2) or
123
Kreb’s buffer were calculated as a percentage o f the control response. The results are 
summarised and the S2/S1 values calculated in table 5.4.
CONDITION S2 (% CONTROL) S2/S1
Control 
1 0 9 M SP
10 8 M SP
1 0 7 M  SP




60.0% * 0.24 * 
87.8% 0.36
TABLE 5.4: EFFECT OF SP ON THE AGONIST-EVOKED S2/S1 RATIO. Values are the mean for n=3-
*
4, SEM were <10% of the mean in each case, = significantly different from control at p<0.05.
At a concentration o f 1 pM, SP had an small, non-significant inhibitory effect on 
this recovery from desensitisation, an effect which became more pronounced as the 
concentration o f SP decreased from 1 ttM to 1 nM. This is discussed in the section 5.4.2.
5.3.5. [3H]NICOTINE BINDING AND SP
5.3.5.I. Competition Binding
The effects o f  SP on the equilibrium binding o f 20 nM [3H]nicotine to rat 
. hippocampal SI membranes are summarised in table 5.5. At no concentration o f SP is 
the[3H]nicotine binding significantly different (p>0.05) from the control.
CONDITION % CONTROL BINDING (n)
Control 100% 4
10 9 M  SP 103% 4
10 8 M  SP 105% 4
1 0 7 M  SP 119% 3
10 6 M  SP 99.2% 3
1 0 5 M  SP 103% 4
TABLE 5.5: EFFECT OF SP ON THE EQUILIBRIUM BINDING OF 20 nM [3H]NICOTINE. Values 
shown are the mean, SEM <10% at each concentration. Control (binding in absence of SP) defined 
independently in each individual assay. 100% control binding = 20.0 ± 5.8 fmol/mg protein. Protease 
inhibitors were included in the assay buffer to stabilise SP (section 2.3.1.2.).
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It appears unlikely that SP is an inhibitor o f [3H]nicotine binding to hippocampal 
membranes, though it is possible that no apparent inhibition was observed because the 
range o f  concentrations o f SP was too narrow. Min & Weiland (1993) described no SP 
inhibition of l25I-a-B gt binding to Torpedo membranes, until the SP concentration 
exceeded 100 pM. However such high concentrations o f  peptide are probably 
unphysiological and not relevant to the superfusion studies described above, where the 
highest concentration o f SP used was 10 jaM. SP concentrations in rat brain are reported to 
be * approximately 100 pmol/gram brain tissue (McGeer, 1987) compared with 
approximately 25 nmol/gram, for ACh. Thus it is likely that endogenous concentrations o f 
SP would not exceed high nanomolar/low micromolar.
5.3.5.2. S a tu ra tion  B inding
The approximate EC5o value determined in functional studies o f  SP inhibition o f 
nAChR activation (Boyd & Leeman, 1987; Simasko et al., 1987; Min & Weiland, 1992), is 
10 pM  SP. This concentration o f SP was used by Min & Weiland (1993), who determined 
that at 10 |iM , SP increased the affinity o f [3H]ACh binding to Torpedo membranes 
approximately threefold, from 250 ± 60 nM to 85 ± 2 nM. In six independent experiments 
carried out in triplicate, the saturation binding o f  [3H]nicotine was examined in the presence 
and absence o f  10 (iM SP. The results are shown in table 5.6., figure 5.2. is a representative 
saturation isotherm.
CONDITION Kd (nM ) Bmax
(fmol/mg protein)
CONTROL  
+ 10 (iM SP
4.4 ± 1.5 29.9 ± 5 . 4  
5.2 ± 1.2 30.1 ± 5 . 9
TABLE 5.6: EFFECT OF SP ON SATURATION BINDING OF [3H]NICOTINE TO HIPPOCAMPAL SI 
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FIGURE 5.2. A REPRESENTATIVE ISOTHERM SATURATION BINDING OF 
[3HlNICOTINE TO HIPPOCAMPAL SI MEMBRANES. Membranes were incubated with increasing 
concentrations of [3H]nicotinc (0.5 - 25 nM) as described in section 2.2.1.
At a concentration o f 10 pM, SP did not significantly affect either the observed 
maximum number o f binding sites, or the apparent affinity of the agonist for these sites.
5.3.6. [3H]SP BINDING AND NICOTINE
5.3.6.I. Saturation binding
A single [3H]SP saturation binding experiment was performed in triplicate in order 
to estimate the approximate Bmax and Kd of NK1/SP binding sites in the hippocampal SI 
membrane preparation.
The experiment yielded the following saturation curve (figure 5.3.) with an 
approximate Kd o f 20 nM and Bmax o f 80-100 fmoles/mg protein. This crude estimation 
agrees rather well with other reported studies such as Utkin et al., (1989), who reported a 
binding density o f 60 ± 10 fmoles/mg protein, and a Kd of 9.0 ± 6.0 nM using [125I]BH-SP 
as a ligand to probe NK1/SP sites in rat brain membranes. According to Quirion & Dam 
(1993), [3H]SP apparently binds to a single class o f high affinity (IQ = 1.4 ± 0.5 nM), low 
capacity (Bmax = 160 ± 3.0 fmol/mg protein) sites in rat brain homogenates. The same 
authors report that at concentrations approximating Kd values, specific binding reached 
rapid equilibrium (< 30  min) at 25°C and represented between 70 and 75% of total binding. 
The ligand [3H]SP specifically and selectively labels the NK1/SP receptor subtype since 
only NK1 competitors such as substance P and unlabelled [Sar9,M et(02)1 ^ substance P 
behave as potent competitors (Kj in low nanomolar range) in this assay whereas selective
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NK2 ([Nle10]NKA4 -io) and NK3 (senktide) analogues are virtually inactive (Dam et a l, 
1990). As a first approximation, the single saturation experiment reported in this study 
yields Kd and B max values in the right range, it is also possible that the density found in rat 
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FIGURE 5.3. SATURATION ISOTHERM  FOR THE BINDING OF [3H] SP TO 
HIPPOCAM PAL SI MEMBRANES. Membranes were incubated with increasing concentrations of 
[3H]SP (0.01 - 200 nM) as detailed in section 2.3.3.1.
The Bmax for [3H]SP binding was approximately three times greater than the Bmax 
for [3H]nicotine binding sites. Even allowing for high affinity SP binding to the nAChRs (1 
SP site/nAChR; Min et a l, 1994), the density o f SP/NK1 receptors greatly exceeds the 
density o f the nAChRs. According to Min et a l, (1994), SP binding to the nAChRs is 
increased 300 - 400% if the binding assay is performed in the presence o f nicotinic agonist. 
Hence a [3H]SP competition assay versus nicotine was conducted.
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§.3.6.2. Competition Binding
Binding o f [3H]SP at its approximate Kd value (20 nM) to hippocampal SI 
membranes was carried out in the presence and absence o f  increasing concentrations o f 
nicotine (10 '1° - 10'6 M). A single competition assay was performed in triplicate. The 
results are shown in table 5.7. A 300 - 400% increase in binding would be rather obvious 
but was absent, and although this was only a single experiment, it seems unlikely that the 
SP ligand was binding to the hippocampal nAChRs, or if it was, the binding was unchanged 
in the presence o f a variety o f  concentrations o f nicotinic agonist.
CO N D ITIO N %  C O N T R O L  BIN D IN G
C O N T R O L 100%
10 10 M  N IC O T IN E 102%
1 0 9 M  N IC O T IN E 92.4%
10 8 M  N IC O T IN E 104%
1 0 7 M  N IC O T IN E 108%
1 0 6 M  N IC O T IN E 89.1%
TABLE 5.7: COMPETITION BINDING OF [3H]SP AGAINST NICOTINE. Values are the mean of 3 
observations in 1 experiment. 100% binding = 45.5 ± 8.7 fmol/mg (total cpm = 1269, non-specific = 463).
5.4._ D IS  C USmS  ION
5.4.1. REPETITIVE AGONIST STIMULATION
The [3H]Ch-loaded synaptosomes were subject to  two agonist (nicotine or cytisine) 
challenges at thirty minute intervals, SI and S2. The same concentration o f agonist was 
used for both stimuli, and it was found that with increasing concentrations o f  agonist, the 
ability o f a successive agonist challenge, S2, to evoke [3H]ACh release was increasingly 
attenuated as measured by the ratio S2/S1.
Rapier et a l, (1988) concluded that repeated exposure to agonist (nicotine) caused 
desensitisation o f  the presynaptic nAChR modulating [3H]dopamine release from striatal 
synaptosomes. In a more extensive study in 1990, the same authors (Rapier et a l, 1990) 
found that a second stimulation o f  agonist (nicotine, ACh, and carbamylcholine) at high 
concentration (100 pM), resulted in an S2/S1 ratio o f  between 0.38 and 0.50. These results 
are concordant with the present study given the differences in brain region, transmitter, and
possible differences in the propensity o f  the two different presynaptic nAChRs (striatal 
heteroreceptor compared with hippocampal autoreceptor) to desensitise, which may be a 
property inherent to the particular nAChR subtype. Using mouse striatal synaptosomes, 
Grady et a l, (1994), determined that repetitive stimulation with micromolar concentrations 
o f nicotine caused an attenuation in the release o f [3H]dopamine o f  up to 75%, i.e. the 
minimum S2/S1 ratio was 0.25, very close to the value reported for nicotine (0.21) and 
cytisine (0.17) in this study. The further decrease below 0.25 might be either the 
contribution o f  pool depletion from the hippocampal synaptosomes, or again differences in 
species, brain region and technique. Grady et a l, (1994) calculated rates o f  recovery from 
desensitisation by varying the length o f  time between the SI and S2 pulses. Though not 
directly comparable because the authors used differing concentrations o f nicotine for the SI 
(3 jiM) and S2 (10 jjM) pulses, the calculated half time (tv,) o f recovery from micromolar 
nicotine-induced desensitisation was approximately 12 min. This is very different from the 
rate o f recovery o f the hippocampal nAChRs: after a 30 min recovery period, at every 
nicotine or cytisine concentration over 1 |uM, there was still considerably less than 50% 
recovery (S2/S1 < 0.35), suggesting that the tv, for recovery is considerably greater than 12 
min, indeed at agonist concentrations exceeding 5 jaM, the ability o f  a subsequent agonist 
challenge to evoke the release o f [3H]ACh, was still maximally attenuated (S2/S1 < 0.25). 
As well as calculating tv, for recovery from micromolar agonist-induced desensitisation, 
Grady et a l,  also pretreated their synaptosomes for 20 minutes with 30 nM nicotine, 
allowed varying lengths o f recovery time and then studied the release o f  [3H]dopamine 
evoked by a subsequent stimulus o f 10|aM nicotine. In this way the authors calculated that 
the tv, for nanomolar agonist-induced desensitisation was approximately 6 min. The fact 
that desensitisation was observed following exposure to nanomolar agonist indicates that in 
the present study the S2/S1 ratio for 100 nM concentrations o f cytisine and nicotine (1.17 
and 1.00 respectively) could either indicate no desensitisation or recovery o f the nAChRs, 
within the 30 min interval between SI and S2 stimulations.
5.4.2. POOL DEPLETION
Depletion o f  the releasable pool o f transmitter has a confounding effect on the 
interpretation o f  nAChR desensitisation in this study. Within the synaptosome, ACh is 
stored in tw o metabolically different pools (reviewed by Solsona et a l,  1991; see also 
Dolezal et a l, 1993), the bound pool is associated with synaptic vesicles and the so-called 
free pool may represent ACh associated to a specially labile fraction o f  synaptic vesicles, or 
it may correspond to the cytoplasmic fraction o f ACh. Using vesamicol, a potent inhibitor
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of ACh uptake into isolated synaptic vesicles, various reports (e.g. Anderson et a l, 1983) 
have shown inhibition o f  recently synthesised ACh from Torpedo synaptosomes while being 
ineffective on release o f  preformed ACh (Michaelson et a l, 1986). This observation was 
taken was taken as support for the vesicular origin o f the released transmitter. Disruption 
o f the plasma membranes by homogenisation and/or freezing and thawing does not affect 
the synaptic vesicles, hence estimations o f the bound versus free ACh can be made. The 
bound ACh compartment, protected from hydrolysis by acetylcholinesterases, comprises 
60-70% o f total ACh and has a slow turnover (Dolezal e ta l ,  1993). Dolezal et al., (1993) 
labelled this bound pool using 10 nM  [14C]Ch and reported that the ACh synthesised per 
hour represented 7% o f the total ACh content o f the synaptosome.
In the present study it is expected that following uptake o f  [3H]Ch into the 
synaptosome, the labelled precursor is acetylated to form [3H]ACh by the enzyme ChAT, 
and transported into the synaptic vesicles.. Following the 30 min incubation, the 
synaptosomes were washed to remove any unbound [3H]Ch and then superfused for a 
washout period o f 45 min to achieve a stable transmitter baseline before the start o f each 
experiment. Hence, at the start o f  the superfusion, [3H]ACh is expected to comprise less 
than 10% o f the bound pool o f ACh (see above), the pool which is preferentially released 
upon depolarisation (Solsona et al., 1991; Dolezal et a l, 1993). Since there is no free 
[3H]Ch to continue synthesis o f [3H]ACh during the course o f  the superfusion experiment, 
the pool o f releasable [3H]ACh is finite and can be expected to decline in two ways. Firstly, 
approximately 1% o f the total [3H]ACh content o f the synaptosomes is released per 3 min 
fraction (section 3.3.4.), constituting basal release, hence in a typical 30 fraction 
experiment, approximately 30% o f the total pool is depleted, by the end. Ten fractions 
typically separate the first and second agonist stimuli (SI and S2), hence basal pool 
depletion would be expected to contribute 10% to any decrease in S2/S1 ratio. Secondly, 
the labelled pool would be depleted following evoked release: maximal agonist-evoked 
release never exceeded 3% o f the total tissue content however, so the maximum decrease 
in S2/S1 due solely to evoked pool depletion would be approximately 3%. Altogether, pool 
depletion would be unlikely to  account for more than a 10 - 13% reduction in S2/S1 ratio 
in the present system. Further reductions would therefore appear to implicate nAChR 
desensitisation/inactivation.
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5.4.3. EFFECTS OF SP ON NICOTINE-EVOKED [3H|ACh 
RELEASE
Livett & Zhou (1991) summarised the actions o f SP, with regard to nicotinic 
stimulation o f  catecholamine (CA) release from bovine adrenal chromaffin cells. At SP 
concentrations > 10‘7 M, the peptide inhibited CA secretion evoked by non-desensitising 
concentrations o f  nicotine in a dose-dependent manner (Khalil et al., 1988), however at 
high concentrations o f nicotine, SP (10'9 - 10'5 M) protected against nicotinic 
desensitisation, an effect which outweighed the inhibition o f release, and led to facilitated 
CA secretion (Khalil et a l, 1988). Lyford et al., (1990) reported directly conflicting 
results. Also working with CA release from bovine chromaffin cells, the authors reported 
that the rate o f  desensitisation o f CA release due to stimulation with a nicotinic agonist 
appeared to be enhanced in the presence o f  SP and diminished immediately following its 
removal. In addition, the removal o f SP was reported to lead to a delayed and relatively 
slow phase o f  CA secretion. To further cloud a rather muddy issue, as long ago as 1981, 
Role et a l, reported that preincubation with SP did not affect the secretion o f  CA during a 
subsequent nicotinic challenge in cells from guinea-pig adrenal medulla.
How does the literature compare with the transmitter release studies in sections 
5.3.3. and 5.3.4.? The protease inhibitors used to protect the SP and/or the BSA in the 
Kreb’s buffer depressed SI nicotine-evoked [3H]ACh release from the hippocampal 
synaptosomes, but no further effect was seen in the presence o f any concentration o f SP. 
The peptide does affect the S2/S1 ratio in repetitive agonist stimulation experiments, but in 
rather a complicated way. At 10'9 M, SP may have enhanced the desensitisation o f the 
nAChRs, apparently causing a significant decrease in the control S2/S1 ratio from the 
control value o f  0.41 to 0.19, which would agree with Lyford et a l,  (1990). At 
concentrations o f  10‘8 M  and 10‘7 M, SP also significantly enhanced nAChR desensitisation, 
though to a slightly lesser extent than the 10'9 M  concentration. At 10~6 M, SP did not 
significantly enhance desensitisation compared to the control situation. In the experimental 
protocol, the synaptosomes were pretreated with SP for the 6 min immediately prior to the 
S2 nicotine challenge, after which the synaptosomes were superfused with regular Kreb’s 
buffer. Typically, the peak o f  agonist-evoked release was collected in the 2 fractions (6 
min) following the challenge (see chapter 3). It is feasible that removal o f  the peptide 
provokes a ‘delayed and relatively slow phase o f  secretion’ as reported by Lyford et a l, 
(1990). The secretion would overlay any apparent enhanced desensitisation o f  the nAChRs, 
and as the concentration o f SP increased the secretion would slowly offset the decrease
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seen in the S2/S1 ratio, which was indeed what was observed. It remains to be seen 
whether the S2 /S1 ratio would continue to increase and perhaps surpass the control value, 
if the concentration o f  SP was increased sufficiently, and this is certainly an area which 
would be amenable to further investigation. There are a number o f  possible ways that SP 
could provoke transmitter release, though necessarily through no direct action on the 
agonist binding site on the hippocampal nAChRs, as discussed below.
5.4.4. RADIOLIGAND BINDING, NICOTINE AND SP
S.4.4.1. [3H]Nicotine Binding
The values for the binding affinity (Kd = 4.4 nM) and binding density (B max = 29.9 
fmol/mg protein) o f [3H]nicotine are in agreement with the literature (reviewed in 
W onnacott, 1987):
Kd B max Preparation/Author
2 nM 65 fmol/mg (hippocampal P2; Yoshida & Imura, 1979)
2.9 nM 7.3 fmol/mg (rat hippocampus homogenate;
Benwell & Balfour, 1985)
5.3 nM 47 fmol/mg . (rat brain P2; Nukina et al., (1985)
9 nM 108 fmol/mg (rat brain P2; MacAllan et a l,  1988)
3.6 nM 57 fmol/mg (rat brain P2; M artino-Burrows & Kellar, 1987
SP did not significantly affect either the observed maximum number o f binding sites, 
or the apparent affinity o f the agonist fo r  these sites at a concentration o f  10 pM, but this 
may not be surprising since Min et a l, (1994) reported that photoaffinity labelling o f 
Torpedo membranes with an iodinated SP ligand (125I-[Phe8(pBz)]SP) in the presence o f 
100 pM  unlabelled SP to block the neurokinin receptors, led to no specific labelling o f  the 
a  or 0 subunits o f  the Torpedo nAChRs. Rather, the 5 subunit was specifically labelled and 
to a lesser extent, the y subunit and the authors speculated that the affinity labelling was 
consistent with a binding site within the ion channel pore, where the 5 and y subunits are in 
closest proximity.
However a direct interaction o f  SP with rat a3 , a 4  and 02, 04 subunits expressed 
pairwise in Xenopus oocytes has been reported by Stafford et al., (1994). The peptide was 
found to  be a noncompetitive inhibitor o f  all pairwise combinations o f  subunits expressed,
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though the IC 50 values for inhibition o f  ACh-induced current, differed markedly depending 
on the P subunit. The IC5o values for P4-containing receptors was in the range o f  2.5 - 3.5 
tiM, whereas the values for p2 containing receptors was between 65 and 75 ^iM. The a  
subunit that was coexpressed had no significant effect on the apparent affinity for SP. Since 
the inhibition by SP was not voltage dependent it is less likely that in the receptors 
expressed in the oocytes at least, the SP is physically blocking the channel. I f  the positively 
charged peptide entered the channel deeply enough, the inhibition should have been 
sensitive to the potential across the membrane. However, the possibility cannot be ruled out 
that SP may block at the extracellular mouth o f  the channel, outside o f  the potential field o f 
the membrane.
In both Torpedo membrane nAChRs and coexpressed oc/p hetero-oligomeric 
nAChRs expressed in oocytes, SP acts as an inhibitor, and in the present study there was no 
evidence to suggest an inhibitory action on [3H]nicotine binding to hippocampal 
membranes.
In summary, SP did not alter the apparent binding density o f  [3H]nicotine to 
hippocampal membranes, nor the affinity o f  the nAChRs for the ligand, therefore despite 
various reports in the literature using Torpedo membrane preparations and in oocyte- 
expressed rat nAChRs, it would appear that SP did not act as an inhibitor o f  [3H]nicotine 
binding in rat hippocampal membranes.
5.4.4.2. [3H]SP Binding
How can SP affect the S2/S1 ratio, if  there was no evidence for direct interaction 
with the agonist binding site o f hippocampal nAChRs? The saturation binding experiment 
with the NK1 ligand [3H]SP indicates the presence o f  NK1 receptors in the rat 
hippocampus. SP does not affect nicotine-evoked transmitter release directly via the 
nAChRs, Valenta et al., (1993) summarised evidence showing that SP did not directly 
block the nAChR channels o f chicken sympathetic ganglia, indeed Simmons et a l, (1990) 
showed that SP was able to modulate nAChR channels in cell-attached patches when the 
peptide was applied to the ex/ra-patch membrane, i.e. under conditions where the nAChRs 
channels were not exposed to the peptide at all.
Thus SP could modulate nAChRs via the endogenous tachykinin receptors. 
Activation o f  these receptors which are G  protein coupled, may lead to  increased levels o f
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intracellular cAMP, which in turn may result in changes in the phosphorylation state o f the 
nAChRs, an important determinant in the desensitisation state o f  the receptors (Huganir et 
a l, 1986). Activation o f the tachykinin receptors may also result in the direct modulation 
o f transmitter release via G protein-mediated increases in triphosphospoinositol 
(IP3)/diacylglycerol, mobilisation o f  Ca2+/activation o f protein kinase C (PKC), and 
phosphorylation o f synapsin leading to synaptic vesicle exocytosis and transmitter release. 
A number o f  lines o f evidence implicate phosphoinositide (PI)/PKC as the likely second 
messenger mediating SP modulation o f nAChR desensitisation. First activators o f PKC 
kinase precisely mimicked the effects o f  SP on nAChR function (Downing & Role, 1987). 
Second both PI turnover and PKC activation was detected within seconds o f SP treatment 
o f neurons (Valenta et al,. 1993). M ost compelling is the observation that SP modulation 
o f nAChRs was completely blocked by PKC inhibitors (Simmons et al., 1990). It is not yet 
clear how SP stimulates PKC in these neurons, although recent studies o f mast cells 
demonstrate a variety o f cationic amphophilic peptides, including SP that directly activate 
Gj and G0 in a receptor- independent manner, stimulating PI hydrolysis and, presumably, 
PKC activation (Mousli et al., 1990). SP may activate PKC and hence modulate 
hippocampal nAChRs by a similar mechanism.
In summary, SP did not interact with the agonist binding site on the hippocampal 
nAChRs, changing neither the affinity o f  the nAChRs for the ligand [3H]nicotine, nor 
changing the apparent density o f  hippocampal [3H]nicotine binding sites. SP did appear to 
modulate the nicotine-evoked release o f [3H]ACh in a complex manner consistent with a 
possible enhancement o f agonist-induced desensitisation/inhibition o f  recovery from 
desensitisation, counterpointed by an apparent facilitatory action o f  SP on the hippocampal 
synaptosomes, causing [3H]ACh release. The presence o f  hippocampal SP/NK1 receptors, 
demonstrated by binding experiments with the ligand [3H]SP, provide an indirect pathway 
by which SP may effect nAChR modulation, involving the stimulation o f second messenger 
systems.
C H A P T E R  6 I l K R O D I f l L T S I S
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6.1 IN T R O D U C T IO N
6.1.1. IN  VIVO METHODS FOR STUDYING NEUROTRANSMITTER 
RELEASE
6.1.1.1. Cup Perfusion Technique
The cup perfusion method for the study of in vivo transmitter release in the brain, 
was pioneered in the 1950’s by M acintosh & Oborin (1953). A small cylinder is placed on 
the surface o f  the exposed brain, usually the cortex. The cup formed by the cylinder and the 
cortical surface is perfused with a physiological solution. Endogenous compounds diffuse 
from the underlying tissue into the cup solution . This method has been extended to freely 
moving animals using chronically implanted cups (Beani et a l, 1968), and until recently the 
cup technique was the most frequently applied method in physiological and 
pharmacological studies involving the release o f ACh in the brain (Pepeu, 1977; Moroni & 
Pepeu, 1984). The major drawbacks o f the cup perfusion technique include the limited 
applicability to surface areas o f  the brain and the large areas that are perfused.
6.1.1.2. Push-Pull Perfusion Technique
Since the first description o f the technique by Gaddum (1961), several types o f push 
pull cannulae have been developed. Usually two, often concentric, cannulae are implanted 
in a localised brain area. Fluid is driven by a perfusion pump through the protruded inner 
tube and removed through the outer tube. At the tip o f the cannula the fluid streams 
through the surrounding tissue, and substances are taken up in the perfusion fluid . Finally, 
the perfusates are analysed for the compounds o f interest. This technique has been applied 
to measure the release o f ACh from various discrete brain areas (Pepeu, 1977; Philippu, 
1984).
Push-pull perfusions may also be used for infusing exogenous compounds to local 
brain areas, and in contrast with the cup technique, structures deep within the brain can be 
sampled. Tissue damage may occur however, both during the implantation o f  the cannulae
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and during the push-pull perfusions, due to the continuous mechanical contact o f the 
perfusion fluid and the brain tissue (Yaksh & Yamamura, 1974; Nieoullon et a l, 1977).
6.1.1.3. In Vivo Microdialysis
Brain dialysis is a recent addition to the technical armamentarium of the 
neuropharmacologist for the study o f  the mechanisms o f action and preclinical profiles o f 
centrally acting drugs. After a slow beginning, the brain dialysis technique was improved by 
the introduction o f  thin dialysis fibres (Zetterstrom et a l, 1983). Subsequently, extensive 
pharmacological investigations validated its application to the study o f  dopamine release in 
vivo (Imperato & Di Chiara, 1984; 1986). Brain dialysis is now routinely applied to other 
neurotransmitters, including excitatory amino acids (Lehman et a l,  1983), GABA (Kehr & 
Ungerstedt, 1988), noradrenaline (L ’Heureux et a l, 1986), 5-HT (Carboni & Di Chiara, 
1989), and acetylcholine (Damsma et a l, 1987).
The basic principle is the positioning o f a membrane that allows free diffusion o f 
water and solutes between the solution o f  interest (brain interstitial space) and a solution 
lacking the substances concerned which is constantly renewed and sampled for analysis o f 
the substance(s) o f interest.
In brain dialysis, a dialysis fibre (0.3-0.5 mm diameter) is implanted in a selected 
brain region. Low  molecular weight compounds diffuse down their concentration gradients 
from the brain extracellular fluid into a physiological salt solution that flows through the 
fibre at a constant rate. The fluid is collected and analysed. This technique allows many o f 
the substances in the extracellular fluid to be monitored, provided that a sensitive method 
o f detection is available. Brain dialysis has taken advantage o f  the high sensitivity and 
selectivity o f  HPLC with electrochemical or fluorimetric detection, which enables rapid 
analysis o f brain dialysates; the dialysis fibre can even be connected directly to the HPLC 
for on-line determination (Abercrombie et a l, 1989).
The major advantages o f brain dialysis over other techniques for in vivo monitoring 
o f chemical changes in the brain (cup technique, push-pull cannula) stem from the fact that 
it is a closed system in which there is no direct contact between the superfusion fluid and 
the tissue; thus local tissue damage is reduced and relatively clean samples are produced for 
direct chemical analysis. Indeed, although some dialysis probes (e.g. U-shaped probes) can 
cause damage, detailed histochemical examination o f transcerebral probes in situ indicates
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that the degree o f  tissue damage is minimal (Leone & Di Chiara, 1987). Brain dialysis can 
be applied to freely moving rats so that behaviour can be correlated with chemical changes 
in the brain (Imperato et a l, 1986).
The first microdialysis model (Bito et a l, 1966), consisted o f a permeable sack 8-12 
mm long and filled with 6% dextran in saline, and had one major drawback - only one 
sample could be collected per probe. Repeated sampling was developed by Delgado et a l, 
(1971). The same group, a year later, pioneered continuous sampling for assessing 
neurotransmitter levels in conscious Rhesus monkeys for up to 8 months (Delgado et a l, 
1972). It was an adaptation o f the push-pull cannula technique, which they termed a 
transdermal dialytrode since it could incorporate a totally subcutaneous 
stimulating/recording electrode (see figure 6.1.), The probe was formed from two pieces of 
Teflon tubing cemented together, with one tip ending 1 mm shorter than the other; both 
tips were enclosed in a polysulphone bag (3 p,l). The other ends o f  the tubing terminated 
separately in two rubber reservoirs. The system was continuously superfused and drugs 
could be injected into one bag and sample collected from the other.
U-shaped and transcerebral probes were developed in the early 1980’s, by 
Zetterstrom & Ungerstedt, who were also one o f the first groups to couple the technique to 
the highly sensitive detection ability o f  high performance liquid chromatography (HPLC) 
linked to either electrochemical or fluorometric detection. It was only with the advent o f 
HPLC that the full potential o f measuring neurotransmitters from small samples of 
extracellular fluid could be exploited. Transcerebral and U-shaped probes are not suitable 
for use in deep brain structures such as the hypothalamus, since their implantation causes 
too much damage to facial musculature. The three basic designs o f dialysis probe currently 
used, transcerebral, concentric, and U-shaped, are shown in figure 6.1.
Microdialysis offers several advantages over other neurochemical techniques. The 
dialysis probe can reflect rapid changes in the extracellular neurotransmitter levels 
(Auerbach et a l, 1989). Probe implantation produces minimal tissue damage, it is a closed 
system producing clean samples which do not require lengthy preparation before analysis 
and it can be used in anaesthetised and freely moving animals to measure extracellular 
neurotransmitter levels. The probe is stereotaxically implanted into the specific brain region 
with reference to  one o f  two specific points, Bregma and Lambda, on the surface o f the rat 
skull (figure 6.1.)
137
FIGURE 6.1. RAT SKULL AND DIFFERENT TYPES OF DIALYSIS PROBE A. Top view 
of a rat skull showing the position of the two reference points, Bregma and lambda, used for stereotaxic 
implantation of microdialysis probes, adapted from Paxinos and Watson (1982). B. Original transdermal 
dialytrode, after Delgado et al., (1972). C. Transcerebral and D. Concentric (upper) and U-shaped probes 















____________________________________________________________________ |— | 0.5  mm
Stereotaxic surgery uses 3D coordinates: bregma is a reference point for the
anterior/posterior (A/P) plane and the lateral plane. Depth measurements can be taken from 
the intraaural line or the surface o f the skull or dura. Lamda is not generally used as a 
stereotaxic reference point but coincidentally appears near the intraaural line.
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Figure 6.1. D. shows a commonly used microdialysis probe, the concentric probe 
developed by Tossman & Ungerstedt, (1986). The perfusion fluid enters the top end o f the 
inner tube. It leaves the inner tube close to its lower end through two holes in the wall. The 
liquid then flows upward in the space between the dialysis membrane and the inner tube, 
where diffusion o f substances from the tissue takes place. The perfusate leaves the probe 
via a small tube extending at a right angle to the probe. The pore size o f  the dialysis 
membrane determines the molecular-weight limit o f the compounds entering the probe.
The main purpose o f microdialysis is to study the composition o f  the brain 
interstitial space under various conditions. Because microdialysis does not obtain samples 
o f the interstitial space, the concentrations o f substances in the outflow solution are only a 
fraction o f the true brain interstitial concentrations. Therefore, the microdialysis probe has 
to be calibrated before use in vivo. A description o f the procedures usually carried out 
when using microdialysis follows.
C alib ration : The term ‘recovery’ or relative recovery is defined as the ratio 
between the concentration o f a particular substance in the outflow solution and the 
concentration o f  the same substance in the solution outside the probe (Ungerstedt et a l, 
1982). Absolute recovery is the amount o f a substance harvested in the outflow per unit 
time.
Recovery in vitro is usually measured as follows: the probe is continuously perfused 
at a constant flow rate and inserted into an aqueous solution o f the substance at a known 
concentration. The perfusion fluid is identical to the medium outside the probe except for 
the substance o f  interest. The probe is perfused at least 30 min before samples are 
collected. Several samples are collected at fixed intervals (e.g. every 20 min). The 
substance concentration in the outflow is determined (e.g. HPLC), and the relative 
recovery is calculated as
Recovery /n vitro C Qut /  C/ 
where C mt is the substance concentration in the outflow and C, is the substance 
concentration in the medium.
In vivo, the probe is implanted into the brain and perfused for 1 to 2 h before 
samples are collected manually or automatically (fraction collector). Samples are then
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analysed immediately e.g. HPLC (Wages et al., 1986) or frozen at -70°C and stored for 
later analysis.
Finally the true interstitial substance concentration is calculated as
C */' = C*out / recovery in vitro 
where C */' is the true interstitial concentration and C*out is the substance concentration in 
the in vivo outflow solution.
The validity o f these procedures rests on the assumption that conditions in vitro are 
equal to those in vivo. This is obviously not true, and even assuming that insertion o f the 
probe into the brain does not change the tissue microenvironment, the following factors 
affect in vivo and in vitro recovery.
Perfusion flow rate: Perfusion flow rate is inversely related to  relative recovery 
(Benveniste, 1989). However, the flux o f  substances across the dialysis membrane is not 
significantly influenced by perfusion rates above 2.5 (il/min (Zetterstrom  et al., 1982; 
Hamberger et a l, 1983; Ungerstedt, 1984). This is most likely caused by diffusion 
limitation and possibly by a positive hydrostatic pressure gradient across the membrane 
with higher flow rates. A rigid tube design can build up a positive hydrostatic pressure 
across the membrane at higher flow rates and cause a decrease o f  mass transport. At a 
given flow rate, the following additional factors have a significant influence on recovery.
Time after start of perfusion: Relative recovery has been determined to be time 
independent; initially, relative recovery is high but rapidly decreases. H ow ever this may be 
neglected after perfusion for 60 min, because it only constitutes a minor factor (<1% after 1 
h). The problem is circumvented by delaying sample collection for at least 60 min.
Diffusion coefficients: The relative recovery o f various substances measured is 
known to vary. This may be due to differences in molecular weight and, therefore, altered 
diffusion coefficients. Moreover, diffusion in a non-homogeneous medium is impeded by 
cell membranes, which gives rise to tortuosity - a prolongation o f  the diffusion pathway, as 
illustrated in figure 6.2. For this reason, mass transport into the dialysis fibre is less in vivo 
compared with in vitro.
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FIGURE 6.2. Diffusion in a tissue is impeded by cell membranes, which give rise to tortuosity - a 
prolongation of the diffusion pathway. Therefore mass transport into the microdialysis probe is less in vivo 
compared with in vitro. Note also that cells cannot be considered as inactive bodies. The brain interstitial 
substance concentration will depend on (a) transport across the blood brain barrier (BBB) and (b) cell 
(neurons and glial cell) metabolism. Figure redrawn from Benveniste, 1989.
Substance concentrations: Whereas relative recovery is independent o f the outer 
substance concentration, absolute recovery is proportional to it (Hamberger et al., 1983, 
Ungerstedt, 1984).
Substance interaction with the dialysis m em brane: Membrane materials may 
interact with transported substances via unknown mechanisms and affect mass transport. 
For instance, recovery o f acid metabolites is much higher than that o f the parent amine, 
even for substances with similar diffusion coefficients (Ungerstedt, 1984).
T em perature: Diffusion coefficients increase 1-2% / °C and hence recovery at 
37°C is considerably greater than at 22°C. This problem has been circumvented by several 
investigators by performing the in vitro test at 37°C (Zetterstrom et al., 1982)
M em brane area: Relative and absolute recoveries increase in direct proportion to 
the area o f the dialysis membrane area (Hamberger et al., 1983; Ungerstedt, 1984)
A great many factors therefore affect the in vivo recovery o f the substance of 
interest, and the correct determination o f the absolute concentration o f a particular 
substance e.g. neurotransmitter, require complex mathematical models, taking into account 
all of the above-mentioned factors. In practise, many of these variables are difficult, if not 
impossible to estimate, including: diffusion in the interstitial space; cellular uptake, 
exchange mechanisms, and metabolism; the diffusion characteristics for most substances.
It is worth bearing in mind that although simple in principle, brain dialysis is an 
invasive technique: it attempts to monitor the extracellular concentrations o f transmitter
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released from nerve terminals by inserting into the brain, a probe several orders o f 
magnitude larger than the biological structures under study. The outer diameter o f  currently 
available probes (0.3-0.8 mm) is about a thousand times that o f the synapses from which 
neurotransmitter release is to be monitored. Indeed, despite using the term  ‘microdialysis’ 
brain probes are 10-100 times larger than other tools (micropipettes, microelectrodes) 
currently used by neuroscientists. A particular concern is that the blood-brain barrier (BBB) 
is intact during microdialysis to avoid contamination from the systemic circulation. 
Hamberger et a l, (1983) and Hamberger & Nystrom (1984) compared the concentration 
o f amino acids in blood, cerebrospinal fluid (CSF) and tissue w'ith concentrations in 
microdialysis perfusates. They found that interstitial amino acid concentrations calculated 
from the in vitro recovery were distinctly lower than those o f blood and tissue but fitted 
remarkably well with CSF values. Administration of a-aminoisobutyrate, an inert, neutral 
amino acid which does not cross the BBB rapidly, demonstrated that the BBB was intact 
30 min after insertion o f the microdialysis probe but not <10 min after insertion (Benveniste 
et a l, 1984) though this will be affected by the probe size.
Another concern is that the environment surrounding the dialysis probe should be as 
representative as possible o f normal, non-pathological, brain tissue. A histological 
examination o f  tissue reactions to the microdialysis probe was reported by Benveniste & 
Diemer (1987). Within the first 2 days, normal neuropil and only occasional haemorrhage 
surrounded the tube. On the third day, an astrocyte reaction was seen using an antiserum 
against glial fibrillary acidic protein. Hypertrophic astrocyte processes were observed 
within the spongius fibre wall. Fourteen days after the implantation, layers o f  reticulin- 
positive fibres surrounded the dialysis membrane. These chronic reactions are held to be 
unavoidable in the vicinity o f both implants and lesions (Stensaas & Stensaas, 1976). 
.Obviously, the coating o f the probe with inflammatory cells and connective tissue could 
change control diffusion characteristics o f the tissue and fibre.
Changes in local cerebral glucose metabolism (LCMRglc) and blood flow (LCBF) 
are sensitive indicators o f the tissue damage caused by implantation, and may reveal 
damage when brain tissue appears histologically normal. Consistent changes in both 
LCMRglc and LCBF within 3 h following the implantation o f the probe, have been 
reported by Benveniste et a l, (1987). Localised regions o f increased glucose metabolism 
and decreased flow were found in the hippocampus in close proximity to  the fibre. Animals 
allowed to recover for 24h did not show these changes, but they exhibited a slight uniform 
decrease o f LCBF. Changes o f LCBF and LCMRglc could be due to the induction o f a
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spreading depression by the tissue trauma inflicted by insertion o f  the probe into the brain 
matter (Shinohara et a l, 1979). A spreading depression is characterised by arrest o f 
spontaneous and evoked electrical activity, an increase in extracellular potassium 
concentrations, and a decrease o f  calcium content.
In summary, the implantation o f  the dialysis probe causes some disturbance in tissue 
metabolism, but this can be neglected at 24 h after implantation, because the dialysis 
technique is by then stable with respect to LCMRglc and LCBF, (though care should be 
taken to obtain samples before 2 days if possible, to avoid the adverse histological reactions 
mentioned above). Other problems related to disturbed cellular metabolism are perhaps 
obviated by sampling dialysates for 2-3 h to obtain stable baseline concentrations o f various 
metabolites.
6.1.2. MICRODIALYSIS AND ACh RELEASE
The feasibility o f measuring ACh by means of in vivo brain dialysis in freely moving 
rats requires a sensitive assay to detect the picomolar concentrations o f  the transmitter. 
Moreover, because o f the problems o f  ACh degradation by cholinesterases (section 
4.3.4.5.) it is necessary to include a cholinesterase inhibitor such as neostigmine in the 
perfusing solution in order to measure basal ACh levels. The development o f  a sensitive 
HPLC assay facilitated the detection o f  the neurotransmitter in the mid 1980’s (Damsma et 
al, 1985), though radioimmunoassay has also been used. Two groups in 1987 (Damsma et 
a l, 1987; Consolo et a l, 1987) were among the first to demonstrate increased ACh release 
in the rat brain (striatum in both cases), in response to systemic injection o f muscarinic 
drugs. Damsma et a l, (1987) demonstrated a significant increase o f  ACh (250%) 40 min 
after the injection o f the antagonist atropine (10 (imol/kg, i.p.). In contrast no change in 
basal ACh release was reported after injecting the agonist oxotremorine (5 |umol/kg, i.p.). 
Consolo et a l,  (1987) used the antagonist scopolamine (0.34 mg/kg, s.c.) and 
demonstrated an increased ACh release o f  approximately 200-250%, 20 to 40 min after 
injection; oxotremorine, on the other hand, caused a small decrease (60% o f basal) in 
striatal ACh release, 20 min after injection.
In vivo studies involving ACh release have not been limited to  muscarinic agonists 
or solely to studies o f the striatum. H utson et a l, (1991) initially verified the scopolamine 
studies o f  Consolo and Damsma in striatum, and found that a higher dose (1 mg/kg, i.p.) 
caused a large increase (960%) o f ACh release. This was thought to be a centrally mediated
143
effect because repeating the study with N-methyl-scopolamine which has poor penetrance 
o f the blood-brain-barrier, demonstrated a much smaller (177%) increased ACh release. 
Scopolamine (1 mg/kg, i.p.) also mediated a very large increase (2350%) in hippocampal 
ACh release, 40-60 minutes following injection. The authors concluded that the results 
were consistent with an inhibitory action upon the hippocampal muscarinic autoreceptors. 
Hutson et al., (1991) went on to demonstrate increased ACh release (180-200%) in 
response to thyrotropin releasing hormone (TRH), which has been shown to activate the 
cholinergic septo-hippocampal pathway (Kalivas & Horita, 1979). The actions o f  TRH and 
various metabolically stable analogues were found to be specific to the hippocampus, and 
had no effect upon striatal ACh release, but the authors were careful to point out that TRH 
also stimulates noradrenaline release, so it was conceivable that increased hippocampal 
ACh was in indirect effect o f noradrenergic stimulation. This raises an important issue, 
namely that following the systemic injection o f  drugs, a variety o f  brain transmitter systems 
in one or more brain regions are likely to be affected. It is important therefore, not to over­
interpret the results obtained in these studies. For example, while TRH may directly 
stimulate the septo-hippocampal cholinergic system, it is not possible to  rule out indirect 
noradrenergic effects without conducting more experiments. This is an issue which will be 
discussed in relation to the present study in section 6.4.
6 .I.2 .I . Hippocampal ACh Release in Response to Nicotinic Drugs
In 1989 Toide & Arima, (1989), reported the use o f microdialysis to monitor 
effects o f both muscarinic and nicotinic drugs on extracellular levels o f  ACh in the rat 
hippocampus. Administration o f scopolamine (0.5 mg/kg s.c.) caused a profound increase 
in the release o f  ACh (>600% increase over basal release) in the hippocampus, in 
agreement with the studies outlined above. Systemic administration o f  nicotine (0.5 mg/kg 
s.c.) also enhanced hippocampal ACh release, at 30 min and 90 min after administration. 
This nicotine-evoked ACh release was quite modest but significant (160%), which could be 
consistent with stimulation o f presynaptic nAChRs, was also seen in the frontal cortex and 
the striatum, and in each region the release was also biphasic in nature. Toide & Arima 
attributed this phenomenon, whereby ACh release was enhanced, fell back to  basal levels, 
then was enhanced once again (without further injection o f agonist), to ‘receptor 
desensitisation’.
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Since the focus o f  this project was to  study how the presynaptic nAChRs modulate 
ACh release in the hippocampus. So far, the in vitro studies have demonstrated that 
agonists enhance [3H]ACh release from synaptosomes, and it would be interesting to 
demonstrate that this was a relevant physiological phenomenon, i.e. nicotine was able to 
enhance hippocampal ACh in vivo. Hence the initial studies o f  Toide & Arima (1989) were 
repeated, with a view to characterising any nicotine-evoked response in terms o f 
concentration dependency. Using a nicotinic antagonist, it was also hoped that any 
response could be shown to be mediated by nAChRs, just as the in vitro responses were 
shown to be nAChR-mediated (section 4.3.2.2),
6 .2._ ME_TH QDmS
The protocols for the care o f the experimental animals, the surgical procedures, the 
microdialysis perfusion protocol and the analysis o f  samples by HPLC, are all detailed in 
Chapter 2. Microdialysis was always carried out using conscious, freely moving rats over a 
period o f  five hours.
6.3._RE_SULTS
6.3.1. EFFECTS OF SYSTEMIC ADMINISTRATION OF 
NICOTINE
To allow the establishment o f  a stable baseline samples were collected for two 
hours before the rats were injected with nicotine.. Figure 6.3. shows the changes in the time 
course o f  ACh in dialysates o f rat hippocampus following administration o f  (-)nicotine (0.4 
or 0.6 mg/kg s.c. in the right flank). The lower dose o f nicotine (0.4 mg/kg) increased ACh 
release (about 180%) in hippocampus transiently but significantly, 40 min after its 
administration. The ACh level then reverted to  the control value but subsequently increased 
(130-140%) again, during the period 100- 160 min after administration, the second increase 
did not reach statistical significance. The higher dose o f nicotine (0.6 mg/kg) produced 
smaller increases in hippocampal ACh levels: a significant increase was noted at 60 min 
(approximately 150%), after which there was a return to basal release levels, followed by a 




= 0.4 mg/kg (n=4) 













80 120 160 200-120 -80 -40 0 40
TIME (M INUTES)
FIGURE 6.3. NICOTINE-EVOKED, IN  VIVO  RELEASE OF HIPPOCAMPAL 
ACETYLCHOLINE. Values are mean ± SEM release as a percentage of pre-injection basal values. * = 
significantly different from basal release at p<0.05. Basal = 53 fmol/min.
6.3.2. EFFECTS OF SYSTEMIC ADM INISTRATION OF 
M ECAM YLAM INE
In order to further characterise the in vivo response to nicotine, it was necessary to 
demonstrate that the observed increases in hippocampal ACh levels were mediated by 
nAChRs, hence the use o f a nicotinic antagonist. Control experiments were therefore 
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FIGURE 6.4. MECAMYLAMINE-EVOKED, IN  VIVO RELEASE OF HIPPOCAMPAL 
ACETYLCHOLINE. Values are mean ± SEM release as a percentage of pre-injection basal values. * = 
Significantly different from basal release at p<0.05. Basal = 65 fmol/min.
Figure 6.4. shows the results o f administration of mecamylamine (1.0 or 2.0 mg/kg, 
i.p.) at time zero. The dose o f 1.0 mg/kg mecamylamine produced a transient but 
significant (p<0.05) increase (161%) in ACh at 40 min, returning to baseline levels after 80 
min, before increasing modestly (not significant; 140%) after 200 min. This pattern of 
biphasic release mimicked that seen with 0.6 mg/kg nicotine, albeit over a different time 
scale. The higher dose of 2 mg/kg induced behavioural signs in the experimental animals 
(prostrate body position and shallow breathing), and produced a sustained increase in ACh 
release (130-140%), for 2 h post-injection. This increase never reached statistical 
significance because of the large variability in response between animals, indicated by the 
standard error bars in figure 6.4.
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6 .4 .m D IS C  USmS  IO N
6.4.1. NICOTINE ADMINISTRATION
As mentioned in section 6.1.2. a single research paper has been published (Toide & 
Arima, 1989) detailing the effects o f nicotinic agonists on ACh levels in the rat 
hippocampus, cortex and striatum. The report described a transient 160% increase in 
hippocampal ACh release following administration o f nicotine (0.5 mg/kg, s.c.). this initial 
rise was followed an hour later by a more modest rise o f 130%, a pattern similar to the 
results reported in section 6.3. Toide & Arima stated that this biphasic pattern o f  release 
could ‘presumably be attributed the desensitisation effect’, whereby they postulated that ‘a 
prolonged exposure to nicotine could induce desensitisation’.
Results from the superfusion studies (chapter 6) indicate that the hippocampal 
nAChR undergo rapid desensitisation within seconds/minutes. The fact that nicotine was 
injected subcutaneously in the microdialysis protocol means that the drug enters the brain 
over a period o f  time, rather than as a single discrete bolus. Benowitz et a l., (1990) 
reviewed the pharmacodynamics o f (-)nicotine: in a rat o f  between 170 and 340 g (the rats 
in the present study were always 250-350 g), at a dose o f 0.4 mg/kg, the terminal half life 
o f the nicotine is approximately 55 min. Exposure o f  the nAChRs to a desensitising 
concentration o f  agonist would result in a burst o f elevated transmitter release, followed by 
receptor desensitisation - resulting in a return to basal release, followed by a refractory 
period in which the receptors could be expected to slowly resensitise, as the concentration 
o f nicotine in the microenvironment o f the synapse falls. This sequence o f  events would 
explain the pattern o f  ACh change induced by nicotine in figure 6.3. The half life for the 
higher dose o f  nicotine used in this study (0.6 mg/kg), could be expected to  be slightly 
longer than 55 min, and could explain the slightly different temporal pattern o f ACh 
elevation. W hat is not immediately obvious is the reason for the second, modest rise o f 
ACh occurring approximately 1 h after the initial phase o f release. I f  the nAChRs have 
resensitised there is a possibility that there was still a sufficient level o f  nicotine in the 
synaptic microenvironment to  trigger receptor-mediated release o f  ACh. Since the half life 
o f  the agonist is o f  the order o f  1 h, significant levels o f nicotine could be present 120 min 
after the injection, taking into account the fact that nicotine was likely to arrive in the brain 
some minutes after the injection, build up in concentration, then fall as the rate o f 
metabolism exceeds the rate o f delivery.
6.4.2. MECAMYLAMINE ADMINISTRATION
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Mecamylamine seemed to be the ideal antagonist with which to probe whether the 
observed effects o f  nicotine were nAChR-mediated: it is routinely used to block the 
biochemical (Rapier et al., 1990) and behavioural effects (Levin, 1992; Stolerman et al., 
1973) o f nicotine, and readily penetrates the CNS. The experiments with mecamylamine 
alone were designed as controls to demonstrate that the antagonist had no inherent effect 
on ACh release in the hippocampus, prior to experiments in which nicotine and 
mecamylamine w ere to be co-administered. Since the systemic delivery o f  the antagonist 
alone provoked an increase in hippocampal ACh levels, co-administration would not reveal 
whether the nicotine-evoked release was mediated via the nAChRs.
One possible explanation for the ability o f mecamylamine to increase ACh levels in 
the hippocampus is that it is acting in a manner akin to the NMDA antagonist dizocilpine 
(MK-801), which also produces an increase in hippocampal ACh release when injected 
systemically (0.3 mg/kg, i.p.; Hutson, 1993 personal communication). It is unclear whether 
this action o f MK-801 is mediated via the hippocampal nAChRs or is an indirect effect 
following antagonism o f hippocampal NMDA receptors. Alternatively, systemic MK-801 
may inhibit dopamine release from the ventral tegmental area which in turn my activate the 
septal-hippocampal cholinergic pathway and result in increased hippocampal ACh. In 
studies on nicotine-evoked [3H]GABA release from hippocampal synaptosomes, high 
concentrations o f  MK-801 have been shown to directly interact with neuronal nAChRs, 
possibly by acting as a nicotinic channel blocker (W onnacott et al., 1988).
The interaction between mecamylamine and MK-801 is complex: mecamylamine 
and MK-801 are both able to inhibit nicotine-induced locomotor activity in rats (Clarke & 
Kumar, 1983; Shoaib & Stolerman, 1992) and it has been reported that mecamylamine 
inhibited [3H]MK-801 binding to rat brain membranes, and increased [3H]MK-801 
dissociation rates, suggesting that it was acting at the MK-801 binding sites (Reynolds & 
Miller, 1988). Confirmation that mecamylamine is a selective non-competitive antagonist o f 
NMDA receptors was reported by O ’Dell & Christiansen (1988). The possibility that 
mecamylamine increased hippocampal ACh release in the present study via interactions 
with hippocampal NM DA receptors, rules out its further use to characterise the nicotine- 
evoked ACh release.
It was unfortunate that time constraints prematurely ended the microdialysis 
experiments, especially at such an inconclusive stage. From the results o f  the study, 
nicotine can be said to increase hippocampal ACh levels, though it is not possible to state 
with any certainty whether this is a peripherally- or centrally-mediated effect. One approach 
to distinguish the two possibilities would be to use a peripheral nicotinic antagonist such as 
hexamethonium, which has poor CNS penetrance and which would differentiate between 
the peripheral and central actions o f systemically-administered nicotine (Rosecrans, 1987). 
Another approach is to administer nicotine directly into the hippocampus either by injection 
(icv) or via the microdialysis probe itself, which ideally, would obviate the need to use 
peripheral antagonists. The problem o f demonstrating that nAChRs mediate the nicotine- 
evoked hippocampal ACh release, could be resolved using an alternative nicotinic 
antagonist such as D HpE either systemically or, like nicotine, via the dialysis probe. It 
would obviously be necessary to initially ascertain whether D H pE itself affected 
hippocampal ACh release.
One problem with studying the nicotinic enhancement o f  ACh release in the brain is 
that the nicotine-evoked responses were small. The peak response to nicotine in this study 
and that o f Toide & Arima (1989) was an increase o f only 150-180% o f  basal ACh release, 
compared to the peak muscarinic antagonist-evoked release o f  ACh which was 
approximately 2000% (Toide & Arima, 1989; Hutson et a l, 1991). This would be less o f a 
problem except basal ACh release was found to be quite variable. Basal release was 
calculated as the mean ACh release over the two hour period immediately prior to drug 
treatment. Rats tended to vary considerably with respect to one another in terms o f mean 
basal ACh release values (range = 32-98 fmol/min), and to further complicate 
interpretation, the basal release for individual rats, whilst usually remaining fairly steady 
between 80-120% o f the mean, was also subject to occasional ‘spikes’ - increases o f more 
than 140% for isolated time points. This variation resulted in large standard errors even for 
basal release, so drug effects were occasionally masked, or, obvious peaks in the ACh 
release profile struggled to  reach significance. Another factor confounding interpretation o f 
the results was the continuous presence o f  neostigmine in the aCSF used to perfuse the 
probe: the cholinesterase inhibitor was a prerequisite for detection o f  basal ACh levels. 
Necessarily, neostigmine artificially enhanced ACh levels in the local environment 
surrounding the probe and from the results in chapter 4, it is possible that these increased 
ACh concentrations continuously stimulate the hippocampal autoreceptors which regulate 
ACh release. The pattern o f evoked ACh release in figure 6.3. may be complicated by 
autoreceptor desensitisation induced by neostigmine-enhanced ACh levels.
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In summary, systemic injection o f two concentrations o f  nicotine evoked 
hippocampal ACh release in freely moving rats, though this release was not dose- 
dependent. Initial attempts to characterise the evoked release using the nicotinic antagonist 
mecamylamine were frustrated by the ability o f the antagonist to evoke ACh release in its 
own right. Further dialysis work could address the in vivo significance o f  the hippocampal 
nicotinic autoreceptors (discussed in section 7.5.),
C H A P T E R  1. C O N C I V I S I O N S
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The pentameric structure o f the neuronal nAChR and the considerable molecular 
diversity in subunits provides the possibility o f a large number o f nAChR subtypes which 
may be anticipated to subserve a variety of functions within the CNS. This study was 
undertaken to develop a better understanding of the nicotinic presynaptic autoreceptors 
responsible for modulation o f ACh release in the rat hippocampus. In addition to the basic 
goal o f further elucidating the pharmacology of these nAChRs, with the ultimate aim of 
identifying the subtype identity, the study was relevant to the ongoing search for new 
therapeutic targets for dementing diseases such as AD.
7 .1 . n A C h R s  A N D  A D
AD is associated with a loss o f learning and memory abilities, attentional deficits, 
anxiety, agitation and depression (Perry, et a l, 1978). Other impaired brain functions 
include reductions in cerebral blood flow, cerebral glucose utilisation and abnormal EEG 
(Petit et a l ,  1993). Topographically these impaired brain functions correspond to the loss 
o f the cholinergic innervation arising from the basal forebrain (Coyle et a l,  1983) and to 
substantial reductions in neuronal nAChRs (Whitehouse, et a l, 1981; 1986; Perry et al.t 
1986).
Although the prevailing dogma suggests that mAChRs mediate the primary effects 
o f central cholinergic transmission on cognitive performance (Bartus et a l,  1982; 1985) 
and cerebral vasodilation (Lee, 1982; Pinard, 1989; Hamel & Estrada, 1989), replacement 
therapy targeting mAChRs has not been a fruitful approach to the amelioration o f AD 
symptomatology (Arneric & Williams, 1993).
Neuronal nAChRs in the CNS represent an expanding area o f potential therapeutic 
opportunity driven by new findings in the molecular biology o f the system (Changeux et a l, 
1992; Deneris et a l, 1991; Sargent, 1993). The pharmacological properties and 
physiological function o f these newly identified molecular targets remain, to a large extent, 
unknown primarily due to a lack o f potent and selective pharmacological probes. 
Nonetheless, alterations in the activity of the acetylcholine-gated ion channels have been 
implicated in a number o f CNS disorders including AD (Arneric & Williams, 1994). 
Preliminary clinical data indicate that acutely administered nicotine, the prototype agonist
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for nAChRs may be beneficial for the treatment o f the deficits in attention and information 
processing associated with AD (Wesnes & Warburton, 1984; Newhouse et al., 1988; 
Sahakian et al., 1989; Jones et a l, 1992).
Extensive evidence exists to indicate that activation o f nAChRs improves cognitive 
performance and improves cerebral functions in experimental animals and normal humans. 
Nicotine enhances cognitive function in normal rats (Levin et al., 1990; Levin, 1992) and 
attenuates memory deficits produced by destruction o f cholinergic input to the cortex and 
hippocampus (Tilson et a l, 1988; Decker et a l, 1992; Hodges et a l,  1992), an effect 
shared by some other nAChR agonists (Decker et a l, 1993; M eyer et a l, 1994). In 
addition, nicotine improves short-term memory performance in both young and aged 
monkeys (Elrod et a l,  1988; Buccafusco & Jackson, 1991). The involvement o f  nicotinic 
neurotransmission in cognitive functions processes is further substantiated by observed 
deficits in cognitive performance after administration o f mecamylamine, a nAChR channel 
blocker, to rodents (Levin et a l, 1987), monkeys (Elrod et a l,  1988) and humans 
(Newhouse et a l,  1992). M oreover the characteristic cerebral cortical blood flow 
abnormality associated with AD reflects nAChRs deficits. Specifically, it has been 
demonstrated that mecamylamine, but not the muscarinic antagonist, scopolamine, reduces 
resting cerebral blood flow in the parietotemporal cortex o f  humans (Gitelman & 
Prohovnik, 1992), the area most 'consistently implicated in functional brain imaging o f AD 
patients (Heiss et a l, 1990). Reduced nicotinically mediated cerebral blood flow responses 
would thus be consistent with the loss o f nAChRs reported in several cortical regions using 
. various labelling techniques (Araujo et a l, 1988; Aubert et a l, 1992) as well as a report 
suggesting a loss o f  basal forebrain nAChR population in AD (Shimihama et a l, 1986).
7.2. AGONIST THERAPY
Nicotine however, has limited utility as a therapeutic agent for AD because o f its 
dose-limiting side effects in humans, which are primarily gastrointestinal (e.g. nausea, 
abdominal pain) and cardiac (e.g. increased catecholamine resulting in tachycardia, 
peripheral vasoconstriction and elevated blood pressure) in nature. In an aged patient 
population these latter effects may result in more serious complications (Benowitz, 1992), 
especially in patients with pre-existing arrhythmias or angina pectoris. Compounds that 
selectively interact with subtypes o f nAChRs to normalise CNS functions governed by this 
receptor family may, therefore, lead to more effective therapeutic agents.
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The potential for therapeutic use o f nicotinic agonists is further complicated by the 
phenomenon o f  nAChR desensitisation/inactivation. The results presented in chapter 4 
demonstrated “bell-shaped” dose response curves for agonist-evoked [3H]ACh release. 
Nicotinic responses measured biochemically over a similar timecourse (40 s to a few 
minutes) typically result in inverted-“U”-dose responses (Marley, 1988; Boyd, 1987), as 
seen for [3H]ACh release here. Indeed this is a common phenomenon in pharmacology 
(Pliska, 1994), attributed to desensitisation o f some step in the process being measured; in 
this case desensitisation or inactivation o f the nAChR itself is likely (Marley, 1988). 
Because o f  this narrow concentration range over which nicotine increases ACh release, 
therapeutic administration o f nicotine would require careful dosing. Due to the considerable 
individual variability in nicotine metabolism (Benowitz, et a l, 1982) the dose o f drug 
would have to be titrated individually in each patient; ideally the dose would cause maximal 
transmitter release and minimal nAChR desensitisation.
The propensity o f  nAChRs to desensitise, is in addition to the side-effects such as 
nausea and emesis associated with nicotine administration, detailed above. A potential 
therapeutic outcome o f developing compounds that selectively interact with nAChR is that 
they do not necessarily elicit a side-effect profile like nicotine. Behavioural testing o f  the 
agonist ABT 418, have indicated that compared with nicotine, ABT 418 is significantly less 
potent in producing hypothermia, acute toxicity, overt seizure activity, altered resting 
cerebral blood flow and reducing locomotor activity (Decker et al., 1994). As such the 
agonist ABT 418 may represent the first o f new class o f compounds that selectively 
activate neuronal nAChRs without eliciting the dose-limiting side effects typically observed 
with nicotine, though it remains to be seen whether nAChR desensitisation observed in 
vitro would be reflected in vivo. The potential for developing nAChR ligands for use in 
treating AD (not to mention smoking cessation, anxiety, and depression) appears high, 
providing a challenge and emerging therapeutic opportunity. Table 7.1 outlines the various 
lead compounds presently in development.
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COM PANY COMPOUND INDICATION STATUS
Ciba, W arner- Nicotine patches Smoking cessation Launched
Lambert AD?
DynoGen Lobeline, 7 day Smoking cessation Phase III
injectable
Abbott ABT-418 patch AD/smoking Phase I
formulation cessation
Taiho/Univ. GTS-21/anabaseine AD Preclinical
Florida, Gainesville analogues (patients)
R.J. Reynolds RJR 1401 AD Preclinical
neurodegeneration (patients)
Philip Morris Nicotine analogues Unknown Preclinical
SIBIA Patent application AD Preclinical
for human nAChRs
Lilly Iso-arecolone AD Preclinical
analogues (patients)
M erck Anatoxin analogues AD Preclinical
(patients)
TABLE 7.1: POTENTIAL THERAPEUTIC DRUGS BASED ON NICOTINE AGONISTS. Adapted from 
Williams et al., 1994.
7.3. HIPPOCAMPAL nAChR AUTORECEPTOR SUBTYPE
Attempts to delineate the nAChR subtype(s) responsible for the modulation o f 
hippocampal ACh release were not entirely successful. The paucity o f  ligands selective for 
the various putative nAChR subtypes effectively limits the investigation o f  native nAChRs 
to pharmacological comparisons with heterologously expressed nAChRs (cell lines, 
oocytes) and the use o f the few selective ligands (aB gt, ML A). Nevertheless significant 
progress was made. The reported lack o f  inhibition by the a7-selective toxin aB gt 
(W onnacott et a l,  1989) was confirmed using another a7-selective antagonist - MLA, 
indicating that a7-containing nAChRs cannot account for the observed pattern o f 
transmitter release. The finding that cytisine was a full agonist in the hippocampal 
preparation seemed to rule out p2-containing nAChRs (Luetje & Patrick, 1991), the 
agonist rank-order o f  potency of:
ANTX > nicotine «  cytisine »  ACh > iso-arecolone
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matched none o f the oocyte data in the literature however, in which cytisine was found to 
be a weak agonist and much less potent than nicotine on P2-containing nAChRs, and 
conversely in P4-receptors cytisine was a more potent agonist than either nicotine or ACh 
(reviewed in Zwart et a l, 1994). It is clear that the oocyte data do not tell the whole story 
though: the subtype identity o f native neuronal nAChRs is unclear, agonist potency rank- 
orders o f native nAChR-mediated currents in rat medial habenula and interpeduncular 
nucleus for example, also do not resemble any o f the rank-orders o f  nAChRs expressed in 
oocytes (Mulle et a l, 1991). This is not surprising since it has been shown that neurons 
may express nAChRs composed o f  more than two types o f  subunits and more than one 
nAChR subtype (Vernallis, et al., 1993). Both the expression o f  more complex subunit 
assemblies and the co-expression o f more than one type o f  nAChR might give rise to a 
mixed pharmacological profile.
A comparison o f the agonist potency rank-order and the EC 50 values in the present 
study with data from 86Rb+-flux experiments using chick a4 p 2  nAChRs stably expressed in 
mouse M10 fibroblasts (Stephens, 1994; section 4.4.1.) was instructive. Cytisine was a full 
agonist at chick p2 subtype-containing receptors. Moreover, a comparison o f  the agonist 
EC 50 values obtained in the two systems is instructive: despite species differences (chick vs. 
Rat nAChR) and large differences in the two methodologies, the values compare 
reasonably well and the a4 p 2  subtype remains a plausible candidate for the rat hippocampal 
autoreceptor. The lack o f availability o f  selective ligands, especially the a3-selective toxin 
neuronal Bgt, have frustrated the further delineation o f  the possible nAChR subtype(s) 
* located presynaptically in the hippocampus.
Defining the hippocampal autoreceptor subtype(s) is certainly an area in which the 
present w ork could develop. It would seem that as far as the hippocampal synaptosome 
preparation is concerned, there are limited immediate opportunities: development awaits 
advances in molecular biology, for example the expression o f  further defined nAChRs in 
model systems such as the chick a4 0 2  nAChRs in M10 cells, or natural product/synthetic 
chemistry to provide novel, selective nicotinic ligands.
7.4. nAChRs AND SP
SP did not appear to interact with the agonist binding site on the hippocampal 
nAChRs, changing neither the affinity o f  the nAChRs for the ligand [3H]nicotine, nor the 
apparent density o f  hippocampal [3H]nicotine binding sites. While SP had previously been
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shown to be a competitive antagonist o f nicotinic agonist binding using nAChR-enriched 
Torpedo membranes, this effect was thought to be dependent on the 6 and to a lesser extent 
the y subunit o f  the Torpedo nAChR, and if this were the case, the hippocampal nAChRs 
presumably lacking both 5 and y subunits, would not be expected to display SP antagonist 
sensitivity. SP did however appear to modulate the nicotine-evoked release o f  [3H]ACh in a 
complex manner consistent with a possible enhancement o f  agonist-induced 
desensitisation/inhibition o f recovery from desensitisation, counterpointed by an apparent 
facilitatory action o f  SP on the hippocampal synaptosomes, causing [3H]ACh release. The 
presence o f hippocampal SP/'NKl receptors, demonstrated by binding experiments with the 
ligand [3H][Sar9,M et(02)n ]SP provide an indirect pathway by which SP may effect nAChR 
modulation, involving the stimulation o f second messenger systems, involving PI turnover 
and PKC activation (sections 5.4.3. and 5.4.4.),
7.5. MICRODIALYSIS
The microdialysis study, carried out over three months at Merck, Sharp & Dohme, 
was successful in that increased hippocampal ACh release was demonstrated in response to 
systemic injection o f  nicotine, agreeing with the literature (section 6.4.1.), M ost frustrating 
however was the demonstration o f increased ACh release in response to the antagonist 
mecamylamine, casting doubt on the specificity o f  the nicotine-evoked results. This work 
has good potential for development and would complement the in vitro studies well. 
Ultimately, the synaptosome superfusion system is only useful as a paradigm if  it is shown 
to model the in vivo events in the rat hippocampus, something which could be evaluated by 
complementary in vivo work. The in vivo significance o f the hippocampal nicotinic 
autoreceptors has not been satisfactorily demonstrated to date, but the microdialysis 
technique has the potential to delineate the role(s) o f these receptors in a manner which the 
in vitro studies cannot address. For example if  a suitable lesioning agent were found that 
produced 70-80%  depletions in ChAT and therefore more closely modelled the cholinergic 
deficit in AD (see appendix), it would be possible to directly assay the functional activity of 
the remaining hippocampal autoreceptors by infusing nicotine or other agonists down the 
microdialysis probe, and studying the release o f  ACh, therefore estimating the usefulness o f 
agonist therapy at an early stage. Such studies using conscious, freely moving rats could be 
carried out simultaneously with behavioural testing to determine not only the biochemical 
but any cognitive-enhancing effects o f nicotinic agonists.
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7.6. EXCITOTOXIC LESIONS
Finally, o f all the aims outlined in the introduction (section 1.8.), the work involving 
lesioned animals remains the least developed. Two studies showed that it was possible to 
produce measurable albeit small ChAT depletions in the cortex and hippocampus using 
excitotoxic acids to lesion the basal forebrain, MSA and nBM areas. These studies set out 
to demonstrate that degeneration o f the cholinergic innervation from these areas resulted in 
reductions in the binding density o f  [3H]nicotine in the hippocampus and cortex, and hence 
the presence o f  high -affinity presynaptic [3H]nicotine binding sites. The main problem was 
not the design o f  the experiments but the fact that small lesions (20% ChAT depletion) 
were produced, which made the successful detection o f a correspondingly small reduction 
in [3H] nicotine binding sites difficult, especially when only a proportion o f  the total sites are 
on cholinergic terminals and therefore subject to the lesion. The first step to developing this 
lesion work would be the demonstration o f  a lesion that was relevant to the cholinergic 
pathology in AD i.e. o f the order o f  70-80%. This would hopefully ease the problem of 
detecting small changes in [3H]nicotine binding density. Once such a lesion could be 
reliably reproduced, numerous avenues are open for functional studies. As outlined above, 
it would be interesting to produce a pathologically relevant lesion, then carry out 
superfusion studies and ultimately microdialysis/behavioural experiments to compare the in 
vitro and in vivo effects o f nicotinic drugs in both the healthy rat (the present work) and an 
animal model o f  cholinergic dysfunction.
In conclusion, the nicotinic stimulation o f ACh release from rat hippocampus, 
defined in this thesis offers hope for therapeutic intervention in AD, although further work 
is required to fully define the nicotinic receptor subtype(s) involved and its in vivo action.
d F P E N b l X :  L E S I O N  S T ^ b l C S
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INTRODUCTION
As outlined in section 1.4.1.2. excitotoxic lesions of the rat basal forebrain produce 
profound deficits in performance on a wide variety of tasks involving discrimination 
learning and memory. These observations have been widely taken to reflect damage of 
cholinergic projections from the nBM and the MSA to the neocortex and the hippocampus, 
respectively. If a sufficiently large proportion o f the high affinity [3H]nicotine binding sites 
(by implication a4{32 nAChRs) are located presynaptically on cholinergic terminals, then 
lesions damaging the cholinergic innervation o f the hippocampus or cortex would be 
expected to measurably decrease the [3H]nicotine binding density in these areas. This was 
the rationale behind the lesion studies detailed in this section.
STUDY 1: INSTITUTE OF PSYCHIATRY
In a study set up with Dr. Helen Hodges o f the Institute o f Psychiatry, four groups 
of eight rats received bilateral MSA-nBM lesions with either ibotenic acid, quisqualic acid, 
a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), or saline (sham lesioned 
to act as controls). These animals were allowed three months to recover from the joint 
bilateral MSA-nBM lesions before behavioural testing was carried out at the Institute, after 
which the animals were sacrificed and the frontal cortex (FC) and the hippocampus (HP) 
dissected out and sent in dry ice to Bath University. These brain regions were assayed for 
[3H]nicotine binding (section 2.2.1.), and the results compared with data from ChAT 
assays, carried out at the Institute of Psychiatry.
RESULTS
The results o f the [3H]nicotine binding assays are presented in the following table.
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CONTROL IBOTENATE QUISQUALATE AMPA
CR 42.9 ±3 . 6 45.7 ± 2 . 6 40.7 ± 7 . 0 34.9 ±4.5
CL 42.5 ±8 . 6 48.0 ± 6 . 2 49.7 ± 7 . 6 37.4 ±3 . 2
HP 29.6 ±3 . 8 34.9 ±4 . 5 33.5 ±4 . 3 32.6 ±3 . 0
TA BLE A .I: pHJNICOTINE BINDING IN THREE BRAIN REGIONS FOLLOWING EXCITOTOXIC 
LESIONS. Values are mean fmol [3H]nicotine bound/mg protein ± SEM, n=8. CR = right frontal cortex, 
CL = left frontal cortex, HP = hippocampus.
Statistical analysis o f these results using a paired Student’s t-test, comparing each 
o f the lesioned groups with the mean control binding in each brain area, showed no 
statistical differences for any o f the lesioning agents at the p<0.05 level o f significance.
The results o f the ChAT assays, performed at the Institute were:
CONTROL IBOTENATE QUISQUALATE AMPA
FC 224 ± 10 171 ± 9 188 ± 9 140 ± 10
(100%) (76%)* (84%)* (62%)*
HP 231 ± 14 243 ± 10 227 ± 12 231 ± 9
(100%) (105%) (98%) (100%)
TA BLE A.2: ChAT ACTIVITY IN CORTEX AND HIPPOCAMPUS FOLLOWING EXCITOTOXIC 
LESIONS. Values are mean pmol [3H]ACh produced/min/mg protein ± SEM (% of control). Left and right 
cortices were combined. FC = frontal cortex. * = significantly different from control at p<0.05.
There were no significant differences between any o f the lesions and the control 
group in the hippocampus, but in the frontal cortex each o f  the lesions produced a 
significant depletion o f ChAT activity.
DISCUSSION
With regard to the hippocampal ChAT and [3H]nicotine binding data, it is difficult 
to draw meaningful conclusions. In the absence o f a demonstrable cholinergic lesion, i.e. 
significant ChAT depletion, the lack o f  change in [3H]nicotine binding is unsurprising. On 
the other hand, each o f the lesioning agents produced a significant ChAT depletion in the 
frontal cortex with no significant decrease in [3H]nicotine binding sites. Since the lesioning 
agents were injected into the nBM, source o f  the neocortical cholinergic innervation, and a 
depletion in ChAT activity implies a degeneration o f the neurons, why was there no 
corresponding decrease in cortical [3H]nicotine binding? This result is not unique in the 
literature, several groups have reported lesions producing ChAT deficits in the
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hippocampus or cortex with no corresponding decrease in [3H]nicotinic agonist binding e.g. 
Vige & Briley (1988), who used ibotenic acid to lesion the nBM and subsequently found 
decreases in ChAT activity in the frontoparietal cortex, but no change in [3H]nicotine 
binding.
The rats in the present study had three months to recover and were then trained for 
the behavioural testing, before sacrifice. The observed decreases in ChAT activity indicate 
that with each o f  the lesioning agents, between 60-80% o f the neurons were spared and it is 
a possibility that during the recovery period there was a compensation by surrounding, or 
postsynaptic neurons leading to a recovery in nAChR number. Similarly the behavioural 
testing may have led to an upregulation o f nAChRs. Dunnett et a l, (1991) reported that 
quisqualate lesions o f the nBM producing 50% reductions in cortical ChAT activity, had 
marginal effects on a variety o f behavioural tasks including standard tests for ‘cognitive’ 
deficits such as disrupted spatial navigation in the Morris water-maze, and delayed 
matching-to-position tasks. The same authors also reported reductions o f  more than 70% 
o f neocortical ChAT activity.
Another possible reason for not demonstrating decreases in [3H]nicotine binding 
despite decreases in ChAT, requires a consideration o f the proportion o f [3H]nicotine 
binding sites that are located on cholinergic neurons. Since nicotine has been shown to 
interact with a variety o f other transmitter systems including dopaminergic, serotonergic, 
GABAergic, it is possible that the proportion o f presynaptic nAChRs on the cholinergic 
terminals affected by the excitotoxic lesions, is relatively small. Also, the ChAT data show 
that only approximately 20% o f the cholinergic terminals were affected, hence the actual 
decrease in [3H]nicotine binding sites may be too subtle to detect.
STUDY 2: MERCK SHARP & DOHME
Following the lesion studies at the Institute o f Psychiatry, it was decided to  set up 
some MSA-lesioned rats (quisqualate; Hodges et a l, 1991) at the industrial sponsor, 
M erck Sharp & Dohme (MSD). Dr Pete Hutson kindly performed the surgery and looked 
after the post-operative welfare o f the animals (4 lesioned, 4 controls), in accordance with 
Home Office guidelines. Three months after the surgery the animals were sacrificed on site, 
and the hippocampi dissected out, by the author. To determine the success o f the lesions, 
ChAT activity was assayed, and [3H]nicotine binding was investigated. Also examined was 
the uptake o f  [3H]Ch by Percoll F4 synaptosomes prepared from the lesioned and control
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rats This parameter has been the standard index of synaptosomal viability used in the 
superfusion experiments, and it was hoped that it would provide insights into the integrity 
of the lesioned tissue. Following partial destruction of the extrinsic cholinergic innervation 
of the hippocampus, it might be expected that there would be fewer presynaptic cholinergic 
neurons surviving to form synaptosomes.
RESULTS
The following table summarises the results o f the three assays:
CONTROL LESIONED
ChAT ACTIVITY 334 ± 18 280 ± 11
pmol/min/mg protein (100%) (84%)*
[3H]NICOTINE BINDING 
fmol/mg protein
23.2 + 5.2 26.8 + 4.7
|3H]Ch UPTAKE 
pmol/mg protein/30 min
72.1 ±2 .7 69.6 ±9 .8
TABLE A.3 EFFECT OF QUISQUALATE LESIONING OF THE MSA ON HIPPOCAMPAL 
CHOLINERGIC PARAMETERS. Values are mean ± SEM (% of control), n=4. * = significantly different 
from control at p<0.05.
There was a small but significant depletion o f ChAT activity in the lesioned group, 
hence the lesioning procedure was deemed to have been successful. There was no 
significant reduction in the binding o f [3H]nicotine, nor was there a significant reduction in 
the [3H]Ch uptake o f the synaptosomes produced from the lesioned rats compared to the 
control rats.
DISCUSSION
The results duplicate the finding o f the previous lesion study, namely that a deficit 
in ChAT activity does not necessarily parallel a corresponding decrease in [3H]nicotine 
binding. The possible reasons for this have been discussed. Interestingly, there was also no 
decrease in synaptosomal viability as measured by uptake of [3H]Ch, following a 16% 
reduction in ChAT activity, and this is harder to explain. This contradicts a report by
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M acintosh & Collier (1976) who noted a reduction in high-affinity Ch uptake after septal- 
hippocampal lesions. If  high-affinity uptake o f Ch was maintained, there is every reason to 
believe that large numbers or presynaptic nAChRs could also be intact, obviating the need 
to invoke postsynaptic nAChR compensation for the apparent lack o f  change in 
[3H]nicotine binding sites.
Reports o f  reduced ChAT activity in Alzheimer patients are numerous (reviewed by 
Bartus et al., 1982; Rossor, 1982), in fact it was the reports o f  reduced cortical ChAT 
activity in post-mortem Alzheimer patients that provided an impetus for the suggestion that 
the widespread changes seen in end-stage cases o f Alzheimer's disease are the result o f  an 
underlying neuronal degeneration. The size o f  the ChAT reduction is dependent upon the 
brain region tested, selected examples are given below.
ChAT REDUCTION BRAIN REGION STUDY
55%, 65% MSA; nBM Henke & Lang, 1983
60-80% hippocampus Nordberg etal., 1983
60-70% various cortical regions Rossor, 1982
75-80% hippocampus Perry et a l, 1986; 1987
Generally there is a substantial reduction in ChAT, which the present lesion studies 
do not model. I f  a more substantial ChAT reduction had been produced then it would have 
been reasonable to expect to measure detectable changes in [3H]nicotine binding density. 
Such changes have been documented in samples from post-mortem Alzheimer patients. For 
example, Perry et a l, (1986), reported an approximate 50% reduction in M 2 mAChR 
binding and nicotinic binding sites in human hippocampus, which is to be expected if there 
has been extensive degeneration o f the septo-hippocampal cholinergic pathway.
In summary, despite measuring significant ChAT deficits in rat hippocampus and 
cortex, produced by excitotoxic lesions o f  the M SA and nBM respectively, there were no 
apparent changes in [3H]nicotine binding density in either region, nor was there a reduction 
o f [3H]Ch uptake into synaptosomes prepared from the hippocampi o f lesioned rats 
compared to controls. The magnitude o f  the ChAT depletion (approximately 20%) was 
small and since only a proportion o f  hippocampal and cortical [3H]nicotine binding sites 
were thought to  be located on presynaptic terminals o f  cholinergic nerves and hence 
affected by the lesions, it is feasible that 20% reductions in cholinergic-neuron-associated 
[3H]nicotine binding density would not be measurable. To represent the cholinergic deficits
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seen in post-mortem Alzheimer brains, a lesion producing 70-80% ChAT reductions would 
be a more accurate model: changes in [3H]nicotine binding density following such a lesion 
would undoubtedly be more helpful in estimating the relative proportions o f presynaptic 
cholinergic nAChRs.























Abdel-Latif, A. A., (1966). A simple method for isolation of nerve ending particles from rat 
brain BIOCHIM. BIOPHYS. ACTA, 121: 403-406.Adolfsson, R., Gottfries, C.G., 
Roos, B E., & Winblad, B., (1979). Changes in the brain catecholamines in patients with 
dementia o f Alzheimer type. B. J. PSYCHIAT., 135: 216-223.
Abercrombie, E D ,  Keefe, K.A., DiFrischia, D.S., & Zigmond, M.J., (1989). Differential 
effects o f stress on in vivo dopamine release in striatum, nucleus accumbens and medial 
frontal cortex. J. NEUROCHEM., 52: 1655-1658.
Aigner, T.G., & Mishkin, M., (1986). The effects o f phystostigmine an scopolamine on 
recognition memory in monkeys. BEHAV. NEURAL. BIOL., 45: 1; 81-87.
Akasu, T., Kojima, M, & Koketsu, K., (1983). Substance P modulates the sensitivity of the 
nicotinic receptor in amphibian cholinergic transmission. B.J. PHARMACOL., 80 123- 
131.
Alberquerque, E X., Kuba, K., & Daly, J., (1974). Effect of histrionicotoxin on the ionic 
conductance modulator o f the cholinergic receptor: a quantitative analysis o f the end- 
plate current. J. PHARMACOLOGY. EXP. THER., 189: 513-524.
Alkondon, M., & Albuquerque, E.X., (1990). a-Cobratoxin blocks the nicotinic 
acetylcholine receptor in rat hippocampal neurons. EUR. J. PHARMACOL., 191: 505- 
506.
Alzheimer, A., (1907). Uber eine eigenartige Erkrankung der Hirnrinde. ALLG. Z. 
PSYCHIAT. 64: 146-148.
Amar, M., Thomas, P., Johnson, C., Lunt, G.G., Wonnacott, S., (1993). Agonist 
pharmacology o f the neuronal a7  nicotinic receptor expressed in Xenopus oocytes. 
FEBS, 3: 284-288.
Anand, R., Peng, X., Ballesta, J.J., Lindstrom, J., (1994). Pharmacological characterisation 
of a-bungarotoxin-sensitive acetylcholine receptors immunoisolated from chick retina: 
contrasting properties of a7  and a8  subunit-containing subtypes. MOL. PHARMACOL. 
44: 1046-1050.
Anderson, D.C., King, S.C., & Parsons, S.M., (1983). Pharmacological characterisation of 
the acetylcholine transport system in purified Torpedo electric organ synaptic vesicles.
MOL. PHARMACOL., 24: 48-54.
Aoshima, H.D., Cash, J., & Hess, G.P., (1981). Mechanism o f  inactivation (desensitisation) 
o f acetylcholine receptors: investigations by fast reaction techniques with membrane- 
vesicles. BIOCHEM ISTRY 20: 3467-3474.
Aracava, Y., Deshpande, S.S., Swanson, K.L., Rapoport, H., Wonnacott, S., Lunt, G., & 
Albuquerque, E.X., (1987). Nicotinic acetylcholine receptors in cultured neurons from 
the hippocampus and brain stem o f the rat characterised by single channel recording. 
FEBS LETT., 222: 63-70.
Araujo, D.M., Lapchak, P.A., Robitaille, Y., Gauthier, S., & Quirion, R., (1988).
Differential alteration o f various cholinergic markers in cortical and subcortical regions 
o f  human brain in Alzheimer’s disease. J. NEUROCHEM., 50: 1914-1923.
Araujo, D.M., Lapchak, P. A., & Hefti, F., (1993). Effects o f chronic basic FGF 
administration to rats with partial fimbrial transections on presynaptic cholinergic 
parameters and muscarinic receptors in the hippocampus : comparison with NGF. J. 
NEUROCHEM ., 61: 899-910.
Armstrong, D.M., & Terry, R.D., 1985. Substance P immunoreactivity within neuritic 
plaques. NEUROSCI. LETT., 58: 139-144.
Arneric, S.P., & Williams, M., (1993). Nicotinic agonists in Alzheimer's disease: Does the 
molecular diversity o f nicotine receptors offer the opportunity for developing CNS 
selective cholinergic channels activators? In: RECENT ADVANCES IN THE 
TREATM ENT OF NEURODEGENERATIVE DISORDERS AND CONITIVE 
FUNCTION, (eds. Racagni, G., Brunello, N., & Langer, S.Z.). pp. 58-70. Karger, Basel.
Arneric, S.P., Sullivan, J.P., Briggs, C.A., Donnelly-Roberts, D., Anderson, D.,
Raskiewicz, J.L., Hughes, M.L., Cadman, E.D., Adams, P., Garvey, D.S., Wasicak, J.T., 
& Williams, M., (1994). (S)-3-methyl-5-(l-methyl-2-pyrrolidinyl) Isoxazole (ABT 418): 
a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I In vitro 
characterisation. J. PHARMACOLOGY. EXP. THER. 270: 310-318.
Ashall, F., & Goate, A.M., (1994). Role o f the P-amyloid precursor protein in Alzheimer's 
disease. TIBS., 19: 42-45.
Ashley, R.H., (1986). External calcium, intrasynaptosomal free calcium and 
neurotransmitter release. BIOCHEM. BIOPHYS. ACTA, 854: 207-212
Aubert, I., Araujo, D.M., Cecyre, D., Robitaille, Y., Gauthier, S., & Quirion, R., (1992). 
Comparative alterations o f  nicotinic and muscarinic binding sites in Alzheimer's and 
Parkinson’s disease. J. NEUROCHEM ., 58: 529-541.
Auerbach, S.B., Minzenberg, M.J., & Wilkinson, L.O., (1989). Extracellular serotonin and 
5-hydroxyindoleacetic acid in hypothalamus o f  the unaesthetised rat measured by in vivo
167
dialysis coupled to high performance liquid chromatography with electrochemical 
detection - dialysate serotonin reflects neuronal release. BRAIN RES., 499: 281-290. 
Autilio, L.A., Appel, S.H., Pettis, P., & Gambetti, P.L., (1968). Biochemical studies o f 
synaptosomes in vitro. 1. Protein synthesis. BIOCHEM. 7: 2615-2622.
— B
Ballivet, M., Nef, P., Couturier, S., Rungger, D., Bader, C.R., Bertrand, D., & Cooper, E., 
(1988). Electrophysiology o f  a chick neuronal nicotinic acetylcholine receptor expressed 
in Xenopus oocytes after cDNA injection. NEURON, 1: 45-54.
Bartus, R.T., Dean, R.L., Beer, B., & Lippa A.S., (1982). The cholinergic hypothesis o f 
geriatric memory dysfunction. SCI., (USA), 217: 408-416.
Bartus, R.T., Dean, R.L., Pontecorvo, M.J., & Flicker, C., (1985). The cholinergic 
hypothesis: A historical overview, current perspective, and future directions. ANN. N.
Y. ACAD. SCI., 444: 332-358.
Baux, G., Poulain, B., Fossier, P., & Tauc, L., (1987). Mise en evidence d ’autorecepteurs 
muscariniques et nicotiniques regulant la liberation d ’acetylcholine au niveau d’une 
synapse centrale identifiee d ’aplysie. C.R. ACAD. SC. PARIS, 304 (HI): 13.
Beal, M.F., & Mazurek, M.F., (1987). Neuropeptides in Alzheimer’s disease. 
NEUROLOGY, 37: 1205-1209.
Beani., L., Bianchi, C., Santiceto, L., & M archetti, P., (1968). The cerebral acetylcholine 
release in conscious rabbits with semi-permanently implanted epidural cups. INT. J. 
NEUROPHARM ACOL., 7: 469-481
Beatty, W.W., Butters, N., & Janowsky, D.S., (1986). Patterns o f  memory failure after 
scopolamine treatment - implications for the cholinergic hypothesis o f  dementia. 
BEHAV. NEURAL BIOL., 45: 196-211.
Beatty, W.W., (1988). Preservation and loss o f  spatial memory in aged rats and humans: 
implications for the analysis o f  memory dysfunction in dementia. NEUROBIOLOGY OF 
AGING, 9: 557-561.
Belcher, G., & Ryall, R.W., (1977). Substance P and Renshaw cells: a new concept o f 
inhibitory synaptic interactions. L. PHYSIOL. (LOND.), 272: 105-119.
Benowitz, N .L., Jacob, P., Jones, R.T., & Rosenberg, J., (1982). Inter-individual variability 
in the metabolism and cardiovascular effects o f  nicotine in man. J. PHARMACOL. EXP. 
THER., 221: 368-372.
168
Benowitz, N.L., Porchet, H., & Jacob, P., (1990). Pharmacokinetics, metabolism and 
pharmacodynamics o f nicotine. In: NICOTINE PSYCHOPHARMACOLOGY: 
MOLECULAR, CELLULAR AND BEHAVIOURAL ASPECTS, (eds. Wonnacott, S., 
Russel, M.A.H., & Stolerman, I.P.), pp. 112-157. Oxford University Press.
Benowitz, N.L., (1992). Nicotine and coronary heart disease. TRENDS CARDIOVASC. 
MED., 1: 315-321.
Benveniste, H., (1989). Brain microdialysis. J. NEUROCHEM., 52: 1667-1679.
Benveniste, H., & Diemer, N.H., (1987). Cellular reactions to implantation o f a 
microdialysis tube in the rat hippocampus. ACTA NEUROPATHOL., (BERL.), 74:
234-238.
Benveniste, H., Drejer, J., Schousboe, A., & Diemer, N.H., (1984). Elevation o f the 
extracellular concentrations o f glutamate and aspartate in rat hippocampus during 
transient cerebral ischaemia monitored by intracerebral microdialysis. J. NEUROCHEM., 
43: 1369-1374.
Benveniste, H., Drejer, J., Schousboe, A., & Diemer, N.H., (1987). Regional cerebral 
glucose phosphorylation and blood flow after insertion o f a microdialysis fibre through 
the dorsal hippocampus in the rat. J. NEUROCHEM., 49: 729-734.
Benwell, M .E.M ., & Balfour, D.J.K., (1985). Central nicotine binding sites: a study o f 
post-mortem stability. NEUROPHARMACOL., 24: 1135-1137.
Berridge, M.J., & Irvine, R.F., (1984). Inositol triphosphate, a novel second messenger in 
cellular signal transduction. NATURE (LOND.), 312: 315-321.
Bertrand, D., Devillers-Thiery, A., Revah, F., Galzi, J-L., Hussy, N., Mulle, C., Bertrand,
S, Ballivet, M., & Changeux, J-P., (1992). Unconventional pharmacology o f  a neuronal 
nicotinic receptor mutated in the channel domain. PROC. NAT. ACAD. SCI. (USA), 89: 
1261-1265.
Birch, P.J., & Fillenz, M., (1985). The regulation o f noradrenaline synthesis in central nerve 
terminals by autoreceptors and heteroreceptors in rat. NEUROSCI. LETTS., 59: 197- 
202.
Birdsall, N.J.M ., & Hulme, E.C., (1987). Characterisation o f muscarinic acetylcholine 
receptors and their subtypes. ISI ATLAS OF SCIENCE PHARM ACOL., pp 98-100.
Birdsall, N.J.M. & Hulme, E.C., (1979). A study o f the muscarinic receptor by gel 
electrophoresis. B. J. PHARMACOL., 66: 337-342.
Birdsall, N .J.M ., Hulme, E., Stockton, J.M., (1984). Muscarinic receptor heterogeneity. 
TRENDS PHARMACOL. SCI., (SU PPL), pp 4-8.
Bito, L., Davson, H., Levin, E., Murray, M., & Snider, N., (1966). The concentrations o f 
free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate o f  brain,
169
and blood plasma o f the dog. J. NEUROCHEM., 13: 1057-1067.
Blessed, G., (1980). Clinical aspects o f the senile dementias. In: BIOCHEM ISTRY OF 
DEM ENTIA (ed. Roberts, P.J.), pp. 1-14. John Wiley, London.
Bogdanski, D.F., Tissari, A., & Brodie, B.B., (1968). Role o f  sodium, potassium, ouabain, 
and reserpine in uptake, storage, and metabolism o f biogenic amines in synaptosomes. 
LIFE SCI., 7: 419-428.
Bogdanski, D.F., Blaszkowski, T.P., & Tissari, A.H., (1970). Mechanisms o f  biogenic 
amine transport and storage IV. Relationship between K+ and the N a+ requirement for 
transport and storage o f 5-hydroxytryptamine and norepinephrine in synaptosomes. 
BIOCHIM. BIOPHYS. ACTA, 11: 521-532.
Boksa, P., & Livett, B.G., (1984). Desensitisation to nicotinic cholinergic agonists and K+, 
agents that stimulate catecholamine secretion in isolated chromaffin cells. J. 
NEUROCHEM ., 42: 607-617.
Boksa, P., (1985). Effects o f substance P on carbachol-stimulated 45Ca2+ uptake into 
cultured adrenal chromaffin cells. J. NEUROCHEM ., 45: 1896-1902.
Boksa, P., (1987). Effects o f  substance P on the long term regulation o f  tyrosine
hydroxylase activity and catecholamine levels in cultured adrenal chromaffin cells. CAN. 
J. PHYSIOL. PHARMACOL., 64: 1548-1555.
Bondareff, W., Mountjoy, C.Q., & Roth, M., (1981). Selective loss o f  neurones o f  origin 
o f adrenergic projection to cerebral cortex (nucleus coerulus) in senile dementia. 
LANCET, 1: 783-784.
Boulter, J., Connolly, J., Deneris, E., Goldman, D., Heinemann, S., & Patrick, J., (1987). 
Functional expression o f two neuronal nicotinic acetylcholine receptors from cDNA 
clones identifies a gene family. PROC. NAT. ACAD. SCI. (USA), 84: 7763-7767. 
Boulter, J., O ’Shea-Greenfield, A., Duvoisin, R.M., Connolly, J.G., & Wada, E., (1990). 
a3 , a5 , and p4: three members o f the rat neuronal nicotinic acetylcholine receptor- 
related gene family form a gene cluster. J. BIOL. CHEM., 265: 4472-4482.
Bourne, H.R., (1986). One molecular machine can translate diverse signals. NATURE 
(LOND.), 319: 368-374.
Bowen, D.M ., & Davison, A.N., (1986). Biochemical studies o f nerve cells and energy 
metabolism in Alzheimer's disease. B. MED. BULL., 42: 75-80.
Bowen, D.M ., & Marek, K.L., (1982). Evidence for the pharmacological similarity 
between the central presynaptic muscarinic autoreceptor and postsynaptic muscarinic 
receptors. B. J. PHARMACOL., 75: 367-372.
Bowman, W .C., Prior, C., & Marshall, I.G., (1990). Presynaptic receptors in the 
neuromuscular junction. ANN. NY ACAD. SCI., 604: 69-81.
170
Boyd, N.D., (1987). Two distinct phases o f acetylcholine receptors o f  clonal rat PC 12 
cells. J. PHYSIOL. (LO N D ), 389: 45-67.
Boyd, N.D., & Leeman, S.E., (1987). Multiple actions o f substance P that regulate the 
functional properties o f acetylcholine receptors o f  acetylcholine receptors o f clonal rat 
PC12 cells. J. PHYSIOL. (LOND ), 389: 69-97.
Briggs, C.A., & Cooper, J.R., (1982). Cholinergic modulation o f  the release o f
[JH]acetylcholine from synaptosomes o f the myenteric plexus. J. NEUROCHEM., 38: 
501-508.
Brown, D.A., Docherty, R.J., & Halliwell, J.V., (1983). Chemical transmission in the rat 
interpeduncular nucleus in vitro. J. PHYSIOL., 341: 655-670.
Brown, D.A., Docherty, R.J., & Halliwell, J.B., (1984). The action o f cholinomimetic 
substances on impulse conduction in the habenulo-interpeduncular pathway o f the rat in 
vitro. J. PHYSIOL., 353: 101-109.
Buccafiisco, J.J., & Jackson, W.J., (1991). Beneficial effects o f  nicotine administered prior 
to a delayed matching-to-sample task in the young and aged monkeys. NEUROBIOL. 
AGING, 12: 233-238.
— c —
Cador, M., Rivet, J-M, Kelley, A.E., Le Moal, M., & Stinus, L., (1989). Substance P 
neurotensin and enkephalin injections into the ventral tegmental area: Comparative study 
on dopamine turnover in several forebrain structures. BRAIN RES., 486: 357-363. 
Candy, J.M., Klinowski, J., Perry, R.H., Perry E.K., Fairbaim, A., Oakley, A.E., Carpenter, 
T.A., Atack, J.R., Blessed, G., & Edwardson, J.A., (1986). Aluminosilicates and senile 
plaque formation in Alzheimer's disease. LANCET, 1: 354-357.
Carboni, E., & Di Chiara, G., (1989). Serotonin release estimated by transcortical dialysis 
in freely-moving rats. NEUROSCIENCE, 32: 637-645., 40 
Caulfield, M .P., (1993). Muscarinic receptors: characterisation, coupling and function.
PHARMACOL. THER. 58: 319-379.
Caulfield, M.P., Straughan, D.W., Cross, A.S., Crow, T., & Birdsall, N.J.M ., (1982). 
Cortical muscarinic receptor subtypes and Alzheimer’s disease. LANCET, 2: 8310;
1277.
Changeux, J-P., (1981). The acetylcholine receptor: an ‘allosteric’ membrane protein. THE 
HARVEY LECTURES. 75: 85-254. The Academic Press, New  York.
Changeux, J-P., Devillers-Thiery, A., & Chemouilli, P., (1984). Acetylcholine receptor: an 
allosteric protein. SCI. (USA), 225: 1335-1345.
Changeux, J-P., (1990). Functional architecture and dynamics o f the nicotinic acetylcholine 
receptor: an allosteric ligand-gated ion channel. FIDIA RES. FOUND. NEUROSCI. 
FOUND. LECT., 4: 21-168.
Changeux, J-P., Galzi, J-L., Devillers-Thiery, A., Bertrand, D., (1992). The functional 
architecture o f  the acetylcholine nicotinic receptor explored by affinity labelling and site 
directed mutagenesis. QUART. REV. BIOPHYS., 25: 395-432.
Chappinelli, V.A., (1991). K-Neurotoxins and a-neurotoxins: effects on neuronal nicotinic 
acetylcholine receptors. In SNAKE TOXINS, (ed. Harvey, A.L.), pp. 223-258. New 
York: Pergamon.
Chesselet, M.F., (1984). Presynaptic regulation o f  transmitter release in the brain - facts 
and hypothesis. NEUROSCI., 12: 2, 247-375.
Christie, J.E., Shering, A., Ferguson, J., & Glen, A.I.M., (1981). Physostigmine and 
arecoline - effects o f intavenous infusions in Alzheimer presnile dementia. B.J. 
PSYCHIATRY, 138: 46-50.
Clapham, D.E., & Neher, E., (1984). Substance P receptor subtype modulating release 
from adrenal chromaffin cells. J. PHYSIOL. (LOND.), 347: 255-277.
Clarke, P.B.S., & Kumar, R., (1983). The effects o f  nicotine on locomotor activity in non- 
tolerant and tolerant rats. B., J., PHARMACOL., 78: 329-337.
Clarke, P.B.S., Schwartz R.D., Paul, S.M., Pert, C.D., & Pert, A., (1985). Nicotinic 
binding in rat brain autoradiographic comparison o f [3H]acetylcholine, [3H]nicotine, and 
[125I]-a-bungarotoxin. J. NEUROSCI., 5: 1307-1315.
Clarke, P.B.S., (1990). The central pharmacology o f nicotine: electrophysiological 
approaches. In NICOTINE PHARMACOL.: MOLECULAR, CELLULAR, AND 
BEHAVIOURAL ASPECTS, (eds. W onnacott, S., Russell, M.A.H., & Stolerman, I.P.), 
pp. 158-193. Oxford: Oxford Univ. Press.
Clarke, P.B.S., (1992). The fall and rise o f  neuronal a-bungarotoxin binding proteins. 
TRENDS PHARMACOL. SCI., 13: 407-413.
Collard, K., Cassidy, D., Pye, M., & Taylor, R., (1981). The stimulus-induced release o f 
unmetabolised 5-hydroxytryptamine from superfused rat brain synaptosomes. J. 
NEUROSCI. M ETHODS, 4: 163-179.
Collerton, D., (1986). Cholinergic function and decline in Alzheimer's disease. 
NEUROSCI., 19: 1-28.
Conroy, W.G., Vemallis, A.B., & Berg, D.K., (1992). The a5  gene product assembles with 
multiple acetylcholine receptor subunits to  form distinctive receptor subtypes in brain.
172
NEURON, 9: 679-691.
Consolo, S., Wang, J-X., Fusi, R., Vinci, R., Forloni, G., & Ladinsky, H., (1984). In vitro 
and in vivo evidence for the existence o f presynaptic muscarinic cholinergic receptors in 
the rat hippocampus. BRAIN RES., 309: 147-151.
Consolo, S.,Fu Wu, C., Fiorentini, F., Ladinsky, H., Vezzani, A., (1987). Determination o f 
endogenous acetylcholine release in freely moving rats by transstriatal dialysis coupled to 
a radioenzymatic assay: Effect o f  drugs. J. NEUROCHEM., 48: 1459-1465.
Cooper, E., Couturier, S., & Ballivet, M., (1991). Pentameric structure and subunit 
stoichiometry o f a neuronal nicotinic acetylcholine receptor. NATURE (LOND.), 350:
235-238.
Cotman, C.W., & Matthews, D.A., (1971). Synaptic plasma membranes from rat brain 
synaptosomes: isolation and partial characterisation. BIOCHIM. BIOPHYS. ACTA,
249: 380-394.
Couturier, S., Bertrand, D., Matter, J.M., Hernandez, M.C., Bertrand, S., Millar, N., 
Valera, S., Barkas, T., & Ballivet, M.A., (1990). Neuronal nicotinic acetylcholine 
receptor subunit (a l)  is developm ental^ regulated and forms a homo-oligomeric channel 
blocked by a-B TX . NEURON, 5: 847-856.
Coyle, J.T., Price, D.L., & DeLong, M.R., (1983). Alzheimer's disease: a disorder o f 
cortical cholinergic innervation. SCI. (USA), 219: 1184-1190.
Cross, A.J., Crow, T.I., Perry, E.K., Perry, R.H., Blessed, G., & Tomlinson, B.E., (1981). 
Reduced dopamine-p-hydroxylase activity in Alzheimer's disease. B. MED. J., 282: 93- 
94.
Cross, A.J., Crow, T.J., Johnson, J.A., Joseph, M.H., Perry, E.K., Perry, R.H., Blessed, G., 
& Tomlinson, B.E., (1983). M onoamine metabolism in senile dementia o f Alzheimer 
type. J. NEUROL. SCI., 60: 383-392.
Cuello, A.C., & Sofroniew, M.V., (1984). The anatomy o f the CNS cholinergic neurons. 
TINS., 7: 74-78.
Cummings, J.L., & Benson, D.F., (1983). DEMENTIA: A CLINICAL APPROACH. 
Butterworths, London.
— D —
Dam, T-V., Martinelli, B., & Quirion, R., (1990). Autoradiographic distribution o f  brain 
neurokinin-1 substance P receptors using a highly selective ligand.
173
[3H][Sar9M et0 2n ]Substance P. BRAIN RES., 531: 333-337.
Damle, V.N., Karlin, A., (1978). Effects o f agonists and antagonists on the reactivity o f the 
binding site disulfide in acetylcholine receptor from Torpedo californica. 
BIOCHEMISTRY, 17: 2039-2045.
Damsma, G., Westerink, B.H.C., & Horn, A.S., (1985). A simple, sensitive and economic 
assay for choline and acetylcholine using HPLC, an enzyme reactor, and an 
electrochemical detector. J. NEUROCHEM., 45: 1649-1652.
Damsma, G., Westerink, B.H.C., DeVries, J.B., Van den Berg, J.C., & Horn, A.S., (1987). 
M easurement o f  acetylcholine release in freely moving rats by means o f  automated 
intracerebral dialysis. J. NEUROCHEM., 48: 1523-1528.
Damsma, G., Westerink, B.H.C., Imperato, A., Rollema, H., DeVries, J.B., & Horn, A.S.,
(1987). Automated brain dialysis o f acetylcholine in freely moving rats - detection of 
basal acetylcholine. LIFE SCI., 41: 873-876.
Damsma, G., Westerink, B.H.C., De Boer, P., De Vries, J.B., & Vezzani, A., (1988). Basal 
acetylcholine release in freely moving rats detected by on-line trans-striatal dialysis: 
pharmacological aspects. LIFE SCI., 43: 1161-1168.
Davies, P., & Verth, A.H., (1978). Regional distribution o f muscarinic acetylcholine 
receptor in normal and Alzheimer’s-type dementia brains. BRAIN RES., 138: 385-392.
Davis, K.L., Mohs, R.C., Tinklenberg, J.R., & Pfefferbaum, A., (1978). Physostigmine: 
improvement o f  long-term memory processes in normal humans. SCIENCE, 201: 272- 
274.
Day, E.D., McMillan, P.N., Mickey, D.D., & Appel, S.H., (1971). Zonal centrifuge profiles 
o f rat brain homogenates: instability in sucrose, stability in iso-osmotic Ficoll/sucrose. 
ANAL. BIOCHEM ., 39: 29-45.
DeBelleroche, J.S., & Bradford, H.F., (1973). The synaptosome: an isolated working, 
neuronal compartment. PROG. NEUROBIOL. 1: 275-305.
DeBelleroche, J.S., & Bradford, H.F., (1980). Presynaptic control o f the synthesis and 
release o f  dopamine from striatal synaptosomes: a comparison between the effects o f 5- 
hydroxytryptamine, acetylcholine and glutamate. J. NEUROCHEM., 35: 1227-1234.
Decker, M .W ., Majchzak, M.J., & Anderson, D.J., (1992). Effects o f nicotine on spatial 
memory deficits in rats with septal lesions. BRAIN RES. 572: 281-285.
Decker, M.W., Majchzak, M.J., & Arneric, S.P., (1993). Effects o f  lobeline, a nicotinic 
receptor agonist, on learning and memory. PHARMACOL. BIOCHEM. BEHAV., 45: 
571-576.
Decker, M.W., Brioni, J.D., Sullivan, J.P., Buckley, M.J., Radek, R.J., Raszkiewicz, J.L., 
Hee Kang, C., Kim, D.J.B., Giardina, W.J., Wasicek, J.T., Garvey, D .S., Williams, M.,
174
Arneric, S.P., (1994). (S)-3-Methyl-5-(l-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a 
novel cholinergic ligand with cognition-enhancing and anxiolytic: II. In vivo 
characterisation. J. PHARMACOL. EXP. THER., 270: 319-328.
Delgado, J.M .R., De Feudis, F.V., Roth, R.H., Ryugo, D.K., & Mitruka, B.K., (1972). 
Dialytrode for long term intracerebal perfusion in awake monkeys. ARCH. INT. 
PHARMACODYN., 198: 9-21.
Deneris,E.S., Connolly, J., Boulter, J., Wada, E., Wada., K., Swanson, L.W., Patrick, J., & 
Heinemann, S., (1988). Primary structure and expression of p2: a novel subunit of 
neuronal nicotinic acetylcholine receptors. NEURON. I: 45-54.
Deneris,E.S., Boulter, J., Swanson, L.W., Patrick, J., & Heinemann, S., (1989). 03: a new 
member o f  nicotinic acetylcholine receptor gene family is expressed in brain. J. BIOL. 
CHEM., 264: 6268-6272.
Deneris,E.S., Connolly, J., Rogers, S.W., & Duvoisin, R., (1991). Pharmacological and 
functional diversity o f neuronal nicotinic acetylcholine receptors. TRENDS 
PHARMACOL. SCI., 1 2 : 34-40, 1991.
Di Chiara, G., & Imperato, A., (1988). Opposite effects of fi-opiate and K-opiate agonists 
on dopamine release in the nucleus accumbens and in the dorsal caudate o f  freely moving 
rats. J. PHARMACOL EXP. THER. 244: 1067-1080.
Di Chiara, G., (1990). In vivo brain dialysis o f neurotransmitters. TIPS, 11: 116-121. 
Dineley-Miller, K., & Patrick, J., (1992). Gene transcripts for the nicotinic acetylcholine 
receptor subunit P4 are distributed in multiple areas o f  the rat central nervous system. 
MOL. BRAIN. RES., 16: 339-344.
« Dolezal, V., Sbia, M., Diebler, M.F., Varoqui, H., & Morel, N. (1993). Effect o f N ,N ’- 
dicyclohexylcarboiimide on compartmentation and release o f  newly synthesised and 
preformed acetylcholine in Torpedo synaptosomes. J. NEUROCHEM ., 61: 1454-1460. 
Dolly, J.O., Albuquerque E.X., Sarvey, J.M., Mallick, B., & Barnard, E.A., (1977).
Binding o f  prehydrohistrionicotoxin to the postsynaptic membrane o f  skeletal muscle in 
relation to its blockade o f acetylcholine-induced depolarisation. MOL. PHARMACOL. 
13: 1-14.
Dowdall, M .J., & Simon, E.J., (1973). Comparative studies on synaptosomes: uptake of 
[N-M e-3H]choline by synaptosomes from squid optic lobes. J. NEUROCHEM ., 21: 969- 
982.
Downing, J.E.G., Harish, O.E., & Role, L.W., (1987). Modulation o f  neuronal
acetylcholine receptor desensitisation by ganglionic peptides and agents that activate 
PKC. SOC. NEUROSCI. ABSTR., 13: 704.
Drapeau, P., & Blaustein, M., (1983). Initial release o f [3H]dopamine from rat striatal
175
synaptosomes: correlation with calcium entry. J. NEUROSCI., 3: 703-713.
Drasdo, A., Caulfield, M., Bertrand, D., Bertrand, S., & Wonnacott, S., (1992). 
Methyllycaconitine: A novel nicotinic antagonist. MOL. CELL NEUROSCI., 3: 237- 
243.
Dunkley, P R., Rostas, J.A.P., Heath, J.W., & Powis, D.A., (1987). The preparation and 
use o f synaptosomes for studying secretion o f catecholamines. In: The Secretory 
Process, 3, In vitro methods for studying secretion, (eds. Poisner, A., & Trifaro, J.M.), 
Elsevier, Amsterdam, pp. 315-334.
Dunkley, P.R., Heath, J.W., Harrison, S.M., Jarvie, P.E., Glenfield, P.J., & Rostas, J.A.P., 
(1988). A rapid Percoll gradient procedure for isolation o f  synaptosomes directly from 
an Si fraction : homogeneity and morphology o f subcellular fractions. BRAIN RES.,
441: 59-71.
Dunnett, S.B., Low, W.C., Iverson, S.D., Steveni, U., & Bjorkland, A., (1982). Septal 
transplants restore maze learning in rats with fimbria-fomix lesions. BRAIN RES., 251: 
335-348.
Dunnett, S.B., (1985). Comparative effects o f  cholinergic drugs and lesions o f  the nucleus 
basalis or fimbria fornix on delayed matching in rats. PSYCHOPHARM., 87: 357-363.
Dunnett, S.B., Everitt, B.J., & Robbins, T.W., (1991). The basal forebrain-cortical 
cholinergic system: interpreting the functional consequences o f excitotoxic lesions.
TINS, 14: 494-501.
Duvoisin, R.M., Deneris, E.S., Patrick, J., & Heinemann, S., (1989). The functional 
diversity o f  the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: 
p4. NEURON, 3: 487-496.
— E —
Elrod, K., Buccafusco, J.J., & Jackson, W.J., (1988). Nicotine enhances delayed matching- 
to-sample performance in primates. LIFE SCI., 43: 277-287.
— F —
Fibiger, H.C., & Vincent, S .R , (1987). Anatomy o f  central cholinergic neurons. In: 
PSYCHOPHARMACOLOGY: THE THIRD GENERATION OF PROGRESS, (ed. 
Meltzer, H. Y.), Raven Press, New York.
176
Fine, A., Dunnett, S B., Bjorkland, A., Iverson, S.D., (1985). Cholinergic ventral forebrain 
grafts improve passive avoidance memory in a rat model o f  Alzheimer's disease. PNAS 
(USA), 82: 5227-5230.
Flicker, C., Dean, R.L., Watkins, D.L., Fisher, S.K., & Bartus, R.T., (1983). Behavioural 
and neurochemical effects following neurotoxic lesions o f a major cholinergic input to 
the neocortex in the rat. PHARMACOL. BIOCHEM. BEHAV., 18: 973-981.
Flores, C.M., Rogers, S.W., Pabreza, L.A., Wolfe, B.B., & Kellar, K.J., (1992). A subtype 
o f  nicotinic cholinergic receptor in rat brain is comprised of a 4  and p2 subunits and is 
upregulated by chronic nicotinic treatment. MOL. PHARMACOL. 41: 31-37.
Forman, S.A., & Miller, K.W., (1988). High acetylcholine concentrations cause rapid 
inactivation before fast desensitisation in nicotinic acetylcholine receptors from Torpedo. 
BIOPHYS. J., 54: 149-158.
Forman, S. A., Firestone, L.L., & Miller, K.W., (1987), is agonist self-inhibition at the 
nicotinic acetylcholine receptor a non-specific action. BIOCHEM., 26: 2807-2814.
Franke, C., Hatt, H., Pamas, H., & Dudel, J., (1992). Recovery from the rapid 
desensitisation o f nicotinic acetylcholine receptor channels on mouse muscle. 
NEUROSCI. LETTS., 140: 169-172.
— G —
Gaddum, J.H., (1961). Push-pull cannulae. J. PHYSIOL. (LOND.), 155: p i.
Gage, F.H., Bjorkland, A., Steveni, U., Dunnett, S.B., & Kelly, P.A.T., (1984). 
Intrahippocampal septal grafts ameliorate learning impairments in aged rats. SCI. 
(USA), 225: 533-536.
Gerzanich, V., Anand, R., & Lindstrom, J., (1994). Homomers of a 8  and a.1 subunits o f 
nicotinic receptors exhibit similar channel but contrasting binding site properties. MOL. 
PHARMACOL., 45: 212-220.
Gilman, A.G., (1984). G  proteins and dual control o f adenylate cyclase. CELL, 36: 577- 
579.
Gitelman, D.R., & Prohovnik, I., (1992). Muscarinic and nicotinic contributions to 
cognitive function and cortical blood flow. NEUROBIOL. AGING, 13: 313-318. 
Glenner, G.G., (1983). Alzheimer's disease: the commonest form o f  amyliodosis. ARCHS.
PATH. LAB. MED., 107: 281-282.
Glenner, G.G., & Wong, C.W. (1984). Alzheimer's disease and D ow n’s syndrome, sharing
177
o f a unique cerebrovascular amyloid fibril protein. BIOCHEM. BIOPHYS. RES.
COMM. 1 2 2 ; 1131-1135.
Goate, A., Chartier-Harlin, M-C, Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, 
L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., 
Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M.,
Hardy, J., (1991). Segregation o f a missense mutation in the amyloid precursor protein 
gene with familial Alzheimer's disease. NATURE, 349: 704-706.
Gottfries, C.G., (1990). Disturbance o f  the 5-hydroxytryptamine metabolism in brains from 
patients with Alzheimer's dementia. J. NEURAL TRANS., (SUPPL.), 30: 33-43.
Gotti, C., Hanke, W., Maury, K., Moretti, Ballivet, M., Clementi, F., & Bertrand, D., 
(1994). Pharmacology and biophysical properties of a 7  and a 7 -a 8  a-Bungarotoxin 
receptor subtypes immunopurified from the chick optic lobe. EUR. J. NEUROSCI. 
6:1281-1291.
Grady, S., Marks, M.J., Wonnacott, S., & Collins, A.C., (1992). Characterisation o f 
nicotinic receptor mediated [3H] dopamine release from synaptosomes prepared from 
mouse striatum. J. NEUROCHEM. 59: 848-856.
Grady, S., Marks, M.J., & Collins, A.C., (1994). Desensitisation o f  nicotine-stimulated 
[3H]dopamine release from mouse striatal synaptosomes. J. NEUROCHEM . 62: 1390- 
1398.
Gray, J.A., (1982). Multiple book review of: The Neuropsychology o f  Anxiety: An Enquiry 
into the Functions o f the Septo-Hippocampal System, BEHAV. BRAIN SCI., 5: 469- 
534.
— H —
Hadhazy, P., & Szerb, J.C., (1977). The effect o f  cholinergic drugs on [3H]acetylcholine 
release from slices o f rat hippocampus, striatum and cortex. BRAIN RES., 123: 311- 
322.
Hagan, J.J., Salamone, J.D., Simpson, J., Iverson, S.D., & Morris, R.G.M ., (1988). Place 
navigation in rats is impaired by lesions o f  medial septum and diagonal band but not 
nucleus basalis o f  Meynert. BEHAV. BRAIN RES., 27: 9-20.
Hall, Z.W., (1987). Three o f  a kind: the p adrenergic receptor, the muscarinic acetylcholine 
receptor and rhodopsin. TRENDS NEUROSCI., 1 0 : 99-101.
Halvorsen, S.W., & Berg, D.K., (1990). Affinity labelling o f neuronal acetylcholine
178
receptor subunits with an a-neurotoxin that blocks receptor function. J. NEUROSCI.,
10: 1711-1718.
Hamburger, A., Berthold, C.H., Karlsson, B., Lehman, A., & Nystrom, B., (1983). 
Extracellular GABA, glutamate, and glutamine in vivo perfusion dialysis o f  the rabbit 
hippocampus. In: GLUTAMINE, GLUTAMATE AND GABA IN THE CENTRAL 
NERVOUS SYSTEM (eds. Hertz, L., Kvamme, E., McGeer, E.G., & Schousboe, A ), 
Alan R. Liss, New York.
Hamberger, A., & Nystrom, B., (1984). Extra- and intracellular amino acids in the 
hippocampus during development o f  hepatic encephalopathy. NEUROCHEM  RES., 9: 
1181-1192.
Hamel, E., & Estrada, C., (1989). Cholinergic innervation o f pial and intracerebral blood 
vessels: Evidence, possible origins and sites o f action. In: NEUROTRANSMISSION 
AND CEREBROVASCULAR FUNCTION, Vol II, (eds. Seylaz, J., Sercombe, R.), pp. 
151-173. Elsevier Science Publishers, New York.
Hamil, O.P., & Sakmann, B., (1981). Multiple conductance states o f  single acetylcholine 
receptor channels in embryonic muscle cells. NATURE (LOND.), 294: 462-464. 
Hammer, R., Berrie, C.P., Birdsall, N.J.M, Burgen, A.S.V, Hulme, E.C., (1980). 
Pirenzepine distinguishes between different subclasses o f muscarinic receptors.
NATURE (LOND ), 283: 90-92.
Hardy, J., Adolfsson, R., Alafuzoff, I., Bucht, G., Marcusson, J., Nyberg, P., Perdahl, E., 
W ester, P., & Winblad, B., (1985). Transmitter defects in Alzheimer's disease. 
NEUROCHEM . INT., 7: 545-563.
* Heaton, G.M., & Bachelard, H.J., (1973). The kinetic properties o f  hexose transport into 
synaptosomes from guinea pig cerebral cortex. J. NEUROCHEM., 21: 1099-1108 
Heidmann, T., Oswald, R., & Changeux, J-P., (1983). Multiple sites o f  action for 
noncompetitive blockers on acetylcholine receptor rich membrane fragments from 
Torpedo mamorata. BIOCHEMISTRY, 22: 3112-3127.
Heiss, W -D., Szelies, B., Adams, J., Kessler, G., Pawlik, G., & Herholz, K., (1990). PET 
scanning for the detection o f  Alzheimer's disease. In: EARLY M ARKERS IN 
PARKIN SON ’S AND ALZHEIM ER’S DISEASE (New Vistas in D rug Research, Vol. 
1), (eds. Sostert, P., Riederer, P., Strolin-Benedetti, M., & Roncucci, R.), pp. 181-196, 
Springer-Verlag, Austria.
Henderson, A.S., (1986). The epidemiology o f Alzheimer's disease. B. MED. BULL., 42; 
3-10.
Henke, H., & Lang, W., (1983). Cholinergic enzymes in neocortex, hippocampus, and 
basal forebrain o f non-neurological and senile dementia o f Azheimer-type patients.
179
BRAIN RES., 267: 281-291.
Hepler, D.J., Wenk, G.J., Cribbs, B.L., Olton, D.S., & Coyle, J.T., (1985). Memory 
impairments following basal forebrain lesions. BRAIN RES., 346: 8-14.
Hess, G.P., Pasquale, E.B., Walker, J.W., & McNamee, M.G., (1982). Comparison o f 
acetylcholine receptor-controlled cation flux in membrane-vesicles from Torpedo 
californica and Electrophorus eleclricus - chemical kinetic measurements in the 
millisecond region. PNAS (USA), 79: 963-967.
Higgins, L.K., & Berg, D.K., (1988). A desensitised form o f neuronal acetylcholine- 
receptor detected by [3H]nicotine binding on bovine adrenal chromaffin cells. J. 
NEUROSCI., 8 : 1436-1446.
Hodges, H., Allen, Y., Kershaw, T., Lantos, P.L., Gray, J.A., & Sinden, J., (1991). Effects 
o f cholinergic rich neural grafts on radial maze performance o f rats after excitotoxic 
lesions o f the forebrain cholinergic projection system-I. Amelioration o f  cognitive 
deficits by transplants into cortex and hippocampus but not into basal forebrain. 
NEUROSCI., 45: 587-607.
Hodges, H., Sinden, J., Turner, J.J., Netto, C.A., Sowinski, P., & Gray, J.A., (1992). 
Nicotine as a tool to characterise the role o f the basal forebrain cholinergic projection 
system in cognition. In: THE BIOLOGY OF NICOTINE: CURRENT RESEARCH 
ISSUES, (eds. Lippiello, P.M., Collins, A.C., Gray, J.A., & Robinson, J.H.), pp. 157- 
182. Raven Press, New York.
Hokfelt, T., Johansson, O., Ljungdahl, A., Lundberg, J.M. & Schultzberg, M., (1980). 
Peptidergic neurones. NATURE (LOND.), 284: 515-521.
. Honer, W.G., Prohovnik, I., Smith, G., & Lucas, L.R., (1988). Scopolamine reduces 
frontal cortex perfusion. J. CEREBRAL BLOOD FLOW & M ETAB., 8 : 653-641.
Houser, C.R., Crawford, G.D., Barber, R.P., Salvaterra, P.M., & Vaughn, J.E., (1983). 
Organisation and morphological characteristics o f  cholinergic neurons - an immuno- 
cytochemical study with a monoclonal antibody to choline acetyltransferase. BRAIN. 
RES., 266: 97-119.
Huganir, R.L., Delcour, A.H., Greengard, P., & Hess, G.P., (1986). Phosphorylation o f the 
nicotinic acetylcholine receptor regulates its rate o f desensitisation. NATURE (LOND.), 
321: 774-776.
Hutson, P.H., Sarna, G.S., Kantamaneni, B.D., & Curzon, G., (1985). M onitoring the 
effect o f a tryptophan load on brain indole metabolism in freely moving rats by 
simultaneous cerebrospinal fluid sampling and brain dialysis. J. NEUROCHEM ., 44: 
1266-1273.
Hutson, P.H., Semark, J.E., & Middlemiss, D .N., (1991). The TRH analogue MK-771,
180
increases acetylcholine release in hippocampus but not striatum o f the conscious rat. 
NEUROSCI. LETTS., 116: 149-155.
— I —
Imperato, A., & Di Chiara, G., (1984). Trans-striatal dialysis coupled to reverse phase high 
performance liquid chromatography with electrochemical detection: a new method for 
the study o f  the in vivo release o f  endogenous dopamine and metabolites. J. 
NEUROSCI., 4: 966-977.
Imperato, A., Mulas, A., & Di Chiara, G., (1986). Nicotine preferentially stimulates 
dopamine release in the limbic system o f freely moving rats. EUR. J. PHARMACOL., 
132: 337-338.
Imperato, A., & Di Chiara, G., (1986). Preferential stimulation o f  dopamine release in the 
nucleus accumbens. J. PHARMACOL. EXP. THER., 244: 1067-1080.
— J —
Jackson, M.B., 1984. Spontaneous openings o f the acetylcholine receptor channel. PROC. 
NAT. ACAD. SCI. (USA), 81: 3901-3904.
. Jackson B.B., (1986). Kinetics o f  unliganded acetylcholine receptor channel gating. 
BIOPHYS. J., 49: 663-672.
Jones, G.M .M ., Sahakian, B.J., Levy, R., Warburton, D.M., & Gray, J.A., (1992). Effects 
o f acute subcutaneous nicotine on attention, information processing and short-term 
memory in Alzheimer's disease. PSYCHOPHARMACOLOGY. 108: 485-494.
Jarrard, L.E., Kant, G.J., Meyerhoff, J.L., & Levy, A., (1984). Behavioural and 
neurochemical effects o f  intraventricular AF64A administration in rats. PHARMACOL. 
BIOCHEM . BEHAV., 21: 273-280.
— K —
Kalivas, P.W ., & Horita, A., (1979). Thyrotropin-releasing hormone: neurogenesis o f 
actions in the pentobabital narcotized rat. J. PHARMACOL. EXP. THER., 212: 203-
210.
Kang, J. Lemaire, H-G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschick, K-H., 
Multhaup, G., Beyreuther, K., & Muller-Hill, B., (1987). The precursor o f  Alzheimer's 
disease amyloid A4 protein resembles a cell-surface receptor. NATURE (LOND.), 325: 
733-736.
Katz, B ., & TheslefF, S., (1957). A study o f desensitisation produced by acetylcholine at 
the m otor end plate. J. PHYSIOL. (LOND.), 138: 63-80.
Kauppinen, R.A., & Nicholls, D.G., (1986). Synaptosomal bioenergetics- the role o f 
glycolysis, pyruvate oxidate and responses to hypoglycemia. EUR. J. BIOCHEM., 158: 
159-165.
Kehr, J., & Ungerstedt, U., (1988). Fast HPLC estimation o f gamma-aminobutyric acid in 
microdialysis perfusates - effect o f nipecotic and 3-mercaptopropionic acids. J. 
NEUROCHEM ., 51: 1308-1310.
Kerlavage, A.R., Fraser, C.M., & Venter, J.C., (1987). Muscarinic cholinergic receptor 
structure: molecular biological support for subtypes. TRENDS PHARMACOL. SCI., 8 : 
426-431.
Khalil, Z., Marley, P.D., & Livett, B.G., (1988). Effect o f  substance P on nicotine-induced 
desensitisation o f  cultured bovine adrenal chromaffin cells: possible receptor subtypes. 
BRAIN RES., 459: 282-288.
Kish, S.T., Robitaille, Y., Elawar, M., Deck, J.H.N., Simmons, J., Schut, L., Chang, L.J., 
Di Stefano, L., & Freedman, M., (1989). Non-Alzheimer-type pattern o f  brain choline 
acetyltransferase reduction in dominantl;y inherited olivopontocerebellar atrophy. ANN. 
NEUROL. 26: 362-367.
Klaff, L., Hudson, A., Paul, M., & Millar, R., (1982). A mehtod for studying synaptosomal 
release o f neurotransmitter candidates, as evaluated by studies on cortical 
cholecystokinin octapeptide release. PEPTIDES, 1: 155-161.
Knowlton, B.J., Wenk, G.L., Olton, D.S., & Coyle, J.T., (1985). Basal forebrain lesions 
produce a dissociation o f trial-dependent and trial-independent memory performance. 
BRAIN RES., 345:315-321.
Kowall, N.W ., Beal, M.F., Busciglio, J., Duffy, L.K., & Yankner, B.A., (1991). An in vivo 
modal for the neurodegenrative effects of p-amyloid and protection by substance P. 
PNAS (USA), 8 8 : 7247-7251.
Kmjevic, K., and Lekic, D., (1977). Substance P selectively blocks excitation o f  Renshaw 
cells by acetylcholine. CAN. J. PHYSIOL. PHARMACOL., 55: 958-961.
Kurokawa, M .T., Sakamoto, M .T., & Kato, M., (1965). Distribution o f sodium-plus- 
potassium-stimulated adenosine-triphosphatase activity in isolated nerve-ending
182
particles. BIOCHEM. J., 97: 833-844.
— L —
L’Heureux, R., Dennis, T., Curet, O., & Scatton, B., (1986). M easurement o f endogenous 
noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis - effects o f 
drugs affecting noradrenergic transmission. J. NEUROCHEM., 46: 1794-1801. 
Lagercrantz, H., & Pertoft, H., (1972). Separation o f catecholamine storing synaptosomes 
in colloidal silica density gradients. J. NEUROCHEM., 19: 811-823.
Lapchak, P. A., Araujo, D.M., Collier, B., & Quirion, R., (1989). Effect o f  chronic nicotine 
treatm ent on nicotinic autoreceptor function and N-[3H]methylcarbamylcholine binding 
sites in the rat brain. J. NEUROCHEM ., 52: 483-491.
Lee, T.J-F., (1982). Cholinergic mechanism in the large cat cerebral artery. CIRC. RES.,
50: 870-879.
LeFresne, P., Rospars, J.P., Beaujouan, J.C., Westfall, T.C., & Glowinski, J., (1978).
ARCH. PHARMACOL. 303: 279-285.
Lehman, A., Isaacson, H., & Hamberger, A., (1983). Effects of in vivo administration o f 
kainic acid on the extracellular amino-acid pool in the rabbit hippocampus. J. 
N EUROSCI., 40: 1794-1801.
Leone, P., & Di Chiara, G., (1987). EUR. J. PHARMACOL., 135: 251-254.
Levin, E.D., Castonguay, M., & Ellinson, G.D., (1987). Effects o f  the nicotinic receptor 
blocker, mecamylamine, on radial-arm maze performance in rats. BEHAV. NEUROL. 
BIOL., 48: 206-212.
Levin, E.D., Lee, C., Rose, J.E., Reyes, A., Ellinson, G., Jaravik, M., & Gritz, E., (1990). 
Chronic nicotine and withdrawal effects on radial-arm performance in rats. BEHAV. 
NEUROL. BIOL., 53: 269-276.
Levin, E.D., (1992). Nicotinic systems and cognitive function.
PSYCHOPHARMACOLOGY, 108: 417-431.
Levy, E., Carman, M.M., Femandez-Madrid, I.J., Power, M.D., Lieberburg, I., Van 
Duinen, S.G., Bots, G.T.A.M., Luyendijk, W., & Frangione, B., (1990). SCIENCE 248: 
1124-1126.
Lewis, P.R., Shute, C.C.D., & Silver, A., (1967). Confirmation from choline acetylase o f a 
massive cholinergic innervation to  the rat hippocampus. J. PHYSIOL. (LOND.), 191: 
215-224.
183
Lindstrom, J., Schoepfer, R., & Whiting, P., (1987). Molecular studies o f  the neuronal 
nicotinic acetylcholine receptor family. MOL. NEUROBIOL., 1: 281-337.
Lingle, C.J., Maconochie, D., & Steinbach, J.H., (1992). Activation o f  skeletal muscle 
nicotinic acetylcholine receptors. J. MEMBRANE BIOL., 126: 195-217.
Livett, B.G., Kozousek, F., Mizobe, F., & Dean, D.M., (1979). Substance P inhibits 
nicotinic activation o f  chromaffin cells. NATURE (LOND.), 278: 256-257.
Livett, B.G., & Boksa, P.,( 1984).Receptors and receptor modulation in cultured 
chromaffin cells. CAN. J. PHYSIOL. PHARMACOL. 62: 467-476.
Livett, B.G., & Zhou, X-F., (1991). Substance P interactions with the nicotinic response. 
ANN. N Y.ACAD. SCI., 632: 249-263.
Loring, R.H., & Zigmond, R.E., (1988). Characterisation o f  neuronal nicotinic receptors by 
snake venom neurotoxins.TRENDS NEUROSCI., 11: 73-78.
Lowry, A., Rosebrough, N.J., Farr, A.L. & Randall, R.J., (1951). Protein measurement 
with the Folin phenol reagent. J. BIOL. CHEM., 193: 263-275.
Luetje, C.W., Wada, K., Rogers, S., Abramson, S.N., Tsuji, K., Heinemann, S., & Patrick, 
J., (1990). Neurotoxins distinguish between different neuronal nicotinic acetylcholine 
receptor subunit combinations. J. NEUROCHEM., 55: 632-640.
Luetje, C.W., & Patrick, J., (1991). Both a -  and p-subunits contribute to the agonist 
sensitivity o f neuronal nicotinic acetylcholine receptors. J. NEUROSCI., 11: 837-845.
Luetje, C.W., Piattoni, M., & Patrick, J. (1993). Mapping o f  ligand binding sites o f  
neuronal nicotinic acetylcholine receptors using chimeric a  subunits. MOL. 
PHARMACOL., 44: 657-666.
* Lukas, R.J., (1989). Nicotinic acetylcholine receptor diversity: agonist binding and 
functional potency. PROG. BRAIN RES., 79: 117-127.
Lukas, R.J., (1990). Heterogeneity o f  high affinity nicotinic [3H]acetylcholine binding sites. 
J. PHARMACOL. EXP. THER., 253: 51-57.
Lyford, L.K., Kent-Braun, J.A., & Westhead, E.W ., (1990). Substance P enhances 
desensitization o f  the nicotinic response in bovine chromaffin cells but enhances 
secretion upon removal. J.NEUROCHEM., 55: 1960-1965.
— M —
Macallan, D .R.E., Lunt, G.G., W onnacott, S. Swanson, K.L., Rapoport, H., & 
Albuqerque, E.X., (1988). Methyllycaconitine and (+)-anatoxin-a differentiate between
184
nicotinic receptors in vertebrate and invertebrate nervous systems. FED. EUR. 
BIOCHEM. SOC. LETT., 226: 357-363.
Macintosh, F.C., & Oborin, P.E., (1953). Release o f  acetylcholine from intact cerebral 
cortex. (Abstr ), in: ABTRACTS OF THE XIX INTERNATIONAL PHYSIOLOGY 
CONGRESS, pp. 590-581.
Mahley, R.W., (1988). Apolipoprotein E: cholesterol transport protein with expanding role 
in cell biology. SCIENCE, 240: 622-630.
M andelkow E-M  & Mandelkow E (1993). Tau as a marker for Alzheimer’s disease. TIBS, 
18: 480-483.
Mann, D.M .A., Lincoln, J., Yates, P.O., Stamp, J.E., & Toper, S., (1980). Changes in the 
monoamine containing neurones o f  the human CNS in senile dementia. B. J. 
PSYCHIAT., 136: 533-541.
Mantyh, P.W ., Gates, T., Mantyh, C.R., & Maggio, J.E., (1989). Autoradiographic 
localisation and characterisation o f  tachykinin receptor binding sites in the rat brain and 
peripheral tissues. J. NEUROSCI., 9: 258-279.
Marchbanks, R.M., (1982). Biochemistry o f  Alzheimer’s dementia. J. NEUROCHEM., 39: 
9-14.
Marchi, M., Paudice, P., & Raiteri, M., (1981). Autoregulation o f  acetylcholine release in 
isolated hippocampal nerve endings. EUR. J. PHARMACOL., 73: 75-79.
Marchi, M., Caviglia, A., Paudice, P., & Raiteri, M., (1983). Calcium-dependent 
[3H]acetylcholine release and muscarinic autoreceptors in rat cortical synaptosomes 
during development. NEUROCHEM. RES., 8(5).
Marchi, M., & Raiteri, M., (1989). Interaction acetylcholine-glutamate in rat hippocampus: 
involvement o f  two subtypes o f  M 2 receptors. J. PHARMACOL. EXP. THER., 248: 
1255-1260.
Marks, M .J., Famham, D.A., Grady, S R., & Collins, A.C., (1993). Nicotinic receptor 
function determined by stimulation od rubidium efflux from mouse brain synaptosomes.
J. PHARMACOL. EXP. THER., 264: 542-552.
Marley, P.D. (1988). Desensitisation o f  the nicotinic secretory response o f  adrenal 
chromaffin cells. TRENDS PHARMACOL. SCI., 9: 102-107.
M artino-Burrows, A.M., & Kellar, K.J., (1987). [3H]Acetylcholine and [3H](-)nicotine 
label the same recognition site in rat brain. MOL. PHARMACOL., 31: 169-174.
Masters, C.L., Simms, G., Weinmann, N.A., Multhaup, G., McDonald, B.L., &
Beyreuther, K., (1985). Amyloid plaque core protein in Alzheimer's disease and Down 
Syndrome. PROC. NAT. ACAD. SCI., 82; 4245-4249
Mateyko, G.M., & Kopac, M.J., (1963). Cytophysical studies on living normal and
185
neoplastic cells. ANN. N.Y.ACAD. SCI., 105: 185-218.
McGeer, P.L., Eccles, J.C., & McGeer, E.G., (1987). MOLECULAR NEUROBIOLOGY 
OF THE M AM M ALIAN BRAIN, p 155, Plenum Press, New York.
McGeer, P.L., (1984). The 12th J.A.F. Stevenson memorial lecture: Ageing, Alzheimer's 
disease and the cholinergic system. CAN. J. PHYSIOL. PHARMACOL., 62: 741-754.
McKinney, M., & Coyle, J.T., (1991). The potential for muscarinic receptor subtype 
specific pharmacotherapy for Alzheimer’s disease. MAYO CLINIC PROC., 6 6 : 1225- 
1237.
McLane, K.E., Wu, X., Conti-Tronconi, B.M., (1990). Identification o f a brain
acetylcholine receptor a  subunit able to bind a-bungarotoxin. J. BIOL. CHEM., 265: 
9816-24.
McLean, S., Ganong, A., Seeger, T., Bryce, D., Pratt, K., Reynolds, L., Siok, C., Lowe, J., 
& Heym, J., (1991). Characterisation o f the activity and distribution o f  binding sites in 
brain o f  a non-peptide substance P (NK1) receptor antagonist. SCIENCE, 251: 437-439.
McLean, S., Ganong, A., Seymour, P.A., Snider, R.M., Desai, M.C., Rosen, T., Bryce,
D.K., Longo, K.P., Reynolds, L.S., Robinson, G., Schmidt, A.W., Siok, C., Heym, J., 
(1993). Pharmacology o f CP-99,994 - a nonpeptide antagonist o f  the tachykinin 
neurokinin-1 receptor. J. PHARMACOL. EXP. THER., 267: 472-479.
McMahon, H.T., & Nicholls, D.G., (1991a). The bioenergetics o f neurotransmitter release. 
BIOCHIM. BIOPHYS. ACTA. 1059: 243-264.
McMahon, H .T., & Nicholls, D.G., (1991b). Transmitter glutamate release from isolated 
nerve terminals evidence for biphasic release and triggering by localised Ca2+. J. 
NEUROCHEM ., 56: 86-94.
Meyer, E.M ., De Fiebre, C.M., Hunter, B.E., Simkins, C.E., Frauworth, N., & De Fiebre, 
N.E.C., (1994). Effects o f  anabaeine-related analogs on rat brain nicotinic receptor 
binding and on avoidance behaviours. D RU G D EV EL. RES., 31: 127-134.
Michaelson, D.M ., Burstein, M., & Licht, R., (1986). Translocation o f  cytosolic 
acetylcholine into synaptic vesicles and demonstration o f vesicular release. J. BIOL. 
CHEM., 261:6831-6835.
Min, C.K., & Weiland, G.A., (1992). Substance P inhibits carbamylcholine-stimulated 
22N a+ efflux from acetylcholine receptor-enriched Torpedo electroplaque membrane 
vesicles. BRAIN RES., 586: 348-351.
Min, C.K., & Weiland, G.A., (1993). Effects o f  substance P on the binding o f  agonists to 
the nicotinic acetylcholine receptor o f the Torpedo electroplaque. J. NEUROCHEM.,
60: 2238-2246.
Min, C.K., Owens, J., & Weiland, G.A., (1994). Characterisation o f  the binding o f
186
[3H]substance P to the nicotinic acetylcholine receptor of Torpedo electroplaque. MOL. 
PHARM ACOL., 45: 221-227.
Minnema, D., & Michaelson, I. A., (1985). A superfusion apparatus for the examination o f 
neurotransmitter release from synaptosomes. J. NEUROSCI. METHODS, 14: 193-206.
Moroni, F., & Pepeu, G., (1984). The cortical cup technique. In: MEASUREMENT OF 
TRANSM ITTER RELEASE IN  VIVO (ed. Marsden, C. A ), pp. 63-81. Wiley & Sons, 
New  York.
Morris, B.J., Hicks, A.A., Wisden, W., Darlison, M.G., Hunt, S.P., & Barnard, E.A.,
(1990). Distinct regional expression o f nicotinic acetylscholine receptor genes in chick 
brain. MOL. BRAIN RES., 7: 305-315.
M oss , S.J., & W onnacott, S., (1985). Presynaptic nicotinic autoreceptors in rat 
hippocampus. BIOCHEM. SOC. TRANS., 13: 164-165.
Mousli, M., Bueb, J-L., Bronner, C., Rouot, B., & Landry, Y.G., (1990). G  protein 
activation: a receptor-independent mode o f action for cationic amphophilic 
neuropeptides and venom peptides. TRENDS PHARMACOL. SCI., 11: 358-362.
Mulder, A.H., Van den Berg, W.B., & StofF, J.C., (1975). Calcium-dependent release o f 
radiolabelled catecholamines and serotonin from rat brain synaptosomes. BRAIN RES., 
99: 419-424.
Mulle, C., Vidal, C., Benoit, P., Changeux, J-P., (1991). Existence o f  different subtypes o f 
nicotinic acetylcholine receptors in the rat habenulo-interpeduncular sytem. J. 
NEUROSCI. 11: 2588-2597.
Mulle, C., Choquet, D., Korn, H., & Changeux, J-P., (1992). Calcium influx through 
nicotinic receptor in rat central neurons: Its relevance to cellular regulation. NEURON,
8 : 135-143.
— N —
Nagy, A., & Delgado-Escueta, A.V., (1984). Rapid preparation o f  synaptosomes from 
mammalian brain using non-toxic isoosmotic gradient material (Percoll). J. 
NEUROCHEM ., 43: 1114-1123.
Nakanishi, (1991). Mammalian tachykinin receptors. ANN. REV. NEUROSCI., 14: 123- 
136.
Namba, Y., Tomonaga, M., Kawasaki, H., (1991). Apolipoprotein E immunoreactivity in 
cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease. BRAIN
187
RES., 541: 163-166.
Neubig, R.R., Boyd, N.D., & Cohen, J.B., (1982). Conformations of Torpedo acetylcholine 
receptor associated with ion transport and desensitisation. BIOCHEM ISTRY, 21: 3460-
3467.
Newhouse, P.A., Sunderland, T., Tariot, P.N., Blumhardt, C.L., Weingartner, H., Mellow, 
A., & Murphy, D.L., (1988). Intravenous nicotine in Alzheimer’s disease: a pilot study. 
PSYCHOPHARM ., 95: 171-175.
Newhouse, P.A., Potter, A., Corwin, J., & Lenox, R., (1992). Acute nicotinic blockade 
produces cognitive impairment in normal humans. PSYCHOPHARMACOLOGY, 108. 
480-484.
Nicholls, D.G., (1989). Release o f glutamate aspartate, and y-aminobutyric acid from 
isolated nerve terminals. J. NEUROCHEM., 52: 331-341.
Nicoll. R.A., Schenker, C., & Leeman, S.E., (1980). Substance P as a transmitter 
candidate. ANN. REV. NEUROSCI., 3: 227-268.
Nicoll, R.A., (1985). The septo-hippocampal projection: a model cholinergic pathway.
TINS, DECEM BER, pp533-536.
Nicoll, R.A., Malenka, R.C., & Kauer, J.A., (1990). Functional comparison o f
neurotransmitter subtypes in the mammalian central nervous system. PHYSIOL. REV., 
70:513-565.
Nieoullon, A., Cheramy, A., & Glowinski, J., (1977). An adaptation o f  the push-pull 
cannula method to  study the in vivo release o f  [3H]dopamine synthesised from 
[3H]tyrosine in the cat caudate nucleus: effects o f  various physical and pharmacological 
treatments. J. NEUROCHEM ., 28: 819-828.
Nordberg, A., Larsson, C., Adolfsson, R., Alafuzoff, I., & Winblad, B., (1983). Muscarinic 
receptor compensation in hippocampus o f  Alzheimer patients. J., NEURAL TRANS.,
56: 13-19.
Nordberg, A., Romanelli, L., Sundall, A., Bianchi, C., & Beani, L., (1989). Effect o f  acute 
and subchronic nicotine treatment on cotical acetylcholine release and on nicotinic 
receptors in rats and guinea-pigs. B. J. PHARMACOL. 98: 71-78.
Nordstrom, O., & Bartfai, T., (1980). Muscarinic autoreceptor regulates acetylcholine 
release in rat hippocampus. ACTA PHYSIOL. SCAND., 108: 347-353.
Nukina, I., Ogawa, N., Takayama, H., & Ota, Z., (1985). Binding differences betwenn 




O ’Dell, T.J., & Christensen, B.N., (1988). Mecamylamine is a selective non-competitive 
antagonist o f  N-methyl-D-aspartate-induced and aspartate-induced currents in horizontal 
cells dissociated from the catfish retina. NEUROSCI. LETTS., 94: 93-98.
Ochoa, E.L., Chattopadhay, A., & McNamee, M.G., (1989). Desensitisation o f the
nicotinic acetylcholine receptor: molecular, mechanisms and effect o f  modulators. CELL 
MOL. NEUROBIOL., 9: 141-178.
Olton, D.S., Hepler, D., Wenk, G., Lehman, J., & Coyle, J., (1984). Lesions o f the nucleus 
basalis magnocellularis and medial septal area in rats produce similar memory 
impairments. Proceedings o f the 3rd Meeting o f the International Study Group on the 
Treatment o f  Memory Disorders Associated with Aging, p. 461, Zurich, Switzerland.
Overstreet, D.H., & Russell, R.W., (1984). Animal models o f  memory disorders. In:
Animal M odels in Psychopathology (ed. Bond, N.W.), pp. 257-278. Academic Press, 
London.
— P —
Papke, R.L., Boulter, J., Patrick, J., & Heinemann, S., (1989). Single channel currents o f 
rat neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. NEURON, 
3: 589-596.
Pasquale, E.B., Takeyasu, K., Udgaonkar, J.B., Cash, D.J., Severski, M.C., & Hess, G.P., 
(1983). Acetylcholine receptor - evidence for a regulatory binding site in investigations 
o f  subery dicholine-induced transmembrane ion flux in Electrophorus electricus 
membrane vesicles. BIOCHEMISTRY, 22: 5967-5973.
Paton, W .D.M ., & Zaimis, E.J., (1949). The pharmacological actions o f  polymethylene 
bistrimethylammonium salts. B. J. PHARMACOL., 4: 381-400.
Paxinos, G., & Watson, C., (1982). The rat brain in stereotaxic coordinates. N ew  York, 
Academic.
Pearce, L.B., Benishin, C.G., & Cooper, J.R., (1986). Substance B: an endogenous brain 
factor that reverses presynaptic inhibition o f acetylcholine release. PROC. NAT. ACAD. 
SCI. (USA), 83: 7979-7983.
Pearce, L.B., Buck, T., Adamec, E., (1991). Rapid kinetics o f  potassium-evoked release o f 
acetylcholine from rat brain synaptosomes: Analysis by rapid superfusion. J. 
NEUROCHEM ., 57: 636-647.
Pedata, E., Giovannelli, L., DeSarno, P., & Pepeu, G., (1986). The effect o f  adenosine, 
adenosine derivatives and caffeine on acetylcholine release from brain synaptosomes: 
interaction with muscarinic autoreceptor mechanisms. J. NEUROCHEM ., 46: 1593- 
1598.
Pepeu, G., (1977). The release o f acetylcholine from the brain: an approach to the study of 
the central cholinergic mechanisms. PROG. NEUROBIOL., 2: 257-288.
Peralta, E.G., Winslow, J.W., Peterson, G.L., Smith, D.L., Ashkenazi, A., Ramachandran, 
J., Schimerlik, M.I., & Capon, D.J., (1987). Primary structure and biochemical 
properties o f  an M 2 muscarinic receptor. SCI. (USA), 236: 600-605.
Pereira, E.F.R., Reinhardt-Maelicke, S., Schrattenholz, A., Maelicke, A., & Albuquerque,
E.X., (1993). Identification and functional characterisation o f a new agonist site on 
nicotinic acetylcholine receptors o f cultured hippocampal neurons. J. PHARMACOL. 
EXP. THER., 265: 1474-1491.
Perry, E.K., Tomlinson, B.E., Blessed, G., Bergman, K., Gibson, P.H., & Perry, R.H, 
(1978). Correlation o f  cholinergic abnormalities with senile plaques and mental test 
scores in senile dementia. B. MED. J., 2: 1457-1459.
Perry, E.K., & Perry, R.H., (1985). New insights into the nature o f senile (Alzheimer-type) 
plaques. TRENDS. NEUROSCI., 8 : 301-303.
Perry, E.K., (1986). The cholinergic hypothesis - 10 years on. B. MED. BULL. 42: (1), 63- 
69.
Perry, E.K., Perry, R.H, Smith, C.J., Purohit, D., Bonham, J., Dick, D.J., Candy, J.M., 
Edwardson, J.A., & Fairbaim, A., (1986). Cholinergic receptors in cognitive disorders. 
CAN. J. NEUROL. SCI., 13: 521-527.
Perry, E.K., Perry, R.H., Blessed, G. (1987) Nicotinic receptor abnormalities in Alzheimers 
and Parkinsons disease J. NEUROL. NEUROSURG. & PSYCH. 50: 806-809.
Perry, E.K., Smith, C.J., Perry, R.H, Johnson, M., Fairbaim, A.F., (1989). Nicotinic 
([3H]nicotine) receptor binding in human brain: characterisation and involvement in 
cholinergic neuropathology. NEUROSCI. RES. COMMUN., 5: 117-122.
Petit, D., Lorrain, D., Gauthier, S., & Montplaisir, J., (1993). Regional spectral analysis of 
the REM  sleep EE G  in mild to moderate Alzheimer's disease. NEUROBIOL. AGING, 
14: 141-146.
Pharmacia Fine Chemicals, Percoll reference list (1982).
Philippu, A., (1984). Use o f the push-pull cannulae to determine the release o f  endogenous 
neurotransmitters in distinct brain areas o f  anaesthetised and freely moving animals. In: 
M EASUREM ENT OF TRANSM ITTER RELEASE IN  VIVO (ed. Marsden, C. A ), pp. 
3-39. Wiley & Sons, New York.
Pinard, E., (1989). Cholinergic innervation o f cerebral blood vessels: Functional aspects.
In: NEUROTRANSM ISSION AND CEREBROVASCULAR FUNCTION, Vol II,
(eds. Seylaz, J., Sercombe, R.), pp. 175-191. Elsevier Science Publishers, New York.
Pliska, V., (1994). Models to explain dose-response relationships that exhibit a downturn 
phase. TRENDS PHARMACOL. SCI., 15: 178-181.
Plotkin, D.A., & Jarvik, L.F., (1986). Cholinergic dysfunction in Alzheimer's disease - 
cause or effect. PROG. BRAIN RES., 65: 91-103.
Poirier J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., Gauthier, S., (1993). 
Apolipoprotein E polymorphism and Alzheimer's disease. THE LANCET, 342: 697-699.
Poirier, J., Hess, M., May, P.C., Pasinetti, G., & Finch, C.E., (1991). Astroglial gene 
expression during reactive synaptogenesis. In: Basic and therapeutic strategies in 
Alzheimer's disease and Parkinson’s disease (eds. Abraham, E.H., Tanaka, K.,), Plenum 
Press, New York, pp 191-194.
— Q —
Quirion, R., Martel, J.C., Robitaille, Y., Etienne, P., Wood, P., Nair, N.P.V., & Gauthier, 
S., (1986). Neurotransmitter and receptor deficits in senile dementia o f  the Alzheimer 
type. CAN. J. NEUROL. SCI., 13: 503-510.
Quirion, R., & Dam, T-V., (1993). Radioligand binding studies o f  the three major classes 
o f  neurokinin receptors. In: M ETHODS IN NEUROSCIENCE VOL. 12. pp223-227.
— R —
Raiteri, M., Angelini, F., & Levi, G., (1974). A simple apparatus for studying the release o f 
acetylcholine by rat cerebral cortex in vitro. B. J. PHARMACOL. 25: 411-414.
Raiteri, M., Leardi, R., Marchi, M., (1984). Heterogeneity o f  presynaptic muscarinic 
receptors regulating neurotransmitter release in the rat brain. J. PHARMACOL. EXP. 
THER., 6 6 : 971-979.
Raiteri, M., Marchi, M., & Caviglia, A.M., (1986). Studies on a possible functional
coupling between presynaptic acetylcholinesterase and high affinity choline uptake in the 
rat brain. J. NEUROCHEM ., 47: 1696-1699.
Ramoa, A.S., Alkondon, M., Arcava, Y., Irons, J., Lunt, G.G., Deshpande, S.S., 
W onnacott, S., Aronstam, R.S., & Albuquerque, E.X., (1990). The anticonvulsant MK-
191
801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J. 
PHARMACOL. EXP. THER. 254: 71-82.
Rapier, C., Lunt, G.G., & Wonnacott, S., (1988). Stereoselective nicotine-induced release 
o f dopamine from striatal synaptosomes: concentration dependence and repetitive 
stimulation. J. NEUROCHEM ., 50: 1123-1130.
Rapier, C., Lunt, G.G., & Wonnacott, S., (1990). Nicotinic modulation o f  [3H]dopamine 
release from striatal synaptosomes : concentration dependence and repetitive stimulation. 
J. NEUROCHEM ., 54: 937-945.
Reavill, C., Spivak, C.E., Stolerman, I.P., & Waters, J.A., (1987). Isoarecolone can inhibit 
nicotine binding and produce nicotine like discriminitive stimulus effects in rats. 
NEUROPHARM ., 26: 789-792.
Reavill, C., W aters, J.A., Stolerman, I.P., & Garcha, H.S., (1990). Behavioural effects of 
the nicotinic agonists N-(3-pyridylmethyl)pyrrolidine and isoarecolone in rats. 
PYSCHOPHARM ., 102: 521-528.
Redbum, D.A., Biela, J., Shelton, D., & Cotman, C., (1975). Stimulus secretion coupling 
in vitro: a rapid perfusion apparatus for monitoring efflux o f transmitter substance from 
tissue samples. ANAL.. BIOCHEM., 67: 268-278.
Reynolds, I.J., & Miller, R.J., (1988). Multiple sites for the regulation o f  the N-methyl-D- 
aspartate receptor. MOL. PHARMACOL., 33: 581-584.
Role, L.W., Leeman, S.E. & Perlman, R.L., (1981). Somatostatin and substance P inhibit 
catecholamine secretion from isoalted cells o f  guinea-pig adrenal medulla. 
NEUROSCIENCE, 67: 249-262.
Romano, C., & Goldstein, A., (1980). Stereospecific nicotine receptors on rat brain 
membranes. SCIENCE, NOVEMBER, pp647-649.
Rosecrans, J.A., (1987). In vivo approaches to studying central cholinergic receptors. In: 
THE PHARM ACOLOGY OF NICOTINE (eds. Rand, M.J., & Thurau, K.), pp. 207- 
226. IRL Press. Oxford.
Rossor, M .N., (1981). Parkinson’s disease and Alzheimer's disease as disorders o f  the 
isodendritic core. B. MED. J., 283: 1588-1590.
Rossor, M .N., (1982). Neurotransmitters and CNS disease. LANCET, Nov. 27; 1200- 
1203.
Rovati, G.E., & Nicosia, S., (1994). Lower efficacy: interaction with an inhibitory receptor 
or partial agonism? TRENDS PHARMACOL. SCI., 15: 140-144.
Rowell, P.P., & Winkler, D.L., (1984). Nicotinic stimulation o f [3H]acetylcholine release 
from mouse cerebral cortical synaptosomes. J. NEUROCHEM., 52: 869-875.
Rowell, P., & W onnacott, S., (1990). Evidence for functional activity o f  upregulated
192
nicotine binding sites in rat striatal synaptosomes. J. NEUROCHEM ., 55: 2105-2110. 
Rowell, P.P., & Hillebrand, J.A., (1992). Desensitisation o f nicotine-stimulated dopamine 
release from rat striatal synaptosomes. THE PHARMACOLOGIST, 34: 154.
Rowell, P.P., & Hillebrand, J.A., (1994). Characterisation o f  nicotine-induced 
desensitisation o f evoked dopamine release from rat striatal synaptosomes. J. 
NEUROCHEM ., 63: 561-569.
Rylett, R.T., Ball, M.J., & Colhoun, E.H., (1983). Evidence for high affinity choline 
transport in synaptosomes prepared from hippocampus and neocortex o f  patients with 
Alzheimer’s disease. BRAIN RES., 289: 169-175.
_ _  _  _ s —  = = = =
St. George-Hyslop, P H., Tanzi, R.E., Polinsky, R.J., Haines, J.L., Nee, L., Watkins, P.C., 
Myers, R.H., Feldman, R.G., Pollen, D., Drachman, D., Growdon, J., Bruni, A., Foncin, 
J.F., Salmon, D., Frommmelt, P., Amaducci, L., Sorbi, S., Piacentini, S., Stewart, G.D., 
Hobbs, W.J., Conneally, P.M., & Gusella., (1987). The genetic defect causing familial 
Alzheimer’s disease maps on chromosome 21. SCIENCE, 235: 885-890.
Sahakian, B., Jones, G., Levy, R., Gray, J., & Warburton, D., (1989). The effects o f 
nicotine on attention, information processing, and short-term memory in patients with 
dementia o f  the Alzheimer type. B. J. PSYCHIATRY. 154: 797-800.
Sargent, P.B., (1993). The diversity o f  neuronal nicotinic acetylcholine receptors. ANN. 
REV. NEUROSCI. 16: 403-443.
Saunders, A.M., Strittmatter, W.J., & Schmechel, D., (1993). Association o f 
apolipoprotein E  allelle e4 with late-onset familial and sporadic Alzheimer’s disease. 
NEUROLOGY, 43: 1462-1472.
Schoepfer, R., Conroy, W.G., Whiting, P., Gore, M., & Lindstrom, J., (1990). Brain a -  
bungarotocin binding proteins cDNAs and MAbs reveal subtypes o f  this branch o f the 
ligand-gated ion channel superfamily. NEURON, 5: 35-48.
Schulz, D.W ., & Zigmond, R.E., (1989). Nueronal bungarotoxin blocks the nicotinic 
stimulation o f endogenous dopamine release from rat striatum. NEUROSCI. LETTS., 
98:310-316.
Scott, I.D., & Nicholls, D.G., (1980). Energy transduction in intact synaptosomes: 
Influence o f  plasma-membrane depolarisation on the respiration and membrane potential 
o f  internal mitochondria determined in situ. BIOCHEM. J., 186: 21-33.
Seguela, P., Wadiche, J., Dineley-Miller, K., Dani, J.A., & Patrick, J.W., (1993). Molecular
193
cloning, functional properties, and distribution o f  rat brain a7 : a nicotinic cation channel 
highly permeable to calcium. J. NEUROSCI., 13: 597-6034
Selkoe, D.J., (1991). Amyloid protein and Alzheimer’s Disease. SCIENTIFIC 
AMERICAN, November, pp40-47.
Shimihama, S., Taniguchi, T., Fujiwara, M., Kameyama, M., (1986). Changes in nicotinic 
and muscarinic cholinergic receptors in Alzheimer-type dementia. J. NEUROCHEM . 46: 
288-293.
Shinohara, M., Dollinger, B., Brown, G., Rapoport, S., & Sokoloff, L., (1979). Cerebral 
glucose utilisation: local changes during and after recovery from spreading cortical 
depression. SCIENCE, 203: 188-190.
Shoaib, M., & Stolerman, I.P., (1992). MK-801 attenuates behavioural adaptation to 
chronic nicotine administration in rats. B. J. PHARMACOL., 105: 514-515.
Simasko, S.M., Soares, J.R., & Weiland, G.A., (1986). Two components o f 
carbamylcholine-induced loss o f nicotinic acetylcholine receptor in the neuronal cell line 
PC12. MOL. PHARMACOL., 30: 6-12.
Simasko, S.M., Durkin, J.A., & Weiland, G.A., (1987). Effects o f  substance P on nicotinic 
acetylcholine receptor function in PC 12 cells. J. NEUROCHEM., 49: 253-260.
Simchowicz, T., (1911). Histologische studien uber die senile demenz. HISTOL. 
HISTOPATH. ARB. GROSSHIRNRINDE, 4: 267-444.
Simmons, L.K., Schuetze, S.M, & Role, L.W., (1990). SP modulates single-channel 
properties o f  neuronal nicotinic acetylcholine receptors. NEURON. 2: 393-403.
Sine, S.M., & Steinbach, J.H., (1984). Agonists block currents through acetylcholine 
receptor channels. BIOPHYS. J., 46: 277-284.
Sitaram, N., (1984). Cholinergic hypothesis o f human memory: review o f  basic and clinical 
studies. DRUG. DEV. RES., 4: 481-488.
Smith, C.M., & Swash, M., (1978). Possible biochemical basis o f  memory disorder in 
Alzheimer's disease. ANN. NEUROL., 3: 471-473.
Sokolovsky, M., & Bartfai, T., (1981). Biochemical studies on muscarinic receptors. 
TRENDS NEUROSCI., 4: 303-305.
Solsona, C., Salto, C., & Ymbem, A., (1991). Effects o f potassium deploarisation on 
intracellular compartmentalisation o f ATP in cholinergic synaptosomes isolated from 
Torpedo electric organ. BIOCHIM. BIOPHYS, ACTA, 1095: 57-62.
Stafford, G.A., Oswald, R.E., & Weiland, G.A., (1994). The P subunit o f  neuronal 
nicotinic acetylcholine receptors is a determinant o f the affinity for substance P 
inhibition. MOL. PHARMACOL., 45: 758-762.
Steinacker, A., & Highstein, S.M., (1976). Pre- and postsynaptic action o f  substance P at
194
the M auther fiber-giant fiber synapse in the hatchet. BRAIN RES., 114: 128-133.
Stensaas, S.S., & Stensaas, L.J., (1976). The reaction o f the cerebral cortex to chronically 
implanted plastic needles. ACTA NEUROPATHOL. (BERL.), 35:187-203.
Stephens, M .W .S., (1994). Pharmacological characterisation o f  the a4P 2  neuronal 
nicotinic acetylcholine receptor. PhD THESIS, University o f  Bath.
Stolerman, I.P., Goldfarb, T., Fink, R., & Jarvik, M.E., (1973). Influencing cigarette 
smoking with nicotine antagonists. PSYCHOPHARM., 28: 247-259.
Stolerman, I.P., Albuquerque, E.X., & Garcha, H.S., (1992). Behavioural effects o f 
anatoxin, potent nicotinic agonist in rats. NEUROPHARM., 31: 311-314.
Stollberg, J., Whiting, P.J., Lindstrom, J., & Berg, D.K., (1986). Functional blockade o f 
neuronal acetylcholine receptors by antisera to a putative receptor from brain. BRAIN 
RES., 378: 179-182.
Suzuki, T., Fujimoto, K., Oohata, H., & Kawashima, K., (1988). Presynaptic M l 
muscarinic receptor modulates spontaneous release o f acetylcholine from rat basal 
forebrain slices. NEUROSCI. LETTS., 84: 209-212.
Swanson, K.L., Allan, C.N., Aronstam, R.S., Rapoport, H., & Albuquerque, E.X., (1986). 
M olecular mechanisms o f the potent and stereospecific nicotinic receptor agonist 
(+)anatoxin-a. MOL. PHARMACOL., 29: 250-257.
Swanson, K.L., Aronstam, R.S., W onnacott, S., Rapoport, H., & Albuquerque, E.X.,
(1991). Nicotinic pharmaocology o f  anatoxin analogs: sidechain relationships at 
peripheral agonist and non-competitive antagonist sites. J. PHARMACOL. EXP.
THER., 259: 377-386.
* Szerb, J.C., & Somogyi, G.T., (1973). Depression o f acetylcholine release from cerebral 
cortical slices by cholineterase inhibition and by oxotremorine. NATURE, NEW  BIOL., 
241: 121-122.
— T —
Thomas, P., Stephens, M., Wilkie, G., Arnar, M., Lunt, G.G., Whiting, P., Gallagher, T., 
Pereira, E., Alkondon, M., Albuquerque, E.X., & Wonnacott, S., (1993). (+)-Anatoxin-a 
is a potent agonist at neuronal nicotinic acetylcholine receptors. J. NEUROCHEM., 60: 
2308-2311.
Thome, B., (1990). Nicotinic regulation o f  acetylcholine release from rat brain 
hippocampus. PhD THESIS, University o f Bath.
Thorne, B., W onnacott, S., & Dunkley, P.R., (1991). Isolation o f hippocampal 
synaptosomes on Percoll gradients: cholinergic markers and ligand binding sites. J. 
NEUROCHEM ., 56: 479-484.
Tibbs, G.R, Barrie, A.P., Van Mieghem, F., McMahon, H.T., & Nicholls, D.G., (1989). 
Repetitive action potentials in isolated nerve terminals in the presence o f  4- 
aminopyridine: Effects on cytosolic free Ca2+ and glutamate release. J. NEUROCHEM., 
53: 1693-1699.
Tilson, H.A., McLamb, R.L., Shaw, S., Rodgers, B.C., Pediaditakis, P., & Cook, L.,
(1988). Radial-arm maze deficits produced by colchicine administered into the area o f 
the nucleus basalis are ameliorated by cholinergic agents. BRAIN RES., 438: 83-94.
Toide, K., & Arima, T., (1989). Effects o f cholinergic drugs on extracellular levels o f 
acetylcholine and choline in rat cortex, hippocampus, and striatum studied by brain 
dialysis. EUR. J. PHARMACOL., 173: 133-141.
Tossman, U., & Ungerstedt, U., (1986). Microdialysis in the study o f  extracellular levels o f 
amino acids in the rat brain. ACTA PHYSIOL. SCAND., 128: 9-14.
— u —
Ungerstedt, U., (1984). Measurement o f neurotransmitter release by intracranial dialysis. 
In: M EASUREM ENT OF TRANSM ITTER RELEASE IN  VIVO (ed. Marsden, C. A ), 
pp. 81-107. Wiley & Sons, New York.
Ungerstedt, U., Herrera-Marchintz, M., Jungnelius, U., Stahle, L., Tossman, U., & 
Zetterstrom, T., (1982). Dopamine synaptic mechanisms reflected in studies combining 
behavioural recordings and brain dialysis. In: ADVANCES IN  DOPAMINE 
RESEARCH (ed. Kotisaka, M.), pp219-231. Pergamon Press, New York.
Utkin, Y.N., Lazakovich, E.M., Kasheverov, I.E., & Tsetlin, V.I., (1989).a-B gt interacts 
with the rat brain tachykinin receptors. FEBS, 255: 111-115.
— V—
Valenta, D.C., Downing, J.E.G., & Role, L.W., (1993). Peptide modulation o f  ACh 
receptor desensitisation controls neurotransmitter release from chicken sympathetic 
neurons. J. NEUROPHYS., 69: 928-942.
196
Verity, M.A., (1972). Regulation o f acetylcholine synthesis in the brain. J.
NEUROCHEM ., 19: 1305-1317.
Vemalis, A.B., Conroy, W.G., & Berg, D.K., (1993). Neurons assemble acetylcholine 
receptors with as many as three kinds o f  subunits while maintaining subunit segregation 
among receptor subtypes. NEURON, 10: 451-464.
Vernino, S., Amador, M., Luetje, C.W., Patrick, J., & Dani, J.A., (1992). Calcium 
modulation and high calcium permeability o f  neuronal nicotinic acetylcholine receptors. 
NEURON, 8 : 127-134.
ViGkroy, T.W ., & Cadman, E.D., (1989). Dissociation between muscarinic receptor- 
mediated inhibition o f adenylate cyclase and autoreceptor inhibition o f  [3H]acetylcholine 
release in rat hippocampus. J. PHARMACOL.. EXP. THER., 251: 1039-1044.
Vige, X., & Briley, M., (1988). Scopolamine induces upregulation o f  nicotinic receptors in 
intact brain but not in nucleus basalis lesioned rats. NEUROSCI. LETTS., 8 8 : 319-324.
Vincent, S.R., Satoh, K., Armstrong, D.M., & Fibiger, H.C., (1983). Supstance P in the 
ascending cholinergic reticular system. NATURE (LOND.), 306: 688-691.
— W —
Wada. K., Ballivet, M., Boulter, J., Connoly, J., Wada, E., Deneris, E., Swanson, L.W., 
Heinemann, S., & Patrick, J., (1988). Functional expression o f  a new pharmacological 
subtype o f  brain nicotinic acetylcholine receptor. SCIENCE, 240: 330-334.
Wada, E., Wada. K., Boulter, J., Deneris, E., Heinemann, S., Patrick, J., & Swanson,
L.W., (1989). Distribution of a2 , a3 , oc4, and (32 neuronal nicotinic receptor subunit 
mRNAs in the central nervous system: A hybridisation study in rat. J. COMP. 
NEUROL., 284:314-335.
Wainer, B.H., Levey, A.I., Rye, D.B., Mesulam, M.M., & Mufson, E.J., (1985).
Cholinergic and non-cholinergic septohippocampal pathways. NEUROSCI. LETTS., 54: 
45-52.
Wages, S.A., Church, W.H., & Justice, J.B., (1986). Sampling considerations for on-line 
microbore liquid chromatography o f  brain dialysis. ANAL. CHEM., 58: 1649-1656.
Walker, J.W ., Takeyasu, K., & McNamee, M .G., (1982). Ion flux and desensitisation rates 
in reconstituted membranes containing purified acetylcholine receptors. FED. PROC.,
41: 1396.
Walsh, T.J., Tilson, H.A., DeHaven, D.L., Mailman, R.B., Fisher, A., & Hanin, I., (1984).
197
AF64a, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and 
cortex, and produces log-term passive avoidancec and radial arm maze deficits in the rat. 
BRAIN RES., 321: 91-102.
Ward, J.M., Cockcroft, V.B., Lunt, G.G., Smillie, F.S., & W onnacott, S., (1990). 
Methyllycaconitine, a selective probe for neuronal a-bungarotoxin binding sites. FEBS 
LETT., 270: 45-48.
Wei, J., Walton, E.A., Milici, A., & Buccafiisco, J., (1994). m l-m 5 Muscarinic receptor 
distribution in rat CNS by RT-PCR and HPLC. J. NEUROCHEM ., 63: 815-821.
Weiler, M .H., (1989). Muscarinic modulation o f endogenous acetylcholine release in rat 
neostriatal slices. J. PHARMACOL.. EXP. THER., 250: 617-623.
Wesnes, K., & W arburton, D.M., (1984). Effects o f  scopolamine and nicotine on human 
rapid information processing performance. PSYCHOPHARMACOLOGY. 82: 147-150.
Wessler, I., Halank, M., Rasbach, J., & Kilbinger, H., (1986). Presynaptic nicotine 
receptors mediating a positive feed-back on transmitter release from the rat phrenic 
nerve. ARCH. PHARMACOL., 334: 365-372.
Wessler, I., Apel, C., Garmsen, M., & Klein, A., (1992). Effects o f  nicotine receptor 
agonists on acetylcholine release from the isolated motor nerve, small intestine and 
trachea o f  rats and guinea pigs. CLIN. INVEST., 70: 173-185. 26
Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T., & DeLong, M.R., (1981). 
Alzheimer's disease: evidence for selective loss o f  cholinergic neurons in the nucleus 
basalis. ANN. REV. NEUROL., 10. 122-126.
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., & DeLong, M.R., 
(1982). Alzheimer's disease and senile dementia: loss o f  neurons in the basal forebrain. 
SCI. (USA), 215: 1237-1239.
Whitehouse, P.J., Martino, A.M., Antuoirio, P.G., Lowenstein, P.R., Coyle, J.T., Price, 
D.L., & Kellar, K.J., (1986). Nicotinic acetylcholine binding sites in Alzheimer's disease. 
BRAIN RES., 371: 146-151.
Whiting, P., & Lindstrom, J., (1987). Neuronal nicotinic acetylcholine receptor P-subunit is 
coded for by the cDNA 0C4. FEBS LETT., 213: 55-60.
Whiting, P., & Lindstrom, J., (1988). Characterisation o f  bovine and human neuronal 
nicotinic acetylcholine receptors using monoclonal antibodies. J. NEUROSCI., 8 : 3395- 
3404.
Whiting, P., Schoepfer, R., Lindstrom, J., & Priestley, T., (1991). Structural and 
pharmacological characterisation o f  the major brain nicotinic acetylcholine receptor 
subtype stably expressed in mouse fibroblasts. MOL. PHARMACOL., 40: 463-472.
Whittaker, V.P., (1969). The synaptosome. In: Handbook o f  Neurochemistry, (ed. Lajtha,
198
A.), pp. 327-364, Plenum Press, New York.
Wilcock, G.K., & Esiri, M.M., (1982). Plaques, tangles and dementia: a quantitative study. 
J. NEUROL. SCI., 56: 343-356.
Wilcock, G.K., Esiri, M.M., Bowen, D.M., Smith, C.C.T., (1982). Alzheimer's disease: 
correlation o f  cortical choline acetyltransferase activity with the severity o f  dementia and 
histological abnormalities. J NEUROL SCI., 57: 407-417.
Wilkie, G.I., Hutson, P.H., Stephens, M.W., Whiting, P., & W onnacott, S. (1993). 
Hippocampal nicotinic autoreceptors modulate acetylcholine release. BIOCHEM. SOC. 
TRANS., 19: 121-124.
Williams, M., Sullivan, J.P., Arneric, S.P., (1994). Neuronal nicotinic acetylcholine 
receptors. D RU G  NEWS & PERSPECTIVES, 7: 205-223.
Wishaw, I.Q., O ’Connor, W.T., & Dunnett, S.B., (1985). Disruption o f  central cholinergic 
mechanisms in the rat by basal forebrain lesion or atropine: effects on feeding, 
sensorimotor behaviour, locomotor activity and spatial navigation. BEHAV. BRAIN 
RES., 17: 103-115.
W onnacott, S, & Marchbanks, R.M., (1976). Inhibition by botulinum toxin o f  
depolarisation-evoked release o f [14C] Acetylcholine from synaptosomes in vitro. 
BIOCHEM. J., 156: 701-712.
W onnacott, S, (1986). a-Bungarotoxin binds to  low affinity nicotine binding sites in rat 
brain. J. NEUROCHEM ., 47: 1706-1712.
Wonnacott, S., (1987). Brain nicotine binding sites. HUMAN TOXICOL. 6: 343-353.
Wonnacott, S., Irons, J., Rapier, C., Thorne, B., & Lunt, G.G., (1989). Presynaptic 
modulation o f  transmitter release by nicotinic receptors. PROG. BRAIN RES., 79: 157- 
163.
Wonnacott, S., (1990). The paradox o f  nicotinic acetylcholine receptor upregulation by 
nicotine. TRENDS PHARMACOL. SCI., 11: 216-219.
W onnacott, S., Jackman, S., Swanson, K.L., Rapoport, H., & Albuquerque, E.X., (1991). 
Nicotinic pharmacology o f anatoxin analogs: sidechain structure-activity relationships at 
neuronal nicotinic ligand bindig sites. J. PHARMACOL. EXP. THER., 259: 387-391.
Woolf, N.J., Hernit, M.C., & Butcher, L.L., (1986). Cholinergic and non-cholinergic 
projections from the rat basal forebrain revealed by combined choline-acetyltransferase 




Yaksh, T.L. & Yamamura, H.I., (1974). Factors affecting performance o f  the push-pull 
cannula in brain. J. APPL. PHYSIOL., 37: 428-434.
Yamada, N., & Murase., T., (1980). Modulation, by apolipoprotein E, o f  lipoprotein lipase 
activity. BIOCEM . BIOPHYS. RES COMMUN., 94: 710-715.
Yamamura, H .I., & Snyder, S.H., (1974). Postsynaptic localisation o f muscarinic receptor 
binding in rat hippocampus. BRAIN RES., 78: 320-326.
Yankner, B.A., Duffy, L.K., & Kirschner, D.A., (1990). Neurotrphic and neurotoxic effects 
o f amyloid p protein: reversal by tachykinin neuropeptides. SCIENCE. 250: 279-282.
Yoshida, K., & Imura, H., (1979). Nicotinic cholinergic recptors in brain synaptosomes. 
BRAIN RES., 172: 453-459.
Z
Zetterstrom, T., Vemet, L., Ungerstedt, U., Tossman, U., Jonzon, B., & Fredholm, B.B., 
(1982). Purine levels in the intact rat brain, studies with an implanted pefiised hollow 
fibre. NEUROSCI. LETTS., 29: 111-115.
Zetterstrom, T., Sharp, T., Marsden, C.A., & Ungerstedt, U. (1983). In vivo measurement 
o f  dopamine and its metabolites by intracerebral dialysis - changes after D-amphetamine. 
J. NEUROCHEM ., 41: 1769-1773.
Zwart, R., Abraham. D., Oortgiesen, M., & Vijverberg, H.P.M ., (1994). a4 p 2  subunit 
combination specific pharmacology o f neuronal nicotinic acetycholine receptors in N1E- 
115 neuroblastoma cells. BRAIN RES.^ 654: 312-318.
